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Abstract  
Tuberculosis and helminth infections are co endemic in many parts of the world. This 
geographical overlap has led to the hypothesis that helminth infections could exacerbate 
the effects of Mycobacterium tuberculosis (Mtb) infection. Anthelmintic treatment has 
been observed to be associated with improved mycobacterial cellular responses and 
decreases in the frequency of Treg cells. The consequence of this immunomodulation 
may affect the ability of the host to restrict the growth of mycobacteria or mycobacterial 
killing. This study aims at investigating the modulations of the immune response profile 
of latent tuberculosis (LTBI) and helminth co-infected patients and whether these 
modulations are associated with a decrease in mycobacterial growth inhibition using a 
mycobacterial growth inhibition assay (MGIA).UK migrants attending University 
College Hospital London, UK with eosinophilia or suspected/diagnosed helminth 
infection (Strongyloides spp and Schistosoma spp) and/or LTBI were bled at recruitment 
(before anthelmintic treatment) and 4 months after completing anthelmintic treatment. 
Helminth infected patients displayed poor growth inhibition on MGIA which was 
improved after anthelmintic treatment which indicated this immunomodulation might be 
helminth mediated. The percentage of CD4+ T cells expressing IFNg, TNFa and IL-2 
were quantified by flow cytometry in PPD and ESAT-6/CFP-10 stimulated PBMC and 
anthelmintic treatment was observed to increase the frequency of CD4+IFNg response. 
LTBI-helminth coinfection was associated with significantly elevated levels of pro-
inflammatory and lower levels of anti-inflammatory cytokines after they were treated. IP-
10 was significantly upregulated and MCP-1 was significantly downregulated in LTBI-
helminth coinfected patients after anthelmintic treatment. The effect of IL-10 and TGFb 
on MGIA were observed and suggested an immunoregulatory role in helminth infected 
patients. Gene expression analysis by qRT-PCR showed varied responses and showed 
significant fold changes of CXCL-10, arginase 1 and CD163 after the treatment. MGIA 
and multiple immune parameters have shown that helminth infection can modulate a 
variety of Mtb specific immune responses. 
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NOS Nitric oxide synthase 
NRAMP Natural resistance associated protein 
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PAMPS Pathogen-Associated molecular pattern 
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RNA Ribonucleic acid 
RNIs Reactive nitrogen intermediates 
ROIs Reactive oxygen intermediates 
ROS Reactive oxygen species 
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UIN Unique identification number 
UNICEF United Nations International Children’s Emergency Fund 
WASH Water, sanitation and hygiene 
WBA Whole blood bactericidal activity 
WHO World Health Organization 
YLD Years lived with disability 
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Chapter - 1     Introduction 
1.1   Tuberculosis 
Tuberculosis (TB) is an airborne infectious disease caused by organisms of the 
Mycobacterium tuberculosis complex. TB is a major public health care problem and 
remains a major cause of morbidity and mortality worldwide (1). In 2015, there were an 
estimated 10.4 million new (incident) TB cases worldwide, of which 5.9 million (56%) 
were among men, 3.5 million (34%) among women and 1.0 million (10%) among 
children. Six countries accounted for 60% of the new cases: India, Indonesia, China, 
Nigeria, Pakistan and South Africa (2). 
 Only 5-10% of these infected groups develop active disease during their lifetimes. The 
remaining 90-95% remain latently infected without developing active disease or 
becoming infectious. The biological risk factors that increase their susceptibility to TB 
include malnourishment, poor housing, HIV infection, diabetes, prison, tobacco smoking, 
etc. Host genetic factors, geographic and ethnic clustering of tuberculosis, strain 
variability and genetic diversity of Mycobacterium tuberculosis (Mtb) contribute to the 
risk of developing tuberculosis  (3). 
It was estimated that in 2014, the global burden of LTBI was 23.0% (95% uncertainty 
interval: 20.4%– 26.4%), amounting to approximately 1.7 billion people. WHO South-
East Asia, Western Pacific, and Africa regions had the highest prevalence and accounted 
for around 80% of those with LTBI (4). Among this large reservoir of asymptomatic 
LTBI patients, 8-10 million active TB cases emerge each year resulting in the deaths of 
nearly 1.7 million people (5). 
 
1.1.1  Tuberculosis in the United Kingdom 
In 2015, a total of 5,758 TB cases were notified in England, a rate of 10.5 cases/100,000 
population. The number of cases and rate of TB in the non-UK born population in 
England have declined year-on-year since 2011, with a decrease of more than 10% each 
year since 2012.The majority (60%) of non-UK born cases occurred among those who 
have lived in the UK more than six years, whereas, the rate of TB in the UK born 
population declined in 2015, with a decrease of 23% since the peak in 2012. Of the UK 
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born TB cases notified in 2015 where the ethnic group was known, the majority (60.0%, 
928/1,547) were from the White ethnic group, 21.5% (332/1,547) from South Asian 
ethnic groups (Indian, Pakistani and Bangladeshi) and 13.3% (206/1,547) from Black 
ethnic groups (Black-Caribbean, Black-African and Black-Other).  
 
 
Figure 1.1: Tuberculosis case reports, rates and annual percentage change, UK, 2000-2015 
 Source: Enhanced Tuberculosis Surveillance system (ETS), Office for National 
Statistics (ONS). Data extracted: April 2016. Prepared by: TB Section, National 
Infection Service, Public Health England (6). 
 
 
In 2015, as in previous years, the most frequent countries of birth for non-UK born cases 
were India, Pakistan, Bangladesh and Somalia (26.3%, 15.9%, 5.2% and 4.4%, 
respectively). 
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Figure 1.2: Tuberculosis case notifications and rates by ethnic groups, UK. (2016) 
 Source: Enhanced Tuberculosis Surveillance system (ETS), Office for National 
Statistics (ONS) Data extracted: April 2016. Prepared by: TB Section, National 
Infection Service, Public Health England (6). 
 
1.1.2  Pathogenesis of tuberculosis 
Mtb is transmitted by the aerosol route from person to person. When inhaled, Mtb are 
deposited into the lower respiratory tract and reach alveoli where they initially infect the 
alveolar macrophages. Although macrophages phagocytose and destroy the bacilli, still 
Mtb has adapted to the intracellular environment which renders them able to survive and 
replicate within these phagocytic cells (7). 
Recognition of mycobacterial components by innate immune cells through different 
pattern recognition receptor (PRR),TLRs,Nucleotide Oligomerization Domain (NOD) 
like receptors, and C type lectin have all been implicated in recognition of 
mycobacteria  and in the initiation of cytokine responses (8). The most important Mtb cell 
surface ligands that interact with TLRs and other receptors include the 19, 27 kDa 
lipoproteins, 38 kDa glycolipoprotein, glycolipids like phosphatidylinositol mannoside 
(PIM),  lipoarabinomannan (LAM) and mannose capped lipoarabinomannan (Man-
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LAM), trehalose dimycolate (TDM) and lipomannan (LM)(9). Signals generated through 
TLR promote proinflammatory immune responses including activation of nuclear 
transcription factor (NF)-κB and production of cytokines and chemokines and recruitment 
of DC-SIGN that induces suppression of immune responses.TLR activation leads to direct 
killing of bacilli by nitric oxide (NO) dependent and NO independent pathways 
(8)(10)(11)(12). The macrophage mannose receptor can facilitate phagocytosis of Mtb. 
The alveolar macrophage can also induce cytokine production–including Interleukins 
(IL)12, IL23, IL27, IL35, interferon gamma (IFNγ) and tumor necrosis factor-alpha 
(TNFα) and can also aid in the production of reactive metabolites such as NO that have 
antimycobacterial properties (13). 
Mtb reside in the phagosome and priming of the CD4+T cell response requires the 
presentation of Mtb antigens through the MHC class II pathway. Class I pathway 
presentation of Mtb antigen may be a result of the exocytosis of phagosomes, uptake of 
apoptotic blebs or recycling of MHC molecules with peptide replacement. NO and RNI 
generated by iNOS in the macrophages exert its toxic effects on the bacilli. iNOS 
recruitment into the phagosome is inhibited by Mtb. Hypoxia and respiration inhibition by 
NO induce a dormant state in Mtb leading to their persistence (14). 
Antimycobacterial mechanisms of the macrophage include lysosomal killing of Mtb 
mediated by ubiquitin derived peptides that destroy Mtb by autophagy, impairing the 
membrane integrity and allowing NO to kill Mtb effectively. During this time bacilli 
resist the bactericidal mechanisms of macrophages by preventing phagosome-lysosome 
fusion, by escape from phagosomes/ phagolysosomes and by causing macrophage 
necrosis (13). The escape from the phagosome is aided by Early Secreted Antigenic 
Target 6kDa (ESAT-6) protein and culture filtrate protein 10 (CFP-10) encoded by region 
of difference (RD) 1, that is present in all virulent Mtb and absent from all BCG strains. 
ESAT-6 also helps in apoptosis of macrophages, cytolysis of alveolar epithelial cells and 
in dissemination of TB (15). The released bacilli multiply extracellularly and are 
phagocytosed by another macrophage that fails to control their growth and is then 
destroyed. 
In the majority of cases, the necrotized lesions heal with scarring and calcification. The 
pathogen can remain silent inside the body without causing any symptoms and less than 
10% of the latent TB cases become reactivated infections. If the patient fails to contain 
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the initial infection, or if it is reactivated in a latently infected individual, the patient 
develops active TB. 
Possible outcomes of TB infection are illustrated in Fig. 1.3. 
 
Figure 1.3: Outcome of Mtb infection. Picture taken from 
http://www.oxfordimmunotec.com/international/products-services/healthcare-
professionals/tuberculosis/ (16).  
 
1.1.3  The innate immune response to Mtb 
The major innate cell types involved in dealing with Mtb infection are macrophages, 
neutrophils, dendritic cells and natural killer cells.  
1.1.3.1 Macrophages and dendritic cells 
Alveolar macrophages and dendritic cells are the first line defence against inhaled 
particles and microorganisms that deposit in the lung. Alveolar macrophages of 
susceptible individuals undergo alternative activation following infection with Mtb.  This 
phenomenon is associated with reduced oxidative radical generation, altered cytokine 
responses and reduced microbial action (17). Macrophages express a variety of pathogen 
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recognition receptors, such as the mannose receptor (MR), dectin receptor (beta-glucan 
receptor), scavenger receptors (SRs), complement receptors (CRs), mannose binding 
lectins (MBL), DC-SIGN, CD14 and TLRs (18)(19)(20). Apart from recognizing their 
ligands and mediating phagocytosis, macrophage receptors are involved in activating 
several downstream pathways and influencing the ensuing inflammatory responses (21). 
Subsequently, the pathogenic bacteria engage with vesicular trafficking machinery 
inducing inhibition of phagosomal maturation. Inhibiting phagosome-lysosome fusion 
and acidification of the phagosome degrade and can avoid killing and degradation (22). 
The natural resistance associated membrane protein (NRAMP) is found on the surfaces of 
the lysosomes of macrophages and migrates to the phagosome compartment after 
phagocytosis, where NRAMP plays an important role in controlling infection by 
removing iron and other divalent cations from the phagosomal environment (23). 
Activated macrophages produce cytokines and according to the pattern of cytokine 
secretion they are classified as M1 and M2 phenotypes. The innate response against Mtb 
begins with the recognition of the bacterial components leading to IFNγ, reactive oxygen 
species (ROS), and reactive nitrogen intermediates (RNI). However, in susceptible 
individuals, the infected macrophages display an alternative activation of macrophages 
which is characterized by diminished RNI and ROS production and increased secretion of 
Th2 cytokines like IL-4, IL-5, IL-10, and IL13. This cytokine profile may inhibit Th1 
responses by antagonizing IFNγ and decreasing IL-1, IL-6 and TNFα(24). Unlike 
macrophages, dendritic cells express CRs, MRs, and DC-SIGN that mediate uptake of 
Mtb in the alveoli of the lungs. DCs act as antigen presenting cells in Mtb infection, 
which helps in bridging between innate and adaptive immunity. Once infected, the 
dendritic cells then migrate to the regional lymph nodes, where they prime naïve T cells 
leading to T cell expansion and secretion of cytokines (25) 
1.1.3.2 Neutrophils  
Neutrophils are less well studied than other immune compartments of the host response to 
Mtb infection. Neutrophils are the most commonly infected phagocyte in the lungs in 
human TB (26). The interaction of neutrophils and macrophages and the downstream 
effects of T cell activity, could result in a range of outcomes from early clearance of 
infection to dissemination of viable bacteria and also an attenuated immune response. It is 
controversial as to whether human neutrophils can kill Mtb.  Both killing and the failure 
of killing are possible outcomes in vivo depending on the host and the mycobacteria. 
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Efficient killing could allow the neutrophil to halt the infection at an early stage while the 
absence of killing would allow the disease to progress locally and also to traffic the 
organism to distant sites including the systemic circulation (27). Neutrophils influence the 
development of acquired immunity through the production of IL-12, MCP and other 
cytokines, which can attract T cells and help their maturation (28). The role of neutrophils 
is still complex and under investigation by the researchers. 
1.1.3.3 Natural killer cells 
Natural killer (NK) cells and macrophages are major components of the body’s innate 
immune system, contributing significantly to the body’s ability to synergistically inhibit 
the growth of Mtb in immune compromised individuals lacking a sufficient T cell 
response. Direct mechanisms of control by NK cells are largely through the secretory 
products perforin, granulysin, and granzymes, as well as multiple membrane-bound death 
receptors that facilitate target directed lysis. NK cells also have a role in indirectly 
stimulating an immune response through IFNγ mediated activation of macrophages and 
monocytes with multiple signalling pathways, including both reactive oxygen species and 
reactive nitrogen species (29). 
1.1.4  Roles of immune cells and cytokines in Mtb infection 
Activation of CD4+T cells leads to secretion of cytokines such as IFNγ and TNFα that 
induce macrophage activation. It causes apoptosis of infected macrophages through 
Fas/Fas ligand interactions, and induction of other immune cells to produce 
immunoregulatory cytokines such as IL-10, IL-12, and IL-15. It is critical for CD4+T cell 
function and can also control the intracellular growth of Mtb by a NO dependent 
mechanism(30). 
CD8+T cells may be cytotoxic for Mtb infected macrophages. They can directly kill Mtb 
via granulysin, perforin, granzyme, hydrolases and extracellular ATP and facilitate the 
control of acute and chronic infection. The cytotoxicity can lead to intracellular killing of 
Mtb and also releases the viable intracellular mycobacteria, which may lead to their 
uptake by effective microbicidal macrophages (31). Unconventional T cells such CD1 
restricted T cells, and γδ T cells also confer protection.  
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B cells may play a role in priming the immune response. B-cell deficient mice have been 
shown to be more susceptible to primary TB infection and had increased bacterial loads 
(32). 
IFNγ is the key component of protective immunity against TB. IFNγ activates 
macrophages to kill intracellular bacilli. It augments antigen presentation leading to 
recruitment of CD4+ and CD8+T cells and participates in mycobacterial killing. 
TNFα provides a major protective role in TB by its involvement in both immunity and 
immunomodulation. It also initiates cell migration and formation of granulomas. TNFα 
induces the expression of chemokines such as IL-8, MCP-1, RANTES and sends signals 
to immune cells for recruitment (33). 
Additional cytokines with important roles include IL-12 and IL-17, produced by Th-17 
cells. In a human study it was shown that 1L-17 producing cells also made IFNγ and had 
the phenotype of Th1 central memory or effector memory T cells (33). IL-4 production is 
induced during clinical TB and indicative of active disease. Immunoregulatory cytokines 
such as IL-10 and TGFβ exert inhibitory responses against TB. 
Granulomas are formed as consequences of the interaction between pulmonary 
inflammation and host immune responses. Granulomas are initiated by resident 
macrophages that phagocytose the bacilli and release proinflammatory cytokines-helping 
in recruitment of immune cells. These are surrounded by collars of lymphocytes including 
CD4+T cells which may enhance the anti-mycobacterial responses by releasing IFNγ. 
The centre of this type of granuloma is caseous, a necrotic state that probably consists of 
dead macrophages and other cells. This area is hypoxic. Mycobacteria in this granuloma 
can be found in macrophages (either in contact with T cells or not) in the hypoxic centre 
or possibly even in the fibrotic rim; this provides the mycobacteria with different 
microenvironments. The other type of granuloma is the non-necrotizing granuloma which 
is usually seen in active disease and consists primarily of macrophages and some 
lymphocytes. Mtb bacilli are found within macrophages in these lesions.  Fibrotic lesions 
are seen mostly in latent tuberculosis but also in active disease and are composed almost 
completely of fibroblasts, with a minimal number of macrophages. Although it is possible 
to culture bacilli from some fibrotic lesions, it is not clear where the bacilli reside 
(possibly in macrophages or in the fibrotic area) or what the microenvironment is like. 
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Well-organized granulomas are entirely dependent on an effector Th1 response and can 
restrict Mtb growth. Non-necrotic and fibrous granulomas are observed in LTBI with 
fewer inflammatory cells. Proper functioning of granulomas can determine the outcome 
of infection. 
 
Figure 1.4: The granuloma. The figure shows a) the classic tuberculous granuloma, b) non-
necrotizing granuloma c) fibrotic granuloma taken from (34) 
 
1.2   Latent TB 
Latent tuberculosis infection (LTBI) is classically defined as measurable immune 
sensitization to Mtb in the absence of active disease manifestations, such as fever, chills, 
night sweats, weight loss, cough, haemoptysis, or a new opacity on chest radiograph. 
Immune reactivity to Mtb is assessed by either tuberculin skin testing (TST) or interferon-
gamma release assay (IGRA), with a positive result by either method indicating LTBI.  
LTBI can be viewed as an equilibrium between host and bacillus. In most cases, the host 
response is sufficient to combat active disease for life time, however, occasionally the 
immune response fails to protect and the infection reactivates to cause active disease (35). 
Latent TB is generally equated with bacterial containment in some inactive form and 
includes a diverse range of individuals from those who have completely cleared the 
infection with substantial memory T cell responses to TB antigens to individuals who are 
incubating actively replicating bacteria in the absence of clinical symptoms (36). The 
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basic mechanisms involved in maintaining a latent Mtb infection or the causes of 
reactivation are still difficult to explain, due to the difficulty in developing and 
manipulating animal models of latent tuberculosis. The design of an adequate animal 
model of latent Mtb infection is hampered by the lack of knowledge about the biological 
characteristics of both the tubercle bacilli and host immunity during human latent 
tuberculosis (37). 
1.2.1  The global burden of LTBI 
The population carrying a LTBI is commonly quoted as “one third” as one third of the 
global population, a reservoir of approximately 2.3 billion individuals (38). Houben and 
Dodd constructed trends in annual risk of infection (ARI) for countries between 1934 and 
2014 using a combination of direct estimates of ARI from LTBI surveys and indirect 
transmission of ARI calculated from World Health Organisation (WHO) estimates of 
smear-positive TB prevalence. In 2014, the global burden of LTBI was estimated to be 
23% amounting to approximately 1.7 billion people. WHO South East Asia, Western 
Pacific and Africa regions were all estimated to have LTBI prevalence in the general 
population of above 20%, whereas the WHO Eastern-Mediterranean, Europe and 
Americas regions all had LTBI prevalence of below 17%. Around 80% of the world’s 
latently infected TB patients are in the WHO South-East Asia, Western Pacific and Africa 
regions (39).  
 
Figure 1.5: Global map of prevalence of LTBI(39) 
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China and India had the highest LTBI burden, having approximately 350 million 
infections, followed by Indonesia at about 120 million infections. The substantial 
increases in TB burden in Africa and South-East Asia are rapidly increasing in the 
younger age groups compared to other ages. It is estimated that 56 million people 
worldwide are at high risk of developing TB disease because of reinfection. Assuming the 
current LTBI activation rate of 0.15% per year, LTBI incidence will be 16.5/100000 per 
year in 2035, which is above the 10/100000 per year target in the End TB strategy (39). 
Health care workers (HCWs) are at increased risk of acquiring LTBI in comparison to the 
rest of the healthy population. The risk of TB in HCWs is higher in the low and middle 
income countries that account for 80% of global TB cases. The estimated annual 
incidence of LTBI is 3.8% to 8.4% among HCWs with varying TB incidence. In country-
wise subgroup analysis, the pooled prevalence of LTBI was lowest in Brazil (37%), 
followed by India (43%), China (54%), and South Africa (64%) among countries with 
higher TB incidence(40).  
Stratified pooled estimates for the LTBI rate for countries with low (<50 cases/100,000 
population), intermediate (50–100/100,000population), and high (>100/100,000 
population) TB incidence were 3.8% (95% confidence interval [CI] 3.0%–4.6%), 6.9% 
(95% CI 3.4%–10.3%), and 8.4% (95% CI 2.7%–14.0%), respectively. Increased 
exposure and suboptimal infection control measures in high burden countries and also 
cough etiquette and respiratory hygiene can predispose to transmission of TB infection at 
the physician-patient interface especially in high burden countries. HCWs with active TB 
are also a potential source of infection transmission to other HCWs (40). 
Studies of immigrants moving from high to low TB burden countries can also be another 
potential risk group for LTBI. Risk of TB is especially high in the first few years of 
migration, although they remain at higher risk of infection for decades after entry to low 
income countries. It is difficult to establish whether this infection is acquired as a delayed 
reactivation or by reinfection following recent transmission from visiting the endemic 
country or from the local community. McCarthy et al., has demonstrated that TB 
diagnosis is rare after 15 years of immigration if individuals havea low risk of reinfection. 
About 230 migrants from high burden countries of South-East Asia who migrated to UK 
were studied.  About 10.4% had arrived in UK 11-15 years previously and 5.6% more 
than 15 years previously (41). 
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1.2.2  Models of LTBI 
The actual “state” of TB bacilli during LTBI continues to be a question for research. 
Autopsy studies in the early 20th century suggested that viable bacteria could be isolated 
from tissue samples in patients who died of TB in endemic countries (42). In LTBI, the 
bacillus stops growing and enters a state of stationary phase and eventually becomes non-
replicating bacilli that retains the ability to resume growth within the granuloma (43). 
These bacilli are often referred to as dormant, persistent and non-replicating bacilli. It is 
assumed that the dormant and nonreplicating bacilli are contained within the granuloma 
but autopsy also suggested that viable bacteria may be present in apparently normal lung 
tissue in patient with tuberculous infection but no clinical disease (44). The physical 
location of the bacilli and the metabolic status of the bacilli in LTBI remains poorly 
understood.  
The first and most well-characterized murine model of LTBI was the Cornell model and it 
was first described in the 1950s (45). In this model, mice were inoculated intravenously 
with 1x106 to 3x106 viable bacilli of Mtb H37Rv, followed by treatment with 
pyrazinamide (PZA) and isoniazid (INH) anti-mycobacterial chemotherapy for 12 weeks 
beginning within 20 minutes after infection to reduce the bacterial load to very low or 
undetectable bacilli levels. In this drug-induced model of LTBI, very low or no bacilli 
were detected for several months after this treatment, analogous to LTBI in humans. But 
in many mice, the latent infection spontaneously reactivated and caused active disease.  
The administration of cortisone reduced the time for spontaneous reactivation for 50% of 
the mice from 7 months to 2.5 months (46). This model was adapted to use an aerosol 
route of delivery of Mtb in order to mimic the natural route of infection (47). This model 
focused more on the ability of mycobacteria to persist or replicate following antibiotic 
regimens than on the host immunity involved in maintaining a latent infection.  The 
modified Cornell model showed that reactivation occurs if the production of reactive 
nitrogen intermediates (RNI) is blocked by a nitric oxide synthase inhibitor-
aminoguanidine, which has relative specificity for NOS2 (48). There is no standard 
protocol for establishing latency with the Cornell model. Scanga et al., examined the 
Cornell model variants for their applicability to immunologic studies of LTBI. They 
evaluated the rate of spontaneous reactivation following the antibiotic regimen or 
reactivation with immunosuppressive regimens that included NOS2 inhibition, in vivo 
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neutralization of IFNg, in vivo neutralization of TNFa and pharmacologic pan-
immunosuppression using glucocorticoids. They showed that the outcome of the Cornell 
model was highly dependent on the parameters used to establish the latency and that each 
variant of the model has certain limitations (37). 
Before the Cornell model, there were two other mouse models of LTBI. In the first 
model, mice were aerogenically infected with a low dose of Mtb (5 to 10 CFU), and 
within 3 months the pulmonary bacillary burden stabilized at 3 to 4 log10 (47). This 
clinically quiescent phase of the infection was maintained for 15 to 18 months but after 
that the infection began to reactivate and the mice succumbed to tuberculosis. This low-
dose model has the important advantage of mimicking natural latency in that it relies 
solely on the host immune response for control of the infection, but it has the 
disadvantage of a high bacillary burden that is unlikely to be found in human LTBI. 
Using a modified low-dose model of murine latent tuberculosis, it was previously 
demonstrated that RNI play an important role in preventing reactivation (49). 
A non-human primate model of latency is currently being developed, which would 
potentially be very relevant to the human clinical condition (50). Cynomolgus macaques 
infected with a low dose of Mtb are the only animal model in which both active disease 
and latent infection have been described and characterized (51). Gross signs of disease are 
observed as early as 4 weeks post infection (52). By the sixth week post infection, greater 
production of mycobacteria-specific IFNg in PBMC was observed among monkeys who 
developed active disease later than in the monkeys with latent infection (51). About 40% 
of cynomolgus macaques infected with such low dose aerosol challenge did not go on to 
get disease and remained latently infected (53).  
A dynamic model of latent infection has been proposed in which endogenous reactivation 
as well as damaging response occurs constantly in immunocompetent individuals. The 
model suggests that during initial stages of infection, Mtb grows well inside the 
phagosome and then escapes from the phagolysosome and released to the extracellular 
milieu due to macrophage necrosis (43)(54)(55)(56). Some of these extracellular bacteria 
stop replicating due to the hypoxic environment, nutrient deprivation and the presence of 
bactericidal enzymes released from immune cells. The metabolically inactive, non-
replicating /dormant bacilli resist killing and may survive in the face of a strong immune 
response (43). The model also suggested a role for foamy macrophages that emerge 
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during the chronic inflammatory process due to phagocytosis of cellular debris rich in 
fatty acids and cholesterol in the dissemination of infection. The model suggested that the 
foamy macrophages phagocytose metabolically inactive, dormant extracellular bacilli. At 
the same time, tubercle bacilli do not grow in the intracellular environment, as the 
macrophages are activated (57)(58)(59)(60). The foamy macrophages containing 
phagocytosed bacilli then drain from the lung granuloma towards the bronchial tree and 
lodge the bacilli into different regions of the lung parenchyma due to aerosols generated 
by inspired air and in this process bacilli may also be lodged in the upper lobe of lungs, 
where they are exposed to higher oxygen pressure. This oxygen pressure in the upper 
lobes also supports rapid extracellular bacillary growth. The subsequent inflammatory 
response leads to tissue destruction, liquefaction and extracellular bacillary growth (60).  
All these models are potentially very useful in modelling human LTBI to evaluate the 
immunological factors important for controlling such infection and also to evaluate 
potential therapeutic options. But these models are very expensive, complex, variable and 
time consuming (61). The outcome of these models depends on certain variables like 
antibiotic regimen, length of the treatment period, dosage of mycobacterial challenge 
used, the length of antibiotic-free rest period and strains of mice used. Botha and Ryffel 
described the limitations of these models which includes spontaneous reactivation, 
difficulties in inducing reactivation and generating phenotypically altered mycobacteria 
(62). Also these models have high inter-group variability and depend on group size, cost 
and availability of a BSL3 containment facility (61).  
1.2.3  Pathogenesis of LTBI 
In the majority of TB cases, Mtb infection induces the development of specific acquired 
cell mediated immunity inhibiting the growth of mycobacteria without their eradication 
(63). In such individuals, tuberculosis bacilli live in a dormant state. Well organised 
granulomas are entirely dependent on an effector Th1 response  and mediate restriction of 
mycobacterial growth either within IFNg activated macrophages or within the adverse 
conditions of the necrotic caseum (64). Granulomas are dynamic lesions with cells dying, 
debris being removed and new cells entering. It is assumed that, within granuloma, there 
is an equilibrium of actively dividing Mtb and Mtb adapted to the stress generated within 
activated or foamy macrophages that do not kill Mtb but are capable of inhibiting their 
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growth. Thus the bacilli are thought to enter a state of non-replicating persistence within 
the necrotic part of the lesion (65).  
The persistence of TB bacilli in granuloma is accompanied by the changes in bacterial 
metabolism and in host metabolism that are driven by Mtb effector proteins and 
glycolipids. In the granuloma the bacilli are subjected to various stress conditions like 
nutrition deficiency, acidic pH and inhibition of respiration by nitric oxide. The 
transcription factor Rv3133c, named dormancy survival regulator (DosR) directly 
coordinates the expression of approximately 50 genes and DosR induces the metabolic 
changes that allow the mycobacteria to enter dormancy. All these factors lead to the 
transformation of Mtb into a dormant state (42). The dormant bacilli are able to minimize 
their metabolic and replicative activity and also inhibit their growth and development. 
They become resistant to immune attack and can avoid elimination by the effector 
immune cells (66). 
The “Wayne” model of hypoxia induced dormancy, where bacteria were grown in liquid 
medium in sealed tubes with limited head space gradually reducing oxygen supply, 
showed a non-replicating state of persistence (NRP) which was characterized by reduced 
metabolism and increased drug tolerance. In this state, bacterial viability remained 
unchanged for weeks to months with synchronized replication resuming following 
reactivation (67). The resultant similarities between bacteria grown in vitro under hypoxic 
conditions and clinical cases of LTBI have made the model an important tool for 
investigating the molecular basis of mycobacterial dormancy (68). 
Activation of DosR, is mediated through two classic transmembrane sensor histidine 
kinases, DosS and DosT. DosS senses cellular redox status and DosT senses dissolved 
oxygen concentration (69). Despite its dominance of gene expression under hypoxia, 
varying responses, such as genetic inactivation of DosR resulted in a mild loss of viability 
in vitro(70)(71)(72). Upregulation of the DosR regulon is not specific to hypoxic changes 
and it can also be activated by CO and NO.  
Studies have shown that, while the DosR regulon is strongly induced at the initiation of 
anaerobiasis, this level is not maintained for a long time. With sustained periods of 
hypoxia another set of genes, called the enduring hypoxia response (EHR) are 
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upregulated. The relevance of the EHR overall bacterial adaptation to the hypoxic 
condition is yet not  understood (73)(74). 
A reduction in net carbon flux is a hallmark of hypoxia-induced dormancy in Mtb, 
whereas a source of carbon and energy are required for prolonged survival and later 
resumption of growth (68).  
Under hypoxia and stress, Mtb experiences significant decreases in ATP and increases in 
its NADH/NAD+ ratio with a blocked electron transport system, whereas ATP synthesis 
via the electron transport system is an important requirement for bacterial survival under 
these conditions. This suggests that despite cessation of replication, Mtb maintains both 
an energized membrane and constitutive ATP production, even in the absence of 
molecular oxygen (75).  
Macrophages undergo substantial phenotypic changes when exposed to reduced oxygen 
tension and it has been suggested that hypoxia modulates the central effector functions of 
macrophages with secretion of significantly enhanced amounts of the major 
proinflammatory cytokines IL-1b and TNFa, chemokines, proangiogenic factors and 
eicosanoids (76)(77). HIF1a plays a key role in macrophage adaptation to low oxygen 
tension and helps in the production of key immune effector molecules like granule 
proteases, antibacterial peptides, TNFa and NO. Mi et al., showed that pattern 
recognition receptor-dependent stimulation of macrophages under hypoxia led to 
increased expression of NOS2 which is very important for antibacterial immunity (78). 
It has been concluded that macrophages cultured at low oxygen tension are less 
supportive of mycobacterial growth. A low PO2 closer to that found in tissue, did not 
affect the free living bacteria but significantly reduced the growth of intracellular 
mycobacteria. This growth inhibitory effect was said not be due to differential response to 
IFNg and TNFa at low oxygen condition but rather it might be due to a shift from 
oxidative towards glycolytic metabolism. This was supported by other studies (79)(80).  
Macrophages in granulomas are both antimycobacterial effectors but also the host cell for 
Mtb. Immunohistochemical analysis of granulomatous lesions from the Mtb infected NHP 
model suggested that macrophages with anti-inflammatory phenotypes (CD163+iNOS+ 
Arg1 high macrophages) localized to the outer regions of granulomas, whereas the inner 
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regions were more likely to contain macrophages with proinflammatory and bactericidal 
phenotypes (CD11c+ CD68+ CD163 dim, iNOs+ eNOS+ Arg1 low macrophages) (68). The 
highly hypoxic granuloma centre is the focus of antimicrobial activity and is surrounded 
by an area of reduced proinflammatory activity and gradually increasing oxygen tension. 
The foamy macrophages are located mainly in the interface region surrounding the central 
necrosis and this location may reflect the perfect niche and prime location for Mtb to 
initiate a new infection. Histologically, a latent lesion shows thick fibrosis, mineralization 
and/or central caseation as shown in chronically infected cynomolgus macaques (81)(82). 
An insufficient upregulation of adhesion molecules on circulating lymphocytes may 
hinder the localization of antigen-specific lymphocytes within the lungs and this might 
affect the formation of granulomas (83). Decreased outer membrane permeability also 
protects Mtb from killing by ubiquitin-derived peptides. Thus some non-replicating bacilli 
may escape elimination by the immune system and so may persist (84).  
Several Mtb components such as 19-kDa lipoprotein, Man-LAM, cord factor etc can 
modulate antigen processing and presentation by mycobacterial protein and glycolipid 
antigens by MHC class I, MHC class II and CD1 molecules. Mtb bacilli may suppress the 
presentation of antigens to T lymphocytes and macrophages (58).  An insufficient 
activation of effector CD4+, CD8+ and g/d T cells, CD1 restricted and cytotoxic T cells, 
will result in defective microbicidal functions of macrophages  and other immune cells 
leading to tissue damage and dissemination (85)(86)(87). 
A particular subset of regulatory T cells, named CD4+CD25+FoxP3+D4GDI+T cells, 
contribute to the containment of Mtb in both human and murine models. These cells 
secrete Rho GDP dissociation inhibitor (D4GD1), instead of immunoregulatory 
cytokines, such as TGFb or IL-10. This factor acts on macrophages, enhancing the 
production of IL-1b, TNFa and reactive oxygen species and indirectly contributes to 
DosR regulon activation , and the arrest of mycobacterial growth (88). 
 
1.2.4  Risk of infection progressing to disease 
Based on epidemiological studies, known risk factors for reactivation of LTBI include: 
HIV, malnutrition, tobacco smoke, renal failure, alcoholism, indoor air pollution, 
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alcoholism, silicosis, diabetes, malignancy and immunosuppressive treatment such as 
with glucocorticoids (38)(89)(90).  
 
Figure 1.6: Progression of LTBI to active disease. The figure shows-a) The fate of TB infection 
is determined by predisposing factors influencing the outcome. b) Precipitating 
factors that may lead to progression of latent TB infection to active TB (91). 
The effect of anti-TNFa therapy is prominent  in the macaque model of LTBI, where 
anti-TNFa resulting in almost complete reactivation in animals with no previous signs or  
symptoms of active disease for at least six months from the time of infection (62). In 
patients treated with Infliximab, the risk of TB is increased initially up to 20 fold with 
43% of TB cases presenting within 90 days of administration of anti-TNFa therapy (92).  
HIV remains the most common risk factor for reactivation of TB. The risk of reactivation 
among HIV patients is almost 10 fold higher than for non HIV patients (93). A higher rate 
of disseminated, extra pulmonary disease was also observed in HIV-infected patients with 
TB. A CD4+T cell count of less than 200 cells/ml regardless of antiretroviral therapy was 
associated with risk of TB progression. In HIV and TB co-infection, there is HIV induced 
loss of mycobacterial specific CD4+T cells, Mtb induced increases in HIV load in serum 
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and macrophages, a shift from a Th1 to a Th2 response via alteration in IL-10, Tregs, IL-
12, IL-4 and TNFa, loss of granuloma integrity and alterations in apoptotic mechanisms 
(94). 
1.2.5  Preventive therapy for LTBI 
Drugs that contribute most to treatment for latent TB (Rifampicin, pyrazinamide) have 
the greatest sterilizing ability, target persisting organisms and provoke resuscitation of 
non-replicating bacilli and couple this with rapidly bactericidal therapies such as with 
isoniazid (95). Monotherapy is used in treating latent tuberculosis as the bacillary load is 
so low that the chance of developing resistant mutants is very unlikely. INH inhibits 
synthesis of mycolic acids, the major constituents of the cell wall, and displays a biphasic 
killing with rapid and early bactericidal activity against actively replicating bacilli but it 
has less efficacy in killing bacilli with low metabolic activity (96). However, this therapy 
does not predict sterilizing activity (efficacy of preventing relapse in humans and in 
animal models). Rifampicin and pyrazinamide  have more potent sterilizing activity and 
newer anti TB drugs such as rifapentine, TMC-207 and moxifloxacin also have also 
potent sterilizing activity (97). Martinson et al., demonstrated that 12 doses of rifapentine 
and INH given weekly for 3 months is an effective preventive therapy for LTBI (98). The 
challenge is to evaluate novel LTBI regimens. The only endpoint for clinical trials is the 
absence of disease and to demonstrate clinical efficacy needs large sample sizes and 
prolonged follow up. A surrogate marker may allow rapid evaluation of the therapy. An 
alternative approach is PET/CT imaging to evaluate treatment response. 18F-
Fluorodeoxyglucose (FDG), a marker for metabolic activityis taken up by activated 
neutrophils and macrophages. Sites of TB even in the absence of clinical sign symptoms 
accumulate FDG avidly and this is reduced following anti-TB therapy 
(99)(100)(101)(102). Whereas, Stephanus et al., showed that even after receiving full TB 
treatment, some APTB patients in South Africa and South Korea were not able to 
eradicate TB completely and showed marked heterogeneity in treatment responses. They 
have showed that the PET/CT scan of these patients at the end of treatment exhibited 
lesions with an ongoing inflammatory response and some patients showed intensified or 
new TB lesions (103). Similar results were observed in a study conducted by Stetzmueller 
et al., (104). Further research is required to unravel the interaction between the local host 
response and TB, disease progression and anti-TB treatment responses (105). 
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1.2.6  Current drug regimens for LTBI 
Drugs Dose(mg) Duration Frequency Comment 
INH  
 
300 6–9 months Daily Standard 1st line in 
HIV−/HIV+ 
 
INH  300 36 months Daily Recent evidence for 
greater efficacy in HIV+ 
 
INH  900 6–9 months Twice weekly Alternative regimen- 
allows directly observed 
therapy 
RIF  
 
600 4 months Daily Alternative regimen 
RIF+INH  
 
600+300 3 months Daily Alternative regimen 
RPE+INH  
 
900+900 3 months Once weekly Recently reported as 
effective in HIV+ and 
HIV− 
RIF+PZA  
 
600+2000 2 months Daily Hepatotoxicity issues in 
HIV- no longer 
routinely recommended 
Table 1.1: Drug regimen for LTBI (106).INH = Isoniazid, RIF = Rifampicin, PZA = 
Pyrazinamide, RPE = Rifapentine 
 
 
The NICE guidelines contain detailed recommendations for persons with LTBI in the 
UK. All HIV-negative persons aged 16 to 65 years of age, migrants, aged 16-65 years, 
who have entered the UK from a high incidence country (≥150 per 100,000 or Sub-
Saharan Africa,  within the last 5 years and had been previously living there for ≥6 
months are eligible for LTBI testing and those who are found to have LTBI are offered 
chemoprophylaxis- either a combination of Rifampicin and INH for three months or INH 
on its own for six months. HIV-positive persons of all age groups with LTBI are offered 
six months of INH and children (positive TST or IGRA and who have not been BCG 
vaccinated) are also offered chemotherapy if they are aged 1 to 15 years of age if they 
have been contacts of patients with smear-positive pulmonary TB. All individuals who 
are eligible for chemotherapy but decline should be given information and advised about 
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symptoms of active TB. NICE previously did not recommend chemoprophylaxis for any 
individuals above the age of 35 years old, unless they were HCWs or had an underlying 
illness with a high risk of reactivation (eg HIV). One reason for this age cut off is that the 
risk of hepatoxicity increases with age (107). 
Until now, TB control has focused on detection and management of active disease, but to 
reach the WHO End TB strategy to reduce the TB death rate by 95% and TB incidence 
rate by 90% by the year 2035, it is also imperative to understand and manage the 
important reservoir of LTBI patients. Safer and more effective treatment of latent TB and 
effective pre or post-exposure vaccines would be the best ways to reduce the incidence of 
TB and to move forward towards the 2035 End TB target. 
1.3   Biomarkers for LTBI identification 
Biomarkers are measurable characteristics that can form the basis of surrogate end points. 
Biomarkers can be indicators of disease or indicative of host immunity. In some cases, 
these biomarkers can be indicative of the protective efficacy of a vaccine as correlates of 
protection. Biomarkers of infection or of risk of progression to disease could also 
contribute to both the development of diagnostic assays for TB and help to identify those 
at greater risk of progression (108). 
Several efforts have been undertaken to distinguish between active and latent TB. LTBI is 
characterized by a high heterogeneity of lesions; some of the latently infected TB patients 
exhibit only the remnants of a waning infection, while some of them present with a 
slowly progressing form of the disease or may progress to a chronic non-progressing 
infection (109). What actually constitutes a protective immune response in this chronic 
infection still remains unclear. There is a need to develop new diagnostic tools and 
systemic screening based on newer biomarkers and/or newer antigens which are 
associated with latent TB, but not with active TB which may direct more efficient 
treatment to the infected individuals. Tools are also needed to screen the treatment 
response to LTBI, or to a post-exposure vaccine, or a screening test that detects 
individuals with LTBI, who are likely to progress in the next 5–10 years, all of which are 
part of Pillar 3 of the WHO End TB strategy (110). 
We need to identify biomarkers for people who are at risk of progressing towards active TB 
disease, in a subclinical phase with minimally active pathology or immunopathology. These 
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predictive biomarkers could be mycobacterial products or markers of host response within 
blood, urine or through skin testing. Careful follow-up of the LTBI population at risk over 
time might allow the identification of some useful biomarkers and correlates of risk. 
There is no gold standard test for the diagnosis of LTBI. The diagnosis of LTBI is based 
on reactive tuberculin skin testing (TST) and /or positive interferon gamma release assay 
(IGRA). IGRA (either QuantiFERON TB Gold In Tubes (Qiagen,the Netherlands; QFT-
GIT) or the newer QFT-GIT Plus or T-SPOT.TB (Oxford Immunotec, Marlborough, MA, 
USA)) measure in vitro IFNg production by whole blood ELISA or an Enzyme-linked 
ImmunoSpot (ELISpot) assay on peripheral blood mononuclear cells (PBMC) 
respectively (111). Blood is stimulated with peptides from Mtb specific antigens (ESAT-
6, CFP10 and TB 7.7 for QFT-GT). The antigens used in this assay are encoded by genes 
that are deleted in the vaccine strain of BCG and most environmental mycobacteria of 
clinical relevance. IGRAs cannot distinguish between LTBI and active TB in 
immunocompetent individuals, in high risk individuals with immunosuppressive 
conditions or in children but are not affected by prior BCG vaccination and have no cross 
reactivity with most environmental mycobacteria. Screening for LTBI in low TB 
incidence countries is aimed towards high risk populations -like recently infected 
individuals, close contacts of active TB cases, recent immigrants from TB endemic areas 
or immunocompromised populations (112). 
TST triggers a PPD-driven T-cell mediated delayed type hypersensitivity reaction (DTH). 
Two IU of the PPD preparation is used and skin induration ≥6 mm to ≥10mm (≥10mm in 
BCG vaccinated, ≥6 mm in HIV infected) is regarded as a positive TST.This response 
involves monocytes and previously primed T-cells, which are attracted to the skin where 
they proliferate and secrete cytokines. TST does not differentiate between infection with 
virulent Mtb, exposure to environmental mycobacteria or prior immunization with BCG. 
Its sensitivity is low in HIV infected or other immunocompromised individuals (113).The 
TST is also influenced by inter and intrareader variability and the immunosuppression 
status of the host (114). 
The TST and IGRA rely on DTH or T cell immune response following reexposure to Mtb 
specific antigens (115). There is good correlation between TST and IGRA in low TB 
endemic settings, but high levels of discordance have been observed with individuals having 
TST negative but IGRA positive results with some reverse reports as well. The discordance 
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is assumed to be due to BCG vaccination which has effect on TST but not on IGRA. 
Neither diagnostic test reflects the activity of any infectious focus or the risk of 
progression to active disease. Both the tests show evidence of spontaneous reversion over 
time that might provide a negative result for those patients who are previously exposed 
and immune sensitized by Mtb. A two-step testing strategy may identify these patients, 
where an initially negative TST boosts the immune response to subsequent TST positive 
(116).To measure alternative cytokines or to detect central memory populations using 
flow cytometric assays could provide a better marker of exposure and history of immune 
sensitization, as the IGRA after its short incubation (16 to 24 hours) identifies primarily 
ESAT-6/CFP10-specific effector cells (117). Host biomarkers may prove important in 
stratifying the risk of development of TB (118). 
Different immunoassays have been proposed to aid LTBI identification- for example, 
IFNg responses in untreated LTBI cases and unexposed subjects, where unexposed 
individuals displayed lower IFNg levels by QFT-GT (119). Evaluation of serum pro-
inflammatory cytokines like IL-6, MCP-1, plasma concentrations of markers involved in 
the TLR 4, fractalkine, IL-4 and monocyte chemoattractant protein (MCP) have been 
described (120)(121).  
One potential candidate to help with diagnosis is the interferon inducible protein (IP-10), 
production of which in response to Mtb antigens could be used as a marker of infection. 
To be used for the diagnosis of LTBI, IP-10 still depends on stimulation with Mtb 
antigens. IP-10 has also been assessed as a potential biomarker to monitor treatment 
response to TB medication. Biraroet al., measured the IP-10 concentrations in QFN 
supernatants from latently infected individuals compared to uninfected contacts and 
active TB. IP-10 was able to differentiate between the uninfected and latently infected 
contacts with sensitivity of 87.1% and specificity of 90.9%(122). However, IP-10 was not 
able to differentiate latent infection from active disease except when Mtb specific to 
mitogen specific ratios were used in HIV negative adults. The study showed good 
agreement between IP-10 and QFN, moderate agreement between IP-10 and TST and 
poor agreement between QFN and TST.  Wergeland et al., also demonstrated how IP-10 
differentiated between active TB disease and LTBI or QFN negative controls in a high 
TB endemic setting. IP-10 therefore has a good potential to diagnose latent TB (123). 
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DosR regulon encoded antigens such as Rv2626c, Rv2624c and Rv2628 were also 
validated in different studies as they were recognized by household contacts or TST 
positive individuals and also could induce the secretion of significant amounts of IFNg in 
comparison to non-infected individuals (124). Other latency antigens such as Rv1733c, 
Rv2029c and HBHA are also promising tools for identifying LTBI individuals and also to 
distinguish recent LTBI from remote LTBI (125)(126).  
Blood transcriptional profiling has the potential to be used as a diagnostic test and has 
improved our understanding of disease pathogenesis. A study by Berry et al., performing 
whole blood gene expression profiling reported an 86-transcript type 1 IFN inducible 
signature that was specific for active TB and the signature was overexpressed in 
neutrophils. The signature was associated with the radiographic extent of pulmonary TB. 
Transcriptional profiles of 10-25% of latent TB patients clustered with active TB patients. 
This proportion was equal to the predicted frequency of patients progressing toward active 
TB (109). Whole blood transcriptomic analysis has the potential to provide biomarkers for 
those with LTBI at highest risk of TB and may act as a diagnostic marker for LTBI with 
sub-clinical active infection or a higher burden latent infection, although longitudinal 
studies are required to validate this. Sweeney et al., compared gene expression in patients 
with LTBI and other diseases versus ATB patients using a validated multicohort analysis 
framework (127). Three public TB gene expression datasets GSE19491, GSE373250 and 
GSE42834 composed of 1023 whole blood patient samples were chosen to be used if they 
were statistically differentially expressed in active TB compared with LTBI and other 
diseases, the diagnostic capability was not affected by HIV status and BCG vaccination, 
and if there was significant correlation with severity of active disease. The three gene set 
could improve clinical diagnosis and treatment response monitoring, although this needs to 
be confirmed by prospective validation with a targeted assay. The three-gene set should 
ease translation to clinical practice and might prove cost effective in the resource-poor 
environments in which tuberculosis is prevalent. The correlation of the tuberculosis score 
with disease severity also suggests that it might be possible to use the test for a predictive 
enrichment strategy for new drug trials. Zak et al., identified a 16 gene signature of risk in 
LTBI and household contacts for South African and Gambian cohorts. The signature 
predicted tuberculosis progression with a sensitivity of 66·1% (95% CI 63·2-68·9) and a 
specificity of 80·6% (79·2-82·0) in the 12 months preceding tuberculosis diagnosis (128). 
The risk signature was excellent for differentiating tuberculosis disease from latent 
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infection and from other disease states. The newly described signature also holds potential 
for highly targeted preventive therapy. 
Multiparameter flow cytometry can be used to evaluate the proportion of T central (TCM) 
and T effector memory (TEM) subsets and multifunctional T cells- where the ratio of 
TCM and TEM can serve as a biomarker of the presence of infection as suggested in 
different studies (129). Studies have analysed the presence of both TCM and TEM in 
PBMCs of individuals with LTBI, where a response to RD1 stimulation in LTBI was 
characterized by TCM phenotype. Adekambi et al., have described a distinct effector 
memory CD4+T cell signature in latent Mtb infection, which was differentiated from that 
in clinically cured TB patients (130). Caccamo et al., suggested that a multifunctional T 
cell profile is associated with the presence of live replicating TB rather than operating as 
a marker of protection (129). Multi-parametric flow analysis of T cells thus has the 
potential to distinguish those with replicating bacteria from those who have naturally 
cured their infection. This will provide insights to target preventive therapy for LTBI. 
Sandgren et al., systemically reviewed data on initiation and completion rates for LTBI 
treatment and observed that the rates were frequently suboptimal and varied greatly 
within and across populations (131). Populations with higher risk of TB infection like 
HCWs, in mates and the homeless were at higher risk of low initiation and completion 
rates. Improvement in treatment adherence and completion at risk groups might improve 
the effectiveness of latent TB treatment and stop progression towards active TB disease. 
An alternative to shortening to treatment can be to target the persisting organisms and 
their resuscitation. Bactericidal drugs like INH can strengthen this process. This approach 
will require more refined understanding of the mechanism behind the resuscitation and 
the complex metabolic states of this organism. 
To find a test that can best evaluate novel LTBI regimens is another challenge. Peripheral 
biomarkers indicative of treatment response of LTBI might prove an important tool. A 
surrogate marker of clinical response, early (2 months) culture conversion in active TB, 
14-day bactericidal activity, etc. may demonstrate the clinical efficacy and selection of 
appropriate therapy to prevent reactivation. Recently PET/CT imaging has been used to 
evaluate the response to therapy. This is a very sensitive imaging modality that can detect 
the early pathological changes in sputum negative asymptomatic individuals and also 
pathology consistent with subclinical pulmonary TB. Esmail et al., 2016, revealed that 
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LTBI patients with fibrotic scarring may undergo some repeated episodes of subclinical 
reactivation, which makes them more susceptible to develop active disease and this 
outcome can be assessed through PET/CT scan imaging (105). Malherbe and colleagues 
observed the PET-CT imaging response patterns in HIV negative patients with PTB after 
6 months of standard treatment and post treatment follow-up until 1 year. The presence of 
Mtb mRNA in sputum and BAL samples in these patients and intense lesions on PET-CT 
indicated that even after a full course of treatment was completed, all the bacteria were 
not eradicated. They suggested that for developing improved and shortened PTB-
treatment strategies, it is necessary to identify a better treatment response marker (132). 
It is critical to develop a better understanding of the immunological correlates of protection 
for LTBI in order to design an effective TB vaccine. The vaccine could be administered pre-
infection to prevent the infection from occurring or designed to be used post- exposure to 
prevent reactivation. H56 is a new multistage vaccine comprising the Ag85B, ESAT-6 and 
Rv2660 antigens which has been designed to be used post-infection in latently infected and 
uninfected adults. This vaccine is now in phase IIa clinical studies in South Africa  (133) .  
Antituberculous treatment and immunomodulation might be another alternative approach to 
shorten the existing therapy. The RUTI vaccine is comprised of heat inactivated, liposome 
fragments of Mtb that are grown in stress and hypoxia conditions. The vaccine is now in 
clinical phase 2 trials in patients with LTBI in South Africa. This vaccine is designed to be 
administered after one month of chemotherapy of LTBI with INH to facilitate the immune 
clearance of the persisting bacilli. Each subject (HIV+/HIV-) will receive two 
administrations, 28 days apart and will be monitored until one month after the second 
inoculation with RUTI (134). 
Improved understanding of the natural infection, protective immunity and immunopathology 
and the mechanism responsible for the reactivation in LTBI, might prove effective ways to 
accelerate the development a vaccine that could prevent reactivation or that was able to 
eliminate LTBI successfully. Also we need to get effective and representative results from the 
existing animal models that will represent better the natural history of LTBI in humans. 
1.4   Helminths 
Helminths  are complex eukaryotic organisms, characterized by their ability to maintain 
long standing chronic infections in humans (135). Approximately two billion people are 
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infected with intestinal helminth parasites, rendering them the most prevalent infectious 
agent in the world today and they are responsible for many chronic, debilitating and 
sometimes disfiguring diseases (136). Helminths are multicellular worms of three 
taxonomic groups: the nematodes (also known as roundworms) include the major 
intestinal worms (also known as soil-transmitted helminths) and the filarial worms that 
cause lymphatic filariasis (LF) and onchocerciasis, whereas trematodes include the 
flukes,such as the schistosomes, and cestodes include the tapeworms (137).  
Helminth parasites have characteristic complex life cycles with different stages of 
development from direct faecal-oral transmission (in roundworm infection) to 
development through free living stages (like hookworm larvae in the environment) or 
dependence on invertebrate vectors (for example snails in schistosome infection) (138). 
The responses may be compartmentalized depending on the anatomic location of the 
parasite, for example in the intestinal mucosa and draining lymph nodes or be systemic 
(135). Helminths may also have different invasion routes including skin (Schistosoma 
etc.), or by mosquito bite although the most common route is the gastrointestinal tract. 
The migration patterns of the parasite may elicit cutaneous, pulmonary or intestinal 
pathology, for example in Strongyloides infection during their lung migratory phase. 
Another hallmark of helminth infection is their chronicity–as some parasites live in the 
host for years. S.stercoralis can cause auto-infection and remain in their host to maintain 
their life cycle for an indefinite period of time (135). Helminth infection can establish 
long term chronic infections associated with significant down-regulation of the host 
immune response. The extraordinary prevalence of helminth infections reflects their 
ability to modulate the immune response in the host (138). 
Helminths compete with the host for nutrition, cause mechanical damage during their 
migration through tissues and in many cases may also drive immune-mediated pathology. 
Certain species of helminths are responsible for significant disability, morbidity and a 
reduction in life expectancy (139).There is variation in helminth infections within 
endemic regions- some people being susceptible to infection whereas others appear to be 
immune to infection with chronic exposure (140). 
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The eradication of helminth infection remains a difficult goal due to a lack of effective 
vaccines, limited pharmacological efficacy, emerging drug resistance, and rapid 
reinfection in places where transmission cannot be prevented. 
1.4.1  Global prevalence of helminth infection 
According to WHO, 24% of the world’s population are infected with soil-transmitted 
helminth infections (STHs) world-wide. Infections are widely distributed in tropical and 
subtropical areas especially where adequate water and sanitation are lacking. The greatest 
numbers of STH infections occur  in sub-Saharan Africa, the Americas, China and East 
Asia, and South America (141). The prevalence of helminth infection has declined in 
some part of the world due to improvements in living conditions and expansion of major 
deworming efforts. However still about one billion people globally are infected with 
helminths (142).  
 
Figure 1.7: Global prevalence of soil transmitted helminth infection (2010) (143). 
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Helminth Disease  Global 
prevalence 
(in millions) 
Regions of prevalence 
Ascaris lumbricoides Ascariasis 807  
Developing regions of 
Asia, Africa, and 
Latin America 
 
Trichuris trichiura Trichuriasis 604 
Necator americanus, 
Ancylostoma duodenale 
Hook worm 
infection 
576 
Strongyloides stercoralis  Strongyloidiasis 30-100 
Wuchereria bancrofti Lymphatic 
filariasis 
120 Developing regions of 
India, Southeast Asia, 
and sub-Saharan 
Africa 
S.haematobium, 
S.mansoni,  
S.japonicum 
Schistosomiasis 207 Sub-Saharan Africa, 
Eastern Brazil, China, 
South East Asia 
Taenia solium Cysticercosis 0.4 Developing regions of 
Asia, Latin America 
and Sub- Saharan 
Africa 
Table 1.2: The major helminth infections and their distribution and global prevalence 
(2010) (140). 
 
Pullan et al., built a modelling framework to provide an update on the global situation in 
2010, and estimated that 1.45 billion people were infected with at least one species of 
intestinal nematodes, resulting in 4.98 million years lived with disability (YLDs). The 
vast majority of infections and burden occurred in Asia, where at least one quarter of the 
population hosts at least one soil transmitted helminth species (142). There is a website, 
named “Thiswormyworld” developed by Simon Brooker. The aim of the website is to 
provide reliable, up-to-date maps on the geographical distributions of NTDs 
(www.thiswormyworld.org) (144).  
1.4.2  Helminth infection in UK migrants 
The global burden of helminth infection is greatest among populations who are heavily 
exposed to helminths specially in low income countries in the tropics (145). However, 
some chronic helminth infections may persist for years after migration from endemic 
countries and occasionally may cause severe disease in patients receiving 
immunosuppressive agents (146). Helminth infection may affect up to 20% of migrants 
from endemic countries at the time of their arrival in the UK (147), including 
Schistosomiasis, S.stercoralis and other soil transmitted helminth infections. 
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Strongyloides is common in South East Asia and the Caribbean, whereas Schistosoma 
infection is acquired by exposure to snail contaminated fresh water in many tropical 
countries particularly Sub-Saharan Africa where it can affect about 20% of travellers and 
residents(147).Travelers and expatriates contract schistosomiasis during their leisure 
activities like water sports, rafting, swimming or showering(148).  Helminth infection is 
the commonest identifiable cause of eosinophilia in the returning traveller or migrant 
(14% to 64%) (149). Schulte et al., showed that >50% migrants from endemic countries 
who present with  blood eosinophilia harboured helminth infection (150). Smith et al., 
observed that eosinophilia was associated with African and Asian ethnicity in an inner 
city gastroenterology service in the UK that serves a migrant population (145). About 
40% of the patients in the clinic were born in an endemic country and residing in the UK 
(a non–endemic country) or had recently travelled to endemic countries and were being 
investigated for peripheral eosinophilia. The majority of the screened migrants had 
helminth infection which was detected by the evidence based screening protocol for 
investigating eosinophilia. They presented with symptoms suggestive of Strongyloidiasis 
and Schistosomiasis and after anthelmintic treatment the symptoms improved in some of 
these patients. Eosinophilia on two or more occasion was diagnosed in 6.3% of travellers. 
The median eosinophil count was higher in those migrants who were parasitology 
serology and microscopy positive. The most prevalent helminths were S.stercoralis and 
Schistosoma spp. in their study. Another study at the Hospital of Tropical Diseases 
(HTD), London showed that immigrants have a lower chance of being symptomatic, 
including in microscopically proven infection although eosinophilia was present in 76% 
of migrants (151).  
The majority of immigrants with Schistosoma infection are also asymptomatic and the 
worm burden remains low. There are significant differences in immune responses in the 
immigrants depending on length of exposure to the helminth, IgE level and eosinophil 
count (12,16).  
1.4.3  Immune responses in helminth infection 
A complete understanding of immune response to helminths is complicated as these 
helminths have various lifecycles, tissue tropism and evasion mechanisms. These 
helminths consequently may activate immunity differently and induce different effector 
mechanisms. The immunological hallmark of helminth infections is their ability to induce 
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T helper type 2 (Th2) associated immune responses characterized by the production and 
marked elevation of cytokines like interleukins IL-4, IL-5, IL-9, IL-10 and IL-13, 
localized or generalized eosinophilia, production of IgE and IgG4 in humans and mucosal 
and goblet mast cell hyperplasia (1,18,19). In helminth infection, the initiation, 
progression and culmination of the type 2 response requires interaction with different cell 
types, including epithelial cells, innate lymphoid cells, antigen presenting cells-DCs, 
macrophages, T cells, B cells, eosinophils, mast cells and basophils (153). Naïve CD4 T 
cells differentiate into Th2 cells in the presence of cytokines such as IL-4, which further 
strengthens the type 2 response by positive feedback. Activation of cells of the innate and 
adaptive immune systems together can mediate a potent host protective immune response 
to helminth infection.  
The protective immune response includes mechanisms that mediate helminth and host 
resistance, resulted in accelerated worm expulsion and also mechanisms for enhancing the 
tolerance to invasive helminthiasis that reduces the damage to the host without affecting 
resistance to the pathogen. In the host response to intestinal helminths, tolerance includes 
direct effects of promoting wound healing and also inhibitory effects on harmful 
inflammation-which is mediated by the Type 1 immune response with elevation of both 
Th1 and Th17 cytokines (139).  
In helminth infection, the immune regulatory cytokines, namely IL-10 and TGFβ, can be 
regulated independently of the type 2 response. In a previous study, neutralization of IL-
10 and TGFβ resulted in increased production of both IL-4 and IFNg,	 suggesting the 
parasite may induce these anti-inflammatory cytokines  to evade the immune response 
and to prevent host immunopathology(154). In gastrointestinal nematode infection, IL-10 
and TGFβ are significantly linked with hyporesponsiveness, susceptibility and patients 
show a higher frequency of circulating CD4+CTLA-4+Tcells (155)(156).This 
immunoregulatory state is a common outcome in diverse range of helminth infections 
(138). 
Macrophages may also mediate immune regulatory effects through expression of 
inhibitory enzymes such as arginase 1, co-inhibitory molecules such as programmed cell 
death ligand 1 (PDL1), PDL2, IL-10 and suppressor of cytokine signalling 1(SOCS1) 
(157). Helminths also target these co-inhibitory molecules expressed on T cells and 
antigen presenting cells (APC) to maintain hyporesponsiveness.  
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Helminth infection can evade the host immune responses through the action of Tregs. The 
induction of Treg cells is required for the establishment of chronic infection and depletion 
of Tregs leads to induction of protective immune response to helminths and worm 
expulsion (158). Maizels et al., in their study showed that neutralization of Treg derived  
IL-10 and TGFβ in vivo restored the anti-parasite response, suggesting the 
immunosuppressive roles of those cytokines which are mediators of Treg-induced 
immunoregulation in helminth infection (159). 
During this acute stage of infection, macrophages have an alternatively activated 
phenotype (M2 type) which is more consistent with wound healing, but also inducing the 
differentiation of Tregs. Helminth infection induces  alternatively activated macrophages 
with nitric oxide (NO) synthase (NOS2) suppression, downregulates the expression of  
Toll- like receptors on APCs and T cells, induces  apoptosis of DCs, T cells and NK cells 
and mediate anergy of cognate T cells (160). The Type 2 response is very important in 
enabling host tolerance of the extensive tissue damage caused by the helminths during 
their life cycle and also in their migratory phase to different primary organs. However the 
prolonged type 2 immune response in chronic infection may also lead to immune 
pathology and fibrosis (161). 
1.4.3.1 Responses to tissue injury 
Helminths cause significant tissue damage during feeding and migration in the intestine, 
which can trigger the release of danger-associated molecular patterns (DAMPs) and 
cytokine alarmins (IL-25, thymic stromal lymphopoietin (TSLP) and IL-33) (162). 
Cytokine alarmins are rapidly released by endothelial and epithelial cells as well as 
necrotic cells following tissue damage and mast cells in response to helminth 
infection(163). Intestinal epithelial cells form the initial barrier between the lumen and 
intestinal tissue and may also be a source of cytokine alarmin production(164). These 
alarmins then activate innate lymphoid cells and other cell types like eosinophils and 
basophils to secret IL-4, IL-5 and IL-13 resulting in activation and differentiation of Th2 
cells and also further amplification of type 2 adaptive immune responses. Activated DCs 
and other innate immune cells migrate from the lamina propria and Peyers Patches to 
regional lymph nodes through lymphatic vessel (165).  
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It is apparent that humans have a robust cytokine alarm system to tissue injury that will 
activate a type 2 immune response in the absence of a more dominant type 1 trigger 
(166). Patel et al., in their study linked the cellular damage caused by helminths to the 
induction of protective immunity in nematode infection and demonstrated that release of 
extracellular adenosine was associated with induction of a Th2 response (167). Helminth 
products can induce Th2 responses in the absence of injury (168)(169). The potentially 
damaging large multicellular organisms may induce a response that resembles a reaction 
to injury. The three major alarmins are IL-33, IL-25 and TSLP. 
1.4.3.2 Interleukin 33 (IL-33) 
IL-33 is a member of the IL-1 family and its receptor is ST2, which  is expressed on mast 
cells, Th2 cells and ILCs and can be highly upregulated on macrophages by Th2 
cytokines (162)(170)(171). Mice lacking ST2 fail to develop primary Th2 responses or 
form Th2 dependent lung granulomas in response to intravenous administration of 
Schistosoma eggs (172). Yin et al., demonstrated that the responses elicited by IL-33 also 
impact on the repair process and this was evidenced by accelerated wound repair 
following  administration of IL-33 (173). There is also emerging evidence that IL-33 is 
also playing an important role in epithelial restoration and mucosal healing in the gut. In 
Trichuris muris infection, IL-33 mRNA was observed to be elevated during early 
infection and administration of rIL-33 resulted in accelerated clearance of the parasites 
(174). Worm expulsion was mediated by IL-13 production by both ILCs and CD4+T cells 
which in turn increases production of the anti-worm effector molecule Resistin-like 
molecule b (RELMβ) by intestinal epithelial cells. RELMβ exerts its anti-helminth effect 
by interfering with parasite feeding on host tissues or it may block pore-like structures 
with chemosensory function and chemotaxis.  IL-33 is critical in worm expulsion and also 
acts to minimize host  damage early in infection (175). 
1.4.3.3 Interleukin 25 (IL- 25) 
IL-25 is a member of the IL-17 cytokine family and produced by epithelial cells. Unlike 
IL-33, it also induces the production of Th2 cytokines by ILCs and it acts as a sensor  of 
epithelial disruption (176). Owyang et al., in their study showed that when mice 
susceptible to Trichuris spp. were treated with IL-25, they could effectively expel the 
parasite, while IL-25 deficiency prevented worm expulsion. They also demonstrated that 
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IL-25 can limit the intestinal inflammation and tissue damage in the colon (177). IL-25 
also promotes allergic responses that can lead to tissue damage and remodelling, fibrosis 
and wound repair (178). 
TSLP is a member of the IL-2 cytokine family expressed predominantly by epithelial 
cells in the lung, gut, liver, central nervous system, etc. where it suppresses inflammatory 
type 1 responses and promotes Th2 responses in response to tissue injury and is also 
associated with protection of mucosal surfaces (179). TSLP amplifies type 2 effector 
responses by enhancing the polarizing effects of IL-13 on macrophages. Mice infected 
with T.muris showed more susceptibility to infection when TSLP was blocked and TSLP 
receptor-deficient mice have enhanced worm burdens (180). In TSLP receptor deficient 
mice, liver fibrosis induced by deposition of Schistosoma eggs and reduced IL-13 
production was observed (181). Neutralization of TSLP resulted in a significant reduction 
in the number of fibrocytes and in skin fibrosis and this tissue remodelling function was 
mostly due to TSLP receptor expression on fibrocytes (182). 
 
1.4.3.4 Innate lymphoid cells (ILCs) 
ILCs are a distinct group of innate cells that display transcriptional and functional 
attributes directly related to the adaptive T helper effector cells, Th1, Th2 and Th17. 
ILC2s can produce IL-5, IL-9 and IL-13 like Th2 cells and require GATA-3 for lineage 
commitment. They also play an important role in induction of adaptive Th2 cells after 
lung allergen exposure and also promote worm expulsion from the gastrointestinal tract 
(183). IL-13 producing ILC2s promote goblet cell mucus secretion and smooth muscle 
contraction and help in worm expulsion.  ILC2s are the predominant IL-9 producing cells 
in the lung. Mice lacking the IL-9 receptor failed to repair the lung damage after larval 
migration, with  delayed worm expulsion and more pathological inflammation in the 
lungs (184).There were also significantly reduced numbers of eosinophils and IL-4Rα 
activated macrophages as measured by RELMα expression, as a result of reduction of 
ILC leading to insufficient IL-5 and IL-13 production and failure to induce a sufficient 
adaptive immune response (51) . 
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1.4.4  Antibody responses in helminth infection 
 IgG1 (in mouse), IgG4 (in human) and IgE antibody responses are a feature of helminth 
infection. Helminth-associated Th2 cytokine responses with IL-4 activation of 
transcription factor STAT6 , are classically associated with class switching in B cells to 
produce IgG and IgE (186). IgE is a primary mediator that binds FcReI on mast cells and 
basophils.   Antigen crosslinking of FcReI-bound IgE triggers mast cell degranulation and 
the release of soluble mediators. In the presence of Th2 responses, there is enhanced IgE 
production resulting in vascular permeability, smooth muscle contractility and also the 
recruitment of Th2 type effector  cells including eosinophils and Th2 cells (187). There is 
variable protection conferred by IgE in different studies. Anthony et al., demonstrated 
that IgE  against helminth infection is not essential for protection against helminth 
infection in mice (188). On the contrary, there are studies such as  where following 
H.polygyrus infection in mice, IgE and IgG1 were observed to promote expansion of 
basophils and provide protective immunity against the helminths (189). 
IgM is the primary antibody type that recognizes larval parasites and might be produced 
in a T-cell independent manner. IgM might be important for macrophage recognition of 
filarial parasites and macrophages express Fc receptors for IgM. Lack of secretory IgM 
results in significant impairment of Brugiya pahangi larval expulsion and is finding was 
supported by in vitro data, where IgM was the only antibody isotype able to bind to the 
parasite’s larvae (190). Polyclonal IgG1 and IgE have been shown to be protective during 
H.polygyrus infection; these antibodies reduce parasite reproduction by targeting egg 
antigens and also halt the development of adult worms (191)(192). 
Whether or not antibodies are protective during helminth infection remains controversial, 
as their function is not as well understood as the prominent Th2 response. In S.mansoni 
infection, administration of IgG2a in mice provides some protection accompanied by 
decreasing granuloma fibrosis (193). Ligas et al., in their study isolated IgM and IgG 
from mice vaccinated with S. stercoralis larvae and this was administered to naïve mice; 
they observed a high level of protection with larval killing via ADCC and it was evident 
that granulocytes and complement were less important (194).  
The profile of antibody isotypes is also an indicator of the regulated status of the host. In 
helminth infection, levels of IgG4 and IgE are important indicator of susceptibility to and 
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protection from infection. In helminth infection, IgE production by B cells is promoted by 
IL-4 and IL-13, but in the presence of regulatory cytokines IL-10 and TGFβ, a switch to 
IgG4 is favoured. IgG4 cannot crosslink receptors on basophils, mast cells and 
eosinophils, does not activate complement or act as an opsonin. IgG4 antibodies  are 
important markers of the Th2 state, potentially blocking IgE and preventing potentially 
damaging inflammation (195). In one study it has been shown that IgG4 titres fall rapidly 
following curative anthelmintic drug treatment.  It was suggested that high levels of IgG4 
in helminth infected patients reflect a dominant regulatory environment (196). 
Although a humoral antibody immune response is typically associated with Th2 type 
responses during the infection, antibodies do not appear to have an essential role in 
helminth protective responses. This response varies with the specific parasitic helminth, 
developmental stages in the host or intensity of infection (197). 
1.4.5  Deficient Acquired Immunity 
In helminth infection, the immune system is unable to clear chronic infections and 
immune memory fails to protect against reinfection even after drug mediated clearance.  
However, effective immunity significantly reduces the parasite burden as is demonstrated 
by irradiated larval or cercarial vaccines in animal models of schistosomiasis. Deficient 
immunity reflects inadequate Th2 responses. The resistance of Schistosoma infected 
patients to reinfection following drug cure correlates strongly with the production of IL-4 
and IL-5. During chronic helminth infection, the Th2 response is downregulated and 
protective immunity is compromised (66)(199)(200). A study on Schistosomiasis showed 
that protection from infection was associated with both  Th1 (IFNg) and Th2 (IL-4 and 
IL-13) gene polymorphisms which indicates the possibility of Th1 derived components 
contributing to immunity to Schistosomes (201). Resistant individuals mount strong IFNg 
responses to parasite antigens, indicating that both Th1 and Th2 arms may be modulated 
in susceptible individuals (202). A link between T cell anergy and the immunoregulatory 
environment in helminth infections is suggested by the strong correlation between IgG4 
levels and unresponsiveness. This hyporesponsiveness can be reversed by the 
chemotherapeutic removal of the parasite burden, which argues that it reflects a direct 
effect of live parasites rather than an inherent incapacity of the host to respond to 
infection (203).  
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In human Schistosoma infection, CD4+CD25high cell frequencies were significantly 
reduced after drug cure of S.mansoni infection, while in children, CD4+ CD25 high 
CD127-Foxp3+ proportions were positively correlated with the S.haematobium parasite 
burden (204). In Schistosoma infection, in adults who were resistant to reinfection to 
parasite, Treg proportions were negatively correlated with infection intensities. Treg 
proportions are also reduced upon infection due to the expansion of the T effector 
population (204). 
1.4.6  Dampening bystander responses in humans 
Helminth infection has immunoregulatory effects on bystander responses in humans 
including those of both immunopathogenic and protective natures. Coinfection with 
helminths suppresses antibacterial, antiviral and antiprotozoal and antitumor immunity 
leading to increased susceptibility and attenuated immunopathology or if there is high 
infection burdens there may be exacerbated pathology.  
There is a growing concern in developing countries that helminth infection may interfere 
with childhood vaccination. It has been observed that in Schistosoma infection, there was 
a weaker IFNγ response to tetanus immunization (205). A similar effect was evident in 
other helminth infections like onchocerciasis, lymphatic filariasis etc., where higher level 
of IL-10 was produced. In mouse models, S.mansoni infection interferes with the 
protective effect of BCG vaccination and there were depressed antimycobacterial T cell 
responses with concomitant increases in TGFβ levels (206). 
1.4.7  Cellular basis of immunomodulation 
1.4.7.1 Dendritic cells (DCs) 
The immunomodulation and stimulation of the host immune system by helminths is 
predominantly determined by the DC population. The depletion of DCs inhibits the Th2 
responses to infection. In Schistosoma infection, lysophosphatidylserine of the parasite 
acts on human DCs to promote IL-10 producing Tr1 cells and the egg molecule ω-1, 
drives murine DCs to induce FoxP3 expression in T cells in vitro (207). DCs are also 
influenced by host “alarmin” such as TSLP. Helminth-specific pattern recognition 
receptors include TLR, C-type lectin receptors (CLRs) and the class A scavenger receptor 
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(208).Certain helminth products also interfere with DC function by blocking antigen 
processing or degrading mRNAs within the host (209). 
Helminths can also secrete a variety of excretory/secretory (ES) products that can directly 
stimulate DCs and macrophages and which can also activate naïve CD4+T cells to 
differentiate into Th2 cells in the presence of IL-4 and / IL-13 (210). These ES products 
can also inhibit DC production of IL-12, costimulatory molecules and factors required for 
Th1 cell differentiation. Helminth derived molecules have been shown to promote 
tolerogenic DCs that promote T cell anergy and the induction of Tregs cells(139). In a 
mouse model, Schistosoma infected TLR-2 deficient mice were less capable of inducing 
Treg cells and exhibited more pronounced immunopathology than the infected wild type 
mice (211).  
1.4.7.2 Alternatively activated macrophages (AAMs) 
AAMs are distinct from classical macrophages in expressing higher level of arginase 1, 
IL-4Ra, the mannose receptor (CD206), the chitinase like molecule Chi3L3 (Ym1) and 
the resistin like molecule RELM-α (212). IL-4, IL-13, IL-10 and IL-21 trigger AAMs. 
AAMs regulate the immune response, wound healing and resistance to parasite invasion. 
In RELM-α deficient mice, there is an exaggerated Th2 response to Schistosome infection 
(213). AAMs can contribute to wound healing by clearing matrix components, cell debris 
and by releasing cytokines, growth factors and angiogenic factors that promote fibroplasia 
and angiogenesis. AAMs may also mediate more direct effects on tissue dwelling 
nematodes by targeting the glycan chitin. AAMs secrete chitinase and chitinase like 
secreted proteins like fizz family member proteins (ChaFFS)–all these mediate resistances 
to helminth infection and promote the Th2 type inflammatory response. When arginase 
function was inhibited it was observed that protection against the tissue dwelling 
nematode, H.polygyrus was also blocked. This study also demonstrated that Th2 cell-
derived IL-4 drives AAMs, which then in turn contributes to parasite clearance through 
an arginase-1-dependent pathway (214).  
1.4.7.3 Regulatory T cells  
Nematode infections can induce and expand naturally occurring regulatory Treg cells in 
humans suggesting a role for these regulatory T cells in helminth-induced modulation of 
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inflammatory diseases. In mice infected with Schistosoma, FoxP3+Tregs are recruited to 
the draining lymph nodes and the periphery of egg induced granuloma in the liver and 
these Tregs  can also control granulomatous pathology at the intestinal stage and reduce 
the size of the granuloma which is correlated with increased CD4+CD25+CD103+ 
FoxP3+cells (215). In the mouse model, the Th2 responses in later stages of chronic 
Schistosoma infection are progressively downregulated and granulomas reduce in size 
and this downregulation is mediated by both regulatory cells and cytokines like IL-10. 
Treg depletion with anti CD25 antibody results in decreased egg production and increased 
granulomatous pathology. Th1 and Th17 dominated inflammatory responses can also be 
fatal in Schistosoma infection. 
An expansion of CD4+ FoxP3+Tregs is also seen in gastrointestinal infection with S.ratti 
in the intestine of mice (216). Depletion of Tregs in mice immediately after infection with 
S.ratti resulted in expression of protective immunity. The blockage of both IL-10 and 
TGFβ increases the resistance to the parasite. In T.muris infection, Tregs accumulate in 
the lamina propria. Depletion of Tregs does not enhance worm expulsion but provokes 
increased gut pathology, indicating that conventional Tregs in this infection control 
pathological but not effective anti-parasite immune responses (217).  
1.4.7.4 Regulatory B cells 
B cells also produce inflammatory and immunoregulatory cytokines, for example as IL-
10 producing B cells. In murine S.mansoni infection, transfer of S.mansoni induced Bregs 
induced the recruitments of FoxP3+Tregs to the inflammatory airways in an IL-10 
dependent manner. This IL-10 in Schistosoma infection, was further shown to be 
important for expansion of IgG1 producing plasma cells in the liver and also for the 
suppression of granulomatous responses during chronic infection (218).Thus both 
immunoregulatory cytokine production and antibody production by B cells are important 
for immunomodulation in chronic Schistosoma infection. 
1.4.7.5 CD4+ T helper effector cells 
Effector Th2 cells induced by helminths are characterized by the production of IL-4, IL-5, 
IL-9, IL-13 and IL-21 and the absence of IFNg and IL-17 production. Autocrine IL-4 
produced by antigen-specific CD4+T cell supports Th2 cell differentiation and expansion 
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during N.brasiliensis infection (188). It has been shown that the expulsion of 
gastrointestinal nematodes is dependent on a T cell response. During helminth infection, 
Th2 cells help the activation and expansion of leukocytes primarily through the 
production of cytokines which is an essential function that serves to amplify and sustain 
the Th2 type response.  Th2 cell-derived IL-4 and IL-13 contribute in a STAT6- 
dependent manner, which is characteristic of helminth infection, in which increased 
luminal fluids and muscle contractility, make the intestinal lumen an inhospitable 
environment for the helminth parasite. This response decreases worm viability and 
increases worm expulsion, rather than killing the parasite. In Schistosoma infection, the 
CD4+T cell response stimulates parasite development and results in an inflammatory 
environment that is required for translocation of helminth eggs from the intravascular 
compartment into the intestinal lumen (219). In the Th2 polarized environment, the 
granulomatous inflammation around eggs helps the parasite to complete its life cycle and 
the same time protects the host from severe, lethal disease. Babu et al.,suggested that Th2 
cells primarily downregulate harmful Th1 and Th17 type inflammatory response either 
directly or through innate immune cell populations (220).  
1.4.8  Innate effector cells in helminth infections 
1.4.8.1 Eosinophils 
The innate immune cells that are typically associated with Th2 type responses, 
eosinophils, basophils and mast cells, have an important role in anti-helminth responses. 
Eosinophils are equipped with receptors for cytokines, chemokines, immunoglobulin, 
complement and serine proteases, that enables them to be recruited into affected tissue 
sites and release granular contents mostly cytotoxic cationic proteins like major basic 
protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) and 
eosinophil derived neurotoxin (EDN).  In helminth infection, ligation of parasite specific 
immunoglobulins to Fc receptors is also important for antibody dependent cellular 
cytotoxicity (ADCC), which results in activation of eosinophils. Following helminth 
infection, eosinophil numbers increase in the blood and they rapidly migrate to the site of 
infection, where they degranulate and release secondary granule proteins 
(ESGPs)(221)(222)(223). In Strongyloides infection, depletion of eosinophils with 
antibodies specific for CC-chemokine receptor 3 (CCR3) resulted in increased 
susceptibility to infection (224). Reiman et al., described the regulatory role of eosinophil 
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by production of cytokines including IL-4 and IL-13 and  also to  present antigen to 
S.stercoralis (225). Eosinophils also play important roles in tissue remodelling, debris 
clearance and mediate the wound healing responses following helminth tissue invasion. 
1.4.8.2 Mast cells and Basophils 
Basophils  share many features with mast cells including  FcRa1 expression, the TLRs- 
TLR2 and TLR4 and the capacity to secrete  reactive oxygen and nitrogen species, Th2 
cytokines and histamine (226). During helminth infection, increased numbers of mucosal 
mast cells are observed which is dependent on Th2 type cytokines, primarily derived from 
CD4+ T cells. In H.polygyrus infection in mice, an increased number of mast cells were 
observed  in or near granulomas in which larvae develop (227). Karasuyama et al., in their 
study indicated the important role of basophil in the Th2 polarization of the immune 
response mainly by secreting IL-4 (228). Basophils contribute to the most of the symptoms 
of allergic inflammation through the release of leukotrienes and histamines and play an 
important role in inducing class switching to IgE in B cells. 
1.4.8.3 Neutrophils 
Neutrophils are also activated and are recruited to sites of infection during tissue invasion 
by helminths (229). Galioto et al., demonstrated that neutrophils play an important role in 
the killing of the larval stages of S.stercoralis (224), whereas Herbert et al., in their study 
showed that in infection with S.mansoni, neutrophils had little or no effect in their larvae 
killing (230). Neutrophils are recognized as important cells attracted to sites of helminth 
invasion.Along with other cell population including eosinophils and macrophages, 
neutrophils can potentially directly damage tissue dwelling helminths (188). Because of 
their predominant phagocytic role in terms of microbial pathogens, neutrophils are often 
overlooked in helminth infections, although this is now being addressed in animal studies. 
1.5   Schistosomiasis 
Schistosomiasis or bilharzia, is a disease caused by trematodes of the genus Schistosoma. 
Human Schistosomiasis is caused by five species of Schistosoma: the intestinal species: 
S.mansoni, S.japonicum, S.mekongi and S.intercalatum and the urinary species 
S.haematobium.  
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Human infection is initiated by penetration of intact skin with infective cercariae. These 
organisms that are released from infected snails in fresh water possess anterior and 
vertical suckers that attach to the skin and facilitate penetration. Once in the skin, 
cercariae transform into Schistosomula with morphologic, membrane and immunologic 
changes.  Schistosomula begin their migration within 2-4 days via venous and lymphatic 
vessels, reaching the lung alveoli and finally the liver parenchyma. Sexually mature 
worms then descend into the venous system at specific anatomic locations: intestinal 
veins in S. mansoni, S.japonicum, S.mekongi and S.intercalatum infection and in the 
vesical veins for S.haematobium. After mating, adult females travel against venous blood 
flow to the venous wall, where they deposit their ova intravascularly. These ova then 
move through the venous wall, traversing host tissues to reach the lumen of the intestinal 
or urinary tract and are voided with stools and urine. The ova that are retained in the 
tissues, are carried by the venous blood flow to the liver or other organs. Schistosoma ova 
that reach fresh water hatch, releasing free living miracidia that search for the snail 
intermediate host and undergo cycles of asexual multiplication. Finally, the infective 
cercariae are shed from the snails. 
The global distribution of Schistosoma infection in human is mostly dependent on 
parasite and host factors. They are estimated to infect 200-300 million individuals in 
South America, the Caribbean, Africa, Middle East and Southeast Asia. Intensity of 
infection follows the increase in prevalence up to the age of 15-20 years and then declines 
markedly in older age groups. Most infected individuals harbour low worm burdens and 
only a small portion suffer from high intensity infection depending on the worm 
infectivity or to a genetic susceptibility in human populations. 
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Figure 1.8: Global distribution of Schistosoma infection (2011) (231). 
 
Adult worms residing in the venous environment are protected from immune attack. 
Multiple factors are important in long-term survival of the worm in the hostile host 
environment such as their  ability to continuously regenerate their outer tegument through 
unique somatic stem cells (232), molecular mimicry (225), by acquiring host antigen 
(234)(235), isotypic shifts in antibody specificities and manipulating host immune 
response immunoregulation (236)(237).  
The associated antigen excess results in formation of soluble immune complexes, which 
may be deposited in different tissues. In chronic infection, most disease manifestations 
are due to egg retention in host tissues. The granulomatous response around the ova is cell 
mediated and is regulated by a cascade of cytokine, cellular and humoral responses. 
Granuloma formation starts with recruitment of inflammatory cells, phagocytes, antigen-
specific T cells and eosinophils followed by fibroblasts, giant cells and B cells in 
response to helminth antigens secreted within by the ova (238).The eggs contain a variety 
of proteases and toxic moieties, which when they are lodged into the tissues may lead to 
necrosis. The host defence comes in the form of granuloma formation, to wall off and 
contain the egg and the proteolytic enzymes they carry (239). The symptology of 
Schistosomiasis is attributed to the egg induced granulomatous inflammatory response 
and associated fibrosis and although these granulomas are detrimental to the infected host 
they also serve  an important host protective-function during Schistosoma infection (240). 
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In areas, endemic for schistosomiasis, in the absence of intervention, this is primarily a 
chronic disease that can persist even for decades.This chronicity largely depends on the 
repeated exposure to the cercariae and the longevity of adult worms (241). 
1.5.1  Immunological aspects of Schistosomiasis 
Animal studies have demonstrated a moderate Th1 response to parasite antigens but there 
is also a robust Th2 response to egg-derived antigens that dominates and induces 
fibrogenesis in the liver (242)(243). In immunocompetent wild type (Wt) mice, a shift 
from a moderate Th1 to a robust Th2-dominant response to Schistosome antigens was 
observed at the onset of egg laying around 5-6weeks after infection (244). Th2 cytokines, 
like IL-4, IL-5 and IL-13 have long been related to fibrosis and to much of the pathology 
(245). In mouse study, vaccination with parasite eggs and IL-12 inhibited the Th1 to Th2 
shift and resulted in hepatosplenic pathology following infection. It was also 
demonstrated in the study that the IL-4/IL-1 mediated STAT6 pathway plays a critical 
role in the development of a granulomatous response and the resulting fibrosis observed 
in Schistosoma infection (246). IFNg may also contribute to granuloma formation, as it 
was shown that  IFNg deficient mice had reduced granuloma sizes (247). 
In IL-10/IL-4 double knockout mice, with  polarized Th1 responses, immunization with 
soluble egg antigen (SEA) in complete Freunds Adjuvant (CFA) also skews the T-cell 
response, resulting in increased inflammation, larger granuloma, extensive pathology and 
severe morbidity (248).  
Deposition of fibrotic material in the extracellular matrix results from the interaction of T 
lymphocytes with fibroblasts and elevated levels of cytokines like IL-2, IL-4, IL-1 and 
TGFb, IL-5, IL-10 and IL-13, whereas higher IFNg levels or IL-12 may play a role in 
modulating the fibrogenesis (249)(250)(251)(252). Maintaining a balanced and controlled 
Th1 and Th2 response is critical for protective granuloma formation without excessive 
pathology (244). 
Egg deposition in the liver also increases the number of AAMs (253). Mice that were 
deficient in macrophage specific IL-4 signalling or in IL-10/IL-4 double KO mice, failed 
to induce arginase expression, suggesting the requirement for Th2 cytokines in arginase 
production following Schistosoma infection (230)(254). Th1 skewed mice displayed 
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enhanced iNOS responses that were associated with smaller granuloma sizes and 
accelerated mortality (254). Lie et al., have demonstrated that Fizz1 expression may be 
important in fibrogenesis, fibroblast differentiation, increased expression of a-smooth 
muscle actin and type 1 collagen, as well as also having some anti-inflammatory 
properties suppressing antigen-specific T cell proliferation in Schistosoma infection in 
vitro (255). Macrophages in Schistosoma infection, play a dual role as an anti-
inflammatory cell as well as by sequestering egg products and helping development of 
granuloma followed by adopting an anti-inflammatory role during chronic infection and 
by indirectly suppressing the function of other cells like T cells and B cells  and 
decreasing the granuloma size (244). 
Newly formed liver granulomas surrounding entrapped eggs decrease in size as the 
infection progresses into the chronic stage. This ‘endogenous desensitization’ is the 
hallmark of granulomatous infection and is critical for host survival in persistent diseases. 
IL-13Ra plays an important role in granuloma downregulation. S.mansoni infected mice 
that are IL-13Ra2-/- fail to undergo this granuloma downregulation. Their granuloma size 
continues to increase as the infection becomes chronic. This defect in granuloma 
modulation suggests that control of IL-13 is required for survival during chronic infection 
with S.mansoni (256)(257). 
Regulatory T cell (Tregs) involvement in chronic Schistosoma infection, is related to 
dampening antihelminth effector responses, allowing chronic infections to develop (258). 
In Schistosoma infection both inducible and natural Tregs play an important role in 
suppression of DC cell activation, the organizing and regulation of Th2 effector 
responses, granuloma development and fibrosis.CD4+CD25+Foxp3+Tcells show 
prominent expansion especially in liver and spleen at 4 weeks post infection with 
S.mansoni (259). The highly immunogenic SEA may be the main potent inducer of both 
effector and Tregs cell during infection (260).  
IL-10 plays an immunoregulatory role during S.mansoni infection and critically regulates 
the liver pathology. The majority of the IL-10 producing T cells appear to be FoxP3+ and 
constitute inducible Treg cells and/or Th2 cells (154). Hesse et al., demonstrate that 
CD4+ cells produce a significant proportion of the IL-10 in S.mansoni infection(261). 
However, non CD4+ derived IL-10 is also an important source of IL-10. IL-10 is very 
important for the control of DC derived IL-12, generation of Th1 responses during 
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infection, and also to skew the T cell response towards a Th2 type (262). IL-10 secreting 
CD4+CD25+T cells were also isolated from the granuloma of chronically infected mice, 
that could suppress the proliferation of naïve CD4+T cells.The accumulation and 
suppressive properties of these cells isolated from the liver of infected mice suggested 
that the roles of Treg cells actively migrate to the inflammatory site to regulate the 
development of liver granuloma in Schistosoma infection (259)(262).   
However, apart from Treg–mediated suppression of T cell function and proliferation in 
Schistosome infection, Tregs cells may also influence the function of macrophages, 
CD8+ cells, B cells and eosinophil recruitment.  The precise mechanism of regulatory T 
cells mediated suppression during Schistosoma infection is still unclear (244). 
A number of studies have suggested that worm death occurring either naturally or upon 
treatment, leads to the release of immunogens that stimulate protective responses 
depending on the exposure histories, different source of transmission, etc. 
(236)(263)(264)(265). Resistance to reinfection with S.mansoni is mostly Th2-associated. 
An association between eosinophils and parasite-specific IgE was observed in studies of 
Schistosoma reinfection. Both high and low affinity IgE receptors on eosinophils and B 
cells were associated with protection against reinfection. Susceptibility to reinfection was 
also associated with IgG4, which serves as a blocking antibody and inhibits the action of 
IgE.  
1.5.2  Clinical features 
During the phase of cercarial invasion, a form of dermatitis called Swimmers’ itch is 
observed in infection with S.mansoni and S.japonicum. This symptom develops usually in 
the first 2 or 3 days after invasion as an itchy maculopapular rash on the skin of the 
affected areas. Cercarial dermatitis is self-limiting. During worm maturation and 
deposition, (4-8 weeks after skin invasion), acute schistosomiasis or Katayama fever-with 
serum sickness like symptoms develops. This also presents with fever, generalized 
lymphadenopathy and hepatosplenomegaly. Individuals with acute Schistosomiasis show 
elevated levels of eosinophils and parasite specific antibodies may be detected at this 
stage. 
The clinical manifestations of chronic Schistosomiasis are species dependent and may 
begin after few months of infection, lasting for years. Intestinal species cause intestinal 
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and hepatosplenic disease. During the intestinal phases, symptomatic patients have 
colicky abdominal pain, bloody diarrhoea and anaemia. The severity of infection depends 
mostly on the intensity of the helminth burden. 
The clinical manifestation of S.haematobium appears early and involves a high 
percentage of infected individuals. The symptoms manifests as terminal haematuria and 
dysuria. The manifestation correlates with intensity of infection and the presence of 
urinary granulomas.  In many endemic countries, an association between squamous cell 
carcinoma and S.haematobium has been observed.  
1.5.3  Diagnosis 
Individuals with Schistosoma infection are diagnosed by endemic country travelling 
history, characteristic clinical presentation, and presence of Schistosoma ova in urine or 
faeces, detecting eggs in rectal biopsy or bladder mucosal biopsy. Filtration techniques 
like Kato-Katz thick smear, Nucleopore filtration etc are used for detecting and 
quantifying Schistosoma eggs. These methods may provide quantitative data on the 
intensity of infection, which is important in monitoring tissue damage and effect of 
chemotherapy. Serological tests using Schistosoma antigens like SEA, AWA antigens are 
also used for laboratory diagnosis. 
1.5.4  Treatment 
Treatment of Schistosomiasis depends on the stage of infection and the clinical 
presentation. The drug of choice is praziquantel that is administered per orally as a total 
of 40 to 60mg/kg in two or three doses over a single day. Praziquantel treatment results in 
parasitological cure in 85% of cases and reduces egg counts by >90%. The effect of 
antischistosomal treatment on disease manifestations varies by stages of the disease. A 
follow up visit with a health care worker is advised, if there is a history of exposure. 
Several control measures have been proved to be useful such as application of 
molluscicides, provision of clean water, sewage disposal, chemotherapy and health 
education. 
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1.6   Strongyloidiasis 
Strongyloides spp is a nematode that is unique among other helminths in being able to 
replicate in the human host. This unique capacity permits ongoing cycles of autoinfection 
as infective larvae are produced internally. Strongyloides spp thus can persist for decades 
in human hosts without further exposure of the host to endogenous infective larvae(266). 
The estimated prevalence of Strongyloidiasis has been estimated to be around 370 million 
infections worldwide (267). 
1.6.1  Epidemiology 
S.stercoralis is distributed in tropical areas and hot, humid regions of sub-Saharan 
Africa, Brazil, The Caribbean, Latin America and Southeast Asia. The parasite is 
found in USA mostly in immigrants, refugees, travellers and military personnel who 
have lived in endemic areas. A study conducted in the USA, observed that about 46% 
of 462 Sudanese and 23% of 100 Somali Bantu refugees were infected with S. 
stercoralis(268). This highlights the potential hazards of the transportation of this 
parasite across borders in mass population movement (269). S.fuelleborni can cause 
human infection and is mainly found in Africa and Papua New Guinea (270). Humans 
normally acquire Strongyloidiasis when filariform larvae in faecally contaminated soil 
penetrate the skin or mucus membranes. 
Predisposing factors for Strongyloidiasis are living in an endemic region, chronic 
malnutrition,malignancies, organ transplantation, diabetes mellitus, chronic 
obstructive pulmonary disease (COPD), alcoholism, chronic renal failure and breast 
milk from an infected mother (266)(271). 
1.6.2  Life cycle 
Strongyloides spp have a parasitic cycle of development and can also undergo a free 
living cycle of development in the soil. Rhabditiform larvae passed in the faeces can 
transform into infective filariform larvae either directly or after a free living phase of 
development. The larvae after entering through skin and mucus membranes, travel 
through the bloodstream to the lungs and alveolar spaces, then they ascend the 
bronchial tree, are swallowed and then travel to the small intestine. There the larvae 
mature into adult worms that penetrate the mucosa of the proximal small bowel. The 
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adult worms reproduce by parthenogenesis. Egg hatch in the intestinal mucosa and 
release rhabditiform larvae that migrate to the lumen and pass out through the faeces. 
Alternatively, rhabditiform larvae in the bowel can develop directly into filariform 
larvae that penetrate the colonic wall or perianal skin and enter the systemic 
circulation to establish the internal reinfection. This autoinfection cycle allows the 
nematode to persist for decades (270)(271)(272). 
 
1.6.3  Clinical manifestations 
The spectrum of Strongyloidiasis includes acute infection with Loeffler’s syndrome, 
chronic intestinal manifestations, symptomatic autoinfection and hyperinfection with 
dissemination (273)(274) .  
In uncomplicated Strongyloidiasis, many patients are asymptomatic or have mild 
cutaneous and/or abdominal symptoms. Recurrent urticaria is the most common 
cutaneous manifestation. Migrating larva can elicit a pathognomonic serpiginous eruption 
called “larva currens”. Adult parasites burrow into the duodenojejunal mucosa and can 
cause abdominal pain (which resembles peptic ulcer pain), discomfort, bloating, nausea, 
vomiting, diarrhoea, anorexia etc. Pulmonary symptoms are rare in uncomplicated 
infection, although intermittent eosinophilia is very common (272). 
Hyperinfection syndrome is usually observed in patients who are on corticosteroid 
therapy or co-infected with Human T Cell Lymphocytic virus 1 (HTLV-1). This invasive 
form is characterized by a spectrum of gastrointestinal complaints including abdominal 
pain, dyspepsia, diarrhoea, constipation, intestinal obstruction, enteritis and/or 
gastrointestinal bleeding. Many patients have worsened pulmonary symptoms like 
haemorrhagic pneumonitis, respiratory failure, etc.(275). Invading larvae can be 
transported to the blood and reach the peritoneum, liver, kidney and central nervous 
system, causing meningitis. In immunosuppression and in HTLV-1 co-infection induces 
strong Th1 responses and weakens Th2 responses, which leads to increased secretion of 
type 1 cytokines and decreases in type 2 cytokines. Decreases in IL-5, IgE, diminished 
mast cell function and reduced eosinophil recruitment all together  cause inadequate host 
responses, which may predispose the co-infected patients to greater parasite burdens, 
organ damage, bacteraemia and death (274).  
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1.6.4  Immunopathogenesis 
Animal studies have suggested a role for innate and acquired/adaptive immune 
mechanisms in mediating resistance to Strongyloidiasis. The innate response is primarily 
mediated by eosinophils and IL-5, with neutrophils and macrophages playing 
supplementary roles. Messias et al., have shown that in Strongyloides infection human 
peripheral blood mononuclear cells and neutrophils adhere to S.stercoralis larvae 
following complement activation, but although this could result in decreased motility, it 
was not sufficient for larval killing (276). However, in vitro studies have shown that, 
when human PBMC or macrophages are complemented with neutrophils, they can kill the 
larvae, both in humans and mice. Parasite killing was also observed in mice, when 
BMDM were cultured with PBMC and neutrophils; complement component C3b was 
observed to be required for larval killing during the primary and secondary immune 
responses (277).  
Complement dependent adherence of macrophages and neutrophils to the larval surface 
may stimulate the release of cytokines or soluble factors. Neutrophil derived 
myeloperoxidase and eosinophil derived major basic cationic protein have been shown to 
be required for cells to kill the parasite (278). 
It is hypothesised that the parasite can trigger a potent immune response in the gut that 
stimulates activated GI-associated DCs to migrate through lymphatic ducts to stimulate 
Th2 cells and regulatory T and B cell responses in the draining lymph nodes (279).  
The adaptive immune response to Strongyloidiasis specifically involves type 2 responses, 
with Th2 cells secreting Il-4, IL-5 and IL-13, B cells producing IgG and IgE and  innate 
lymphoid cells secreting IL-5 and IL-13 (280). Eosinophils may serve as an antigen 
presenting cell and are required for an optimal antibody response in Strongyloidiasis.  
Strongyloides infection can produce a high level of eosinophilia, mucosal mastocytosis 
and control of Th1 mediated excessive inflammatory reactions. Strongyloides infection 
can also stimulate Tregs, cells that reduce injurious host inflammatory and immune 
responses through cell to cell contact, inhibitory cytokines and/or cytokine deprivation. 
This prevents the immunes responses from causing bystander tissue damage during the 
host response. Tregs may also blunt Th2 responses such as the IL-5 dependent eosinophil 
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activation required to kill the parasite. Interplay between Th1, Th2 and regulatory T cell 
responses appears to be crucial in the immune defence against Strongyloidiasis (281).  
Studies have shown that Th2 responses play an important role in the hyperinfection 
syndrome and individuals with Strongyloidiasis may also develop specific antibodies of  
IgG, IgA and IgM and IgE isotypes (281)(282). Brigandi et al., showed that IgM and not 
IgG is protective at 1 week after booster immunization, whereas parasite-specific IgM 
and IgG are both protective 3 to 5 weeks after booster immunization (283)(284). 
Neutrophils have been shown to collaborate with IgG and complement in killing larvae. 
Yung et al., demonstrated that IgM mediated killing of parasites requires the interaction 
between the IgM on the surface of the parasite and its receptor on the macrophages, 
activating the cells to release toxic molecules to kill. Also the capacity of IgM to activate 
the complement system by cleaving C3 may also play an important role in parasite killing 
(285).  
AAMs are associated with Strongyloides infections, these function in modulating the Th2 
responses, reduce pathology by controlling fibrosis and also play an important role in 
wound healing following parasite mediated tissue destruction (286). It was reported in 
earlier studies that AAM had no role in killing helminths although they have shown to 
take part in worm expulsion in other nematodes (287). Sandra et al., demonstrated that 
AAM, but not CAM generated in vitro were capable of killing S.stercoralis larvae in vivo 
during  primary and secondary immune responses. They have also shown that 
macrophage and neutrophil function in killing is restricted to BMDM and AAM and that 
CAM inhibit parasite killing by neutrophils (288).  The highly motile larvae of 
S.stercoralis induced a systemic immune response following a subcutaneous injection in 
presence of AAM in the peritoneal cavity, indicating that AAM are found and maintained 
in the peritoneal cavity. Polarization of AAM in the peritoneal cavity was also dependent 
on IL-4/IL-13 signalling like in other helminth infections (289)(290). The signature 
markers of AAM-Relm-a, Arg-1 and Ym-1 were also studied for their role in 
Strongyloidiasis. The expression of Arg-1 and Relm-a was not required for parasite 
killing, but Relm-b was observed to significantly inhibit the chemotaxis of S. stercoralis 
larvae in vitro (291). 
Rajamanickam et al., examined the systemic cytokine levels of type 1, type 17 and pro-
inflammatory cytokines in Strongyloides infection and observed that S.stercoralis 
 70 
infection was associated with diminished proinflammatory cytokine responses and that 
helminth treatment showed an impact as the majority of these proinflammatory cytokines 
exhibited enhanced concentrations following treatment. Strongyloidoses was associated 
with profound alterations of systemic cytokine responses- the finding of which may relate 
with the auto-infective cycle seen in the nematode (292). ES products of S.stercoralis 
may also help to disseminate the parasites and contribute to the systemic cytokine 
responses (293). As the larvae migrate from lungs to intestine and propagate their life 
cycle in the intestine, a local immune response at these various sites may also contribute 
to the altered systemic responses in Strongyloides infection (292). Toulza et al., 
investigated the potential impact of helminth infection on immune response to Mtb in UK 
migrants who were LTBI patients with or without helminth infection.Patients with 
helminth infection showed a significant increase in CD4+FoxP3+T cells (Tregs) 
compared to those without helminth infection and there was a decrease in the frequency 
of Treg cells, and an associated increase in CD4+IFNγ+T cells after the anthelmintic 
treatment showing the potential role of Tregs in the immunopathogenesis in these patients 
(294).  
1.6.5  Diagnosis 
In uncomplicated Strongyloidiasis, detection of rhabditiform larvae in faeces is 
diagnostic- either by direct smear or formal-ether concentration technique. Rhabditiform 
larvae are 250µm long with a short buccal cavity that distinguishes them from larvae of 
hookworm microscopically. Serial stool examination increases the sensitivity of the 
detection. Charcoal agar media is used to detect Strongyloides larva. Strongyloides larvae 
can also be detected by sampling of the duodenojejunal contents by aspiration or biopsy. 
An enzyme linked immunosorbent assay (ELISA) for serum antibodies to antigens of 
S.stercoralis is a sensitive method of diagnosing uncomplicated infection (272). Sultana 
et al.,examined Strongyloidiasis in Bangladesh, using serological and faecal examination 
and observed that in stool specimens, larvae was detected in 23.1% patients by Harada-
Mori culture, 10.2% by agar plate culture and 0.7% by microscopy. They also detected 
Strongyloides specific IgG, IgG1 and IgG4 in 61.2%, 31.3% and 36.1% respectively of 
patientsby the ELISA method (295). Molecular methods like polymerase chain reaction 
(PCR) is now also being used for diagnosing Strongyloides infection. In disseminated 
Strongyloidiasis, filariform larva can be detected in stool and also from the sites of 
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potential larval migration, including sputum, broncho-alveolar lavage fluid or surgical 
drainage fluid (272).  
1.6.6  Treatment 
Even in asymptomatic Strongyloidiasis, it is recommended to treat patients to prevent the 
subsequent fatal hyperinfection syndrome. Ivermectin (200µg/kg daily for 2 days) is more 
effective than albendazole (400 mg daily for 3 days). For disseminated cases, the dose for 
ivermectin is prolonged to 5-7 days or until the parasite is completely eradicated from the 
body (272). 
1.6.7  Prevention 
Strongyloidiasis is an emerging global infection. This infection remains an important 
helminth disease due to increases in travel, migration to endemic and non-endemic 
countries, lack of adequate sewage disposal system especially in endemic countries and 
the risk of autoinfection which can lead to persistent disease for years. Patients with travel 
history to endemic countries, persistent eosinophilia, or signs of pulmonary and 
gastrointestinal symptoms in immunosuppressed patients should be followed up and early 
diagnosis is very important to manage this neglected helminth disease. Appropriate 
practical preventive measures such as health education campaigns on the disease, proper 
sanitation, regular de-worming, behavioural change through proper disposal of faecal 
waste and the use of protective foot-wear approaches may reduce the prevalence of 
Strongyloidiasis. 
1.7   Control strategies for soil transmitted helminths (STHs) 
The multicomponent integrated control strategy that lead to reductions in STHs includes 
integrated chemotherapy with anthelmintic drugs, improvement in water, sanitation, and 
hygiene (WASH), vaccines and vector control strategies. 
Chemotherapy is the principal way to achieve rapid, substantial reductions in STH 
prevalence and intensity through rapid parasite clearance from the human host 
(296)(297). WASH is an potential means of breaking the STH transmission cycle, 
although achieving adequate and sustained WASH is a complex and expensive long term 
objective in the endemic and poorer countries (298).  
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WHO’s strategy for control of STHs is to prevent and control morbidity through periodic 
treatment of people at risk, such as pre-school aged children, school aged children and 
women of child bearing age (including pregnant women in the second and third trimesters 
and breast feeding women) (299). The control strategies include: 
• periodic drug treatment (deworming) to all the children living in the endemic 
countries, once a year in the countries where prevalence of STH infection is over 
20% and twice a year when the prevalence of infection intensity in the community 
is over 50% to reduce the worm burden. 
• Health and hygiene education to reduce transmission and reinfection by 
encouraging healthy behaviour. 
• Provision of adequate sanitation. 
Four drugs- albendazole, mebendazole, pyrantel, ivermectin are on the WHO model list 
of essential drugs for STH control (300). The bezimidazoles (albendazole and 
mebendazole) have been administered to millions of people and usually as a single dose 
in school children in national helminth control programmes (301).  The efficacy however, 
varies by drug, dose, helminth species, age and intensity of infection. Vercruysse et al., 
reported the cure rate of albendazole for A.lumbricoides, hookworm and T.trichiura are 
98%, 47% and 8% respectively (296). There are varied reports of their effect on 
improvements in haemoglobin, weight, height, appetite, cognitive ability, physical fitness 
and activity levels following chemotherapy in pre-school and school-aged children 
(302)(303)(304)(305)(306). Improvement in maternal haemoglobin levels, infant birth 
weight and reduction in infant mortality at 6 months of age was observed when pregnant 
women were treated for STH infection (307)(308). However, the new Cochrane review 
concluded that there is substantial evidence that mass treatment of all children in endemic 
areas does not improve average nutritional status, haemoglobin, cognition. school 
performance or survival (309). 
For schistosomiasis, the WHO recommends treating school-aged children and other at-
risk populations with praziquantel, with frequency of administration varying with 
prevalence of infection.There are two Cochrane reviews of randomized control trials 
(RCT) of mass drug treatments for schistosomiasis (primarily using praziquantel, though 
occasionally metrifonate or oxamniquine). They both conclude that praziquantel is 
effective in treating schistosomiasis (310).  
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Chemotherapy has disadvantages as well. As treatment cannot prevent reinfection. WHO 
advocates repeated rounds of chemotherapy, even in areas where chemotherapy programs 
have ceased infection and/or intensity of infection. Drug resistance emergence can be 
another outcome after the mass chemotherapy of parasites (311). Reduced efficacy of 
some of the anthelmintic drugs such as albendazole, mebendazole and pyrantel has been 
reported. Reduced efficacy might result in from poor drug quality, reduced absorption, 
parasitological examination performed too early after treatment or poor strain 
susceptibility (312). Recent mathematical and statistical modelling studies indicate that 
chemotherapy of school children may break STH transmission cycles in specific 
epidemiological settings, specially in low transmission settings with strong health systems 
and drug delivery mechanisms, whereas in highly endemic countries, high coverage, high 
frequency and broader community based treatment with additional WASH efforts may be 
needed (313). 
WASH is the provision of access to a safe water supply, appropriately conducted 
sanitation, infrastructure ensuring safe disposal of human excreta, health education and 
promotion of hygiene.In a RCT, that investigated a school-based integrated WASH 
program plus albendazole, a significant reduction in A.lumbricoides reinfection was 
observed among school children who received the intervention compared with 
albendazole alone (314). Improving WASH is enormously challenging as financial, 
logistic difficulties may impair the process and this may also be subject to culture and 
environmental influences. 
Multicomponent integrated control may augment drug-based integrated chemotherapy. 
The Chinese approach with chemotherapy, WASH, agricultural mechanization and 
fencing of water buffaloes has been reported to reduce Schistosoma infection, 
S.japonicum-infected snails and STHs (315). The SAFE (surgery, antibiotics, facial 
cleanliness, environmental improvements) strategy of the Trachoma elimination 
programmes and treating animals to control transmission of Trypanosoma rhodesiense are 
also examples of multicomponent integrated NTD control (316). 
In large parts of Africa, most children are affected with more than one species of STH. 
These frequently overlap geographically and impose a great burden on poorer 
communities.The four major NTDs targeted by WHO through preventive chemotherapy 
are for Schistosomiasis, STH, onchocersiasis and lymphatic filariasis. In Cameroon, 
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considering the high prevalence and spread of these diseases and their geographical 
overlap, an efficient and cost effective integrated control of NTD is being practised. 
Ivermectin and albendazoleare co-administered during the campaign implemented once 
per year allowing an integrated treatment of onchocerciasis, LF and STH. Secondly they 
co-administer mebendazole and praziquantel in school-based deworming campaigns and 
implement the program annually. In school children aged 1-5 years during child health 
week campaigns, albendazole and mebendazole are administered and the campaign is 
implemented twice  a year at 6 monthly intervals and targets children up to 5 years (317). 
In Bangladesh, such interventions are recommended by WHO and UNICEF. Deworming 
tablets (albendazole) are given every six months to children aged 24 to 59 months (318). 
There are still gaps in evidence and challenges in establishing sustainable benefits in 
health outcomes from STH chemotherapy programs or WASH and other integrated 
approaches for STH control, as there is a lack of outcome data for STH chemotherapy and 
WASH. For chemotherapy, research into developing new and effective drugs against 
STH control is still a priority area. Integrated chemotherapy and control for STH infection 
requires considerable national and international scale-up funding, drug donations, human 
and other resource deployment, enhancing diagnostic capabilities and surveillance 
systems to contribute data, in-country technical expertise and political and programmatic 
will. 
1.8   Helminth –Mycobacterium tuberculosis Co-Infection 
Tuberculosis and helminth infections are co endemic in many parts of the world, and this 
geographical overlap has led the hypothesis that helminth infections could also exacerbate 
the effects of Mtb infection. It has been suggested that, by creating an anti-inflammatory 
environment,helminth co-infection might dampen both protective and 
immunopathological responses to Mtb, and thus alter the TB epidemic and disease 
severity in endemic countries. Helminth infection induced Th2 and Treg responses may 
contribute to depressed Mtb specific T cell responses, although the precise mechanism is 
still unknown. 
Helminth and Mtb co-infection is an issue of particular significance in resource poor 
environments where co-infection with these pathogens frequently occurs. In such 
communities, both helminth and TB infection have a tendency to cluster within certain 
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households or families. Helminths are reported as the most common parasites found in 
TB patients and TB is also most prevalent in communities where people are helminth 
infected  (319).  
 
Figure1.9: World map showing the geographical distribution of co-infection with helminths and  
tuberculosis (2013)(320).  
In this map, it is evident that in Sub-Saharan Africa, there is an extensive overlap of the 
presence of helminths and TB. In the co-infected patients, there may be conflicting 
effector cell responses for their control and regulation. It is plausible that, host immune 
responses to TB are modulated by co-infection with helminths and that helminth infection 
may potentially impair vaccine efficacy (205)(321). 
The larvae of STHs migrate through the lungs in their life-cycle. The localized helminth 
induced pulmonary response may therefore directly influence the outcome of a concurrent 
infection with Mtb in addition to the systemic effects.  
1.8.1  Potential mechanisms of helminth-induced modulation 
The immune response induced by most helminth infections is characterized by a type 2 
innate and Th2 skewed immune profile, chronic immune activation and regulatory T cell 
activity. This may modulate the T cell response to effect influence on Mtb infection and 
disease through a variety of mechanisms.  
The Th2 immune response in helminth infection may modulate immunity to TB as the 
Th2 cytokine milieu in the lung facilitates the development of AAMs. CAMs and AAMs 
induce reciprocal inhibition of iNOS and arginase through competition for the common 
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substrate L-arginine. M2 macrophages secrete the anti-inflammatory cytokines IL-10 and 
TGFb and also have higher arginase 1 levels which promotes wound healing and 
mediates resistance to helminths (322). These macrophages may impair the immune 
responses to TB and bacterial control through an IL-4R dependent process. Potian et al., 
reported that Nippostrongylus brasilensis induced Th2 response can enhance intracellular 
persistence of Mtb by mediating the induction of M2 macrophages via the IL-4Ra 
signalling pathway. Co-infected mice lacking IL-4Ra exhibited an improved ability to 
control Mtb infection and accompanied by a significant reduction in M2 macrophage 
accumulation. However, the Th2 response in the co-infected animals did not impair the 
onset and development of the protective Mtb specific Th1 cellular immune response 
(323).  
Another mechanism for the downregulation of Th1 responses and cytotoxic T cell 
responses to Mtb is the ability of helminth infection to target the classical activation of 
DCs. Exposure of DCs to helminth ES products fails to upregulate the surface expression 
of costimulatory molecules such as CD40, CD80 and CD86 and does not result in the 
synthesis of proinflammatory cytokines and chemokines such as IL-12, CCL2 (MCP-1) 
and TNFa (324)(325). After helminth exposure, DCs promote the differentiation of Tregs 
from naive T cell precursors or the further expansion of a pre-existing Treg subpopulation 
(326)(327). DC production of TGFb and /or IL-10 in response to helminth E/S products 
may be one of the potential mechanisms leading to expansion of Tregs and subsequent 
down-regulation of Th1 immunity during TB.  Talaat et al., reported that exposure to 
B.malayi changes the surface expression of adhesion and  costimulatory molecules on 
macrophages and DCs alter their production of cytokines and chemokines making them 
less capable of inducing Th1 immune responses (328). Following exposure to 
microfilaria, there may be down-regulation of the DC-specific ICAM-3 grabbing non-
integrin (DC-SIGN) lectin receptor, the receptor which is used by Mtb to enter DCs. 
Concurrent helminth infection may possibly reduce susceptibility of these DCs for 
infection by Mtb.  Helminths are also potent inducers of regulatory DCs (DCregs) which 
are characterized by the expression of IL-10, TGFb, indoleamine 2,3-dioxygenase (IDO) 
and cyclooxygenase 2. Possibly these DCregs down-regulate protective Th1 responses to 
Mtb, but this requires further investigation (329).  
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A number of studies have shown that in mouse models of infection with filarial parasites, 
there was a persistent type 2 immune response. Sacco et al., showed that a dominant Type 
2 response to Mtb antigens followed Mtb infection (330). Mice infected with N. 
brasiliensis or S.venezuelensis also exhibited impaired bacterial growth control  and 
higher bacterial loads in the lungs (323)(331). 
1.8.1.1 Th1/Th2 shift 
Mutual cross-regulation between the Th1 and Th2 arms of the immune system and the 
balance between Th1 and Th2 cytokines determines whether the immune response will 
result in successful elimination or control of an invading pathogen. Early progression of 
latently Mtb infected household contacts of TB diseases to active TB disease was 
associated with increased Th2 and Treg cytokines such as IL-4 and IL-10 (332). It was 
also observed that progression towards active TB was associated with reduced Th1 and 
increased Th2 responses in vivo. TB patients presented with a markedly increased 
Th1/Th2 (IL-4/IFNg) mRNA ratio compared to uninfected controls and the presence of 
Th2 cytokines IL-4 and IL-10 correlated with progression to active TB (333). A study 
conducted in Ethiopia demonstrated that PBMCs from S.mansoni infected individuals 
displayed poor responsiveness to mycobacterial antigens, characterized by impaired Mtb 
specific IFNg production and reduced T cell proliferation compared to dewormed controls 
(334). 
Most helminths release large amounts of antigenic material, leading to chronic immune 
activation, but as the burden or time after infection increases, the worms seem to modify 
and down-regulate these responses to survive. This chronic immune activation could 
potentially exhaust the local immune potential of the host, leading to the 
hyporesponsiveness and anergy that accompany helminth infections. These changes have 
been reported to revert to normal levels following clearance of the helminth infection 
(335)(336). Helminth-induced immune hyporesponsiveness may also be explained by IL-
10 and TGFb cytokine production during chronic helminth infection, which mediates 
antigen-specific hyporesponsiveness and also by impaired signal transduction.  
Th17 are another important effector lineage that plays a vital role in protective immunity 
to mycobacterial infections. IL-17 and IL-23 have been observed to be essential for an 
accelerated response to limit early bacterial growth and to establish Th17 in the lung 
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during TB infection. Metenou and colleagues reported that co-infection with filarial 
worms robustly inhibited mycobacterial-specific IL-17 and IL-23 cytokine responses in 
Mtb infected individuals (337).This downmodulation was partly mediated through the 
increased expression of the negative costimulatory molecules-cytotoxic T lymphocyte 
antigen (CTLA)-4 and programmed death (PD)-1 expression. It has also been speculated 
that increased evidence of TB following helminth infection may be partly due to 
inhibition of IL-17 production by helminth induced CD4+IL-4+memory T cells 
(338)(339)(340), which presumably downregulates the expansion of Th1 cells, via a Th1-
Th2 crosstalk. Filarial infections also have the additional effect of down modulating the 
expression and function of TLRs, especially TLR-2 and TLR-9.  
 
Figure 1.10: Proposed mechanism of immune modulation caused by helminth infections affecting 
immune responses and susceptibility to TB (341). 
 
1.8.1.2 Regulatory T cells (Tregs) 
Helminth driven Treg responses may have an impact on the host’s ability to cope with a 
concurrent Mtb infection, benefiting pathogen survival by down-regulating protective Th1 
immunity. Increased Treg frequencies and levels of IL-10 and TGFb mRNA are present 
in TB patients and both these cytokines are potent inhibitors of Mtb specific Th1 
responses (326). 
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1.8.2  Effects of helminth infection on diagnostic tests for LTBI 
Helminth infection plays a role in modulating immune response to Mtb PPD and other 
Mtb antigens. This immunomodulation may indirectly affect the diagnostic tests used for 
LTBI. Stewart et al., examined the immune responses of children exposed both to 
mycobacterial infection and Onchocerca volvulus (with microfiladermia) in Cameroon 
and found that the proliferation of PBMC in response to stimulation with adult female 
parasite antigen (OvAg) and PPD was down-regulated with increasing intensity of skin 
MF (342). A similar finding was observed with PPD immunisation of Brugia malayi 
infected mice that exhibited skewed PPD-specific responses towards type 2, but with no 
change in IFNg production (343). Onchocerciasis has also been shown to modulate 
delayed hypersensitivity to tuberculin skin testing in adults in Mali and Chad (344)(345). 
Thomas et al., conducted a community-based study in Bangladesh, which compared TSTs 
with QFT-ITs for detection of LTBI among 302 children and revealed a high proportion 
of indeterminate QFT-GIT results. Risk factors associated with an indeterminate QFT-IT 
result in this cohort included malnourishment and the presence of infection 
with A.lumbricoides and/or T.trichiura (346). Perry et al., screened adult US refugees 
from TB endemic countries to evaluate cytokine responses in LTBI withconcurrent 
Helicobacter pylori and helminth infection (347). It was observed that, Helicobacter 
infection was associated with enhanced Th1 type responses to Mtb antigens even in the 
presence of concurrent helminth infection. A cross sectional study in South India was 
conducted, where individuals aged from 6-65 years were screened for intestinal helminth 
infection, circulating filarial antigenemia, tuberculin reactivity, active TB and BCG 
vaccination status. Intestinal infection was not associated with diminished frequencies of 
PPD positivity, suggesting in this setting that pre-existing intestinal helminth infection or 
filarial infection does not influence the delayed type hypersensitivity to tuberculin 
significantly (348). 
Helminth infections thus appear to influence the reactivity to Mtb antigens, that forms the 
basis of diagnosis of LTBI in at least some settings. The discrepancy in the results of TST 
or IGRA may also vary according to the helminth species involved, the methods used for 
diagnosing the helminth infection or cut-off used for skin test reactivity and due to 
differences between geographic areas (135). 
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1.8.3  Effect on progression towards active TB 
 Helminth infections are known to modulate adaptive immune responses to TB antigens 
in both latent and active TB and to affect the clinical progression of the disease (349). 
George et al., in their study described a profound modulatory function of S.stercoralis 
infection on the systemic pathological responses that characterize disease activity and 
severity of pulmonary TB, an indication that helminth co-infection might dampen the 
severity of TB disease (350). Co-incident S.stercoralis infection in acute pulmonary TB 
patients was associated with significantly decreased levels of acute phase protein, matrix 
metalloproteinase, tissue inhibitors of matrix metalloproteinase, the systemic immune 
activation marker sCD14 and sCD163, all changes specific to ATB. However, animal 
models of mycobacterial challenge using different helminth species have not provided 
consistent results. Hübner et al., carried out a study in white cotton rats with or without 
filarial nematode that were challenged with Mtb and after 2 months, the immunological 
responses, histology and mycobacterial cultures were assessed (351). It was observed that 
Mtb loads and occurrence and size of the granulomas were not increased in co-infected 
animals suggesting that chronic filarial infections do not exacerbate Mtb infection in the 
cotton rat model (351). Studies in mice showed that the presence of the intestinal 
helminth N. brasiliensis had no effect on the M.bovis bacillary load at either 4 or 12 
weeks post infection compared with uninfected controls (352). 
The different studies that have examined the interaction between helminth infection and 
TB have been largely cross-sectional and have shown conflicting results, which might be 
due to ethnic or geographical differences in helminth species or to the limitations of 
observational cross-sectional study design. Hospital-based studies, conducted in Brazil 
and Ethiopia, showed a higher prevalence of active TB disease in helminth infected 
individuals. There was one study in Uganda, that has prospectively examined rates of 
development of active TB in an HIV-helminth infected cohort which demonstrated an 
association between having S.mansoni infection and developing active TB, though no 
such association was observed between the presence of intestinal helminth infection and 
TB incidence rate (353). Chatterjee et al., followed a cohort in South India prospectively  
over an 8 year period to assess the role of coincident helminth infection on the incidence 
and severity of adult pulmonary TB (APT) and assessed the smear positivity, bacterial 
load, PPD responses; they demonstrated that despite the immunomodulatory effects of 
helminth infection, baseline comorbid infection with these parasites had little effect on 
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clinical progression from latent TB to active TB (341). In contrast, Elias et al., 
demonstrated that intestinal helminth infection may be one of the risk factors for the 
development of APT. They determined the prevalence of helminth infections in active TB 
patients and their household contacts in a study conducted in North West Ethiopia. They 
evaluated the association between the number of helminth species a person carried and 
active TB and showed that the odds of being an active TB patient increased progressively 
with the number of species of helminth the person carried.In this study a significant 
association with active TB was found for A. lumbricoides, hookworm and S. stercoralis 
(354). Resende et al., showed similar results (355). In their study, the co-infected patients 
showed depressed anti-Mtb immunity and also showed more severe radiological 
pulmonary disease, indicating that concomitant intestinal helminth infection in patients 
with newly diagnosed TB skews their cytokine profile toward a Type 2 response, which 
could potentiate persistent Mtb infection and more severe disease progression (355). In 
contrast, Abate et al., indicated that in patients with asymptomatic helminth infection, 
active TB was associated with lower sputum positivity, leading to the  conclusion that 
there was a beneficial effect of helminth infection on bacterial burden (356). The 
influence of helminth infection on the development of active TB or outcome following 
antiTB treatment is not therefore completely understood. The conflicting results in 
different studies makes it very difficult to address the influence of helminth infection on 
progression from latent TB to active TB. 
1.8.4  Effect of helminth infection on BCG vaccination 
Cellular immune responses to Mtb antigens are decreased in individuals with concurrent 
helminth infection and this coincides the reduced efficiency of BCG in helminth-endemic 
regions of the world (357). Chatterjee et al.,in their study demonstrated that there was no 
significant difference in BCG vaccination status and TST responses in helminth co-
infected patients and patients without helminths (341). A study done in Ethiopia showed 
that helminth infection influences the outcome of BCG vaccination by improving PPD 
specific cellular responses in helminth treated individuals compared to untreated controls. 
A randomized control trial in Ethiopia shown that deworming improved the efficacy of 
BCG vaccination (358). Elias et al., showed poor immunogenicity of BCG vaccination of 
PPD negative individuals in a helminth infected population in Ethiopia and concluded 
that  this impairment was associated with strong Th2 bias of the immune responses by 
chronic helminth infection (358). In a study in Sweden, S.mansoni infection, was shown 
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to reduce the protective efficacy of BCG vaccination against Mtb possibly by attenuation 
of protective immune responses to mycobacterial antigens and /or by polarizing the 
general immune responses to the Th2 profile (359). However, the effectiveness of BCG 
vaccination was unaffected by a primary malaria co-infection in a mouse model of Mtb 
infection (360). Th2 like IL-10 responses induced by intestinal helminth infection may 
also be interfere with BCG induced Th1 like IFNg responses and may significantly alter 
the protective immune response to BCG vaccination (361). The impact of helminth 
infection on BCG vaccination is mostly due to modulation of cell mediated immunity and 
antigen specific and this low vaccine efficiency may  be due to the impairment of immune 
responses to recall antigens (362).Later it was demonstrated that helminth- induced 
immune sensitization during gestation persists into childhood and skews subsequent 
childhood immune responses away from protective Th1 immune responses (363). In 
another study, BCG vaccination induced T cell responses to Mtb were significantly 
downregulated both before and after BCG vaccination. This impact appears to be 
reversible since it could be overcome through elimination of intestinal worms during 
BCG vaccination using broad spectrum anti-helminth treatment (357). Chronic helminth 
infected individuals have an increased susceptibility to infections normally cleared by 
Th1 dependent immunity as well as altered immune responses to BCG vaccination.  
BCG vaccination provides the least protection in developing countries like such as 
Malawi and India, where helminths are endemic, in contrast to the UK, where BCG 
showed 80% protection against TB in the MRC trials. The reasons for this was speculated 
to be environmental mycobacteria exposure, high prevalence of endemic and chronic 
infectious diseases including helminth infections (364)(365)(366)(367).  
The area of greatest impact of the modulation of the immune responses by helminth 
infections likely involves attenuation of vaccine-induced immune responses, so it is 
imperative that the influence of concurrent helminth infection is considered in the vaccine 
studies in helminth-endemic areas of the world (349). 
1.8.5  Deworming and TB-helminth coinfection 
The impact of helminth infections can also be assessed by studying the effects of 
deworming. A reduction or elimination of intestinal helminths using broad spectrum 
anthelmintic treatment resulted in enhancement of T cell proliferation and IFNg production 
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by PBMC stimulated with PPD. T cell responses to PPD were found to be improved in 
filarial infected subjects after treatment with diethylcarbamazine (323)(343)(368). It was 
also observed in this study that prior BCG vaccination had no significant effect either on 
the in vivo or the in vitro responses to PPD (369). Treatment with an anthelmintic, in this 
case, albendazole  during BCG vaccination was associated with significantly increased 
proliferative and IFNg responses to PPD implying that exposure to chronic helminth 
infection during BCG vaccination may contribute to a decreased T cell response to 
mycobacterial antigens. It was observed that only albendazole had no direct effect on the 
cellular immune responses. It was suggested that the removal of intestinal helminths by 
deworming would remove the inhibitory effects of Th2 cells and cytokines on Th1 
responses (355).  
Toulza et al., investigated how anthelmintic treatment modulates antimycobacterial 
immune responses in UK migrants. Patients with helminth infection showed a significant 
increase in CD4+FoxP3+T cells (Tregs) and a lower frequency of CD4+IFNg+T cells  and 
these effects were reversed after anthelmintic treatment (370). This was supported by 
other studies where anthelmintic treatment against Schistosoma infection in Gabon 
resulted in a marked reduction in CD4+FoxP3+T cells post treatment (371).  
Given that the immune changes accompanying helminth infections are profound and 
universal, and that they revert to normal after eradication of the helminth infection, their 
role in the interaction between the host and the other infections may be very important 
(372).  
Differential effects were observed in studies on helminth and TB co-infection. These 
varied responses may be attributed to different species of helminth, their location in the 
body, different life cycles, different E/S products, or Mtb infection. Different strains of 
Mycobacteria and their route of administration may also contribute. In vitro studies have 
demonstrated the impact of helminth infection on Mtb infection- both on the immune 
response and the severity of disease, although the clinical outcome is not clearly 
understood, which may be due to underpowered studies, type or intensity of infecting 
helminths and the different methodologies used for the detection of helminth infection 
(135). 
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1.9   Mycobacterial growth inhibition assay 
A recent development in TB biomarker discovery has been the establishment of 
automated techniques that allow the measurement of mycobacterial growth inhibition in 
vitro (373). Functional assays such as mycobacterial growth inhibition assays (MGIAs) 
that measure the summative effect of a range of cellular mechanisms might prove to be 
better surrogates of protection than measuring T cell responses or cytokines as biomarkers 
(374). MGIA directly measures the ability of heterogeneous populations of human 
lymphocytes and other mononuclear cells to limit the intracellular growth of 
mycobacteria. The immune mediated inhibition of mycobacterial growth correlates more 
directly with protective TB immunity than other immunological responses (375). This 
assay represents an unbiased surrogate marker of protection against TB and allows for the 
investigation into the potential roles of immune mechanisms in mediating this protective 
effect (371). Assays of immune inhibition of mycobacterial growth may provide a more 
direct measure of in vivo resistance against Mtb. 
The MGIAs which are being evaluated for use in assessing vaccine induced protective 
immune responses in clinical trials of TB vaccines have varying designs and endpoints 
(376)(375)(377)(378)(379). BCG and Mtb based assays have been used to evaluate 
vaccine induced immunity in humans. 
Youmans et al., demonstrated that lymphokine  secreted from splenocytes of immune 
mice when added to mouse peritoneal macrophages, enhanced inhibition of Mtb growth 
in vitro (380).This method was adapted later for use with PBMC isolated from healthy 
volunteers, both immune (TST positive or BCG vaccinated) and nonimmune. 
Lymphocytes were cultured for 72 hours with trypsin extracted soluble 
antigen/tuberculoprotein to induce lymphokine production. Macrophages were then 
infected with attenuated or virulent mycobacteria (M. bovis BCG and Mtb Erdman) and 
cultured for 7 days with or without the addition of immune lymphokine obtained from the 
lymphocyte stimulation assay. Enhanced inhibition of intracellular bacillary replication 
was observed in cultures containing lymphokine produced only by lymphocytes of 
immune subjects, of whom there were three kinds: tuberculin positive naturally 
immunized, M. bovis BCG immunized, and trypsin-extracted bacillary antigen 
immunized. The human immunity to mycobacteria was measured by inhibition of 
[3H]thymidine incorporation, counts of AFB, and morphological comparisons of culture 
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(381). Crowle and May also showed that the active vitamin D3 metabolite 1,25-(OH)2 
cholecalciferol had the ability to inhibit  mycobacterial growth in macrophages(382). The 
same group assessed the antimycobacterial effects of lymphokine and recombinant IFNg 
using murine peritoneal macrophages and human alveolar lavage cells.This study showed 
that addition of recombinant IFNg or crude lymphokine reproducibly activated strong 
anti-mycobacterial mechanisms in the murine cells, however, these stimuli had weak and 
variable effects on human alveolar cells. These studies indicated a number of potential 
reasons for the difficulty in demonstrating inhibition of intracellular growth of Mtb; for 
example host susceptibility, use of high bacterial to cell ratios, higher concentrations of 
cytokines or synergistic effects of multiple cytokines, and necessity of cell to cell 
interaction in the containment of intracellular bacteria etc. However, vitamin D and A 
have some ability to activate Mtb infected human mononuclear cells and TNFα may 
contribute to the in vitro containment of avirulent Mtb. But none of the mediators limits 
the growth of the organism within human mononuclear cells with an efficacy compared to 
that of the murine cells (383).  
Chen et al., studied the mononuclear cells from healthy British school children (aged 13-
15 years) who were BCG vaccinated before and 8 weeks post vaccination. The monocytes 
were then infected with M.microti in microtiter trays at a low bacterium/monocyte ratio 
for 24h to allow phagocytosis and monolayer development.The monolayers then received 
pulsed exposures to autologous lymphocytes for 2h every day for 3 days. Monocyte 
monolayers were then infected with M.microti for 24h and the bacillary changes in 
monolayers and supernatants over 4 days were quantified by colony counts. M.microti 
growth was significantly inhibited at days 3 and 4 of the culture using cells from pre and 
post vaccinated children. Growth rates in lymphocyte-pulsed monolayers were 
significantly lower after vaccination than before. It was proposed that this difference 
reflected the protective effect of vaccination (384).  
1.9.1  PBMC based mycobacterial growth inhibition assays 
1.9.1.1 Primary lymphocyte inhibition assay 
This assay measured the ability of freshly harvested blood lymphocytes to inhibit the 
intracellular growth of virulent Mtb. In 1998, Silver et al., developed this assay using low 
level infection of isolated monocytes with Mtb H37Rv for 1 hour followed by a 7 day 
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culture either alone or with unstimulated autologous lymphocytes (377). At days 0 and 7, 
co-cultures were lysed with SDS and viable bacteria counted by CFU. Unstimulated 
lymphocytes induced significant inhibition of mycobacterial growth after 4 and 7 days of 
culture for both PPD negative and positive subjects and this is indicative that the assay is 
measuring early innate immune responses. This study also indicated that non adherent 
cells (NAC) from both PPD-positive and PPD-negative subjects were more effective at 
limiting the intracellular growth of H37Rv than either cytokines or transferred cytokines. 
Depletion of CD4+T cells eliminated the growth inhibition capacity of non-adherent 
PBMC from PPD-positive individuals, but did not reduce the inhibitory effects of NAC 
from PPD-negative subjects. Depletion of CD8+T cells did not affect the ability of NAC 
from either group of subjects to contain Mtb. Antigen-specific immunologic memory in 
PPD reactive individuals could not be measured in this study. Addition of rIFNγ and 
rTNFα to infected monocytes did not show any significant effect on mycobacterial 
growth inhibition and even additions of blocking antibodies to these cytokines were not 
able to alter the growth inhibitory capacity. 
1.9.1.2 Secondary lymphocyte inhibition assay 
Worku and Hoft described this assay(385).They investigated the ability of T cells 
expanded with mycobacterial antigens from healthy PPD reactive donors prior to co-
culture with infected monocytes to inhibit the intracellular growth of BCG (378). 
Adherent monocytes were cultured for 6 days followed by overnight infection with BCG. 
PBMC were cultured for 7 days in media alone or with the addition of antigen like 
mycobacterial whole cell lysate, live BCG or tetanus toxoid (TT) as control. Expanded 
effector T cells were added to autologous monocyte targets for 72h. After 72 hours, 
supernatants were aspirated and cells lysed with 0.2% saponin. Viable bacteria were 
determined by radiolabelling. Lysates were diluted in media and pulsed with [5,6-3H] 
uridine and incubated at 37ºC for 72 hours, after which BCG bacteria that were 
incorporating the label were placed on glass-fibre filter mats. The amount of titrated 
uridine incorporation in the BCG bacteria determined by liquid scintillation counting. The 
percentage of inhibition of BCG growth was determined by comparing the amount of 
reactivity and CFU estimations in antigen-expanded effector cell co-cultures with that in 
medium-rested T cell co-cultures. In this assay, BCG growth was not inhibited by TT 
expanded lymphocytes which indicated that the effects were mediated by expansion of 
antigen specific T cells. Interestingly, in this assay γδT cells were the predominant T cell 
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subset expanded in response to mycobacterial antigens and that were efficient in 
inhibiting intracellular growth of BCG, suggesting a memory like phenotype but there 
was no statistically significant mycobacterial growth inhibition in presence of enriched 
CD4+ and CD8+T cells. Spencer et al., showed that this γδT cell population produce 
soluble granzyme A in a TNFα dependent manner, which might correlate with their 
ability to improved mycobacterial growth inhibition (386).  
Hoft et al., compared different methods of MGIA (375). In a primary lymphocyte assay, 
unexpanded lymphocytes were added and that provides an unbiased sampling of 
peripheral blood responses. The lack of in vitro stimulation, may thus overemphasize the 
effects of nonspecific defences. In contrast, the secondary lymphocyte inhibition assay, 
may have higher sensitivity for the detection of memory immunity. Vaccine-induced 
enhancement of secondary lymphocyte inhibition was statistically more robust in this 
comparative study . Interestingly, Worku and Hoft investigated the effects of peripheral 
blood mononuclear cells (PBMC) expanded with irrelevant control and mycobacterial 
antigens on the intracellular growth of BCG in human macrophages. When T cells were 
stimulated with purified mycobacterial antigens, levels of resulting growth inhibition 
varied depending on the antigen used. BCG vaccination was shown to significantly 
enhance antigen-specific T-cell inhibition and purified mycobacterial antigens were 
shown to stimulate inhibitory T cells.The results were characteristic of antigen-specific, 
memory-immune T-cell responses (385). 
 
Figure 1.11: Mycobacterial growth inhibition assays (375). 
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1.9.2  Whole blood mycobacterial growth inhibition assays 
Whole blood culture has been widely used to evaluate pathogen-induced immune 
functions and immune mediated killing of intracellular M.bovis BCG. Walis et al., 
described an ex vivo model for measuring the whole blood bactericidal activity (WBA) of 
drugs-isoniazid, rifampicin, ethambutol, levofloxacin by whole blood culture (387). This 
WBA is an adaptation of Schlichter and MacLeans’s concept of the serum bactericidal 
assay to monitor therapy for infective endocarditis(388). Blood was collected before, and 
at intervals after drug administration. Mtb was mixed with blood and incubated at 37ºC 
for 72 hours with constant mixing. The cells were then disrupted by hypotonic lysis and 
bacilli were sedimented and resuspended in BACTEC medium before adding to MGIT 
tubes. Mycobacterial survival was determined by comparing the days-to–positivity (DTP) 
of the control and experimental cultures. In this WBA, growth indices of actively growing 
BACTEC cultures increase exponentially in proportion to CFUs. BACTEC growth 
indices were used as a surrogate for CFU to measure intracellular survival of Mtb in other 
studies (389). In this study, DTP was observed to improve accuracy and dynamic range. 
The inhibition was shown to correlate with sterilizing activity observed in vivo during 
therapy.  
Another WBA was developed using BCG transfected with luciferase (BCG-lux) as a 
reporter (379). Expression of recombinant luciferase enzymes has been widely used as a 
reporter, to monitor changes in cell viability in bacterial and eukaryotic systems. In 
mycobacteria, luciferase reporters have also been used mainly to monitor the effect of 
drugs on viability in earlier studies (389), but they have also found to detect immune-
mediated killing in animal models (390)(391). Diluted whole blood was diluted with 
BCG lux for 96 hour followed by isotonic lysis to obtain a final concentration of RLU/ml. 
Mycobacterial growth was expressed as a ratio of growth in the sample relative to the 
control. Silver et al., later optimised the assay for smaller blood volumes  to improve 
suitability for paediatric studies (377). Kampmann et al., suggested that  luciferase 
promoters that are differentially regulated during the course of the infection represent a 
possible approach to further enhancement of the discriminatory ability of the WBA (379). 
Tena et al., showed that this WBA demonstrated reduced ability of whole blood from 
HIV-infected infants to inhibit mycobacterial growth in comparison to healthy control 
infants (392). In a secondary lymphocyte inhibition assay, it was observed that adding 
rIFNγ or rTNFα or blocking antibodies against these cytokines did not alter the 
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mycobacterial growth inhibition (393). But in this BCG Lux assay, mycobacterial growth 
was partially enhanced, when blocking antibodies were used against these cytokines.  
WBA require small volume of blood, which is an advantage for some studies for 
example, paediatric studies. WBAs cannot distinguish between intracellular and 
extracellular mycobacterial growth, whereas a cellular assay has the advantage of 
removing nonphagocytosed bacteria by washing. When attempting to assess a vaccine 
response, neutrophils in whole blood may be less relevant or a strong effect could mask 
the functionality of the long term specific responses.  
Fletcher et al., adapted the Wallis whole blood MGIA into a PBMC assay (394). 
Following BCG vaccination, PBMC of British adults exhibited significantly enhanced 
growth inhibition at both 4 and 8 weeks after vaccination but the growth inhibition had 
returned to baseline levels by 6 months post vaccination (394). Harris et al., adapted this 
WBA of MGIA in a BCG challenge study comparing antimycobacterial immunity 
induced by BCG and MVA85A vaccination. The assay could not detect any significant 
difference between groups (395). 
1.9.3  The BACTEC MGIT assay   
The BACTEC MGIT 960 is a fully automated system that contains a modified 
Middlebrook 7H9 broth with a fluorescence quenching based oxygen sensor that detects 
the amount of oxygen consumption by growing microorganisms. PBMC were added into 
2 ml screw cap micro tubes with a predetermined, optimal quantity of mycobacteria. 
Tubes were incubated at 37°C with 360º rotation for 96 hours. Following incubations, 
cells and remaining BCG were pelleted and lysed and are then transferred into 
corresponding MGIT tubes. Time to positivity (TTP) is determined by using BACTEC 
MGIT 960. A standard curve enables conversion of TTP into initial mycobacterial 
volume which is then converted into CFU(394). Smith et al., measured a population of 
PPD specific, CD4+T cells that demonstrates polyfunctional (IFNγ+TNFα+IL2+) 
capabilities in infants of UK who have received BCG vaccination at 6 weeks of age. The 
study demonstrated that PPD specific polyfunctional CD4+T cells secreting IFNγ, TNFα 
and IL-2 together with the induction of antigen-specific Th-17 cells showed a significant 
correlation with growth inhibition(396). Fletcher et al., recently conducted the PBMC 
MGIT assay as a part of a case control analysis of immune correlates of risk of TB 
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disease in BCG vaccinated infants from South Africa.  In the study, reduced risk of TB 
disease was associated with BCG specific IFNγ ELISpot responses and Ag85A antibodies 
but was not associated with MGIA. This lack of correlation might be attributed to the low 
frequency of BCG antigen specific T cells detected in this study. 
 
 
Figure 1.12:MGIA using BACTEC MGIT 960. 
 
1.9.4  MGIAs in preclinical animal models 
MGIAs have also used in animal models- especially in cattle, mouse and non-human 
primate (NHP) models. Developing MGIAs in animal models can provide the ability to 
validate a vaccine candidate and its correlates of protection. 
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Reference Method overview 
Cowly and Atkin 
(397) 
Bone marrow macrophages cultured for 7 days and then infected 
with Mtb Erdman for 2 hours. Splenocytes were primed by in 
vitro Mtb infection followed by chemotherapy to clear the 
infection. Addition of harvested primed splenocytes to the 
macrophage cultures resulted in significant growth inhibition.  
Parra et al.,(398) Adapted the Cowly and Atkin assay to evaluate the vaccine 
efficacy of novel vaccine. Enhanced growth inhibition of Mtb 
was observed whenco-cultured with bone marrow macrophages 
from BCG vaccinated mice compared with naïve controls.  
There was a significant correlation between in vitro growth 
inhibition  and in vivo protection of 5 novel vaccines. 
Marsay et al.,(374) Splenocytes were infected with BCG for 96 hours with 360º 
rotation. Cells were lysed and TTP was calculated by 
BACTEC MGIT. Inhibition of growth was significantly 
enhanced in splenocytes from BCG vaccinated mice compared 
with control mice. 
Carpenter et al.,(399) PBMC from immunized cattle expanded by PPD stimulation 
and added to BCG-infected autologous macrophages.  BCG 
growth was significantly reduced in cultures containing 
autologous PBMC from both immunized and control cattle.  
Yang et al.,(400) Splenocytes were directly infected with Mtb from vaccinated mice 
and quantified mycobacteria using MGIT. Vaccine-mediated 
immunogenicity detected by this assay correlated with protection. 
Zelmer et al.,(401) Optimized ex vivo mycobacterial growth inhibition assay using 
a murine Mtb infection model. Assessed the combined ability of 
host immune cells to inhibit mycobacterial growth in response 
to vaccination. C57BL/6 mice immunized with BCG and 
growth inhibition of mycobacteria by splenocytes was assessed.  
McShane et al.,(394) Human whole blood, PBMC and mouse splenocytes infected 
with BCG for 96 hours with 360º rotation. Cells were lysed and 
mycobacteria quantified by BACTEC MGIT TTP. Significant 
inhibition of growth was observed at 8 weeks post-BCG in 
whole blood, 4 and 8 weeks post-BCG in PBMC. There were 
significant differences in growth inhibition between naïve and 
BCG vaccinated mice.  
Table 1.3: Overview of MGIAs in animal models. 
 
In animal models, mycobacterial growth inhibition can be observed in vitro following 
BCG immunization in animals and this can be correlated with protection from Mtb 
challenge, although in small animal models the blood volume may impede the use of 
WBA MGIAs.  In different studies it has been concluded that splenocytes are most 
realistic cells to use, although BCG has a propensity to persist in the spleen, which makes 
it difficult to study live vaccines and responses in the spleen may not be representative of 
immunopathogenesis in the periphery or the lung. 
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1.10   Rationale of the study 
The study investigated the effect of helminth coinfection on the ability of patients with 
LTBI infection to inhibit mycobacterial growth and also observed the impact of 
anthelminthic treatment on modulation of antimycobacterial immune responses in these 
coinfected patients. To our knowledge, no other studies have investigated the immune 
mediated control of the growth of Mtb in LTBI and helminth coinfected patients. The 
results of this study may provide an insight on immune correlates of protection against 
latent TB in these patients. 
1.11   Hypothesis 
Anthelminthic treatment modulates the ability of the LTBI and helminth coinfected 
patients to inhibit the growth of Mtb.  
1.12 Study Aims 
The aims of the study are: 
1. To measure the magnitude of IFNγ T cell responses to Mtb antigens in these 
patient groups and controls before and after anthelminthic treatment by ex-vivo 
ELISpot assay and intracellular cytokine responses of PBMC using flow 
cytometry.	
2. To determine the effect of helminth infections on mycobacterial growth inhibition 
and to observe whether anthelminthic treatment affects the ability of the cells to 
control mycobacterial growth.	
3. To explore the association of antibodies and macrophage subsets with 
mycobacterial growth inhibition in the MGIT assay to gain a better 
understanding of the immune mechanisms underlying LTBI-helminth 
coinfection. 
     4.    To analyse differential gene expression in helminth and LTBI-helminth coinfected     
                patients after anthelmintic treatment.  
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Chapter - 2     Materials and Methods 
2.1   Study design 
To identify and characterize the effects of helminth infection and of anthelmintic 
treatment on the immune response to TB, UK migrants attending the Hospital of Tropical 
Diseases (HTD) and TB clinic of University College London (UCL), with eosinophilia or 
with suspected / diagnosed helminth infection and or latent TB between January 2014 and 
September 2016 were recruited. All participants were enrolled in this study during their 
first visit (V1). Blood was drawn to detect helminth infection and to detect LTBI. These 
patients were given anthelmintic treatment according to their parasitology serological 
results. All the recruited patients were requested to come back at least 4 months later for a 
follow-up visit (V2).  
2.1.1  Inclusion criteria 
Patients who fulfilled the following criteria were eligible to participate in the study and 
considered as the sample population: 
- Migrants in UK or history of living in tropical countries 
- UK migrants presenting with eosinophilia  
- Male and female aged over 18 years of age 
- Suspected or diagnosed helminth infection (no evidence of previous treatment) 
- Suspected or diagnosed cases of latent TB (IGRA positive) 
2.1.2  Exclusion criteria 
Any individual characterized by at least one of the following criteria was not eligible to 
participate in the study: 
- Male and female migrants below the age 18 
- Diagnosed cases of HIV or any immunosuppressive condition 
- Patients with previous anthelmintic treatment  
- Patients with LTBI treatment (ongoing or previous) 
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2.1.3  Ethical considerations 
Research clinical approvals for this study were obtained from the Health Research 
Authority, National Research Ethics Service Committee (reference 11/H0713/12), 
London and from the Ethics Committee of London School of Hygiene & Tropical 
Medicine (LSHTM) (reference number: 7758) (Appendix I). 
2.1.4  Study subject’s recruitment 
At the HTD and the TB clinic at UCLH, patient information leaflets were distributed in 
the waiting area. A research nurse from the clinical care team identified all patients who 
met the inclusion/exclusion criteria and approached them to discuss the study. Those 
patients who had agreed to participate in the study signed an informed consent. Each 
patient was allocated a unique identification number (UIN) by the research nurse to 
maintain the anonymity of the samples. Research samples comprised approximately 3 ml 
blood for Quantiferon Gold in-tube assay to diagnose TB, 6 ml of blood to test for 
antigens indicative of helminth infection, 3 ml blood for full blood count, 20 ml blood for 
immunology and 3 ml of blood for RNA preparation for gene expression in a TempusTM 
blood RNA tube (Applied Biosystems, USA). All the clinical samples were labelled 
according to NHS standard operating procedures. Stool and urine samples were collected 
for microscopy and processed through the routine diagnostic laboratory as per guidelines. 
All other samples were sent to LSHTM. 
2.1.5  Study groups 
There are four study groups- controls, helminth infected, LTBI and LTBI and helminth 
co-infected groups. Blood was also collected from healthy donors from LSHTM to 
perform different immunological methods and to be used as healthy controls. 
Helminth infected patients  
Patients with a history of living in endemic countries attending HTD outpatient clinics or 
inpatients at UCLH with suspected or proven helminth infection belong to this group. The 
suspected helminth infected persons are those who have symptoms suggestive of 
helminth infection or with parasitological investigations to diagnose helminthiasis.  Some 
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patients were referred from another clinic as diagnosed helminth infected patients. Those 
patients were subjected to further investigation and treatment. 
Control group  
Patient who had no eosinophilia on their full blood count (FBC) and no evidence of 
helminth infection or no proven TB infection but had a history of living in tropical 
countries were recruited as controls. They had attended the clinic with gastrointestinal 
and respiratory symptoms.  
LTBI patients 
This group comprised of patients who had a history of living in tropical countries who 
attended the UCLH TB clinic for suspected or proven TB infection. All LTBI patients 
were IGRA test positive. All the patients were tested for Mtb infection, using the QFT-
GIT assay. Patients with clinical symptoms of TB were screened for TB disease and 
excluded from this study if active TB disease was diagnosed. 
LTBI- helminth co-infected patients 
This group comprised of patients who were IGRA positive or had previously diagnosed 
LTBI and had evidence of helminth infection based on symptoms or serological 
examination. Participants to be recruited were grouped according to the result of 
immunological procedures performed on samples obtained at visit 1. 
Group 1: Helminth negative, latent TB negative 
Group 2: Helminth negative, latent TB positive 
Group 3: Helminth infected, latent TB negative 
Group 4: Helminth infected, latent TB positive  
2.1.6  Blood collection  
Visit 1 
Following enrolment, about 25 ml venous blood is collected from each participant into 
commercial heparinized vacutainer® tubes (BD, Franklin, USA) at the clinic by the 
phlebotomist. The phlebotomist in charge labelled and documented the date, UIN and 
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visit number. During recruitment or Visit 1, 3 ml of blood sample for QFT-GIT assay was 
collected from subjects recruited to diagnose LTB infection and 6 ml blood was used for 
diagnostic parasitology. Also, stool and urine samples were used for diagnosing helminth 
infection. Around 20 ml blood in heparinized vacutainer tubes and 3 ml whole blood in a 
Tempus tube ®were sent to the LSHTM laboratory for immunological analysis and for 
the gene expression study. Three ml of whole blood in Tempus tubes were kept at room 
temperature for 2 hours and then stored at -80°C for further gene expression analysis. 
Four weeks after visit 1 participantwere asked to attend the clinic again. According to the 
serology results and microscopic helminth diagnostic tests, anthelmintic treatment was 
chosen, prescribed and supervised by the attending physician.  Some patients had another 
blood sample collection for immunological analysis.  
Visit 2 
About 16-24 weeks after anthelmintic treatment, participants re-attended for a further 
blood examination for immunological assays, which also included blood for Quantiferon-
Gold In–Tube assay, helminth serology and FBC. About 20 ml of venous blood in the 
heparinized tube and 3 ml blood in a Tempus tube was sent to LSHTM laboratory for 
immunological analysis of the post-treatment samples. Four ml of venous blood was 
collected for a full blood count and sent to the Pathology laboratory. 
Blood in heparinized tubes was brought to the laboratory at LSHTM. PBMC isolation 
was carried out inside a sterile safety cabinet and cells stored in cryovials in -80°C for 24 
hours and then the cryovials were transferred to liquid nitrogen for longer storage. Plasma 
was collected from the blood and stored at -80°C and kept for further immunological 
analysis. 
2.1.7  Clinical data collection 
A structured questionnaire was used for clinical and demographic data for each study 
participant. The data collection sheet included the demographic, clinical and laboratory 
data information following the standard guidelines. Baseline data included hospital ID, 
study UIN, age, sex, contact details, referral route, doctor/nurse name, country of origin, 
and years of stay in UK and history of travelling to tropical/ endemic countries. Clinical 
data included helminth symptoms, previous TB history, BCG vaccination history and 
HIV status. Diagnostic data included previous eosinophil count, lymphocyte count, 
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serology and microscopy results for helminth, IGRA results etc. For all the patients, basic 
laboratory tests like FBC and haemoglobin concentration were obtained at a baseline visit 
and at follow-up and recorded in a predesigned data sheet in Microsoft Excel file. All the 
clinical, socio-demographic, laboratory data, sample collection date and time were 
collected and stored in a password protected Microsoft Excel file. 
2.1.8  Tests for TB latency and helminth infection 
Latent TB detection 
All the recruited participants were tested for TB. To detect latent TB infection, 
aQuantiFERON®-TB Gold (QFT®) ELISA test was performed. QFT is a test for cell-
mediated immune (CMI) responses to peptide antigens from mycobacterial proteins. 
These proteins, ESAT-6, CFP10, and TB7.7, are absent from all BCG strains and from 
most nontuberculous mycobacteria with the exception of M.kansasii, M.szulgai and M. 
marinum. Individuals infected with Mtb complex organisms recognize these 
mycobacterial antigens. This recognition process involves the generation and secretion of 
the cytokine, IFNγ. The detection and subsequent quantification of IFNγ form the basis of 
this test. The test was performed according to the manufacturer’s instructions, using equal 
volumes of plasma (50µl) and conjugate (50µl) in the first step of the assay. OD values 
were measured using an ELISA reader. The QFT Analysis Software was used to analyze 
raw data and to calculate results. The software makes all the calculations, generates a 
standard curve and provides a test result for each subject. For the QuantiFERON-TB Gold 
test to be valid, the nil value must be less than or equal to 8.0 IU/mL, and the mitogen 
value (a positive control for IFNg production) must be at least 0.5 IU/mL higher than the 
nil value. The QuantiFERON-TB Gold test is considered positive if the IFNγ response if 
the TB antigen minus nil value is at least 0.35 IU/mL. The tests were performed by the 
routine diagnostic laboratory at UCH who reported results as QFT positive and negative; 
this result was used to classify the subjects as LTBI positive or negative.  
Tests for helminth infection 
Most of the patients in this study were infected with Schistosoma spp and/or 
Strongyloides spp with a few tapeworms. For Strongyloides spp, serum samples were 
analysed by a commercial ELISA for anti-Strongyloides antibodies according to the 
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manufacturer’s protocol that uses a variable cut-off based on a low positive serum. This is 
a solid phase in vitro quantitative assay for the indirect detection of IgG to S.ratti somatic 
larval antigen (Bordier, France). According to the Bordier affinity S.ratti kit the test 
sensitivity is 88% and specificity 100%. Faeces samples were also cultured to detect 
Strongyloides or hookworm using the charcoal culture method. Afterwards, visual 
interpretation was also performed microscopically to distinguish whether the larvae were 
of Strongyloides or hookworm. 
For anti-schistosome antibodies, an in-house ELISA assay was performed, using the 
standard clinical diagnostic tests currently in use in the National Parasite 
ReferenceLaboratory of the UK, based at the HTD. This in vitro quantitative assay 
detects IgG antibodies to Schistosoma egg antigens. Stool analysis was performed 
following formolether/ethyl acetate faecal concentration using a Midi Parasep®fecal 
concentrator to increase the possibility of detecting ova or cysts that may not be 
detectable by direct microscopy. Terminal urine microscopy was also performed to see 
the characteristic eggs of Schistosoma spp.  Filarial serology was performed if the patient 
was from Africa or had clinical evidence of filarial infection. Tapeworms were diagnosed 
by a routine stool microscopy test. A full blood count was performed to detect 
eosinophilia. 
2.1.9  Immunological methods 
PBMC isolation, cryopreservation and thawing 
PBMCs were isolated from heparinized whole blood obtained from healthy donors at 
LSHTM/ patients from HTD or UCL, using density centrifugation on Histopaque (Sigma, 
UK). Ficoll Histopaque was brought to room temperature. Fifteen ml of whole blood was 
taken into a 50ml Falcon tube and diluted with PBS to make it up to 50 ml. Fifteen ml of 
Ficoll Histopaque was added to a 50ml Falcon tube. Twenty-five ml of diluted blood was 
layered on the top of the Ficoll layer. Then the tube was centrifuged at 673g for 25 
minutes without a brake. Ficoll separates blood into layers of plasma, PBMCs, 
granulocytes and red blood cells. The PBMC layer was collected from the interface 
between the plasma and Ficoll layers using a Pasteur pipette (Fisher Scientific, UK) and 
taken into a new Falcon tube and topped up to 45 ml with PBS and centrifuged at 673g 
for 10 minutes with brake. The supernatants were removed and pellets and resuspended in 
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45 ml of phosphate buffer saline (PBS-0.01M: NaCl 0.138M, KCL 0.0027M, pH 7.4).The 
tube was centrifuged at 149g for 15 minutes at 4°C for a further wash. 
For cryopreservation, cells were resuspended in cryopreservation medium. The freezing 
media was prepared with pre-cooled 90% foetal bovine serum, FBS (heat inactivated), 
(GIBCO®Life technologies, UK) and 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich®, 
UK) and mixed by inversion. Cells were immediately aliquoted into 2 ml cryovials 
(Sigma Aldrich, UK) at 1 ml per vial. Each cryovials was labelled with donor ID, date 
and visit number. The cryovials were transferred to a pre-cooled Mr Frosty freezing 
container containing isopropanol, which was stored at -80ºC. After 1 to 2 days, vials were 
transferred to liquid nitrogen for long term storage. 
To thaw PBMC, the cryotubes removed from liquid nitrogen were placed on dry ice. 
About 11 ml of pre warmed RPMI was placed in a 15 ml Falcon tube for each vial of 
PBMCs. Cells were thawed in a water bath at 37ºC until 70% had melted. The cryotubes 
were opened under the hood. Around 0.5ml of Roswell Park Memorial Institute-1640 
(RPMI) (Sigma Aldrich, UK) HEPES supplemented with 10% L-glutamine and sodium 
pyruvate (Gibco, UK) was added into the vials. Using a Pasteur pipette, the solution was 
gently pipetted up and down until the icy portion was completely thawed. Cells from the 
vial were transferred into the Falcon tube containing RPMI media and centrifuged at 1400 
rpm for 7 minutes. The supernatant was discarded and cells were resuspended in RPMI 
media at approximately 1x106 PBMC per ml (10 ml per vial thawed). About 2µl of 
Benzonase nuclease (Sigma Aldrich, UK) per ml RPMI was added and incubated for 2 
hours at 37°C in an incubator with 5% CO2 (with the lid of the Falcon tube slightly 
loosened) before counting the cells. 
Cell counting 
Twenty µl of cell sample was taken to a well of round well microtiter plate, (Sigma 
Aldrich, UK) and mixed with 10µl of Trypan blue solution at 0.4% (Sigma Aldrich, UK) 
to count the live cells. Ten µl of the cell mix was mounted on a Neubauer chamber. Cells 
in the 25 inner squares of the Neubauer chamber were counted and the total number of 
cells/ml was obtained by multiplying the counted cell number by the dilution factor (2) 
and 104. 
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2.2   Mycobacterial Growth Inhibition Assay (MGIA) 
BCG Aeras Pasteur was used as the immune target for the Mycobacterial Growth 
Inhibition Assay (MGIA) in this study. The stock BCG was aliquoted in vials in 0.5ml 
volumes at a concentration of 1x 108/ml. The BCG was grown in shaken flasks in 7H9 
medium OADC (Oleic acid, bovine albumin fraction, dextrose and catalase) enrichment 
and with addition of 0.2% glucose and 0.05% Tyloxapol to an OD of 4. Then the tube 
was spun down and resuspended in half the volume of formulation buffer (20% glycerol, 
0.85% NaCl and 0.05% Tyloxapol). 
 
Mycobacteria stock titration and standard curve for MGIT 
Materials required: 
• BCG Pasteur Aeras stock (0.5ml) 
• Sterile Eppendorf tubes -2 ml (Sigma Aldrich, UK) 
• BACTEC MGIT (mycobacterial growth indicator tube) tubes and PANTA 
enrichment (BecktonDickinson, BD) 
• Sterile filter tips (Starlab, UK) 
• Sterile PBS-Tween 80 (0.05%) (BD) 
• 7H11 agar plates with 10% OADC (BD) and 0.5% glycerol (Sigma Aldrich, UK) 
• Cling film (Sphere, UK) 
MGIT tube preparation 
One bottle of lyophilized MGIT PANTA was reconstituted with 15 ml MGIT growth 
supplement. It was mixed by turning it over until it was completely dissolved.  About 
800µl of MGIT PANTA enrichment was added to each BACTEC MGIT tube. For each 
dilution two tubes were prepared.  
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Stock titration 
BCG Aeras Pasteur was used as the immune target for the MGIAs in this assay. One vial 
of BCG stock was thawed and brought to room temperature. To make the stock titration 
for the standard curve, 7 serial 10-fold dilutions of the stock BCG were prepared by 
adding 1.08ml PBS–Tween to each of the seven Eppendorf dilution tubes, labelled as 10-
1, 10-2, 10-3, 10-4, 10-5, 10-6, 10-7. One hundred and twenty	µl undiluted stock was added to 
the first tube and mixed thoroughly by pipetting up and down. From the first tube (1 in 10 
dilution), 120µl was taken out and transferred to the next tube. Seven 10 fold serial 
dilutions of the stock were prepared. Duplicate MGIT tubes for each dilution were 
inoculated by adding 500µl of each dilution to the respective MGIT tube. The MGIT 
tubes were then placed into the BACTEC MGIT instrument.  
Agar plates were prepared and used to detect and count colony forming units (CFUs). The 
7H11 agar plate was divided into 4 quarters and labelled with different dilutions. Twenty 
µl of each dilution was inoculated into labelled dilution sectors. The plates were covered 
with cling film and placed in the incubator at 37ºC with 5% CO2. Colonies were counted 
as soon as they were visible, approximately 10-12 days. The number of colonies counted 
for the 1 x 108 BCG dilution was 100 CFUs. This value was then extrapolated to give the 
CFUs for each concentration.  
Standard Curve 
A standard curve was calculated by plotting Time to Positivity (TTP) against the CFU 
count determined by plating of the equivalent volume of the stock BCG and regression 
analysis was used to obtain the equation that can then be used to convert any TTP to 
volume or CFU. The regression analysis provided a R2 value and the equation describing 
the line. The equation of the standard curve was x=(y-c)/m, where y=TTP, m=slope, c=y 
intercept. By inserting the TTP, the number of CFU or log10 CFU initially added to the 
tube was calculated. The log10 CFU data was plotted in a graph. The number of log10 
CFU were divided by the number of log10 CFU in the direct-to-MGIT control to obtain 
the read-out of relative growth of bacteria. 
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Figure 2.1:  MGIT standard curve.  
PBMC preparation for the MGIA 
Cryopreserved PBMCs were thawed in a water bath at 37°C, washed and resuspended in 
RPMI-MGIT media (RPMI-1640 medium with 25mM HEPES (Sigma), 2mM L-
glutamine, 10% filtered, heat inactivated, pooled Human AB Serum) at a concentration of 
1 x106 cells/ml and incubated for 2 hours with benzonase nuclease (10 units/ml of cell) 
 (Novagen) in a 37°C incubator with 5% CO2. Cells were counted, washed and 
resuspended in RPMI-MGIT media at a concentration of 1 x106 cells/ml per 300µl 
medium and added to a 2 ml screw-cap micro tubes. Three hundred µl cell suspension 
was added to 2 ml screw cap tubes (Sarstedt, Germany) in duplicate.  
Preparation of BCG master mix 
The total number of tubes to be inoculated was calculated. The total volume of bacterial 
suspension required from the stock BCG concentration (1x108 /ml) for all the samples 
were also calculated. For each sample, one 2ml screw cap tube is used for the control 
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(only cells and media) and one for cells with BCG. First 300µl of the RPMI-MGIT media 
was added in each tube. An aliquot of BCG Pasteur was thawed and the total volume of 
BCG needed was calculated. The neat stock at 1 x 108/ml was diluted 1 in 10 with RPMI-
MGIT media (900µl RPMI+ 100µl of BCG stock) to give a concentration of 1 x 107/ml. 
Aliquots of 10µl from this 1/10 dilution were taken out and added to 990µl of RPMI-
MGIT to make a further 1/100 dilution to give a final 1/1000 dilution of the stock BCG at 
1 x 105/ml and then 5µl of the 1 in 1000 dilution was added to 5000µl of RPMI (a further 
1/1000 dilution) to prepare the working solution at 1 x 102/ml or 100 CFU/ml. A volume 
of 300µl of the working stock solution contained 3 x 101/ml (30 CFU).  
Preparation of Direct-to-MGIT BCG viability control tubes 
Two mycobacterial growth indicator tubes (MGIT) were supplemented with 800µl 
PANTA enrichment. First, 300µl of BCG master mix was added to each of the two 
control tubes. Another 200µl of PANTA/OADC enrichment (Becton Dickinson, UK) 
supplemented Middlebrook 7H9 from a spare tube was added to each tube to make the 
total volume added to the tube 500µl as per the manufacturer’s recommendation. The 
control tubes were then placed in the BACTEC MGIT 960 instrument. These duplicate 
MGIT tubes were inoculated on day 0, with the same volume of BCG (300µl) as added to 
the sample cultures. These tubes act as control tubes, as sample net growth values are 
normalized to the growth of their corresponding control. This also allows variability 
between different assay runs using the same BCG stock to be estimated. 
BCG and cells co-culture 
Three hundred µl of BCG master mix was added in labelled 2ml screw capped tubes and 
equal volumes of cell suspension containing 1 x 106/ml cells were added and mixed. The 
tubes were placed on a 360°C tube rotator inside a 37°C incubator for 96 hours. In 
duplicate tubes, only cells and media were incubated, which acted as the negative control. 
Preparing the samples for Mycobacterial Growth Inhibition  
After 96-hours incubation, cultures were centrifuged in a bench top microcentrifuge at 
12000 rpm for 10 minutes. About 500µl of supernatant were removedmaking sure that the 
pellet remained intact and the supernatant stored at -80ºC. The PBMCs were then lysed 
with 100µl tissue culture grade sterile water (Sigma Aldrich, UK). The tubes were 
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vortexed for 30 seconds and incubated at room temperature for 5 minutes and the process 
was repeated twice. Four hundred µl of PANTA/OADC enrichment broth were added to 
the lysate. Tubes were vortexed again for 30 seconds and then the cell suspension was 
then transferred to a BACTEC MGIT tube supplemented with PANTA antibiotics and 
OADC enrichment broth. The tube was then placed in a BACTEC MGIT 960 machine 
and incubated until growth/ time to positivity was detected. 
Interpretation and analysis of the assay 
To calculate the net growth, the mean TTP for matched duplicates of the samples and 
controls was converted to an initial mycobacterial inoculum volume. For that a standard 
curve was prepared based on the BCG stock titration. The equation of standard curve was 
x= (y-c)/m, where y= TTP, m= slope, c= y intercept. The volume is then converted to 
CFU by multiplying it by the CFU/µl value of the stock and the result is then log 
transformed.  
 
Figure 2.2 : MGIT standard curves for Mtb 
 A standard curve was created using inoculum volume, CFU and log10 CFU against 
TTP values. The calculated equation was y=m(lnx)+c, where y= TTP, m=slope and 
c= y intercept (non-linear regression, semi log line). 
 
 
 Equation Slope Intersect 
Curve equation non-
linear (volume) 
y=-36.73log(x)+ 75 -36.73 75 
Curve equation non-
linear (CFU) 
y=-36.73log(x)+ 278 -36.73 278 
Curve equation non-
linear (log 10 CFU) 
y=-36.73log(x)+ 241.2 -36.73 241.2 
Table 2.1: MGIT standard curve equations. 
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To determine inoculum volume, the following formula is used in a Excel file. 10^ (TTP-y 
intercept)/ slope. For example, if TTP is 204 hours, then the inoculum volume will be 10^ 
(204-75)/-36.73. CFU and Log10 CFU can also be calculated using the formula generated 
from the curve. Relative growth is calculated by subtracting the Log10 CFU of sample 
from Log10 CFU of the control. 
 
 
2.3  Flow Cytometry 
Intracellular cytokine staining (ICS) of stimulated PBMC followed by flow cytometric 
analysis was performed to detect the T cell immune responses and cytokine responses. 
ICS enabled the simultaneous detection of CD4 and CD8 positive T cells and secretion of 
cytokines such as IFNγ, TNFα, IL-2 in PPD and ESAT-6/CFP10 stimulated PBMC from 
uninfected individuals, helminth-infected patients, LTBI individuals and patients 
coinfected with LTBI and helminths. 
The aims were 
• To measure CD4+IFNγ+T cells in PPD and ESAT-6/CFP10 stimulated PBMCs 
from uninfected individuals, helminth-infected patients, LTBI individuals and 
patients coinfected with LTBI and helminths. 
• To measure the production of IFNγ, TNFα, IL-2 by CD4+ and CD8+ T cells after 
stimulation with PPD, ESAT-6/CFP10  
• To detect the frequency of CD4+IFNγ+T cells in stimulated PBMCs after 
anthelmintic treatment in helminth infected and LTBI-helminth infected patients. 
 
 
 
 
 
 
 
 106 
 
Marker Fluorophore Clone Company Catalogue 
no 
Surface antibody 
CD14 PE 61D3 Ebiosciences 12-0149-42 
CD19 Eflour450 HIB19 Ebiosciences 48-0199 
CD4 APC-H7 RPA-T4 BDBiosciences 560158 
Intracellular antibody 
CD3 Horizon BV510 UCHT1 BD Biosciences 563109 
CD8 APC SK1 BD Biosciences 344722 
IFN- γ Per-CP-Cy5.5 45.B3 Biolegend 502526 
TNFα PE-Cy7 Mab11 BD Biosciences 557647 
IL-2 FITC 5344.111 BD Biosciences 340448 
 
Table 2.2: Panel of antibodies used. 
 
FMO controls 
Fluorescence minus one (FMO) controls contain all the fluorescent antibodies except the 
one of interest.  
Antibody titrations 
To determine the optimum antibody titres required to stain the PBMC samples, all the 
antibodies were titrated in 5 dilutions with the manufacturer’s recommendation as the top 
dilution. Cells from healthy donors at LSHTM were used for titrating antibodies. 
Unstained cells were used as negative controls. The median fluorescence intensity (MFI) 
of positive and negative populations was then calculated. Then the staining index, named 
as a signal to noise ratio was calculated for each antibody and a scatter plot was obtained 
for the log antibody concentration versus the staining index. 
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Figure 2.3: Antibody titration to determine the optimum amount of antibody required for single 
stain. In the example, 5 µl of CD14 antibody is the optimal volume to be used in the 
250µl of final volume of staining. 
 
 
PBMC stimulation assay 
Frozen PBMC were thawed and used in this experiment, that were previously 
cryopreserved at -80ºC in freezing medium (RPMI 1640 (Invitrogen) +20% foetal calf 
serum (FCS) (Sigma) +10% dimethylsulphoxide (DMSO) (Sigma). PBMCs were 
resuspended to around 2x106 PBMC/ml R10 (RPMI, 10% FCS, Penicillin/streptomycin, 
L-glutamine and sodium pyruvate) media in 15 ml Falcon tubes. Ten µl Benzonase 
nuclease (Invitrogen) (2µl/ml) was added to each tube and the cells rested for 2 hours in a 
37ºC incubator with 5% CO2. PBMC were then washed in pre-warmed R10 media and 
resuspended to 1x106 PBMC/ml R10. One ml of PBMC (1x106 PBMC/ml ) was aliquoted 
into labelled 5 ml FACS tubes and  was stimulated with media alone, purified protein 
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derivative (PPD; Statens Serum Institute, Copenhagen, Denmark; 20µg/ml concentration 
from a stock of 1mg/ml), ESAT-6/CFP10 fusion protein (Lionex, Braunschweig; 10µg/ml 
concentration from a stock of 1mg/ml) and Staphylococcus enterotoxin B (SEB; Sigma-
Aldrich, St. Louis, MO; 5µg/ml concentration from a stock of 1mg/ml) and kept in the 
37ºC incubator with 5% CO2 for 2 hours. After 2 hours, Brefeldin A (3µg/ml) and 
monensin (1/2000 final dilution, 2µmol) were added to block the cytokine secretion. The 
tubes were then incubated for 18 hours in a 37ºC incubator in 5% CO2.  
Cell surface and intracellular staining 
Following overnight incubation, the cells were washed with FACS buffer (0.1% bovine 
serum albumin (BSA) (Sigma), 0.01% sodium azide in PBS (Sigma) and stained with live 
dead stain (1:40 dilution with dH2O) (Invitrogen) and incubated at 4ºC in the dark for 10 
minutes. Cells were then surface stained with anti CD4-APC-H7, anti CD19-efluor450 
and anti CD14-PE for 30 minutes at 4ºC. 
Compensation tubes were also prepared with compensation beads (CompBead, BD 
Biosciences) individually stained for each fluorophore except for CD19 and CD3 
(compensated with cells) during surface antibody incubation. After vortexing the beads, 2 
drops of positive and negative beads (each) were added with 2µl of antibody suspended in 
100µl of FACS buffer. For cells, in 100µl of FACS buffer, 20µl PBMCs from patients were 
added in tubes. Compensation tubes were incubated in the dark at 4ºC for 20 minutes.  
The cells and compensation controls were fixed and permeabilized with a commercial kit 
(BD Cytofix/Cytoperm™ Fixation/Permeabilization kit, BD Biosciences, UK) following 
the manufacturer’s protocol. After 20 minutes incubation, the compensation control beads 
were washed and resuspended in FACS buffer. The cells were finally stained 
intracellularly with anti-CD3-BV510, anti-CD8-APC, anti IFNγ PerCP-Cy5.5, anti 
TNFα-PE-Cy7, anti-IL-2-FITC for 30 minutes in the dark at room temperature. Cells 
were washed with PERM wash buffer (Sigma), resuspended in FACS buffer and filtered 
prior to acquisition on an LSRII flow cytometer (BD Biosciences). 
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Data acquisition 
After staining, cells were analysed on an LSRII flow cytometer. After PMT voltage setup, 
compensation matrices were calculated using BD FACS DIVA Software V8.0.1 (BD 
Biosciences, UK). One million events were routinely collected. Doublets were excluded 
from the analysis by the use of a gate defined by the FSC-A and FSC-H parameters that 
include only single cells. Viable CD3+ T lymphocytes were gated and from this gate CD4 
and CD8 populations were separated and finally a cytokine gate added to derive the 
frequency of cytokine-positive events. All the data were analysed using FlowJo software 
version 9 (Treestar, Ashland, OR).  
 
 
The complete gating strategy is shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: The flow cytometry gating strategy. Successive gates were applied to identify 
lymphocytes, singlet cells, CD3+ T cells and subsequently CD4+ and CD8+ T cells. 
Evaluation of cytokine production, (IFN γ, TNF α and IL-2) in unstimulated cells and 
following PPD stimulation was then performed. Figures refer to frequency of cells in 
the corresponding gate or quadrant. 
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2.4   Ex vivo IFN-γ ELIspot 
The ELISpot assay is frequently used for the detection of cytokine production by antigen 
specific T cells. The ELISpot assay is an effective tool to count the number of cells 
producing IFN-γ in response to a whole series of antigens, including peptides, peptide 
pools, proteins and bacterial extracts. Fletcher et al., compared immunological responses 
in BCG vaccinated individuals with mycobacterial growth inhibition, where IFN-γ 
responses were measured by ELISpot(394). They showed a significant increase in the 
IFN- γ ELISpot responses to PPD following primary vaccination and revaccination with 
BCG.  
The ELISpot assay was performed in this study to observe the effect of anthelmintic 
treatment on the frequency of IFN-γ responses to PPD in LTBI, helminth, LTBI-helminth 
co-infected and control patients.  
The appropriate number of vials were retrieved from liquid nitrogen and put onto ice. To 
thaw, vials were defrosted quickly in a 37ºC water bath and the contents transferred to a 
15 ml centrifuge tube containing 12 ml of R10 media. R10 media was prepared using 
RPMI 1640 (Sigma Aldrich, UK) with 10% L-glutamine, 10% FCS (Biosera, cat S1810), 
penicillin/streptomycin at 100µg/mL concentration (Sigma Aldrich, UK) and sodium 
pyruvate (1ml/100ml RPMI) (Gibco, UK). Cells were centrifuged at 439g for 7 minutes 
and the pellet resuspended in the medium at approximately 1x106 PBMC per ml. 
Benzonase nuclease (10 units/ml) was added and incubated at 37°C in an incubator with 
5% CO2 for 4 hours. 
Ninety-six well polyvinylidene fluoride ELISpot plates (Mabtech, cat MAIPS4510, 
Millipore, USA) were pre-coated with 15µg/mL of monoclonal antibody 1-D1K against 
IFNγ (Mabtech, Sweden). Fifty microliters of this solution was added to each well of an 
ELISpot plate which was tapped until the base of each well was covered. The plate was 
incubated overnight at 4°C. The following day, the ELISpot plate was washed 5 times 
with sterile PBS with flicking and blotting between each wash. The plate was blocked by 
adding 100µl of R10 media at 37°C for 2-5 hours. After 5 hours of blocking, the blocking 
solution was flicked out and 100µl of PBMC were added at 3x106/well in the plate.  
Mtb PPD antigen (Staten Serum Institute) was used at a final concentration of 10µg/ml 
and SEB (Staphylococcal enterotoxin B) as a positive control at a concentration of 
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40µg/ml. The final volume was 100µl/well. Two negative control wells contained cells in 
R10 alone with no antigen.  
Next day the media was flicked off and washed 5 times with PBS containing 0.05% 
Tween 20. Fifty µl of biotinylated anti-IFNγ secondary antibody (Mabtech, Human 
ELISpot Kit, cat 3420-2A) (diluted 1/1000 in PBS) was added and incubated for 2 hours 
at room temperature. The plate was then washed 5 times with PBS containing 0.05% 
Tween 20 (200µl/well). Fifty µl/well of streptavidin (diluted 1/1000 in PBS) was added to 
the plate, followed by aone hourincubation at room temperature. The plate was washed 
with wash buffer after one hour and 50µl/well developing buffer was added and incubated 
for approximately 10 minutes at room temperature until distinct spots developed. The 
substrate reaction was stopped by rinsing out the plate in tap water 3-4 times and leaving 
it to dry overnight. Spots were counted on an automated ELISpot reader (AID Germany, 
software version 5.0.  
Results were reported as spot forming cells (SFU) per 1 x 106 PBMC. In the negative 
control or unstimulated cell wells PBMC must have less than 20 spots/well. For the 
positive control, ≥ 200 spots was considered as positive. The result was calculated by 
subtracting the mean number of spots of the unstimulated PBMC from the mean count of 
duplicate antigen wells. This number is then divided by 0.3 to give a result in SFC/million 
PBMC. Responses were considered positive if the mean count is at least twice and at least 
5 spots more than that of the unstimulated or negative control wells. Data were analysed 
using Microsoft EXCEL and Graphpad Prism (Version 7.0). 
2.5   ENZYME-LINKED IMMUNOSORBENT ASSAY 
A sandwich ELISA was used to measure the quantity of total IgE, IgG4, IgA and IFNα. 
In this technique, the capture antibody is immobilised on a microtiter well. A plasma 
sample containing unknown amounts of antigen is allowed to react with the immobilized 
antibody. After the well is washed, enzyme-conjugated secondary antibody is added 
which is specific for that antibody class and allowed to react with the bound antigen 
followed by addition of substrate. The coloured reaction product is then quantified using 
an ELISA reader. 
About 20 ml whole blood was collected from each patient during their enrolment visit and 
during visit 2. From that 1 ml of whole blood was placed in a 2 ml Eppendorf tube and 
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centrifuged in a micro-centrifuge machine at 5000 rpm for 5 minutes. About 500µl of 
plasma was collected into a 2 ml tube and stored at -80°C for further analysis. Prior to the 
ELISA assay, the plasma sample was aliquoted in a micro well plate in volumes of 
50µland stored at -80°C to prevent repeated freeze thawing.  
A Ready-Set-Go Sandwich ELISA was used for detection and quantification of the 
antibodies mentioned above in the plasma obtained from the whole blood collected from 
the clinical samples. A 96 well flat bottom Nunc MaxiSorp® ELISA plate (Affimetrix, 
eBioscience, UK) was coated with 100µl/well of capture antibody (pre-titrated, purified 
anti-human IgE/IgG4/IgA/IFNα) in 1:10 dilution of coating buffer (PBS in deionized 
water) for each antibody.  Plates were sealed and incubated overnight at 4°C. 
The plates were washed twice with 400µl/well wash buffer with a one-minute interval 
during each wash step. The plates were blotted on absorbent paper to remove any residual 
buffer.The plates were blocked with 250µl/well of blocking buffer (Assay buffer 
concentrate, provided in the kit) for two hours at room temperature. The blocking solution 
was flicked off and blotted. 
Meanwhile, two-fold serial dilutions of a standard were prepared for each antibody and 
100µl/well of the serially diluted standard was pipetted into the first two columns of the 
plates in duplicate. Samples were prepared by diluting test plasma 1:4 and 1:10 in assay 
buffer. One hundred µl of sample was added per well and 100µl of assay buffer added to 
the blank wells and the plates sealed and incubated for 2 hours at room temperature on a 
micro plate shaker at 400 rpm. 
The contents were then discarded and the plates were washed 4 times with wash buffer 
with a one-minute interval between each wash. After blotting, about 100µl/well of diluted 
detection antibody (pre-titrated, horseradish peroxidase (HRP) conjugated anti-human 
IgG4/IgE/IgA/IFNα monoclonal antibody) was added, plates were sealed and incubated 
for 1 hour at room temperature on a micro plate shaker at 400 rpm. 
Plates were flicked and washed 4 times as described above followed by adding 
100µl/well substrate solution Tetramethylbenzidine (TMB) substrate solution and 
incubated at room temperature for approximately 15 minutes. About 100µl/well of Stop 
solution (2N H2SO4) was added and optical density (OD) at 450nm was measured using 
an ELISA plate reader (Microplate Reader, Biorad). Results are shown for samples dilited 
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1 in 10. As the samples were diluted 1:10, the concentration from the standard curve was 
multiplied by dilution factor (x10). 
 
Antibody Sensitivity Standard curve 
range 
Sample 
dilution 
ELISA Kit and catalog 
number 
IgE 7.8 ng/ml 1000-7.8ng/ml 1:4 and 1:10 eBioscience; 88-50610 
IgG4 31.3 ng/ml 2000-31.3ng/ml 1:4 and 1:10 eBioscience; 88-50590-22 
IgA 1.6ng/ml 100-1.6ng/ml 1:4 and 1:10 eBioscience; 88-50600-22 
IFNα 3.2pg/ml 7.8-500pg/ml 1:4 and 1:10 eBioscience; BMS216 
Table 2.3: Antibodies used for ELISA. 
 
 
2.6   Luminex 
The Multiplex MAP Human Cytokine/Chemokine Panel-Premixed 41 Plex-Immunology 
Multiplex assay was used to analyse plasma /culture supernatants for multiple cytokine 
and chemokine biomarkers in a Bead-based Multiplex Assayusing Luminex technology. 
The concentration of 41 analytes in the plasma and culture supernatants included 
cytokines, chemokine and growth factors: sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3 
ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFNα2, IFNγ, IL-1α, IL-1β, IL-1ra, IL-2, IL-
3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, 
IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, 
RANTES, TGFα, TNFα, TNFβ, VEGF. Analyte concentrations were calculated following 
the manufacturer’s instructions (Cat no HCYTMAG-60K-PX41, Merck Millipore, UK). 
Plasma and 96 hour MGIT culture supernatants were thawed and aliquoted at 100µl/well 
in a 96 well micro titre plate and in triplicate. The plate was stored at -80°C. Before use 
the frozen samples were thawed completely and mixed well by vortexing and centrifuged 
prior to use in the assay. Neat plasma and culture supernatant was used. 
To prepare Antibody-immobilized Beads, the premixed beads in the bottle were sonicated 
for 30 seconds and then vortexed for 1 minute before use. Sixty µl of the antibody beads 
was added to the mixing bottle and the volume was made up to 3mL with bead diluents. 
The beads were then vortexed well. 
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Before use, Quality Control 1 and Quality Control 2 prepared in 250µl deionized water 
were prepared. The vials were inverted several times to mix and vortexed. The vial was 
allowed to sit for 5-10 minutes and then transferred to an appropriately labelled 
polypropylene microfuge tube.The 10X wash buffer was brought to room temperature 
and mixed well to bring all salts into solution. Then 60 ml of 10X wash buffer was diluted 
with 540mL deionized water. 
To prepare the serum matrix, 1 ml of deionized water was added to the bottle containing 
lyophilized serum Matrix, mixed well and left for 10 minutes for complete reconstitution. 
Standards were prepared according to the manufacturer’s manual by serial dilution. Prior 
to use, the Human cytokine standard was reconstituted with 250µl deionized water to give 
a 10,000pg/ml concentration of standard for all the analytes. The vial was inverted several 
times to mix properly and then vortexed for 10 seconds. The vial was allowed to sit for 5-
10 minutes and then transferred to an appropriately labelled polypropylene microfuge 
tube. Five polypropylene microfuge tubes were labelled as 2000, 400, 80, 16 and 3.2 
pg/ml. About 200µl of assay buffer was added to each tube. Serial dilutions were 
prepared by adding 50µl of the 10,000 pg/ml reconstituted standard to the 2000 pg/ml 
tube and mixed well. Different standard concentrations were prepared by serial dilution. 
Before use in the assay, all the reagents were warmed to room temperature (20-25ºC). A 
worksheet was prepared to design the sample and standard placement. All the samples 
were run in duplicate. First, 200µl per well of wash buffer was added to the Luminex 
plate. The plate was then sealed and mixed on a plate shaker for 10 minutes at room 
temperature. Wash buffer was decanted by inverting and blotting, and 25µl of each 
standard was added in the appropriate wells. Two wells of assay buffer were used to 
determine the background. Twenty five µl of assay buffer was added to all the sample 
wells and 25µl of serum matrix was then added to the background, standards and control 
wells and then 25µl of plasma/culture supernatant was added into the appropriate wells. 
The mixing bottle containing beads was vortexed well and 25µl of the premixed beads 
were added to each well. The plate was sealed, wrapped in foil and incubated on a plate 
shaker for 2 hours at room temperature at 400 rpm. 
The well contents were then aspirated and the plate rested on a magnet for complete 
settling of the magnetic beads for 60 seconds before gently decanting and blotting. The 
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plate was removed from the magnet and washed with 200µl of wash buffer. The wash 
procedure was repeated twice. Then 25µl of the detection antibody was added to each 
wells. The plate was sealed, wrapped in foil and incubated on a plate shaker for 1 hour at 
room temperature at 400 rpm before 25µl of Streptavidin. Phycoerythrin was added to 
each wells. The plate was sealed, wrapped in foil and incubated on a plate shaker for 30 
minutes at room temperature at 400 rpm. The well contents were then carefully aspirated 
and the plate was washed twice using the magnet as described above. About 150µl of 
Sheath Fluid was added to each well and the beads were resuspended on the plate shaker 
for 5 minutes.  
The plate was then run on the Luminex200 machine and analysed using xPOTENT 
software. The machine was set to analyse in each well a minimum of 50 analyte-
specific beads per region for fluorescence. The MFI was analysed using a 5 parameter 
logistic (5-PL) algorithm. After the samples were run, a curve fit was applied to each 
standard curve by adjusting the ratio of the calculated value to the expected value of 
each standard between 80 and 120% following the manufacturer’s instruction. The 
concentrations of cytokines were then determined by interpolation from the standard 
curves, those that were outside the standard curve but within the calculable limits was 
estimated by extrapolation and marked with an asterisk by the software. Concentrations 
of cytokines that were above or below the available detection limits were marked as Out 
of Range (OOR) OOR>orOOR< respectively. When the curve fitting was completed, 
the results were exported into an Excel spreadsheet labelled with the plate number and 
date of run. 
2.7   Real time PCR assay 
Using real time quantitative reverse transcriptase (qRT-PCR) assay, the mRNA 
expression levels for genes- Indoleamine 2,3-dioxygenase 1 (IDO-1), CD14, Arginase 1, 
Hypoxia inducible factor (HIF) HIF1α, HIF2α, IL-10, CXCL10, CD163 and CD86 were 
determined in blood samples obtained from controls, helminth infected, LTBI and LTBI-
helminth co-infected patients. In qRT-PCR, RNA was first transcribed into 
complementary DNA (cDNA) by reverse transcriptase from total RNA. The cDNA was 
then used as the template for the qRT-PCR reaction. The qRT-PCR assay included total 
RNA extraction, cDNA synthesis and qRT-PCR assay. 
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Collection and storage of blood in RNA stabilisation tubes 
Following enrolment and at visit 2, 3ml blood were drawn into TempusTM blood RNA 
tubes (Applied Biosystems, USA) from patients of all four groups in the clinic. These 
tubes contain RNA Stabilizing Reagent and RNA expression is, therefore, stable in the 
collection tube for up to  five days at room temperature (18-25°C). Immediately after 
the Tempus tube was filled, blood was stabilised by shaking the tube vigorously for 10 
seconds to ensure that the stabilising agent inside the tube made uniform contact with 
the blood sample. After collection, these tubes were sent to the LSHTM laboratory 
(within 4-6 hours of collection) The tubes were then frozen at -80°C for prolonged 
storage.  
Extraction of ex vivo RNA 
Tempus tube blood RNA extraction was performed using the Tempus Spin RNA 
Isolation kit (Applied Biosystems, USA). Tempus tubes were thawed for 30 minutes in 
ice and then brought to normal temperature (18-22ºC). After thawing, the tubes were 
inverted 5-10 times. The caps from the tubes were removed and the blood was poured 
into clean 50mL Falcon tubes. Blood samples were washed with PBS and vortexed 
vigorously for 30 seconds to ensure proper mixing of contents. Then the tubes were 
centrifuged for 30 minutes at 4ºC at 3000 x g. The supernatant was discarded and tubes 
were left inverted on absorbent paper for 1-2 minutes. Then 400µl of RNA Purification 
Resuspension Solution was added to the RNA pellet and vortexed briefly. The 
resuspended samples were kept on ice until the next steps of purification. A RNA 
purification filter was inserted into a collection tube. The filter was pre-wetted with 
RNA purification wash solution. Cell lysate was pipetted directly into the filter and 
centrifuged at 16,000 x g for 30 seconds and the wash step and centrifugation were 
repeated twice. DNA digestion was performed as part of the extraction method using 
RNase-Free DNase Set (Qiagen, Germany). This treatment is required for complete 
removal of genomic DNA. This set contains RDD buffer and RNase free DNase and 
contains 1500 Kunitz units of lyophilized enzymes.  Eighty ul of the solution (DNase in 
DNase buffer, 1 in 6) was added to the samples before incubation at room temperature 
for 15 minutes. DNase was washed away with further washes prior to the elution of 
RNA. The Nucleic Acid Purification Elution solution was added  in tubes which were 
incubated for 2 minutes at 70°C in Eppendorf Thermomixer Compact (Eppendorf, 
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USA) without shaking and then centrifuged. Ninety µl of eluted RNA was collected in  
newly labelled collection tubes. The total RNA extracted by this method was stored at -
80°C for further cDNA synthesis and qRT-PCR. 
RNA quantification  
Extracted mRNA was quantified using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific, UK). This spectrophotometer can measure 1µl RNA elute with high accuracy 
and reproducibility. The manufacturer’s protocol was followed and after quantification 
sample concentrations are given in ng/µl based on absorbance at 260 and 280 nm. The 
260/280 ratio is used to assess the purity of extracted RNA and a ratio of ~2.0 is generally 
accepted as “pure” for RNA. Samples were diluted to 200ng total RNA in 11µl water for 
the downstream assay. 
First-Strand cDNA synthesis 
Complementary DNA (cDNA) was synthesized from the extracted RNA using 
Superscript III (AB Applied Biosystems, UK). Extracted RNA in tubes were thawed on 
normal ice.  Calculated volumes of water and RNA were added to PCR tubes. 
Meanwhile, the PCR machine (C1000 thermal cycler, BIO-RAD) was turned on to heat 
the lid up to 105° C and a program created on the machine. In a nuclease-free 
microcentrifuge tube (Ambion, USA) Master Mix 1 was prepared using 1µl of 200ng/µl 
of Oligo(dT) and 1µl of 10mM dNTP each per tube and vortexed briefly. Two µl of 
Master Mix 1 was added to each PCR tube, making the total reaction volume of 13µl.  
The PCR tubes were heated for 65° C for 5 minutes and incubated on ice for 1 minute. 
During that 5 minutes interval Master Mix 2 was prepared using 4µl of 5X First-Stranded 
Buffer,1µl of 0.1M DTT, 1µl of RNaseOUT (40 units/µl) (Recombinant RNase inhibitor, 
Invitrogen, USA ) and 1µl of SuperScriptTM III RT (200 units/µl) (Invitrogen, USA) each 
per sample. Seven µl of the Master Mix 2 was added to each tube and mixed by brief 
vortexing.  The samples were incubated at 50° C for 1 hour and inactivated at 70° C for 
15 minutes and chilled at 4° C. The tubes were then transferred for freezing at -80° C. 
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Choice of control gene  
To perform suitable reliable gene expression quantification analysis, reference genes need 
to be validated. Reference (or normalizer) genes are defined as those with a stable 
expression under previously defined conditions, thus appropriate to quantify gene 
expression levels of specific targets. Previously three reference genes TATA box binding 
protein (TBP), Human acidic Ribosomal Protein (HuPO) and Hypoxanthine 
phosphoribosyltransferase (HPRT) were chosen as housekeeping genes. These reference 
genes have been described in whole blood and PBMC samples to have minimum 
variability and stable expression (402). In this experiment, HPRT was stably expressed in 
all the clinical samples and was expressed more than TBP and HuPO. So HPRT was 
chosen as the housekeeping gene that was assigned as the endogenous control in the 
experiments. In this experiment, another gene was used as normalizer- CD14. CD14 is 
stably expressed in monocytes and macrophages and monocytes play an important role in 
the growth, survival and replication of the mycobacteria. CD14 was used in this 
experiment to normalize mRNA for monocyte frequency. The variation in the expression 
of these two genes may reflect that they may be not be constantly expressed or there 
might be differences in expression stability. 
 
 
 
 
 
 
 
 
 
 119 
A  Helminth infected                     B LTBI-helminth coinfected 
 
 
          C   LTBI patient                               D Control 
 
 
Figure 2.5: Variability in expression of three reference genes (HuPO, TBP and HPRT). Gene 
expression was assessed in helminth (A), LTBI-helminth coinfected patients (B), 
LTBI (C) and controls (D). HPRT showed less variability in the pattern and level of 
expression. 
 
Primers used 
All the primers were designed using Primer3 software (403). The primers for CD163 and 
CD86 were designed by Dr. Jacqueline M Cliff and Dr JiSook Lee and for HPRT was 
designed by Dr.Martin Holland. The mRNA sequences were obtained from the National 
Centre for the Biotechnology Information (NCBI) data bank 
(https://www.ncbi.nlm.nih.gov).Primers between 18-20-24 nucleotides in length were 
designed across intron/exon boundaries on the mRNA sequence. The optimal design 
parameter were included as-the Primer Tm 62-63.5-65° C, Primer GC% 30-50-70, 
maximum self-complementarity 5.00 and maximum 3Ꞌself-complementarity 3.00 were 
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also considered when designing the primers. All primer sequences were blasted on the 
NCBI data bank to confirm their specificity. A 100µM primer stock solution was 
prepared according to the Manufacturer’s recommendation, by dilution in water the 
working stock of 10.0µM prepared and kept at -20ºC until used. All the primer pairs were 
purchased from Sigma-Aldrich. 
 
Primer  
 
Sequence  
 
Length 
 
Tm 
(ºC) 
 
% GC 
ratio 
 
Amplicon 
size (bp) 
 
Accession 
number 
CD163 F ACTGCAAGAACTGGCAATGG 20 65.2 50  
136 
NM_004244.5 
 CD163R CCATGCTTCACTTCAACACG 20 64.4 50 
CD 86F CAGGGAGGGGTTTTGGTGAT 20 67.1 55  
130 
NM_001206924.1 
CD86 R CAGCCAGGAGTGGAAAGTCC 20 66.1 60 
HPRT F CCTGGCGTCGTGATTAGTGA 20 66.8 55  
146 
NM_000194 
 HPRT R CCCTTTCCAAATCCTCAGCA 24 65.7 41.6 
IDO-1 F AGGCAACCCCCAGCTATCAG 20 67.4 60  
150 
NM_002164 
 IDO-1R GCATGTCCTCCACCAGCAGT 20 67.8 60 
CD14-F GGAAGAGAGGTGGGGAGGTG 20 67.2 65 87 NM_001174104 
 CD14-R TCGGCTGCCTCTGACAGTTT 20 67.3 65 
Arginase 1 F ATTCCCGATGTGCCAGGATT 20 67.6 50 89 NM_001244438 
 Arginase 1R CCAGGGTCCACGTCTCTCAA 20 67.7 60 
HIF 1α F GCCGCTGGAGACACAATCAT 20 67.5 55 112 NM_001243084 
 HIF 1α R TGGGTGAGGGGAGCATTACA 20 67.7 55 
HIF 2α F GTCGTCAGCCCACAAGGTGT 20 67.6 60 109 XM_011532698 
 HIF 2α R GGGCACGTTCACCTCACAGT 20 67.6 60 
IL-10F TCCATTCCAAGCCTGACCAC 20 67.4 55  
97 IL-10R GCAGTTAGGAAGCCCCAAGC 20 67.0 60 NM_000572 
CXCL10 F ACGCTGTACCTGCATCAGCA 20 67.0 55 93 NM_001565 
 CXCL10R CGTGGACAAAATTGGCTTGC 20 67.5 50 
 
Table 2.4: Primer sequences and properties of primers used in the qRT-PCR experiments. 
 
qRT-PCR/ Real-time quantitative PCR 
PCR was performed using SYBR-GREEN (Applied Biosystems) on an ABI Prism 7500 
Fast machine, followed by melt curve analysis. qRT-PCR was run using the target genes 
CD163, CD86, IDO-1, CD14, Arginase 1, HIF1α. HIF2α, CXCL10, IL-10 and IL-4 and 
reference gene HPRT to ensure better quality RNA. During the initial experiments, the 
primers for IL-4 did not work well for the clinical samples- as they did not amplify as 
 121 
expected or sometimes the expression was too heterogeneous in individual samples. So 
IL4 was not included in the experiments afterwards.  
For the PCR reaction, a Master Mix was prepared in a 1.5µl  Eppendorf tube. The mixture 
comprised of RNase free water (Ambion, USA),10µl Fast SYBR Green Master Mix 
(Applied Biosystems, USA) and forward and reverse primers (1µl of 10µM primer 
concentration) to make a reaction mix volume of up to 15µl. cDNA was diluted to 1 in 10 
and 5µl of the diluted cDNA added to the wells of a 96 well PCR plate (FrameStar Fast 
Plate, 4titude, UK). An Eppendorf Combi-tip Repeating Pipettor was used to dispense 
15µl of the reaction mix to each well. Negative controls were included without reverse 
transcriptase, to exclude genomic DNA contamination. The plate was sealed with 
adhesive sealing sheets and then spun in the centrifuge very briefly to mix the contents of 
the wells properly and to remove air bubbles. The plates were first loaded into the plate 
holder in the instrument. A plate lay out was designed in the software and target genes 
and endogenous control and reference sample was assigned. The run method in the 
machine was set. The thermal profile consisted of a holding stage, cycling stage and 
melting curve stage. The conditions set were 95 for 15 seconds, followed by 40 cycles of 
95 C for 15 seconds and 60C for 60 seconds. The primer-dimer formation was checked by 
melt curve analysis.Relative gene expression quantification was achieved using a relative 
Ct method and analysed using Fast 7500, version 2.3 (Applied Biosystems 7500 Fast Real 
Time PCR System). 
Calculating the relative gene expression 
The relative gene expression was analysed by using the 2∆∆CT method. The CT value is the 
threshold number for the amplification of the target gene. The CT values were obtained 
for the target gene, and control gene for each patient at two different time points- pre and 
post treatment. An average of all the Ct values of controls were calculated. The difference 
in CT value was obtained by subtracting the CT of the target gene from the CT of the 
control gene and designated as ∆CT. To compare the relative target gene expression in 
LTBI, helminth and LTBI-helminth coinfected patients, ∆∆CT value was calculated by 
subtracting ∆CT of the controls from the ∆CT of LTBI, helminth and LTBI-helminth 
coinfected groups. The fold change was obtained by using the formula 2-∆∆CT. 
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 To compare the modulation in gene expression in helminth and LTBI-helminth 
coinfected patients after completing the anthelmintic treatment, ∆∆CT value of pre-
treatment samples (V1) were subtracted from the post treatment samples. The fold change 
for target gene expression in patients from the pre-treatment level was calculated using 
the formula 2-∆∆CT. 
Statistical analysis 
Differential gene expression in different groups (∆CT) were compared using two-way 
ANOVA. ANOVA was followed by a Bonferroni post–test to compare the mean of all 
groups with one another. To compare the fold change of each of the target gene in LTBI, 
helminth and co-infected groups compared to control samples two-way ANOVA was 
used followed by Dunnett’s post-test. The gene expression modulation after anthelmintic 
treatment in helminth and LTBI-helminth co-infected group were observed using a paired 
t test- Wilcoxon matched-pairs signed rank test. Heat maps were created using GraphPad 
Prism version 7.01 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com). 
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Chapter - 3     Characterization of the migrant cohort 
3.1   Characterization of the migrant cohort 
A total of 155 patients were enrolled in this study since 2013. Of these, 32 were latently 
infected TB patients (LTBI), 36 helminth infected patients, 16 LTBI- helminth coinfected 
patients and 32 controls. The patients in this cohort were recruited on their first visit to 
the clinic when they received anthelmintic treatment if required, and were requested to 
come back at least 4 months later. Those not treated for helminths were also asked to 
come back 4 months later. The rate of follow-up at visit 2 was 43.7% for LTBI, 38.8% for 
helminth infected, 37.5% for controls and 50% for coinfected patients. The time intervals 
between V1 and V2 were 6 months (4-9 months) for controls, 6 months (3-11 months) for 
LTBI patients, 4.8 months (4-8 months) for helminth infected patients and 5.7 months (4-
8 months) for LTBI-helminth coinfected patients. 
This recruitment was a continuation of a project funded by the EU Consortium IDEA that 
ran from 2011-2015. In that period, 108 helminth infected patients, 48 LTBI-helminth 
coinfected patients, 58 LTBI patients and 29 controls were recruited till December 2014. 
The rate of follow-up for this recruitment at visit 2 was 77.5% for LTBI, 73.1% for 
helminth infected, 58.6% for controls and 85.4% for coinfected patients. Dr. Frederic 
Toulza was working on the IDEA project and finished the immunological tests for IDEA 
on those samples in 2014. He investigated the anthelmintic treatment modulation of 
antimycobacterial immunity in this cohort. He observed the frequency of CD4+IFNγ+T 
cells measured following stimulation with PPD and ESAT-6/CFP-10 antigen and 
measured the concentration of IFNγ in culture supernatants using ELISA and multiplex 
bead array. He also observed the changes in CD4+FoxP3+T cells (Treg) after 
anthelmintic treatment. The patient recruitment was extended afterwards for this study to 
use some more immunological methods and to look at the host cell ability to control the 
growth of mycobacteria in these groups of patients along with other parameters like 
cytokines, antibodies, etc. Since the patient data for the whole combined cohort was 
available, the epidemiological data and the haematological parameters were analysed for 
all these recruited. In this chapter all demographic data and haematological analysis will 
be discussed for all the patients recruited since 2011 and immunological analyses will be 
described in the consecutive chapters for the patients recruited since January 2014. 
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A total of 217 males and 137 females were recruited overall and the male to female ratio 
was 2:1 (Table 1). The median age for males was 41 years (21-84 years) and for 
females36 years (20-79 years). The mean ages of the coinfected males and females were 
higher than the controls and slightly higher in LTBI males, helminth infected male, and 
females than the controls. 
In this cohort, in total 284 patients were BCG vaccinated. Sixteen patients were not 
vaccinated and 54 could not confirm their BCG vaccination status. Among all the LTBI-
helminth coinfected patients,12 could not confirm their BCG vaccination status and the 
rest were BCG vaccinated. Among the controls, 2 were not vaccinated. In LTBI patients, 
5 patients were non vaccinated and the vaccination status was not known for 12 patients. 
Most of the helminth infected patients were BCG vaccinated but vaccination status was 
not known for 28 patients (Table 3.1).  
Two hundred ninety-eight patients were known to be HIV negative. Sixty-two patients 
were not sure about their HIV status or had never been tested for HIV. Two male patient 
with helminth infection and one coinfected patient could not confirm their HIV status, 
also 2 controls (one male and 2 females) had never been tested for HIV. It is not 
considered appropriate to test for HIV in this setting unless this is required clinically. 
3.1.1  Migrant status 
The largest group of patients recruited in this study were from Bangladesh followed by 
Nigeria, India, Philippines, Kenya, Ghana, Zimbabwe, Somalia, Eretria, Ethiopia, 
Pakistan, South Africa and Sierra Leone (Figure 3.1). The study population was very 
heterogeneous ranging from few years’ spent in the UK to migrants that had been living 
in UK for more than 20 years. The mean length of stay in UK for these migrants was 17.3 
years for controls and the stay was similar for LTBI and helminth infected patients. 
However, for LTBI-helminth coinfected patients the mean length of stay in UK was 
somehow longer than the other groups (23 years). 
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Figure 3.1: The country of origin of migrants recruited in the study (in the combined cohort). 
In the control groups, the majority of the patients were from Bangladesh (32%) followed 
by Nigeria (16%), Ghana (10%) India (8%), Kenya (7%), Pakistan (7%). In the LTBI 
group of patients, the majority of the patients were from Bangladesh (23%) followed by 
Nigeria (17%) Philippines (12%), India (6%), Ethiopia (6%).In the helminth infected 
patients, the majority of the migrants were from Bangladesh (45%), followed by Nigeria 
(7%), Ghana (6%), Zimbabwe (5%), (Figure 3). In the LTBI-helminth coinfected patients, 
the migrants were predominantly from Bangladesh (31%), Nigeria (11%) and Ghana 
(8%).  
3.1.2  Clinical data and history of treatment 
In this cohort, 14 patients had a previous history of TB. Four patients could not remember 
their previous TB history and BCG vaccination status. All the other patients were born in 
endemic countries like Bangladesh, Ethiopia, Somalia, Philippines, and Jamaica, with the 
majority from Bangladesh. These patients had been living in the UK for more than 10 
years. Four of them were coinfected with LTBI and helminth infection and presented with 
helminth infection in the clinic and were infected with multiple helminths. Two were not 
BCG vaccinated; they had a previous episode of TB more than 10 years earlier and had 
treatment. 
Of the 90 LTBI patients in this cohort, 33 of them received treatment for LTBI after visit 
1. Of the LTBI patients, 25 were HCWs. Twenty-three HCWs received treatment for 
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LTBI and two were offered treatment but they declined treatment. None of the LTBI 
patients included in this study was on treatment for their LTBI at visit 1. The average age 
of LTBI patients, who received treatment were 33.72 years of age and of the HCWs were 
of 34.7 years. Previous UK policy was to only offer treatment for LTBI to those aged less 
than 35 years, although this was recently changed to 65 years. 
In our cohort, 40.67% were helminth infected and 18.07% were LTBI-helminth 
coinfected patients. Of the helminth infected group, 66.6% of the patients presented with 
Strongyloidiasis, 15.27 % with Schistosomiasis, 4.16% with tapeworm infection, 4.16% 
with both infections and 3% with Strongyloidiasis, Schistosoma infection and filariasis. 
Of the 64 LTBI-helminth coinfected patients, 78.1% patients presented with 
Strongyloidiasis, 14.1% with Schistosoma infection and 3.47% with tapeworm infection. 
Most of the helminth infected patients presented with symptoms of helminth infection for 
example fever, abdominal pain, nausea, diarrhoea, bloating, vomiting, respiratory 
symptoms like cough, wheeze and cutaneous symptoms like itchy urticarial or 
maculopapular rash. Any history of urinary symptoms like haematuria or dysuria 
suggestive of S.haematobium infection etc. was also investigated. None of these patients 
were previously treated for helminth infection. Ten patients with latent TB infection, also 
presented with symptoms consistent with helminth infection, but microscopically and 
serologically they were not positive for helminths. Twelve of the control patients also 
exhibited helminth infection symptoms, but were serologically negative. None of these 
controls received treatment for helminth infection, except for 3 who were empirically 
treated with Tinidazole as they had eosinophilia and symptoms of helminth infection but 
were serologically negative for any helminths. 
3.1.3  Laboratory diagnosis of helminth infection 
Strongyloides infections were diagnosed by faecal microscopy and stool culture for the 
demonstration of larvae. For Strongyloides spp, serum samples were analysed by a 
commercial ELISA for anti-Strongyloides antibodies according to the manufacturer’s 
protocol that uses a variable cut-off based on a low positive serum. This is a solid phase 
in vitro quantitative assay for the indirect detection of IgG to S.ratti somatic larval 
antigen (Bordier, France). According to the Bordier affinity S.ratti kit the test sensitivity 
is 88% and specificity 100%. There is known to be cross reaction between lymphatic 
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filariasis, onchocerciasis, loiasis and hookworm in ELISA tests. Strongyloides serology 
showed 73% sensitivity in travellers and 98% in migrants and the specificity was shown 
to be 94% in non-endemic area and 77% in person with other parasitosis(404). Faeces 
samples were also cultured to detect Strongyloides or hookworm using the charcoal 
culture method. 
For anti-schistosome antibodies, an in-house ELISA assay was performed, using the 
standard clinical diagnostic tests currently in use in the National Parasite Reference 
Laboratory of the United Kingdom, based at the HTD. A minimum of 0.5ml of serum is 
required.The ELISA is reported to detect about 96% of S.mansoni and 92% of 
S.haematobium infections. The test does not distinguish active from treated infections. 
The actual time taken to become seronegative post- treatment varies, but in some patients 
the test may remain positive for over two years after treatment. Positive results are 
reported at Levels 1 to 6. Levels 1 and 2 are regarded as weak positives; levels 5 and over 
are strong positives. It is known that patients may become seropositive through contact 
with cercaria from animal species of schistosomes and probably when harbouring 
unisexual infection with human species. The schistosomal egg antigen used in the ELISA 
may give a false positive, cross reactive response in trichinosis cases or with those with 
hepatitis cases in some instances.  
For Schistosomiasis definitive diagnosis is by demonstration of the characteristic ova in 
clinical material. For S.haematobium, a terminal urine sample (the last 10 to 20ml of 
urine passed) is required. Faecal samples are the best specimens for the detection of 
S.mansoni (and S.japonicum) but as S.mansoni and S.haematobium overlap in 
geographical distribution and can affect both genitourinary and alimentary systems a 
terminal urine sample and a minimum of three faecal samples should be sent from all 
patients being investigated for schistosomiasis when serology is positive.  
PCR for Strongyloides spp were performed for selected patients using primer for 
Strongyloides spp (n=67). Forty patients were seropositive, of these one was positive on 
microscopy and an additional 5 positive on culture. Of these 6 parasite-positive cases, 4 
were PCR positive. An additional 11 were negative on microscopy and culture but PCR 
positive. PCR had the sensitivity of 66% against culture as gold standard and 38% against 
serology as a gold standard. Of the 27 who were seronegative, none were positive on 
microscopy or culture, four were positive on PCR. Of the 4 PCR positive patients who 
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were seronegative, were all presented with asymptomatic eosinophilia. One of them had 
symptoms of helminth infection. Three of them were treated empirically with 
anthelmintic and one of them refused treatment as no infection was detected at that stage.  
Strongyloidiasis causes mostly asymptomatic infection and diagnosis of latent infections 
is difficult due to limitations of current parasitological and serological methods. In 
uncomplicated cases of Strongyloidiasis, the intestinal worm load is very low and the 
output of larvae is minimal and irregular, hence the sensitivity of direct observation of 
larvae decreases considerably (405).The detection rate of conventional methods is low 
and repeated examination of stool over a number of consecutive days is essential for the 
diagnosis. Serodiagnostic tests ELISA have exhibited variable sensitivity and specificity 
in studies for diagnosis of Strongyloides infection. Serology may overestimate the burden 
of disease, because serology remains positive after resolution of the infection and the 
presence of the cross reactivity. In different studies, agar plate culture of stool samples 
has reported to be a sensitive method to detect Strongyloides infection. However, this 
method requires multiple fresh stool samples and an experienced microscopist. Brown et 
al., conducted a study of interaction of helminth infestation and HIV in a cohort of 412 
HIV-infected people in Uganda, where analysis of a single stool sample underestimated 
the helminth prevalence, especially in low intensity infections. Thirty-nine percent of 
patients were diagnosed to have S.mansoni infection using formol-ether concentration, 
Kato-Katz and charcoal culture, but the detection was 49% when all three tests were done 
along with ELISA for S.mansoni (406).  
In recent years, some PCR based techniques have been developed and used for detection 
of different intestinal parasites in faecal samples and in some studies, PCR has been 
stated as a highly sensitive method for detection of helminth infections. Standardization 
of these techniques is necessary to overcome the limitations of the current diagnostic 
methods.  The difficulty encountered in this method involves the extraction of DNA from 
larvae of Strongyloides, due to the presence of a resistant cuticle which is difficult to 
disrupt mechanically.There may be irregular release of larvae in the faeces and presence 
of inhibitor of DNA in the environment, in addition, small sample size may lead to false 
negative results, laborious standardization and expensive equipment is required. The 
detection rate in the current study was very low, which might be due to low 
concentrations of parasite DNA in presence of PCR inhibitors.  
 129 
3.1.4  Eosinophilia in helminth infected patients 
Helminth infection is one of the commonest cause of eosinophilia in the returning 
traveller or migrants. In the UK, about 852 asymptomatic returning traveller had 
eosinophilia (8%) and in Canada, among 1605 individuals returning from the tropics, 
10% had eosinophilia (407). Sometimes migrants are infected with multiple species of 
helminths with more pronounced eosinophilia. There may be some non-infectious causes 
of eosinophilia in these groups of patients for example, drugs like beta lactam antibiotics, 
atopy (asthma, eczema, hay fever) and allergy. There are some malignant causes as well 
but in these cohorts, malignancy or any immune deficiency was excluded. Most travellers 
who become infected with Schistosoma spp or Strongyloides spp have a very low worm 
burden and remain asymptomatic-which makes the routine investigation of exposed 
travellers of limited benefit. Worms can persist long after migration from endemic 
countries. Although in these patients in non-endemic settings heavy infection is rarely 
observed early recognition and treatment of these patients may avoid any consequences. 
A study conducted in the East London Gastrointestinal Clinic on migrants found that 
Schistosoma and Strongyloides were the most prevalent helminth species in the patients 
referred to the HTD with eosinophilia and that 56% of Schistosoma infected patients were 
asymptomatic. Fifty-six percent of Schistosoma infected patients had an absolutely 
normal eosinophil count (145). 
In this cohort 95 patients, out of 353 patients, had eosinophilia (>0.45 x109/ml); the rest 
of all the patients had a normal eosinophil count. Within the 95 patients, 21 were controls, 
13 LTBI patients, 52 helminth infected patients and 12 LTBI-helminth co-infected 
patients. Fourteen helminth infected patients, 4 LTBI, 12 controls and 6 coinfected 
patients with eosinophilia, had no symptoms of helminth infection. Some of them had 
presented with respiratory or allergic symptomsin the clinic. Of the patients with 
eosinophilia, the majority of the patients were from Bangladesh (25), Nigeria (12), 
Pakistan (10), Ethiopia (7), India (6) and the rest of the patients were from the African 
and Asian regions. In this cohort, 62% of the migrants had normal eosinophil counts. In 
returning travellers, this might be due to the “window period” between infection and egg 
production, so post-travel screening of travellers, especially stool and urine microscopy 
and serological tests should be delayed for atleast three months after exposure. 
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Patients who had eosinophilia and confirmed helminth infections were provided with 
appropriate anthelmintic treatment. Post-treatment eosinophil counts were obtained from the 
computerized patient records. After assessment of the clinical symptoms in the clinic, patients 
were ranked as “improvement”, “non-improvement” and “some improvement”. Information 
on the helminth infection symptoms, diagnosis, clinical symptoms, eosinophilia, ethnicity 
were all explored for evidence of improvement after anthelmintic treatment.  
Of the 46 helminth infected patients who exhibited eosinophilia (>0.45 x 109/ml) and 
eosinophilia reduced significantly after the treatment (p<0.0001).The median eosinophil 
count was higher in those with helminth infection than in the controls from the clinic. The 
median eosinophil count in the helminth infected group was 0.53 x109/ml and the median 
eosinophil count post treatment was 0.2 x 109/ml.  There were no significant differences 
in eosinophil count in controls and helminth infection, as most of the controls recruited in 
this cohort are either allergic or have some respiratory symptoms and moreover most of 
them had eosinophilia. Similar observations were also obtained in LTBI-helminth co-
infected patients. There were no significant changes in eosinophil count in LTBI infected 
patients at the two points of recruitment. Interestingly, there was a significant change in 
eosinophil count between controls and LTBI infected patients (0.5 x109/ml Vs 
0.3x109/ml). Breen et al., demonstrated that, many patients with TB presented no 
abnormalities in their blood inflammation markers- as in the very initial stages of Mtb 
infection, the blood profile may not reflect the characteristic changes during the 
progression from infection (408). However, these controls are not absolutely healthy 
controls, they mostly presented with high eosinophil counts and had some allergic or 
respiratory symptoms. 
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Figure 3.2: Absolute eosinophil count (x 109/ml) in controls, LTBI, helminth and LTBI-helminth 
coinfected patients (n=40).  Eosinophil count in controls and LTBI infected patients 
(n=45) (A), A one-way ANOVA was performed, where *** represents a p value of 
<0.0007. Bars represent the mean with SD values. (B) Absolute eosinophil count in 
helminth infections both before and after treatment (n=61) and LTBI-helminth 
coinfected patients before and after treatment (n=40) (C). A Wilcoxon matched-pairs 
signed rank test was performed, where *** represents a p value of <0.001 and **** 
represents a p value of <0.0001. 
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The patients were tested for IFNγ production to Mtb peptides in the QUANTIFERON 
IGRA test. To determine the correlation between IFNγ production and cell counts, each 
cell counts are compared with IFNγ production levels (IGRA test). There was no 
significant correlation between absolute eosinophil count and IGRA values in helminth 
infected patients (pre-treatment and post treatment) or LTBI infected patients.The 
absolute eosinophil count was significantly related to the LTBI- helminth co-infected 
patient’s pre-treatment IGRA value (P <0.01). Post treatment IGRA values were not 
available.  
 
Figure 3.3: Correlation between absolute eosinophil count and IGRA values of LTBI-helminth 
coinfected patients. Pearson r correlation between absolute eosinophil count and IGRA values of 
LTBI-helminth coinfected patients. (IGRA test is considered positive if the interferon-
gamma response in the TB antigen minus nil value is at least 0.35 IU/mL) 
 
 
3.1.5  Other blood cell counts in these patients 
Polymorphonuclear cells (PMNs) have been implicated in the control of mycobacterial 
infections, but it is not known whether these cells have direct protective functions.  
Human and animal studies indicate that neutrophils may play an important role in the 
transition from innate to adaptive immune responses by producing critical cytokines and 
chemokines (409)(410) ; although these roles of neutrophils in TB resistance and 
pathogenesis is still unclear. Monocytes were previously shown to be major effector cells 
in protecting the host against Mtb infection (411). 
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The absolute count of monocytes was significantly increased in LTBI-helminth co-
infected patients (p<0.01). There were no significant changes in the monocyte count in 
pre and post treatment helminth infected patients, control vs LTBI, helminth and 
coinfected patients. 
 
(A) 
 
(B)                                                                   (C) 
  
 
Figure 3.4: Absolute monocyte counts in controls (n=30), LTBI (n=30), helminth infected (n=14) 
and LTBI-helminth coinfected (n=8) in their visit. A one-way ANOVA was 
performed. Bars represent the mean with SD values. Absolute monocyte count in 
patients with helminth infections both before and after treatment (n=14) (B) and in 
LTBI-helminth coinfected patients before and after treatment (n=8) (C). A Wilcoxon 
matched-pairs signed rank test was performed, where *represents a p value of 0.01. 
 
The absolute monocyte count was not significantly related to IGRA values in LTBI, 
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interaction of neutrophils with macrophages and the downstream effects of T cell activity, 
could determine the clinical and immunological outcome of infection. This might range 
from an early innate response to uncontrolled replication, excessive inflammation and 
primary progressive disease (412).  
The absolute neutrophil count was significantly increased following anthelmintic 
treatment (p<0.01) in LTBI-helminth coinfected patients, although there were no 
significant changes in the absolute neutrophil count in controls, helminth infected or 
LTBI patients. The absolute count of neutrophils was not significantly related with any of 
the clinical groups. 
    
 
(A)                                           (B)                                          (C)  
 
Figure 3.5: Absolute neutrophil counts in the controls, LTBI and LTBI-helminth infected patients 
before treatment (n=14) (A) in helminth infected patients, both pre and post treatment 
(n=14) (B), LTBI-helminth coinfected patients before and after treatment (n=8) (C). 
 
There was no significant change in the absolute lymphocyte counts in any of four clinical 
groups and they were not related to IGRA values in these patients. 
3.1.6  Monocyte/lymphocyte (ML) ratio and Neutrophil/lymphocyte (NLR) ratio in 
the migrants 
There are reports that the ratio of monocytes to lymphocytes in peripheral blood 
correlated with extent of TB disease in both humans and rabbits (413). Sabin and 
colleagues, between 1921 and 1931 found that the number of monocytes and lymphocytes 
may be related to TB susceptibilityand showed that the number of monocytes were 
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increased following experimental infection of rabbits with M.bovis(414).  We looked at 
the ML ratio in our cohort. The ML ratio was significantly altered in LTBI-helminth 
coinfected patients after treatment. There were no significant alterations in any other 
groups. 
 
 
 
Figure 3.6: ML ratio in controls and helminth infected patients (n=31) (A) in helminth infected 
patients both before and after treatment (n=14)and in LTBI-helminth coinfected 
patients before and after treatment (D). Bars represent the mean with SD values. A 
Wilcoxon matched-pairs signed rank test was performed, where * represents a p value 
of <0.001. 
 
NLR is determined by dividing the absolute count of neutrophils by the number of 
lymphocytes in the complete blood count. NLR has emerged as a new marker of 
inflammation in TB, sarcoidosis etc (415).The NLR in these clinical groups, was not 
significantly altered in any of four groups and the ratios were not related to IGRA values.  
IGRA values were not available for all the post treatment helminth and LTBI-helminth 
infected patients and so it was difficult to observe a change in the IGRA values in those 
patients.  
 
Figure 3.7: IGRA values in IU/ml in helminth infected pre and post treatment patients (n=12). A 
Wilcoxon matched-pairs signed rank test was performed. 
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Altered host iron status has been previously identified as a risk factor for progression to 
TB among HIV-infected individuals, and a number of studies have indicated thatMtb iron 
acquisition plays an important role in TB pathogenesis (416).We looked at the 
haemoglobin concentrations in these groups of patients. There were no significant 
changes in the haemoglobin concentration in any of the four of the groups.  
 
 
 
Figure 3.8:   Haemoglobin concentration. Haemoglobin concentrations (gm/dl) are shown in 
control (n=32), helminth (n=32), LTBI (n=32) and LTBI-helminth coinfected patients 
(n=14). Bars represent the mean values with SD; a Kruskal-Wallis test was performed 
where there were no statistically significant differences. 
 
Interestingly, haemoglobin concentration was significantly related to LTBI patients IGRA 
values (p<0.01) but was not significantly related to any other clinical groups. 
 
 
Figure 3.9: Correlation between haemoglobin concentration (gm/dl) and IGRA values of LTBI 
patients. Pearson r correlation between haemoglobin concentration and IGRA values 
of LTBI patients. 
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We also tested if age or sex is related significantly with the IGRA values in these patients. 
Sex was not significantly related to IGRA values, although age was significantly 
associated with IGRA results in controls, but not in the other groups.  
 
Figure 3.10 : Correlation between age (in years) and IGRA values of controls (n=20). Pearson r 
correlation between age in years and IGRA values of controls (after outlier correction 
by ROUT method).  
 
Most of the migrants in this cohort were from Bangladesh followed by Nigeria, India, 
Philipines, and Ghana. Mean length of the stay in UK was 17-23 years. Twenty-seven 
percent of the migrants had eosinophila that reduced significantly after anthelmintic 
treatment. The eosinophil count was correlated significantly with IGRA values in LTBI-
helminth coinfected patients. LTBI-helminth infected patients showed significant changes 
in neutrophil and monocyte count, ML ratio after anthelmintic treatment. Haemoglobin 
concentration was significantly related to IGRA values of LTBI patients. 
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Chapter - 4     
4.1   T cell responses to Mtb in clinical samples 
As discussed in the previous chapter, the recruitment in this project was a continuation of 
the IDEA project funded by the EU Consortium, that ran from 2011 to 2015. In that 
period Dr. Frederic Toulza was working on the IDEA project and carried out the 
immunological tests. One hundred eight helminth infected patients, 48 LTBI-helminth 
coinfected patients, 58 LTBI patients and 29 controls were recruited. He measured the 
impact of anthelmintic treatment on the immune response to Mtb in LTBI in this migrant 
cohort in London, measuring the frequency of CD4+IFNγ producing T cells, and 
CD4+FoxP3+Treg cells to assess the potential impact of these cells in helminth infected 
patients. It was observed that, helminth-infected groups had lower CD4+T cell responses 
to PPD and ESAT-6/CFP10 than those without diagnosed helminth infection. The 
memory immune response to TB before anthelmintic treatment and after treatment was 
also observed and it was shown that anthelmintic treatment increased the memory 
immune response to Mtb. The LTBI-helminth infected group showed a significant 
increase in the frequency of CD4+ IFNγ+ T cells after anthelmintic treatment when the 
PBMC from these patients were stimulated with Mtb specific PPD and the fusion protein 
ESAT-6/CFP10. Patients with helminth infection, showed a significant increase in 
CD4+FoxP3+Treg cells compared to those without helminth infection. There was a 
significant decrease in the frequency of Treg cells and an associated increase in 
CD4+IFNγ+T cells and these effects were reversed after anthelmintic treatment (370). 
With the continuation of the recruitment, it was planned to do more immunological work 
and to look at how the cells controlled the growth of mycobacteria.  
Aims 
• To measure the frequency of CD4+IFNγ+T cells in helminth infected patients, and 
LTBI infected patients. 
• To measure the secretion of IFNγ, TNFα and IL-2 by intracellular cytokine 
staining after stimulating the PBMC overnight with PPD, ESAT-6/CFP10, SEA 
and SEB. 
• To detect the frequency of CD4+IFNγ+T cells in stimulated PBMCs after 
anthelmintic treatment in helminth infected and LTBI-helminth infected patients. 
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• To measure the IFNγ responses to PPD, ESAT-6/CFP10 using ELISpot in 
controls, LTBI, helminth and LTBI-helminth coinfected patients on their pre-
treatment visit and second visit. 
4.1.1  Results 
Intracellular cytokine staining (ICS) of stimulated PBMC followed by flow cytometric 
analysis was performed to detect the T cell and cytokine immune responses. ICS enabled 
the simultaneous detection of CD4 and CD8 positive T cells and secretion of cytokines 
such as IFNγ, TNFα, and IL-2 in PPD and ESAT-6/CFP10 stimulated PBMC from 
uninfected individuals, helminth-infected patients, LTBI individuals and patients 
coinfected with LTBI and helminths. PBMC were stimulated with PPD, ESAT-6/CFP or 
SEB overnight and then stained with a panel of antibodies recognising lymphocyte 
markers and the cytokines IFNγ, TNFα, and IL-2. Both the pre and post treatment 
samples were tested at the same time using the same protocol. Helminth infected and 
LTBI-helminth coinfected patients were requested to come back 4 months after their first 
recruitment and after they have finished the treatment (V2). The LTBI and control groups 
were also analysed at least 4 months after the initial visit (V1), although they were not 
given any anthelmintic treatment. 
Following gating on singlet and live cells and the exclusion of CD14 or CD19-expressing 
cells, single cytokine expression was examined in CD4+T cells. IFNγ expression was 
detected in all four clinical groups, the median IFNγ expressing CD4 T-cells proportion 
of subset being 0.31% in controls, 0.41% in helminth infected and 0.19% in LTBI-
helminth coinfected patients, which after treatment, was 0.29% in controls, 0.44% in 
LTBI, and 0.39% in LTBI-helminth coinfected patients in response to PPD (Fig. 4.1).The 
median IFNγ expressing CD4+T cells in response to ESAT-6/CFP10 in LTBI patients pre 
and post treatment were 0.23% vs 0.29% and in LTBI-helminth coinfected patients it was 
0.18% vs 0.33%.   
The frequency of CD4+IFNγ+T cells in LTBI-helminth coinfected patients was lower 
than that of LTBI infected patients, although the difference was not significantly 
different. The frequency of CD4+IFNγ+T cells were significantly higher in LTBI patients 
than in the controls (p<0.005). LTBI-helminth coinfected patients had lower percentages 
of CD4+IFNγ+T cells before treatment. The result showed that anthelmintic treatment 
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induces a significant increase in the frequency of CD4+IFNγ+T cells after stimulation 
with PPD, ESAT-6/CFP10, Schistosoma egg antigen (SEA) or SEB as positive stimulants 
in LTBI-helminth coinfected patients (p<0.0001). No significant changes were observed 
in the frequency of CD4+IFNγ+T cells after stimulation by PPD and ESAT-6/CFP10 in 
LTBI and controls compared to their initial visit. Helminth infected patients had lower 
proportions of CD4+IFNγ+T cells than the controls in response to PPD before treatment. 
After anthelmintic treatment the % CD4+IFNγ+T cells increased but this was not 
significant.  
 
 
Figure 4.1: Impact of anthelmintic treatment on CD4+IFNγ+T cells in LTBI-helminth coinfected 
patients. The frequency of CD4+IFNγ+T cells were also measured in LTBI and 
controls. Antigen stimulated PBMC from fifteen patients from each group were used 
in this experiment. A non-parametric paired Wilcoxon test was performed, where 
**** represent a p value of <0.0001.  
 
In helminth infected patients and LTBI-helminth coinfected patients, the PBMC were 
stimulated with PPD, ESAT-6/CFP10, or SEA antigen overnight and frequency of 
expression of IFNγ, TNFα and IL-2 was measured (Fig 4.2). In helminth infected 
patients, IFNγ responses to PPD, ESAT-6/CFP10 and SEA were significantly greater than 
in the unstimulated cells. TNFα expression was greater with PPD and SEA stimulation 
than with ESAT-6/CFP10 stimulation. IL-2 expression was greater in response to ESAT-
6/CFP10 than PPD or SEA antigen. 
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(A)  helminth infected                         (D)  LTBI-helminth coinfected 
  
(B) helminth infected                       (E) LTBI-helminth coinfected 
  
(C) helminth infected                             (F) LTBI-helminth coinfected 
  
Figure 4.2: PPD, ESAT-6/CFP10 and SEA antigen specific cytokine expression in CD4+ T cells. 
Frequency of CD4+IFNγ, TNFα and IL-2 measured by intracellular cytokine staining 
in helminth infected patients (A, B, C) and LTBI-helminth coinfected patients (D, E, 
F). Line represents the median value. One-way ANOVA was performed, where **** 
represents a p value of <0.0001, ***represents a p value of <0.0005 and **represents 
a p value of <0.005. 
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In LTBI infected patients, TNFα and IL-2 was also measured in PBMC stimulated with 
PPD, ESAT-6/CFP10, SEA antigen and in unstimulated cells (Fig. 4.3). TNFα expression 
was detected in LTBI patients, the median TNFα expressing CD4+T cells proportion 
being 0.38% in unstimulated cells, 0.69% in response to PPD, 0.81% in response to 
ESAT-6/CFP10 and 0.49% in response to SEA antigen. The median IL-2 expressing 
CD4+T cells were 0.14% in unstimulated cells, 0.38% in response to PPD, 0.37% in 
response to ESAT-6/CFP10 and 0.31% in response to SEA antigen. Stimulation of cells 
with the positive control SEB produced detectable expression of IFNγ, TNFα, and IL-2 
(data not shown). 
 
Figure 4.3:  The frequency of CD4+TNFα+T cells and CD4+IL-2+T cells in LTBI patients. 
Antigen stimulated PBMC from fifteen patients of LTBI was used in this experiment. 
A non-parametric paired Wilcoxon test was performed. The horizontal line represents 
the median response, the box represents the interquartile range and the whiskers 
represent the overall range. 
 
The frequency of CD8+IFNγ+T cells was also measured (Fig. 4.4). There were no 
significant changes in the IFNγ positive CD8 T cells with the treatment. There were some 
changes in LTBI-helminth coinfected patients, although the change was not statistically 
significant (p=<0.99).  However, the median proportion of IFNγ positive cells in the CD8 
T cells was less than <0.07% in LTBI. <0.05% in helminth infected patients, 0.215% in 
LTBI-helminth coinfected patients and 0.023% in controls. 
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Figure 4.4: The frequency of CD8+IFNγ+T cells was measured in controls, LTBI patients, 
helminth infected patients and LTBI-helminth coinfected patients. PBMC from 
fifteen patients per group were stimulated with PPD antigen. A non-parametric paired 
Wilcoxon test was performed. The horizontal line represents the median response, the 
box represents the interquartile range and the whiskers represent the overall range. 
 
4.1.2  IFN γ ELISpot response to PPD and ESAT-6/CFP10 
PBMC from all the patients were stimulated overnight with PPD and ESAT-6/CFP10 and 
the IFNγ responses were measured (Fig.4.5). There was a statistically significant increase 
in the IFNγ responses in LTBI-helminth coinfected and helminth infected patients in 
comparison to controls both before and after anthelmintic treatment (p<0.0001). The PPD 
stimulated IFNγ responses were increased after the treatment in LTBI-helminth infected 
patients (p= 0.0010). Interestingly, the response did not change significantly after the 
anthelmintic treatment in helminth infected patients.  
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Figure 4.5: IFNγ ELISpot responses to PPD stimulation in controls, LTBI, helminth infected and 
LTBI-helminth infected patients. An IFNγ ELISpot was performed against PPD using 
cryopreserved PBMCs from 15 control, LTBI infected, helminth infected and LTBI-
helminth infected patients before and after anthelmintic treatment. Bars represent the 
median values; a Kruskal-Wallis with a Dunn’s post-test was performed where **** 
represents a p value of <0.0001, *** represents a p value of <0.005. 
 
The ESAT-6/CFP-10 stimulated IFNγ responses were significantly greater in LTBI and 
LTBI-helminth coinfected patients than in controls and helminth infected patients 
(Fig.4.6). The response was greater in coinfected patients than in the helminth infected 
patients (p<0.0001). There was no significant difference in IFNγ response between 
control and helminth infected patients. The Mtb specific IFNγ responses were 
significantly greater in LTBI infected patients in comparison to controls and helminth 
infected patients (p<0.0001). There was a significant increase in IFNγ responses in LTBI-
helminth coinfected patients after anthelmintic treatment, although the treatment did not 
alter the IFNγ response in helminth infected patients after treatment. 
 
Figure 4.6: IFNγ ELISpot responses to ESAT-6/CFP-10 stimulation in controls, LTBI, helminth 
infected and LTBI-helminth infected patients. An IFNγ ELISpot was performed 
against ESAT-6/CFP10 using cryopreserved PBMCs from 15 control, LTBI 
infected, helminth infected and LTBI-helminth infected patients before and after 
anthelmintic treatment. Bars represent the median values; a Kruskal-Wallis with a 
Dunn’s post-test was performed where **** represents a p value of <0.0001 and *** 
represents a p value of <0.005. 
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4.2  Discussion 
LTBI is considered a broad spectrum of infection states that differ by the degree of the 
pathogen replication, host resistance and characteristics of immune activation and 
inflammation (34)(110). As the bacilli cannot be directly detected in vivo during latent 
asymptomatic Mtb infection, a test that could quantify the number of bacteria or the levels 
of replication might help to define the stages of infection and better understanding of the 
pathogenesis and immunity during this asymptomatic infection (417). The control of Mtb 
infection requires a Th1 response (IL-2, IFNγ, TNFα and to some extent Th17 response) 
for the induction and protective immune responses in the control of latent infection 
(418)(419). Reactivation of latent infection may result from factors inducing suppression 
of these Mtb specific immune response. The severity of TB, where helminth infections 
are prevalent and the geographical coincidence of these two pathogens has led to the 
hypothesis that helminth infection could also exacerbate the effects of Mtb infection 
(186).  The strong mucosal Th2 immunity and T regulatory cell responses induced by 
helminths could down modulate the protective immune response against Mtb infection 
(370).  
In this study, a London cohort of immigrants who had presented with helminth infection 
with or without helminth infection were recruited to observe the impact of anthelmintic 
treatment on the antimycobacterial immune responses. These migrants had negligible 
chance of risk of exposure and reinfection, as these helminth infections are not prevalent 
in the UK. This provided an advantage to study the impact of anthelmintic treatment on 
anti mycobacterial immune responses in helminth infected patients. A previous study of 
our group in this cohort, looked at the frequency of CD4+IFNγ+T cells following 
stimulation with PPD or ESAT-6/CFP10 and the concentration of IFNγ in culture 
supernatants was measured by Luminex and multiplex bead array. It was observed that 
helminth infected patients had lower responses to PPD and ESAT-6/CFP10 in 
comparison to other groups and that anthelmintic treatment reversed the CD4+IFNγ+T 
cell responses and also modulated the frequency of CD4+FoxP3+T cells (370). Following 
these observations more samples were used to look at the Th1 cytokines like IFNγ, TNFα 
and IL-2 using intracellular cytokine staining and to observe the effect of anthelmintic 
treatment on modulation of the protective immune responses against Mtb infection. 
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The frequency of CD4+IFNγ+T cells were 0.31% in controls, 0.41% in LTBI, 0.19% 
LTBI-helminth coinfected patients and 0.14% in helminth infected patients before they 
received treatment for helminth infection. At their second visit, the frequency of 
CD4+IFNγ+T cells increased in helminth and LTBI-helminth coinfected patients (0.26% 
and 0.39% respectively). The frequency was significantly reduced in helminth infected 
patients and the coinfected group of patients. This might be due to down modulation of 
immune responses by concomitant or coexisting helminth infection and TB and is 
characterized by decreased T cell proliferation and decreased production of IFNγ and IL-
2. This was observed in other parasitic diseases like filariasis and hook worm 
infections(420)(421).  In a pulmonary mouse model of Mtb infection, S.mansoni 
coinfection reversibly impaired Mtb specific T cell responses. These responses were 
mediated by macrophages  expressing arginase-1 and were reversed with anthelmintic 
treatment(422). There was no significant variation in the frequency of CD4+IFNγ+T cells 
in controls and LTBI infected patients between their first and second visit.  
In the study, The PPD specific response was higher in LTBI than controls. PBMC from 
all the patients were also stimulated with ESAT-6/CFP10. The response to ESAT-6/CFP 
10 was slightly higher than in the controls. These observations were in keeping with the 
study conducted in Brazilian TB patients, where the levels of IFNγ in response to ESAT-
6 in Brazilian controls were much lower than those in TB patients (423). Accordingly, the 
rate of cells positive to PPD detected by flow cytometry was higher than that of cells 
positive for ESAT-6 in that study. The majority of TB patients (35 to 92%) can recognize 
ESAT-6 , as estimated by the production of IFNγ, whereas, healthy unrelated controls 
from regions of low endemicity cannot(424)(414). Interestingly, some of the BCG 
vaccinated controls in this study also responded to ESAT-6/CFP10, presumably as they 
are latently infected accompanied by T cell responses to Mtb specific antigens. They had 
presented in the clinic with eosinophilia and helminth symptoms. However, they were all 
tested for LTBI and were negative in the IGRA test used. 
There was a decrease in CD4+IFNγ+T cells in helminth infected patients and the 
coinfected groups when stimulated with PPD and ESAT-6/CFP10 both at the baseline in 
comparison to controls and LTBI infected patients suggesting the complex host pathogen 
interaction in coinfected patients. Helminth infections appear to influence the reactivity to 
TB antigens (135). Similarly, in an ex vivo study, Th1 responses to PPD and ESAT-
6/CFP10 were significantly lowered in LTBI and filariasis coinfection compared to those 
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without filarial infection.The potential factors for such down modulation were highlighted 
as increased expression of the negative co-stimulatory molecule, CTLA-4, PD-1 and also 
expression of TLRs , specially TLR2 and TLR9 (220)(426). 
After clearance of helminths, the PPD response to CD4+IFNγ+T cells increased in 
helminth infected patients and in the coinfected group. This suggests the impact of 
anthelmintic treatment on CD4+IFNγ+T cells in helminth infected patients. When the 
PBMC from these patients were stimulated with ESAT-6/CFP-10, increases in the 
frequency of CD4+IFNγ+T cells were observed in coinfected patients but no change was 
observed in controls, confirming the specificity of this antigen for Mtb. 
The frequency of CD4+T cells and CD8+T cells producing IFNγ, TNFα and IL-2 were 
measured in helminth infected and LTBI-helminth coinfected patients following 
stimulation with PPD, ESAT-6/CFP10 and SEA antigen of S.mansoni during their first 
visit. The IFNγ response was more pronounced in both the groups than that to ESAT-
6/CFP10. Before treatment, both groups showed lower proportions of IL-2 and higher 
proportions of TNFα producing cells. A similar pattern was also observed in LTBI 
infected patients. IFNγ and TNFα are both are well known to play a vital role in the 
control of Mtb infection and mutation of IFNγ or TNFα  genes in humans results in 
increased susceptibility to TB (427)(428). TNFα participates by regulating and 
maintaining the structural integrity of granuloma and preventing reactivation (429), 
although TNFα also has a negative impact by promoting growth of Mtb in human 
monocytes and is also known to contribute many of the immunopathological features of 
TB( 427)(431). Studies have shown that CD4+T cells secreting TNFα are more 
predominant in TB patients than healthy controls or household contacts (432)(433). 
Although the exact reason and pathology behind the clonal expansion and differentiation 
of T cells in TB and healthy contacts are still unclear, yet quantification of these 
cytokines secreted by the T cells can be a promising approach for diagnosis and 
monitoring of TB(434). Interestingly, the expression of this cytokine was substantially 
increased in the proportion of TNFα  positive cells in the subjects with active disease and 
was been considered a predictor of diagnosis of active vs latent infection (432). Further 
prospective works on this signature are required to conclude the roles of these cytokines 
in helminth and coinfected patients. 
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Simultaneous measurement of IFNγ and IL-2 at the single cell level identifies T cell 
cytokine profiles which reflect their memory phenotype and defines three main functional 
T cell subsets: effector cells that mainly secrete IFNγ only, effector-memory cells 
primarily secreting both IFNγ and IL-2, and central memory cells secreting only IL-2 
(435). Latently infected patients display an immunological signature consistent with 
persistent low antigen load and long-term immune control, dominated by dual IFNγ/IL-2 
secreting effector-memory T cells accompanied by IL-2-secreting central memory T cells. 
The frequency of LTBI patients in this study finding is consistent with a role in long-term 
immune control. 
In this experiment, TNFα and IFNγ production in response to SEA antigen was higher 
than that of IL-2. The response was higher in coinfected patients in comparison to 
helminth infected patients without LTBI. An immunocompetent host mounts 
immunological response to parasite eggs with the development of a collagen rich 
granulomatous response around the eggs (244). In immunocompetent wild-type (Wt) 
mice, immune responses to schistosome antigens causes a shift from a moderate Th1 to a 
robust Th2 response; which is responsible for most of the immunology (436). Mice 
deficient in IFNγ signalling have a reduction in granuloma size and this causes transition 
into the chronic phase of the response suggesting that IFNγ contributes to granuloma 
formation (437). Patients presenting with severe fibrosis have been associated with 
production of TNFα, IL-5, IL-10, IL-13, whereas patients with low fibrosis patients had 
higher IFNγ levels (438). 
Although CD4+T cells play a central role in immunity to Mtb infection, CD8+T cells are 
also important in TB immunity. Mtb specific CD8+T cell can secrete cytokines such as 
IFNγ, TNFα, similar to that of CD4+ cells. These cells can also act as cytotoxic effector 
cells, releasing the cytotoxic granules into the contact zone between CD8+T cells and 
macrophages (439). The CD8+T cells were also explored in this study to observe the 
cytokine profile in all the four groups. The median proportion of IFNγ positive cells in the 
CD8 T cells was less than <0.07% in LTBI. <0.05% in helminth infected patients, 
0.215% in LTBI-helminth coinfected patients and 0.023% in controls. TNFα and IL-2 
production was very low by CD8+ T cells in all these groups. IFNγ+CD8+T cells 
significantly increased post-treatment in LTBI-helminth coinfected patients. Although 
stimulation with PPD showed no difference in cytokine producing CD8+T cells between 
LTBI, controls and helminth infected patients. Pinxteen et al., in their studies showed that 
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during the acute phase of the infection, treatment with anti-CD4 exacerbated the 
pulmonary disease, whereas, the reverse was found during the latent phase of the 
infection, where treatment with antiCD8 mAb led to a greater increase in bacterial 
numbers in the lung than did administration of anti-CD4 mAb. This suggests that during 
the acute phase of disease, CD4+T cells may be more important in controlling bacterial 
replication. In contrast, CD8+ T cells may have a greater role in maintaining control of 
the infection during latency, possibly via immunosurveillance of heavily infected cells 
that have lost the capacity to inhibit bacterial replication (440).  
To take the experiments one stage further, individual T cells secreting IFNγ were then 
measured in all the clinical samples by ELISpot assay. PBMC from all the patients were 
stimulated overnight with PPD and ESAT-6/CFP10 and the IFNγ responses were 
measured. There was a statistically significant increase in the IFNγ responses in LTBI-
helminth coinfected and helminth infected patients in comparison to controls both before 
and after anthelmintic treatment (p<0.0001). After anthelmintic treatment the IFNγ 
responses increased significantly, however, there was no significant changes in helminth 
infected patients after they received their treatment. Interestingly, PPD responses and 
EAST-6/CFP10 responses were different in helminth infected patients. IFNγ ELISpot 
responses to ESAT-6/CFP 10 were lower in helminth infected patients than that of 
controls.  
Although IFNγ is an important component of protective immunity, there is increasing 
evidence that it does not provide a read out of protective immunity (394). IFNγ that is 
produced do not parallel control of bacterial growth and also in some animal model 
studies, greater IFNγ production is associated with more pathology. Polyfunctional T 
cells (T cells capable of making IFNγ, TNFα and IL-2) are a better indicator of protective 
immunity than the measurement of IFNγ alone. CD8+ T cells and the cytotoxicity of 
infected macrophages can also lead to killing of intracellular bacteria and a reduction in 
CFU (441). Helminth specific antigen stimulation also showed changes in the cytokine 
profile especially in helminth and LTBI-helminth coinfected patients. Helminth infections 
appear to play an important role in modulating the immune response to Mtb specific PPD 
and other Mtb antigens through a complex immune mechanism, downregulating the 
expansion of Th1 cells (442). To measure the changes in CFU following the incubation of 
infected monocytes/macrophages with T cells may therefore provide a highly relevant 
read-out of protective immunity in this cohort. To explore this, the next step was taken to 
 150 
perform mycobacterial growth inhibition assays using a commercial BACTEC system. 
The MGIA provides a measure of a range of different immune mechanisms and their 
interactions. To assess how the cells in these group of patients control the growth of 
Mycobacteria and also the impact of anthelmintic treatment on antimycobacterial immune 
responses- MGIA was performed on all the samples, which will be discussed in the 
following chapter. 
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Chapter - 5 Optimization of the MGIT Assay 
5.1   Optimization of the MGIT Assay 
5.1.1 Introduction 
A number of groups have recently investigated the potential use of mycobacterial growth 
inhibition assays (MGIA) using both whole blood and cryopreserved PBMCs in both Mtb 
exposed and BCG vaccinated cohorts (387)(394)(443). This assay can directly measure 
the ability of a heterogeneous cell population to limit the intracellular growth of 
mycobacteria that could correlate directly with protective TB immunity.This is a 
relatively simple assay in comparison to traditional CFU counting.To quantify 
mycobacteria in this method is potentially more accurate as it can avoid the pre 
stimulation steps of cell culture and also avoid the laboursome steps of traditional cultures 
including serial dilution, clumping, pipetting errors and colony counting. The MGIT 
system utilizes oxygen depletion as its method to assess the number of the viable bacteria. 
This fluorescence based technology can utilize the bacterial usage of oxygen as a 
requirement of growth and metabolism and the computer based system provides a read 
out as TTP.However, this assay needs to be validated for accuracy, precision, 
reproducibility,specificity and linearity. Some optimization of the assay has been done, 
for example- timing of processing the sample, BCG inoculation time, use of serum, 
antibiotics, BCG inoculum volume, BCG declumping methods etc. However, despite the 
numerous optimization experiments that have been performed-there is still a large 
concern about the reproducibility of this assay (Tanner R, Development of Mycobacterial 
Growth Inhibition Assay for the early evaluation and gating of novel TB vaccine 
candidates. PhD [Thesis]. Oxford :University of Oxford; 2015).  
In this study, MGIA was performed in a LTBI and helminth coinfected cohort for the first 
time to observe how these subjects can control the growth of mycobacteria and whether 
the anthelmintic treatment has any impact on the ability of the cells to control 
mycobacterial growth effectively. In this study PBMC were used to perform the MGIA 
assay. In this study PBMC were preserved to perform the MGIA and other 
immunological assays; as it was not possible to perform the MGIT immediately and cells 
needed to be preserved for testing the paired samples pre and post treatment 
simultaneously.  Although whole blood could have been useful in this study to observe 
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the role of neutrophils, to make the assay logistically simple, PBMC were used rather 
than whole blood. Using an optimized assay protocol, different aspects of assay 
variability at different stages of the assay were tested, for example, pre culture conditions- 
cell clumping, cell rest, antibiotic use in the medium, serum in the medium, and also 
individual variation in the MGIA was observed.  
Aims 
The aims of the experiments detailed in this chapter were  
• to compare the variability of the assay using different assay conditions for 
example-BCG clumping methods, effects of anticoagulants, impact of antibiotics, 
choice of serum, heat inactivation of serum etc. 
• to reduce the variability of the assay and optimize the assay protocol. 
5.1.2  BCG declumping to reduce variability 
Three different methods of declumping BCG were compared using cultures of cells from 
ten healthy donors at LSHTM. The methods were- vortexing, vortexing with glass beads, 
sonicating and the aim was to use a suitable method to reduce the variability of the test. 
Ten vials of BCG stock were thawed and declumped by these three methods. Vortexing 
was done on the highest speed for 5 minutes. BCG stock was also taken into a 2mm tube 
containing sterile glass beads and vortexed on full speed for 3 minutes. The BCG stocks 
were sonicated for 1 min and placed in an ice box for one minute and the steps were 
repeated twice more.  The BCG were then transferred into BACTEC MGIT tubes and the 
tubes were placed in a MGIT 960 machine to detect the TTP. Variability was measured as 
standard deviation. Mycobacterial recovery, as measured by TTP was shortest with 
vortexing with glass beads (median 243 hours). Other methods resulted in some loss of 
mycobacteria (the medians for vortexing was 256.5 hours and for sonication was 250 
hours). These changes were not statistically significant. Variability between these three 
methods, was lowest for sonication (CV=9.63%) and was highest for vortexing 
(CV=12.71%) (Fig 5.1).  
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Figure 5.1: Methods of declumping BCG. PBMC MGIT data was obtained using three different 
methods of declumping BCG Pasteur prior to inoculation into the MGIT tubes for the 
culture. PBMC were collected from 10 healthy donors at LSHTM. The bars represent 
the median value. A Kruskal-Wallis non parametric test was performed. There were 
no significant changes among these three methods of declumping.   
 
Initially during the optimization steps, sonication was used as a method of declumping; 
but afterwards we started to use BCG Aeras stocks with a concentration 1.1 x108/ml. The 
BCG was grown in shaking flasks in 7H9 medium without OADC but with the addition 
of 0.2% glucose and 0.05% Tyloxapol to an OD of about 4. The BCG was then spun 
down and resuspended in half the volume of formulation buffer (20% glycerol, 0.85% 
NaCl and 0.05% Tyloxapol) and frozen in the formulation buffer. Addition of Tyloxapol 
made it easy to avoid the declumping methods. Afterwards, the BCG stock was thawed 
and diluted to be used in the MGIT assay- no declumping methods like vortex, sonication 
etc. were used.  
5.1.3  Effect of anticoagulant on MGIA 
EDTA and sodium heparin were compared as anticoagulants used for collecting the blood 
samples. PBMC separated from EDTA anticoagulated blood showed shorter TTP. 
However statistically there was no difference in these two anticoagulants in terms of cell 
recovery or viability (Fig. 5.2). 
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Figure 5.2: Effect of heparin and EDTA on MGIA. PBMC from 10 healthy donors were 
collected. PBMCs were collected in heparin sprayed and EDTA sprayed tubes. There 
were no significant differences observed between the groups (p=0.235). The bars 
represent median values. 
5.1.4  Impact of antibiotics on MGIA 
In this experiment, cells were rested in standard MGIT media (RPMI containing 10% 
FBS, L-glutamine and sodium glutamine and HEPES buffer) in post-freezing and pre-
thawing steps, before washing and re suspending in culture medium. To see the effect of 
antibiotics- standard tissue culture concentrations of penicillin-streptomycin (pen-strep) in 
the culture medium, pen-strep and penicillin alone were used in the post-freezing and pre 
thawing cells steps. Cryopreserved PBMC from 3 LSHTM donors were tested for this 
experiment. The pen-strep combination had a pronounced inhibitory effect when the cell 
rest medium and post-thawing medium contained these antibiotics- even though the cells 
were washed afterwards (Fig.5.3). The inhibitory effect was not that noticeable when the 
cell medium only had penicillin in it. To remove this inhibitory effect of antibiotic at the 
phases of this experiment- no antibiotic was added in the pre culture state.  
 
Figure 5.3: Effect of penicillin-streptomycin antibiotics and penicillin alone in the cell rest 
medium. PBMC from 3 healthy donors were collected. Pen strep antibiotic mix, 
penicillin alone and no antibiotics were compared in the cell rest medium in post- 
freezing and pre-thawing steps.  The bars represent mean values with S. A one way 
ANOVA were performed, where * represents a p value of <0.05. 
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5.1.5  The effect of serum in the cell culture medium 
Most protocols with PBMCs use serum to provide optimal conditions for cell viability, 
reactivity and expansion to provide a more favourable environment for the cells. For this 
experiment, foetal bovine serum (FBS) and human AB serum (PHS) were used. To 
determine whether the addition of FBS or PHS effect on mycobacterial growth and the 
variability, the MGIT assay was performed in 10 healthy donors with either FCS or PHS 
in the medium. Mycobacterial growth was observed to be significantly higher using 
human AB serum compared with FBS (Figure -5.4). For the experiments onward, human 
AB serum was used in the culture medium. 
 
Figure 5.4 : Comparison of human and bovine serum in the culture medium. PBMC were 
cultured with FBS and human AB serum in the culture medium before adding to 
MGIT tubes.  Bar represents the mean values with SD. A Wilcoxon matched-pairs 
signed rank was performed where ** represents a p-value of  0.0039.  
 
5.1.6  Impact of heat inactivation of serum 
To observe the effect of heat inactivation of human AB serum, PBMC were used from 10 
healthy donors at LSHTM and MGIT was performed. The mycobacterial growth was 
significantly lower when heat-inactivated serum (HI) was used in comparison to normal 
serum (p<0.001) (Fig.5.5).  
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Figure 5.5: Effect of heat inactivation of serum on mycobacterial growth. PBMC from 10 donors 
were cultured with normal unheated human serum or HI human AB serum in the 
culture medium. Bars represent the mean values with S. A paired test was performed 
where **** represents a p-value of <0.0001.  
 
5.1.7  Culture mixing and rotation  
The original MGIA protocol included 360º rotation of the cell cultures. The effect of 
standing and 360º rotation of the cultures were observed. PBMC from 10 healthy donors 
were used for MGIT experiments to observe the effect. There were significant changes in 
the mycobacterial growth inhibition when rotating the culture at 360º was compared to 
standing stationary (p=<0.0001).  Mycobacterial growth inhibition was significantly 
higher when cultures were rotating at 360º compared to stationary cultures (Fig 5.6). The 
cultures were rotated at 360º rotation for 96 hours in the further experiments. 
 
Figure 5.6: Effect of culture mixing and rotation on growth inhibition. MGIT was performed 
using PBMC from 10 healthy donors, where cultures were kept standing for 96 hours 
and with 360º rotation. The barsrepresents mean values with SD. An unpaired t-test 
was performed, where ****represents a p-value of <0.0001. 
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5.1.8  Cell lysis with sterile water 
In this protocol cells are lysed after 96-hour culture to release the intracellular bacteria. 
The effect of this cell lysis step on the mycobacterial growth inhibition was analysed. For 
this experiment, PBMC from 8 healthy donors were used and the cells were lysed with 
water or kept without lysis. After removing the 96-hour culture supernatants, about 100µl 
of sterile water added to the residual and kept for 5 minutes, and vortexed at the highest 
speed for 1 min and then kept at room temperature for 5 minutes.  The lysis step with 
sterile water did not have any significant effect on mycobacterial growth when compared 
to the no lysis cultures (Fig.5.7).  
 
Figure 5.7: Effect of lysing with sterile water on mycobacterial growth inhibition. MGIT was 
performed using PBMC from 8 healthy donors, where cells were lysed with water at 
the end of 96-hour culture and compared with no lysis of cells. Bar represents mean 
value with SD. A Wilcoxon matched-pairs sign rank test was performed. There was 
no significant difference between the groups. 
 
5.1.9  Individual variation in MGIA 
To observe whether the patterns of individual variation were stable over the period of a 
year, MGIA was performed with PBMC from 7 healthy donors at LSHTM and repeated 
after one year under the same conditions. There was no significant change in the pattern 
of mycobacterial growth inhibition after one year. The pattern was similar both in BCG 
vaccinated and non BCG vaccinated healthy donors (Fig. 5.8). 
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(A) 																																																													(B)	
 
BCG vaccinated healthy donor                   BCG non vaccinated healthy donor 
Figure 5.8: Individual variation in MGIA. MGIT was performed using PBMC from 7 healthy 
donors at two different time points, 1 year apart (0 month and 12 months). There were 
no significant changes in mycobacterial growth inhibition patterns after 1 year in 
BCG vaccinated (A) donors or in BCG non-vaccinated (B) donors. A Wilcoxon 
matched-pairs sign rank test was performed.  
 
5.1.10  BCG vaccination and MGIA 
To observe if there are any significant change in the mycobacterial growth inhibition in 
BCG vaccinated and non-vaccinated individuals, PBMC were collected from 10 BCG 
vaccinated and 10 BCG non-vaccinated healthy donors at LSHTM. Mycobacterial growth 
was significantly reduced in the BCG vaccinated healthy donors in comparison to the 
non-vaccinated healthy donors (p<0.001) (Fig. 5.9).  
 
Figure 5.9: MGIA variation in BCG vaccinated and BCG non-vaccinated healthy donors. MGIT 
was performed using PBMC from 10 BCG vaccinated and 10 BCG non vaccinated 
healthy donors at LSHTM.  A Mann Whitney test was performed, where **** 
represents the p value of <0.0001.  
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5.1.11  Effect of PPD stimulation of cells in MGIA 
To see the effect of PPD stimulation on MGIA, PBMC from six healthy donors at 
LSHTM were collected, and PBMC were stimulated with PPD overnight before MGIA.  
The aim was to see if there was any fold change in growth inhibition if the cells were pre-
stimulated with PPD before the culture with BCG. There were no significant changes in 
the mycobacterial growth inhibition when the cells were stimulated with PPD overnight. 
This experiment was performed in clinical samples afterwards, which is described in 
Chapter 7.  
 
 Figure 5.10: Effect of PPD stimulation on MGIA. MGIT was performed using PBMC from 6 
healthy donors, where cells were stimulated with PPD overnight. After normalization 
a Wilcoxon matched-pairs sign rank test was performed. There were no significant 
changes between the groups (p=0.3215). 
 
 
5.2  Discussion 
Ex vivo MGIA directly assesses the summative ability of the host immune system to 
inhibit the growth of Mycobacteria. This assay could help to determine the underlying 
immune mechanism of protection by investigating different common factors in samples 
with efficient growth inhibition (401). The assays of inhibition of mycobacterial growth 
previously studied were developed for other research applications and for their ability to 
detect vaccine-induced immune enhancement. The lymphocyte based growth inhibition 
assays were developed to study the capacities and mechanisms of various lymphocyte 
populations to enhance killing of  intracellular bacteria and whole blood based assays 
were developed primarily designed for studies of TB immunity in large populations.This 
chapter describes several steps to optimize an existing mycobacterial growth inhibition 
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assay to develop an optimized protocol that could be used for this study in LTBI and 
helminth coinfected patients, to measure the ability to control the host cell to control the 
growth of mycobacteria.  
There are two main protocols for MGIA-whole blood and PBMC based. The MGIAs 
encountered significant difficulties with both inter and intra- assay variability, which is 
still considered an issue with this assay. The PBMC based MGIT assay has also the same 
variability issue, although the assay is relatively simpler, does not involve the complex 
pre culture preparation and stimulation of the cells. The BACTEC MGIT assay has some 
advantages over the conventional CFU counting method, for example avoiding serial 
dilution, clumping, pipetting error, contamination and subjectivity of the conventional 
methods (444). The BACTEC MGIT assay is more rapid than colony counting, dependent 
on the initial bacterial number but is also influenced by the replication characteristics of 
the particular bacteria and the metabolic rate. 
Although the whole blood inhibition assay is simpler to perform, it lacks any cell 
separation and may reflect contributions by neutrophils, antibodies and red blood cells to 
mycobacterial immunity. A small volume of blood is required for the assay. However, the 
whole blood assay cannot distinguish between intracellular and extracellular inhibition of 
bacterial growth, and it seems less useful for dissecting the mechanisms underlying 
mycobacterial inhibition than lymphocyte-based assays (375).  
For this study the PBMC assay were selected. It was selected as this could gave the 
strongest experimental design and was logistically simple. The samples were collected at 
two points and it was planned to test the pre and post treatment samples simultaneously to 
observe the treatment effect and the other immunological parameters. Running all the 
samples in a single batch would reduce the variability. Using cryopreserved PBMC 
helped to evaluate the processing and analysis at a later date.  
To optimize the steps of the assay, some of the variables were investigated both pre- 
culture, and during the culture steps.  The individual responses and variation of MGIA 
was also observed. Cells were stimulated with mycobacteria specific antigen to observe 
the changes in the pattern of growth inhibition of mycobacteria. 
First, heparin and EDTA were compared as anticoagulants and their effect on growth 
inhibition assay was observed.   With EDTA, TTP was shorter than with heparin, but the 
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difference was not statistically significant. Segura et al., investigated the effect of EDTA 
in substrate adherence capacity of rat inflammatory macrophages and whether the 
macrophage function was altered. They concluded that EDTA decreased substrate 
adherence capacity of macrophages significantly and may inhibit the macrophage 
function (445).  Mouse macrophages possess heparin receptors on the cell surface and 
heparin has been reported to activate monocyte/macrophages, including the release of 
IFNγ and promotion of lysosomal enzyme secretion (446). Duvigneauet al., (2007) 
investigated heparin and EDTA as anticoagulant and their effect on cytokine mRNA level 
of cultured porcine blood cells. They showed that PBMC isolated from EDTA 
anticoagulated blood showed a higher cytokine expression capacity (IL-1 IL-2, IL-4, IL-
6, IL-10, IFNγ) than PBMC from heparinized blood, though EDTA as anticoagulant is 
not recommended for the cytokine detection method, as this requires maximal influx of 
calcium ions for intracellular protein accumulation (447). A different finding was 
observed in the study by Patil et al., (2013), where they assessed the influence of heparin 
and EDTA as anticoagulants on various cytokine levels in plasma and concluded that 
TNFα, IFNγ, IL-4,IL-5 and G-CSF levels were significantly higher in plasma with 
EDTA, whereas the level of IL-6, IL-8,IL-10, IL-17, MIP-1β, GM-CSF and MCP-1 were 
found to be higher in plasma with heparin (448). Since there was no statistically 
significant difference in the anticoagulant used in this study, afterwards heparin 
containing vacutainer tubes were used to collect blood.  
One of the potential causes of variability in these assays can be clumping of BCG. 
Different methods of resuspension were compared to improve the reproducibility of the 
test. Although there were no significant differences between the methods, the variability 
was lowest for sonication other than vortexing in comparison to glass beads with 
vortexing alone. TTP was shorter with vortexing and the other methods showed some loss 
of BCG in MGIA protocol. Initially sonication had been used as a method of declumping. 
When AERAS prepared a large batch of BCG, they added a surface active agent called 
Tyloxapol. Tyloxapol is a detergent which is commonly used in mycobacterial research to 
prevent clumping. Tyloxapol is a non-ionic liquid polymer of the alkyl polyether alcohol 
type and is used as a surfactant to aid liquefaction. Tyloxapol has been used as a more 
stable and detergent agent in mycobacteria culture than Tween80, which is unstable and 
more likely to break down to oleic acid. This oleic acid can be used as a carbon source for 
the growth of mycobacteria (449). Although sonication was the method of choice, the use 
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of AERAS BCG containing Tyloxapol removed the need for a vortexing or sonication 
step in further analysis. To avoid pipetting error, BCG was always pipetted into small 
volumes and then a large dilution prepared to use in the experiment. 
Initially when the sample recruitment started in 2011 in the IDEA study, PBMCs were 
cryopreserved in media which contained pen-strep in the media and also complete 
medium was used for cell separation and in pre-thawing, pre-freezing media when 
PBMCs were used for intracellular cytokine assays. When these cryopreserved cells were 
used for MGIT assays, the growth of mycobacteria was very low or absent. Log CFU 
values generated in the PBMC based assay were predominantly negative, which indicates 
more growth inhibition than was expected. To see if there was any inhibitory effect of 
that pen-strep in the growth inhibition of mycobacteria, an experiment was performed 
where cells were rested in pen-strep, with only penicillin and without any antibiotic in the 
washing, pre-thawing and pre-freezing steps of culture.  There was a pronounced 
inhibitory effect when pen-strep was present in the cell rest medium in the post-thawing 
stage. There was not such an inhibitory effect if the antibiotic was present in the pre-
freezing medium alone. The inhibitory effect was not that pronounced when penicillin 
alone was used. Penicillin has no established role in antimycobacterial treatment; 
although amoxicillin-clavulanic acid and meropenem have recently been showed to have 
some activity against mycobacteria and WHO currently lists amoxicillin-clavulanic acid 
as a third line (and last line) agent with unclear efficacy for treatment of drug resistant 
mycobacteria (450).  Streptomycin, which is an effective anti-TB drug, is a protein 
synthesis inhibitor. It binds to the small 16S rRNA of the 30S subunit of the bacterial 
ribosome, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit. 
Drug entry into the bacteria causes the active export of cations out of the cytosol and it 
hyperpolarizes bacteria inducing an electrophoretic driving force that promotes the entry 
of aminoglycosidesso they can be sequestered in the lysosomes (451). In bacteria, 
streptomycin induces mistranslation and inhibition of protein synthesis, resulting in 
bacterial death (452). It is possible that streptomycin was taken up by the cells and 
entered their cytosol during the rest period, and was retained there even after the wash 
step. This might explain the inhibitory effect of the pen-strep during post-freezing and 
pre-thawing in the growth inhibition assay. Removal of antibiotics from the cell rest 
medium, reversed the growth inhibition. Although there were not significant changes due 
to the presence of antibiotics in pre-freezing stage it might be helpful to prevent the 
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bacterial contamination. Since there was some inhibitory effect still observed and to avoid 
any individual variation in how the cells take up or retain the antibiotic it is preferable not 
to use any antibiotic in the cell rest media for MGIT. For the remainder of the samples, no 
antibiotics were used in the tissue culture medium. Initially in this project the PBMCs 
from the patients were stored for long term in freezing media containing pen-strep and 
FBS. Some of the stored samples were tested for MGIT and most of them did not show 
any growth of mycobacteria. The antibiotic may have some inhibitory effect and also FBS 
might have some cross reacting antibodies from bovine serum. Other groups in Oxford 
University performed optimization experiments to reduce the reproducibility issues. They 
also observed that the pen-strep used in cell rest medium had a pronounced inhibitory 
effect on mycobacterial growth in the assay (personal communication).  
For any effective cell based culture, it is important to choose the most appropriate 
reagents to promote cellular activity. FBS has been widely used for this purpose. 
Interestingly, in MGIT it was observed that using FBS rather than pooled human AB 
serum, resulted in decreased mycobacterial growth. Although viability was not affected 
by using any of these sera in the cell culture medium, FBS might give some background 
of non-specific cell stimulation.The thesis of Rachel Tanner, 2015 assessed the cell 
culture conditions and found that using pooled human AB serum rather than FBS in the 
culture medium resulted in increased mycobacterial growth suggesting that the FBS may 
mediate a direct inhibitory effect on mycobacteria. For further MGIT assays, human AB 
serum was used (R.Tanner PhD Thesis, unpublished).  
Heat inactivation of human AB serum resulted in reduced mycobacterial growth in 
comparison to normal serum. Heat inactivation of serum results in destruction of growth 
factors, vitamins, amino acid and other protein components like complement. In 
mycobacterial cultures, heat inactivation of serum markedly reduces the adherence of Mtb 
and also reduces uptake of mycobacteria into the monocytes due to destruction of 
complement (453). Monocytes are considered to be important for mycobacterial growth 
and replication. Reduced monocyte invasion might lead to reduced net mycobacterial 
growth.  For further experiments, heat inactivated serum was used.  
The final yields of tubercle bacilli in submerged cultures is limited by the rate of diffusion 
of oxygen through the liquid medium.  Increased oxygenation can be obtained by forced 
aeration or by mechanical agitation of the culture. It is assumed that gentle agitation or 
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aeration is favourable to the growth of the organisms in liquid media since it helps in 
breaking up clumps of cells. It has been shown that aeration by continuous rotation used 
in cultures are preferred as it increases availability of oxygen supply that aids the 
multiplication of the bacilli (454). In the previous cell based MGIT assay, cultures were 
done in stationary plates (375)(398). In this study, the cultures were rotated for 96 hours 
in an incubator with 5% CO2. Rotating cultures gave significantly greater inhibition of 
mycobacterial growth. This was greater with 360º rotation in comparison to stationary 
cultures. In standing cultures cells would have less chance to get mixed with the 
mycobacteria. In rotating cultures, the mycobacteria would get in contact with more of 
the monocytes and effector immune cells like T cells would have greater contact with the 
infected cells and that might explain the increased growth inhibition rate. Jackson et al., 
showed in their study that agitation enhances the growth of the mycobacteria as it may 
improve the distribution of the nutrients, and oxygen  content in the medium (455). For 
the assays, cultures continued to be rotated at 360º. There were no significant differences 
in mycobacterial growth between the lysis steps using sterile water and no lysis state. 
To observe if there is any individual variation in MGIT assay responses in healthy 
donors, 10 donors were bled twice at one year intervals to see the growth inhibitory 
capacity. All these individuals are healthy, UK born and BCG vaccinated. There was no 
significant difference over the year in their pattern of growth inhibition. When the growth 
inhibition pattern was observed among the BCG vaccinated and non-vaccinated healthy 
donors at LSHTM, there was significantly greater growth inhibition in BCG vaccinated 
individuals than the non-vaccinated donors. BCG vaccination has variable efficacy 
though the efficacy is higher in non-endemic countries like UK (456).Using a 
mycobacterial inhibition assay, Silver showed an association between in vitro lymphocyte 
responses and inhibition of intracellular Mtb growth (377), thus this assay reflects the 
contribution of mycobacteria-specific T cells to protection. Hoft et al., found that 
inhibition of intracellular Mtb replication significantly increased after BCG vaccination of 
initially PPD-nonreactive persons (375), thus reflecting BCG-induced protective 
immunity.We also looked at the effect of PPD pre-stimulation on the MGIT assay. The 
cells were stimulated with PPD overnight and then used in the cells in MGIT to see if 
there was any fold change in growth inhibition pattern in PPD stimulated cells compared 
to non-stimulated cells co-cultured with BCG. PPD responses in individuals may be due 
to latent TB, prior BCG vaccinations, exposure to environmental mycobacterium-it 
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indicates some immunity from prior exposure to mycobacterium. Kang et al., in their 
studies have shown that strongly PPD-reactive TB contacts without ESAT-6/CFP10 
responsiveness showed significantly better mycobacterium inhibition activity than ESAT-
6/CFP10-responsive TB contacts with the same PPD reactivity. In TB contacts, stronger 
PPD reactivity was associated with improved mycobacterial killing, whereas ESAT-
6/CFP10 responders showed the opposite result (457). 
The aim of these optimization steps were to reduce the variability of the test and also to 
have an optimized protocol to be used for the clinical samples. This optimised protocol 
(Appendix 4) was taken forward to do the further experiments and analysis. 
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Chapter - 6  Cellular components in MGIA 
6.1   Cellular components in MGIA 
6.1.1  Introduction 
An understanding of the immune mechanisms underlying mycobacterial growth 
inhibition in vitro, to identify the mycobacteria specific cytokine responses, how these 
responses affect the capacity of the cells to control the growth of mycobacteria, and also 
the contribution of different immune cells in the immunopathogenesis of LTBI-helminth 
co-infected patients might provide important information on the major immunological 
effects of helminth coinfection on immune responses to TB. Among the various 
regulatory mechanisms, IL-10 and TGFβ appear to play the most profound role in 
influencing the T cell responses to mycobacterial antigens in the context of helminth-TB 
co-infection (458). Helminth infection is also associated with a decreased frequency of 
CD4+ IFNγ secreting T cells, as previously shown in a similar group of patients (370). 
The roles of these cytokines were explored, to observe how they can affect the growth 
inhibition of mycobacteria.  
 
Aims 
The aims of the experiments discussed in this chapter were to: 
• investigate the immune mechanisms underlying mycobacterial growth inhibition 
as measured in the BACTEC MGIT assay. 
• investigate the role of monocytes in the control of growth inhibition 
• explore the roles of cytokines like IFNγ, IL-10 and TGFβ in growth inhibition in 
the helminth infected patients and to investigate whether blocking these cytokines 
with antibodies can reverse the growth inhibition. 
 
6.1.2  Monocyte depletion 
Methods 
CD14 Micro beads (Miltenyi, Cat no 130-050-201) were used for the depletion of human 
monocytes from PBMC. PBMC were collected from ten BCG vaccinated and ten BCG 
 167 
non-vaccinated healthy donors at LSHTM. Afterwards PBMC from 5 more non BCG 
vaccinated donor PBMC were added to the study. PBMC were counted and placed in 
Eppendorf tubes at a concentration of 107 cells/ml. The cell suspensions were centrifuged 
at 300g for 10 minutes and the supernatant was aspirated completely. The cell pellet was 
resuspended in 80µl MACS buffer per 107 total cells and 20 µl CD14 micro beads per 107 
total cells were added. The cell suspension was mixed well and incubated for 15 minutes 
in the refrigerator (4°C). Cells were washed with MACS buffer and 1 ml of buffer per 107 
cells was added and centrifuged at 300g for 10 minutes. The supernatant was then 
aspirated completely. The cell pellet was resuspended in 500 µl of MACS buffer and 
placed on ice. A MS magnetic column was placed in the magnetic field of the MACS 
separator. The column was rinsed with 500 µl buffer. The cell suspension was applied 
onto the column and the effluent collected. The column was washed three times with 
MACS wash buffer. The column was removed from the separator and was placed on a 
collection tube. About 500 µl of MACS buffer was pipetted onto the column. 
Magnetically labelled cells were flushed out by firmly pushing the plunger into the 
column. Cell solutions were centrifuged at 1800rpm for 5 minutes, supernatant removed 
and resuspended in 10 ml of RPMI-MGIT for counting. Monocyte-depleted cells were 
stored in freezing medium and kept at -80°C overnight.  The depletions were confirmed 
by flow cytometry. The monocyte depletion ranged from 76 to 90%. The undepleted and 
the depleted samples were then thawed and added to MGT tubes to determine the 
mycobacterial growth.  
 
Figure 6.1: Human monocyte depletion. The MGIT assay was performed using depleted and 
undepleted PBMC (n=10). PBMC were depleted of monocytes using magnetic beads. 
There were significant differences in growth inhibition between monocyte depleted 
and undepleted PBMC. A non-parametric paired Wilcoxon test was performed, where 
* represent a p value of <0.05. The horizontal line represents the median response, the 
box represents the interquartile range and the whiskers represent the overall range. 
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The growth inhibition pattern in monocyte-depleted and undepleted PBMC in BCG 
vaccinated and BCG non-vaccinated healthy donor at LSHTM were observed. There were 
no significant differences in growth inhibition between monocyte depleted and 
undepleted PBMC among BCG vaccinated and non-vaccinated healthy donors, although 
the non-vaccinated group gave varied results (Fig. 6.2). 
  
Figure 6.2: Human monocyte depletion in BCG vaccinated and non vaccinated healthy donors at 
LSHTM. The MGIT assay was performed using monocyte depleted and non depleted 
PBMC. A non-parametric paired Wilcoxon test was performed. The horizontal line 
represents the median response, the box represents the interquartile range and the 
whiskers represent the overall range. 
 
The absolute monocyte counts in these patients was analysed to see if there is any 
correlation between monocyte count and the IGRA values, which were discussed in 
previous chapter 4. There were no significant correlations between monocyte count and 
the mycobacterial growth in LTBI, helminth, LTBI-helminth coinfected patients and the 
controls. The absolute monocyte counts in these patients at their visit 2 was also 
available. The result was similar as at visit 1, there was no significant correlation between 
helminth infected and LTBI-helminth coinfected patients.  
6.1.3  ML ratio and MGIA 
To further explore the effect of ML ratio, ML ratios calculated from the haematological data 
of these patients were correlated with the mycobacterial growth. There was a weak trend to 
positive association between ML ratio and mycobacterial growth in LTBI, LTBI-helminth 
coinfected patients and helminth-infected patients.  
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(A)   LTBI patients                    (B) Helminth infected        (C) LTBI-helminth coinfected 
    
Figure 6.3: Association of ML ratio and mycobacterial growth (visit 1). Mycobacterial growth 
inhibition was assessed by MGIA using frozen PBMC and ML ratio was calculated 
from lymphocyte and monocyte count obtained from cell counts performed at UCH. 
Spearman’s correlation between ML ratio and mycobacterial growth measured in the 
PBMC MGIT assay in (A) LTBI patients (n=23) (p= 0.4386) (B) helminth infected 
patients (n=28) (p= 0.3245) and (C) LTBI-helminth coinfected patients (n=15) 
(p=0.273) on their 1st visit (pre-treatment).  
After anthelmintic treatment, there was a stronger trend of positive association for the ML 
ratio and mycobacterial growth in helminth infected and LTBI-helminth co-infected 
patients during their visit 2, but again the correlation was not statistically significant (Fig. 
6.4).  
(A)                                              (B) 
  
Figure 6.4: Association of ML ratio and mycobacterial growth (visit 2). Mycobacterial growth 
inhibition was assessed by MGIA using frozen PBMC and ML ratio was calculated 
from lymphocyte and monocyte count obtained from cell counts performed at UCH. 
Spearman’s correlation between ML ratio and mycobacterial growth measured in the 
PBMC MGIT assay in (A) helminth infected patients (n=13) (p=0.2966) and (B) 
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LTBI-helminth coinfected patients (n=8) (p= 0.2316) on their 2nd visit (post-
treatment). 
6.1.4  The neutrophil:lymphocyte ratio (NLR) and MGIA 
The NLR was also explored to see if there is any correlation with the mycobacterial 
growth in all the four groups. There NL ratio was not significantly associated with 
mycobacterial growth in LTBI infected patients and helminth infected patients before and 
after their treatment.  
6.1.5  Frequency of eosinophil count and MGIA 
The absolute eosinophil count was also explored in all four clinical groups to observe if 
there was any correlation with the mycobacterial growth inhibition. There was a weak 
trend of positive association between eosinophilia and mycobacterial growth in LTBI 
infected patients, helminth infected patients, controls and LTBI-helminth infected patients 
in their first and second visit but there was a weak negative trend for eosinophilia and 
mycobacterial growth in LTBI-helminth coinfected patients after their treatment (data not 
shown).  
6.2  The role of cytokines in the mycobacterial growth inhibition assay  
6.2.1 The role of IFNγ in MGIA 
When associations were explored between IFNγ ELISpot response and mycobacterial 
growth in the PBMC MGIT, there were no significant associations in all the clinical 
groups. There was a weaker trend of negative association for IFNγ ELISpot response to 
PPD and mycobacterial growth in controls, LTBI patients, and coinfected patients in their 
first and second visit (Fig. 6.5).  
 
 
 
 
 
 
 
 
 171 
 
 
      (A)                                                         (B) 
	  
          (C )                                                           (D) 
	  
     (E)                                                      (F) 
  
Figure 6.5:  Association between IFNγ ELISpot responses to PPD and mycobacterial growth. An 
IFNγ ELISpot was performed against PPD using cryopreserved PBMCs from control, 
LTBI infected, helminth infected and LTBI-helminth infected patients before and 
after anthelmintic treatment (n=15). Spearman’s correlation between PPD 
IFNγELISpot and mycobacterial growth in the PBMC MGIT assay in LTBI 
(p=0.5335) (A), controls (p= 0.4507) (B), helminth infected on their first visit (p=-
0.2081) (C), helminth infected ontheir post-treatment visit (p=0.02736) (D), LTBI-
helminth coinfected ontheir first visit (p=0.8065) (E) and on second visit (0.8545) (F). 
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The association of IFNγ ELISpot responses to ESAT-6/CFP10 and mycobacterial growth 
was explored in all four clinical groups (Fig. 6.6). The response was very low in controls 
and helminth infected patients. There was a weak trend of positive association in ESAT-
6/CFP10 responses and mycobacterial growth in control and helminth infected patients. 
In coinfected patients, the ESAT-6/CFP10 response was showed weaker trend of positive 
association in IFNγ ELISpot responses but after treatment the association was negative, 
as was also seen in LTBI infected patients.  
(A)                                                                 (B) 
  
(C)                                                                         (D)         
  
Figure 6.6:  Association of IFNγ ELISpot responses to ESAT-6/CFP-10 and mycobacterial 
growth. An IFNγ ELISpot was performed against ESAT-6/CFP10 using 
cryopreserved PBMCs from control, LTBI infected, helminth infected and LTBI-
helminth infected patients before and after anthelmintic treatment (n=15). Spearman’s 
correlation between ESAT-6/CFP10 IFNγ ELISpot and mycobacterial growth in the 
PBMC MGIT assay in LTBI-helminth coinfected in V1 (A) and in V2 (B), helminth 
infected in V1 (C) and in V2 (D). 
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6.2.2  The role of IL-10 in MGIA 
IL-10 inhibits the protective immune response to pathogens by blocking the production of 
proinflammatory cytokines, such as TNFα and the Th-1-polarizing cytokine IL-12, by 
directlyacting on antigen-presenting cells such as macrophages andDCs. IL-10 can also 
inhibit phagocytosis and microbial killing through limiting the production of reactive 
oxygen and nitrogen intermediates in response to IFNγ all of which are pivotal for 
mediating immunity to Mtb.  To further explore the effect of IL-10 on mycobacterial 
growth, initially recombinant IL-10 (rIL-10) was added to three healthy donors PBMC. 
There was significantly increased mycobacterial growth in cultures, when assays were 
supplemented with rIL-10 in comparison to controls. It was observed that an increased 
concentration of rIL-10 was associated with increased mycobacterial growth.  
(A) 
 
(B) 
 
Figure 6.7: Effect of IL-10 on mycobacterial growth. The MGIT assay was performed in PBMC 
collected from healthy donors at LSHTM (n=6 in figure A and 3 in figure B). The 
effect was observed in PBMC added with rIL-10 and without rIL-10 (A) (bars 
represent the median value, a paired t-test was performed, where * represents a p 
value of <0.005). Increasing concentration of rIL-10 was added to the PBMC of these 
donors (B), where point represent the mean of duplicate cultures. 
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6.2.3  The role of TGFβ in MGIA 
TGFβ is another cytokine that plays an immunoregulatory role in TB. This cytokine also 
plays an important regulatory role in helminth infection. Various models of parasite 
infection have implicated a different number of cytokines and cell types, including IL-10 
and TGFβ and FoxP3+Tregs in controlling the host immune response and the resulting 
immunopathology. The effect of TGFβ on mycobacterial growth was assessed and as for 
IL-10, three healthy donors PBMC were used for the experiment. Recombinant TGFβ 
(rTGFβ) was added to the PBMC and then with increasing concentrations, to assess if 
there is any effect on mycobacterial growth. 
There was also a significant increase in mycobacterial growth in cultures supplemented 
with rTGFβ and like IL-10, with increased concentrations of TGFβ, there was increased 
mycobacterial growth (Fig. 6.9).  
 
(A) 
 
 
(B) 
 
 
Figure 6.8: Effect of TGFβ on mycobacterial growth. The MGIT assay was performed in PBMC 
collected from healthy donors at LSHTM (6 in figure A and 3 in figure B). The effect 
was observed in PBMC with or without rTGFβ. (bars represent the median value, a 
paired t-test was performed, where * represents a p value of <0.005). Increasing 
concentration of rTGF-β was added to the PBMC of these donors (B), where points 
represent the mean of duplicate cultures. 
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The cytokines IL-10 and TGFβ play immunoregulatory roles in TB and also helminth 
infections. The experiment also showed that there was significantly increased 
mycobacterial growth when supplemented with rIL-10 and rTGFβ, suggesting their 
immunoregulatory role. To explore further the effect of these cytokines on mycobacterial 
growth, anti-cytokine antibodies were used to block the cytokines. PBMC from 15 
helminth infected patients were used for this experiment and anti IL-10, anti TGFβ and 
anti IFNγ was added to the PBMC. Reduced mycobacterial growth inhibition was 
observed when IFNγ was blocked using anti-IFNγ antibody indicating IFNγ is needed for 
better growth control. When IL-10 and TGFβ were blocked there was significantly more 
growth inhibition suggesting their immunoregulatory role (Fig. 6.10). 
 
Figure 6.9 :Effect of blocking IL-10, TGFβ, and IFNγ using antibodies on mycobacterial growth. 
MGIT assay was performed using frozen PBMC in 15 helminth infected patients. 
Anti-IL-10, anti TGFβ and anti IFNγ were added in the culture supernatant. A two-
way ANOVA were performed followed by Bonferroni multiple test,where  **** 
represents a p value of <0.0001.  
 
To further identify the other important cytokines in these group of patients and if there is 
any correlation with mycobacterial growth, cytokines were measured in supernatants 
taken at 96 hours. The cytokines were measured using a Luminex assay- which will be 
discussed in next chapter. 
6.3  Discussion 
In the previous chapters, the optimization steps of this assay were described to adapt a 
PBMC based MGIT assayto measure the mycobacterial growth inhibition in vitro. This 
assessment of the capacity of the PBMC compartment to inhibit the growth of 
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mycobacteria may allow the investigations into the potential roles of immune 
mechanisms of interest in mediating this protective effect (375)(385)(396). To expand 
this more, the immune mechanisms underlying growth inhibition including the role of 
monocytes, eosinophils, ML ratio, NLR, cytokines, antibodies were investigated in 
controls, LTBI infected patients, helminth infected and LTBI-helminth coinfected UK 
migrants.  
Mtb can establish lifelong, chronic infection in the face of seemingly appropriate immune 
responses. This extraordinary persistence may be explained by the fact that Mtb resides 
predominantly inside cells of the immune system itself. Monocyte represent the main host 
cell for mycobacterial survival, growth, replication. Macrophages are the first cells to 
encounter Mtb (459). The signalling program initiated by macrophage receptors, 
including TLRs,CD14 co-receptor,C-type lectin receptors etc. results in the activation of 
transcription factors leading to expression of inflammatory mediators. The signals 
induced by CD14 and TLRs activate feedback inhibitory mechanisms and this transition 
from a strong inflammatory signalling into a weak activated state may be important in the 
immune control of Mtb infection (460).The MGIT assay was performed using depleted 
and undepleted PBMC. PBMC were depleted of monocytes using magnetic beads. There 
were significant differences in growth inhibition between monocyte depleted and 
undepleted PBMC. In the depleted monocyte state, there was less monocytes present, and 
lack of target cells for mycobacterial infection might have resulted in an overall reduction 
in the number of bacteria. Monocyte depletion had similar effects on mycobacterial 
growth inhibition in BCG and non-BCG vaccinated healthy donors. The non-BCG 
vaccinated donors exhibited varied results regarding mycobacterial growth. Kleinnijenhus 
et al., have shown that BCG vaccination in healthy volunteers led to NOD2-dependent 
epigenetic reprogramming of monocytes, which resulted in an increased expression of 
cellular receptors on the monocytes, accompanied by higher cytokine production in 
response to non-related pathogens (461).  
The absolute monocyte count obtained from the clinical data from HTD were then 
explored to see if they have any association with MGIA. There were no significant 
association between the number of absolute monocyte count in controls and helminth 
infected patients. A weak trend of positive association was observed for LTBI patients for 
eosinophil count and mycobacterial growth. The frequency of absolute monocyte count 
was increased after treatment in LTBI-helminth coinfected patents, but when we explored 
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the association with MGIA, there was a weak trend of negative association between them. 
It is unclear to what extent the association in LTBI-helminth coinfected patients may be 
usefully interpreted, given the small numbers of samples tested (both pre and post 
treatment).  
CD4+T cells and monocytes/macrophages were previously shown to be major effector 
cells in protecting the host against Mtb infection. It was explored whether there were any 
differences in the monocyte compartment in LTBI and helminth infected patients, 
measuring their absolute numbers and the effect of ML ratio on their ability to control the 
growth inhibition of Mtb. There was a significant change in ML ratio in coinfected 
patients but no significant changes from controls, LTBI, or helminth infected patients 
during their first visit. The ML ratio was not associated with mycobacterial growth in any 
of the four groups. There was a strong trend for LTBI-helminth coinfected and helminth 
infected patients for ML ratio and mycobacterial growth to be associated during their 
second visit. There was a reduction in mycobacterial growth with reduced ML ratio. 
However, the ML ratio predicted the risk of active TB development in HIV infected 
patients co-infected with Mtb (462). Recent data also have highlighted that an increase of 
the ML ratio is associated with changes of gene transcription in monocytes that may 
influence their functional antimycobacterial profiles (463).In an animal study, ML ratio 
has been associated with inhibition of mycobacterial growth (464). It has been described 
that human CD14+ monocyte are composed of two subsets based on CD16 expression 
and that relative percentages of CD16+ monocytes increase along with TB disease 
severity (463). It would have been interesting to study the functional profile of monocytes 
and their effect on mycobacterial growth inhibition on these coinfected patients. Turner et 
al., showed that in S.mansoni, S.haematobium or coinfected patients, monocyte 
recognition of E/S products released by skin invasive cercariae, or eggs, of S.mansoni  
assessed by flow cytometry showed that intermediate CD14brightCD16+monocytes had a 
significantly enhanced ability to bind to cercarial and egg E/S. This is potentially of 
significance in the development of schistosome-specific protective immunity or 
immunopathology (465). Studying the phenotype of monocytes might provide important 
information regarding the subtypes of monocyte related to immunopathology in helminth 
infection. The lymphocyte count had no change between visits in all the groups.  Manna 
et al., in their studies have shown that patients with active TB had a very high ML ratio, 
as compared to LTBI and healthy contacts, as well as cured TB patients. In active TB 
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patients, ML ratio was significantly correlated with increased monocyte counts and lower 
lymphocyte count and can be used as an indicator of active TB (466). ML ratio and its 
association with  IFNγ was also explored in the current study, ML ratio changes in blood 
are likely a marker of changes in the frequency of lineage based haematopoietic stem 
cells (HSC) and mycobacterial infection has been shown to alter haematopoiesis through 
IFNγ levels (467). But there was no significant association in LTBI, helminth or LTBI-
helminth coinfected patients.  
Absolute neutrophil count was observed in the patients and also the treatment effect on 
neutrophil count was explored. Comparing the values in groups, there were no significant 
changes in neutrophil count in the clinical samples after anthelminthic treatment. 
However, in LTBI-helminth coinfected patients, there was a significant reduction in 
neutrophil count (p<0.05). With neutrophil depletion using specific monoclonal antibody 
NIMP-R14 during chronic Mtb infection, there was a decrease in CFU rather than an 
increase (468). In humans, the risk of LTBI in contacts of patients with active disease is 
inversely proportional to the peripheral blood neutrophil count, consistent with the 
concept that higher neutrophil counts are protective against early infection (469). 
Absolute neutrophil count was not associated with MGIA in this study. Interestingly, free 
human neutrophil peptide (HNP) can be taken up by the macrophages and this increases 
their ability to kill and impair macromolecular biosynthesis of Mtb suggesting their 
potential antimycobacterial role (470). It has been reported that granules or entire 
apoptotic neutrophils may be phagocytosed by mononuclear cells with trafficking of  their 
contents to endosomes enhance restriction of mycobacterial growth (471). Because of 
neutrophils predominant role in phagocytosis of microbial pathogens, neutrophils have 
often been overlooked in helminth infection, although it would be interesting to address 
the role of neutrophils in the sustained inflammatory milieu in helminth infection  (472).  
The NLR, another measure of the myeloid: lymphoid cell proportion, has been reported to 
be associated with cancer and some cardiovascular disease outcome. The NLR of pleural 
fluid has been evaluated as an adjunctive toll in patients with TB pleurisy and also used as 
a marker of inflammation and for discriminating patients with pulmonary TB and 
bacterial pneumonia (473). In this study there was no significant change in neutrophil and 
lymphocyte counts in the patients during their 2 visits, only a slight reduction in LTBI-
helminth coinfected patients after they received treatment.  
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In the previous chapter, the absolute eosinophil count was explored in all the clinical 
samples. The count was significantly reduced in LTBI compared to the controls. After 
treatment, in helminth infected and LTBI-helminth coinfected patients, the eosinophil 
count was significantly reduced (p<0.0001 and p<0.005). The association of absolute 
eosinophil count and mycobacterial growth was explored. There was a weak positive 
trend in all the samples, however, LTBI-helminth coinfected patients showed a reverse 
association after they were treated with anthelmintic treatment. Eosinophil infiltration of 
the lungs and peripheral eosinophilia have been associated with tuberculosis disease in 
Mtb-infected patients (474). It was hypothesised that eosinophil influx may exaggerate 
the disease severity because eosinophils, which have been shown to phagocytose 
mycobacteria, may provide an intracellular habitat in which BCG could proliferate in an 
unrestricted manner. BCG-infected eosinophils might also have contributed to 
haematogenous dissemination of BCG, leading to an increased bacterial load in other 
tissues (475). 
In order to compare immunological responses in the LTBI, helminth and LTBI-helminth 
coinfected patients with growth inhibition, IFNγ responses were first measured by 
ELISpot. There was a significant increase in the magnitude of IFNγ ELISpot responses to 
PPD following LTBI-helminth coinfected patients after they received anthelmintic 
treatment during their second visit. When the groups were compared, it was found that the 
IFNγ ELISpot responses were significantly higher in LTBI infected patients in 
comparison to the controls, helminth and coinfected patients (p<0.0001). When the IFNγ 
ELISpot responses were observed in response to ESAT-6/CFP10, there was a similar 
pattern of expression. Interestingly, there was no difference in controls and helminth 
infected patients, as that of PPD responses. However, in LTBI-helminth coinfected 
patients, the IFNγ response to ESAT-6/CFP10 was significantly increased after 
anthelmintic treatment. The relationship between the induction of antigen specific T cell 
responses in LTBI, helminth and LTBI-helminth coinfected patients and their ability to 
control mycobacterial growth in vitro was explored. There was no significant correlation 
between mycobacterial growth inhibition and IFNγ ELISpot responses in LTBI, and 
controls. There was a weak negative trend for helminth and LTBI-helminth coinfected 
patients for mycobacterial growth inhibition and IFNγ ELISpot responses before they 
receive anthelmintic treatment and a weak inversion after they received the treatment. 
This indicates that a T cell response may contribute to the control of mycobacterial 
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growth after the anthelmintic treatment. After treatment, after removing helminths from 
the patients, there is induction of a greater number of PPD antigen-specific T cells, 
although this increased number of T cells does not result in an improved capacity to 
control mycobacterial growth in vitro. IFNγ secreting T cells alone did not reflect the 
overall capacityof cells to control mycobacterial growth. This was consistent with other 
studies where increased IFNγ responses were not correlated with MGIA 
(394)(476)(477).In helminth infected patients the IFNγ response were significantly 
increased after treatment. A hallmark of helminthic infections, both in experimental 
models and human infection is the generation of profound Th2 and T regulatory cell 
responses that have the potential to impede Th1 cell development. Children with 
onchocerciasis exhibit lowered cellular responses to PPD antigens (478). Coincident 
helminth infection is also associated with reduced Th1 responses in active and latent TB 
(355)(426). Studies regarding interaction of helminths with mycobacteria, but none of 
these studies fully explored the mechanistic basis for how helminth-modulated immune 
response has an impact on host control of Mtb infection. The lack of association between 
the IFNγ ELISpot responses and MGIT assay in these coinfected patients might 
necessitate to address the more complex host-pathogen interaction and to look at the other 
immune parameter for better understanding of the underlying immunopathogenesis. 
Infection of various cell types with Mtb has been shown to induce IFNα (479). It has been 
shown that a hyper virulent strain of Mtb induces higher levels of IFNα than normal 
strains and kills infected mice at a faster rate- which is partially caused by the failure to 
induce a proper Th1 response and partly production of type 1 IFNs and dampening of the 
immune response by strong IL-10 induction (480).  Antonelli et al., shown that type 1 
IFN receptor deficient mice chronically infected with Mtb strains showed reduced 
bacterial loads (481). The level of IFNα in all the patients in this cohort was measured. In 
LTBI and helminth infected patients IFNα concentrations were reduced compared to the 
controls. There was a significant increase in IFNα concentrations in LTBI-helminth 
coinfected patients in comparison to LTBI patients. It would be interesting to explore the 
levels of IFNα after the anthelmintic treatment to see if the treatment leads to the 
disappearance of this signature and also to measure IL-10, as it has been shown that type 
1 IFNs induce the immunosuppressive cytokine IL-10,which might contribute to loss of 
Mtb infection control (482). 
IL-10 and TGFβ have diverse roles during mycobacterial infection ranging from immune 
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evasion to immune protective.In helminth infection, the immune response is specially 
related to IL-4, IL-10 and TGFβ production, preferentially generated by Th2 or Treg cells 
(483). The effects of the regulatory cytokines, IL-10 and TGFβ on mycobacterial growth 
was evaluated in this study. To explore the immunoregulatory effects of IL-10 and TGFβ, 
the MGIT assay was performed using human PBMC cultured with or without addition of 
rIL-10 and rTGFβ in helminth infected patients. When cultured with rIL-10 and rTGFβ, 
there was significantly greater growth of mycobacterium in comparison to culture without 
rIL-10 and rTGFβ. In animal models, chronic infection with Fasciola hepatica enhances 
IL-10 and TGFβ by PBMCs in response to parasite antigen (484). IL-10 can enhance the 
intracellular survival of bacilli via inhibiting phagosomal maturation, reducing nitric 
oxide production and blocking IFNγ signalling in macrophage and can antagonize the 
development of Th1 responses through suppressing antigen presentation and IL-12 
production (485). However, the combination of TGFβ and certain other cytokines, may 
induce T cells to differentiate into non-regulatory phenotypes such as Th17 effectors in 
the presence of IL-6. The action of TGFβ on T cells is antagonized by IFNγ and IL-4 
(486). In vitro studies have shown that SEA induces the expression of FoxP3 in naïve T 
cells via TGFβ, which confers Tregs cell-expanding or tolerogenic properties on DC 
(487). The findings in this experiment, are consistent with the evidence in the literature 
that IL-10 and TGFβ has immunosuppressive activity and may contribute to 
mycobacterial disease (488)(489). To further explore the immunoregulatory effects of IL-
10 and TGFβ, the cytokines were blocked with anti-IL-10 and anti-TGFβ and also anti 
IFNγ was also used. Blockage of IL-10 and TGFβ (culture with out cytokines) caused 
significant reduction in mycobacterial growth in comparison to culture with these 
cytokines, whereas, blocking IFNγ increased the mycobacterial growth-suggesting the 
role of IFNγ in controlling mycobacterial growth.  Neutralization of IL-10 and TGFβ 
resulted in increased production of both IL-4 and IFNγ, suggesting the parasite may 
induce these anti-inflammatory cytokines to evade the immune response also suppression 
of IFNγ production by parasites may mediate parasite survival the disease. However, the 
cellular source of these cytokines are needed to be explored (490). 
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Chapter - 7    MGIA in clinical samples 
7.1   MGIA in clinical samples 
Helminth infection modulates the immune response by skewing the Th1/Th2 balance and 
thereby attenuating the effects of the BCG vaccine (356). However, clinical studies 
investigating the impact of deworming during active TB in humans remain very few in 
number and the responses obtained were varied (296)(306)(297). A randomized double-
blind clinical trial examining the effect of anthelmintic treatment on clinical improvement 
of TB after 2 months showed no significant effect of anthelmintic (albendazole) treatment 
over placebo (491). In previous study by Toulza et al., the impact of deworming on the 
in-vitro T cell memory responses to Mtb was observed in the IDEA London cohort of 
immigrants. The study showed a potential role for Treg cells is downregulating CD4+ 
IFNγ T cells and Treg numbers decreased and that of CD4+IFNγ+T cells increased after 
anthelmintic treatment (370). To further explore the effect of anthelmintic treatment on 
mycobacterial growth inhibition, the MGIT assay was performed in the clinical samples. 
The aim was to observe the effect of anthelmintic treatment on mycobacterial growth 
inhibition in helminth-infected and LTBI-helminth coinfected patients before and after 
anthelmintic treatment. The MGIA was also performed in patients with LTBI and 
controls at V1 and V2. For most of the experiments described in this project, BCG was 
used as a surrogate for Mtb. To explore how helminth infection affects the growth 
inhibition of virulent Mtb, Mtb Erdmann and Mtb H37Rv were also tested. 
Aims 
The aims of the experiments detailed in this chapter were to 
• investigate the potential effect of anthelmintic treatment on mycobacterial growth 
inhibition in helminth and LTBI-helminth coinfected patients 
• observe the effect of antigen stimulation (PPD, ESAT-6/CFP-10 and helminth 
antigen- SEA antigen of S.mansoni and S.haematobium, AWA antigen of 
S.mansoni and S.haematobium) on the pattern of mycobacterial growth control. 
• test how helminth infection affects the growth inhibition pattern of Mtb Erdman 
and Mtb H37Rv and whether anthelmintic treatment affects the growth inhibition. 
• explore if BCG provides an estimation of growth inhibition of Mtb by observing if 
there is any correlation between growth inhibition of BCG and Mtb Erdman. 
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7.1.1  Mycobacterial growth inhibition in controls, LTBI, helminth and LTBI-
helminth coinfected patients 
The MGIT assay was performed in helminth-infected patients and LTBI–helminth 
coinfected patients before and after anthelmintic treatment (V1 and V2). The growth 
inhibition was also observed in controls and LTBI at V1 and V2. In these experiments, 
the potential effect of anthelmintic treatment on mycobacterial growth inhibition in 
helminth infected patients was also observed. Cryopreserved PBMC were used for these 
experiments. 
At recruitment, there was significant reduction in mycobacterial growth inhibition in 
LTBI (p=0.02), in helminth infected patients (p=0.0009) and in LTBI-helminth coinfected 
patients in comparison to controls (Fig. 7.1).  Growth inhibition in coinfected patients, 
was reduced in comparison to LTBI (p=0.0017) and to helminth infected patients 
(p=0.04). There were no significant differences in TTP between helminth infected and 
LTBI. 
 
Figure 7.1: Mycobacterial growth inhibition in controls, LTBI, helminth-infected and LTBI-
helminth infected patients (visit 1). The MGIT assay was performed pre-treatment 
(V1) in helminth and LTBI-helminth coinfected patients, LTBI and controls (15 
patients per group). Fifteen donors were tested per group. Bar represents median 
values. A one-way ANOVA was performed, where * represents p value of 0.02, ** 
represents a p value of <0.005 and **** represents a p value of <0.0001. 
A similar experiment was performed in the four clinical groups to see the effect of 
anthelmintic treatment in helminth infected people. Cryopreserved PBMC were used for 
the experiment both pre-treatment and post treatment, with the paired samples for each 
donor. Mycobacterial growth inhibition was significantly reduced in helminth infected 
and LTBI-helminth coinfected patients, which reversed after anthelmintic treatment 
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(p<0.001). There was no significant change in MGIA in controls and LTBI patients at two 
time points (Fig. 7.2). There was significant improvement in mycobacterial growth 
inhibition in  LTBI-helminth coinfected patients (p<0.001). In LTBI-helminth coinfected 
patients, the lowest growth inhibition was shown pre-treatment, and they had the greatest 
change post-treatment. 
 
Figure 7.2: Mycobacterial growth inhibition in controls, LTBI, helminth infected and LTBI-
helminth infected patients (visit 1 and 2). The MGIT assay was performed in pre and 
post anthelmintic treatment (V1 and V2) in helminth and LTBI-helminth coinfected 
patients. PBMC from LTBI and controls were collected at V1 and V2 (without any 
treatment) and the MGIT assay performed. Fifteen donors were tested per group. A 
one-way ANOVA was performed, where, * represents a p-value of <0.01 and *** 
represents a p-value of <0.001.  
In this study, 11 patients (4 controls, 2 LTBI, 3 helminth-infected and 2 LTBI-helminth 
coinfected patients) were bled at 3 points- the first one during their recruitment, the 
second after one month of recruitment and the third after they finished their anthelmintic 
treatment- 4 months after visit 1 (recruitment). The log CFU change was observed in all 4 
groups at these 3 time points to see the baseline level of variation in immune responses 
(Fig. 7.3). No significant change was seen between growth inhibition at the first and extra 
second visit.  
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    (A)  Controls                                           (B) LTBI patients 
 
   (C )  Helminth infected                          (D) LTBI-helminth coinfected 
 
Figure 7.3: Mycobacterial growth inhibition in controls (n=4)(A), LTBI (n=2)(B), helminth 
infected  (n=3)(C) and LTBI-helminth infected patients (n=2)(D). The MGIT assay 
was performed pre-treatment (visit 1), one month after recruitment and post 
anthelmintic treatment (Visit 2) in helminth and LTBI-helminth coinfected patients. 
PBMC from LTBI and controls were also collected at these three points and the 
MGIT assay performed. A one-way ANOVA was performed. 
7.1.2  Effect of antigen stimulation on mycobacterial growth inhibition  
 The effect of mycobacterial and helminth antigen stimulation was explored in controls, 
helminth, LTBI, LTBI-helminth coinfected patients using cryopreserved PBMC. Cells 
were stimulated with PPD, ESAT-6/CFP-10, SEA of S.mansoni and AWA antigen of S. 
mansoni added at the same time as the BCG in the culture for 96 hours and the MGIT was 
performed (Fig 7.4).  
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In controls there were significant changes in mycobacterial growth inhibition in response 
to stimulation with SEA and AWA antigen when compared to PPD (p=0.03) and ESAT-
6/CFP10 antigen stimulation (p=0.001). When PBMCs were stimulated with SEA and 
AWA antigen, there was a trend towards significantly increased mycobacterial growth in 
the LTBI, helminth and LTBI-helminth coinfected patients compared to the control 
cultures without stimulation and this was statistically significant.  
     (A)  Controls                                                         (B)  LTBI 
 
 
      (C )    Helminth infected                                      (D) LTBI-helminth coinfected 
 
Figure 7.4: Mycobacterial growth inhibition responses with stimulation using PPD, ESAT-
6/CFP-10, SEA and AWA antigen.  MGIT was performed in PBMC stimulated with 
PPD, ESAT-6/CFP-10, Schistosoma antigen- SEA and AWA antigen in controls (A), 
LTBI (B), helminth infected (C) and LTBI-helminth coinfected patients (D). Five 
donors were tested per group. Bar represents the median values. A Kruskal-Wallis 
with a Dunn’s post-test was performed. 
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The experiment was repeated. For the MGIA, helminth antigens were dilulted with 
endotoxin-free PBS and the antigens were used from the stock solution. The helminth 
antigens were used at 10µg/ml final concentration. Mycobacterial growth in response to 
addition of SEA and AWA antigen were significantly reduced compared to that of first 
expeirment. The antigens had been aliquoted in PBS which was not endotoxin free–
possibly after using the LPS free PBS, the cytotoxicity was removed. 
7.1.3  MGIT using Mtb Erdman and Mtb H37Rv 
For all the optimization steps of the MGIT assay and for most of the tests using the 
clinical samples, BCG was used. Mtb Erdman and Mtb H37Rv was used in this 
experiment, to explore how the growth of virulent Mtb is modulated in helminth 
coinfection and the effect of anthelmintic treatment on their growth.  We also wanted to 
explore whether there was an association between growth inhibition of BCG and of Mtb 
and whether BCG can be used to evaluate growth inhibition of virulent Mtb. This work 
was done in the Category 3 Laboratory with an optimized protocol.  
The MGIT assay with Mtb was performed using PBMC from healthy controls at LSHTM 
and from LTBI infected patients. Alhtough the PBMC MGIT assay detected a difference 
in mycobacterial growth inhibition between LTBI infected patients and healhty controls 
at LSHTM, the difference was not statistically significant. There was little difference in 
growth inhibition of Mtb H37Rv and Mtb Erdman strains between the healthy controls 
and LTBI infected patients (Fig. 7.5). The reduction in mycobacterial growth observed 
using Mtb H37Rv in LTBI patients was significantly different than that seen in controls 
(p=0.018). LTBI infected patients exhbited significant differences in growth inhbition 
pattern when MGIT was performed with H37Rv and Mtb Erdman strain (p=0.05). The 
Mtb Erdman strain was selected for the next experiment to see the effect of anthelmintic 
treatment and to explore the pattern of growth inhibition of BCG and Mtb. 
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Figure 7.5: MGIT assay in healthy controls and LTBI infected patients using BCG, Mtb Erdman 
and Mtb H37Rv. The PBMC MGIT assay was performed in healthy controls and 
LTBI patients using  BCG, Mt bErdman, and Mtb H37Rv. Five donors were tested 
per group. Bars represent the median values. Having passed a normality test, a 
repeated measures ANOVA was performed followed by a Dunn’s post-test.  
 
The MGIT was then performed with BCG and Mtb Erdman strain to see whether there 
was any variation in mycobacterial growth inhibition in helminth and LTBI-helminth co-
infected patients. The experiment involved 10 patients per group- and used both pre and 
post treatment samples. A significant reduction in mycobacterial growth was observed 
following treatment in helminth infected patients (p=0.0070) and LTBI-helminth 
coinfected patients (p= 0.0190) when either Mtb Erdman strain or BCG were used (Fig. 
7.6). Unlike the previous experiment, where we looked at the impact of anthelmintic 
treatment on mycobacterial growth in all four clinical groups (in 15 patients each group) 
using BCG, there were significant changes in helminth and LTBI-helminth coinfected 
patients that reversed after treatment. Similarly, when we explored the Mtb Erdman 
strain, helminth infected and LTBI-helminth coinfected patients showed the similar 
pattern, but the change was not statistically significant maybe because of the smaller 
sample size. 
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Figure 7.6: MGIT assay in helminth infected and LTBI-helminth co-infected patients using BCG 
andMtb Erdman. The PBMC MGIT assay was performed in helminth-infected and 
LTBI-helminth co-infected patients using BCG and Mtb Erdman. Ten donors were 
tested per group. Bars represent the median values. A repeated measures ANOVA 
was performed followed by a Dunn’s post-test, where ** represents a p value of 
<0.05 and * represents a p value of 0.023. 
 
Next it was explored if the inhibition of BCG provides a satisfactory estimate of Mtb  
growth inhibition and can correlate with the clinical outcome, so that BCG could be used 
instead of Mtb. The experiment was performed with each of the species (BCG and 
MtbErdman) to see if there is any correlation between growth inhibition of the two strains 
in controls, LTBI, helminth-infected and LTBI-helminth coinfected patients both pre-
treatment and post-tretament. There was no significant corrrelation between the growth of 
BCG and Erdman in controls and LTBI infected patients, although there was a weak trend 
towards a positive association of growth of BCG and Mtb Erdman in LTBI-helminth 
coinfected patients at V1. Interestingly, there were significant positive associations in 
helminth infected patients between growth inhibition of the two species both pre and post 
treatment ( p= 0.0060 and p=0.0034 respectively) (Fig. 7.7). 
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       (A)                                                   (B) 
  
   (C )                                                            (D) 
  
Figure 7.7: Correlation between BCG Aeras and Mtb Erdman growth. Spearman’s correlation 
between TTP of BCG Aeras and Mtb Erdman in MGIT culture of PBMC from LTBI-
helminth coinfected patients both at V1 and V2 (A and B) and helminth infected 
patients at V1 (C) and V2 (D). Ten donors were tested per group. 
 
The MGIA pattern in patients infected with - Schistosoma spp and Strongyloides spp-
were compared in these helminth infected and LTBI-helminth coinfected patients, to see 
if  there is any significance difference in the ability of these helminth species to affect 
antimycobacterial immune responses. MGIA was performed in 15 Schistosomiasis 
infected and 15 Strongyloidiasis infected patients, 8 Schistosomiasis and LTBI coinfected 
patients and 7 Strongyloidiasis and LTBI coinfected patients. There was no significance 
difference in the mycobacterial growth inhibition in patients infected with Schistosoma or  
Strongyloides spp (Fig. 7.8).  
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Figure 7.8: MGIT assay in helminth infected and LTBI-helminth co-infected patients infected 
with Schistosoma and Strongyloides spp. The numbers tested were 15 
Schistosomiasis infected and 15 Strongyloidiasis infected patients, 8 Schistosomiasis 
and LTBI coinfected patients and 7 Strongyloidiasis and LTBI coinfected patients.  
Bars represent the median values. A repeated measures ANOVA was performed 
followed by a Dunn’s post-test. 
 
7.2  Discussion 
Helminth infections modulate the immune system toward a Th2 profile with regulatory 
responses rather than Th1 responses. Cytokines that mediate humoral immunity can 
inhibit Th1 immunity, leading to immune polarization and this impacts on the Th1-based 
immunity required for control of Mtb infection (488) 
(493). Chronic helminth infestations are also associated with anergic immunosuppressive 
conditions such as HIV, diabetes mellitus and malnutrition that may be associated with false-
negative test results for Mtb infection (494)(495)(496). It was hypothesized that anthelmintic 
treatment in LTBI-helminth coinfected UK migrants would lead to reconstitution of the Th1 
response and improve the capacity of the cells to control the growth of mycobacteria. To 
explore the effect of anthelmintic treatment on mycobacterial growth inhibition, the MGIT 
assay was performed in the clinical samples. The aim was to observe the effect of 
anthelmintic treatment on mycobacterial growth inhibition in helminth-infected and LTBI-
helminth coinfected patients before and after anthelmintic treatment. 
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In this experiment, a London cohort of immigrants who had presented with or without 
LTBI were recruited to evaluate the impact of deworming on the in vitro T-cell responses 
and the ability of the cells to control the growth of mycobacteria. This cohort provided the 
opportunity to study these responses in a setting where the risk of reexposure and 
reinfection was negligible and was an ideal situation in which to study the impact of 
anthelmintic treatment on the antimycobacterial immune responses. 
The MGIT assay was performed using PBMC from controls, LTBI, helminth infected and 
LTBI-helminth co-infected patients at baseline (recruitment). There was significant 
reduction in mycobacterial growth inhibition in LTBI (p=0.02), in helminth infected 
patients (p=0.0009) and in LTBI-helminth coinfected patients (p<0.001) in comparison to 
controls. Helminth infections, in addition to Th2 responses, can induce the suppressive T 
cell population, Tregs which produce inhibitory cytokines such as IL-10 and TGFβ that 
suppress Th1 type responses and interfere with effector T cell activation (497). Studies have 
shown that mice chronically infected with M.avium and subsequently infected with 
S.mansoni infection developed granuloma-derived lymphocytes producing PPD-specific 
IL-4, not IFNγ in coinfected mice, in contrast to the Th1 cytokine pattern by lymphocytes 
of M.avium–only infected mice with impaired resistance against subsequent infection by 
Mtb BCG (498). A similar finding was observed in the mouse model study conducted by 
Monin et al., where coinfection with S.mansoni or immunization with SEA antigens could 
reversibly impair Mtb specific Th1 cell responses but without severely affecting the ability 
of the macrophages to limit Mtb control (422). S.mansoni infection resulted in accumulation 
of arginase-1 expressing macrophages in the lung, forming type 2 granulomas and resulting 
in increased lung fibrosis and mucus plug formation, exacerbating disease severity and 
inflammation in Mtb coinfected mice. Helminth related alterations of T cell response could 
also be explained by comparing the immune activation status and cellular response to PPD 
in chronically helminth infected patients, where PBMC from these people were found to 
have a greater expression of CTLA-4, a negative regulator of T cell responses that leads to 
downregulation of Th1 type cytokines (354). 
A similar experiment was performed here in the four clinical groups to see the effect of 
anthelmintic treatment in helminth infected people. Cryopreserved PBMC were used for 
the experiment both pre-treatment and post treatment, with the paired samples for each 
donor tested in the same experiment. In helminth coinfected and LTBI-helminth 
coinfected patients, there was an increase in mycobacterial growth at baseline compared 
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to that in controls, which reversed after anthelmintic treatment. The anti-schistosome 
immune response after praziquantel therapy has been characterized in animal models and 
humans. It has been shown that, damage to tegument exposes antigens that induce strong 
type 2 immune responses, characterized by increased production of schistosome-specific 
IL-4, IL-5, IgG and total IgE concentrations, peripheral eosinophilia and histamine 
concentrations. Increases in such Th2 responses might be expected to affect the immune 
response, with suppressed Th1 cytokine response and increased Th2 cytokine responses 
(499).  A study conducted in Ethiopia demonstrated that PBMCs from S.mansoni infected 
individuals display poor responsiveness to mycobacterial antigens, characterised by 
impaired Mtb specific IFNγ production and reduced T cell proliferation compared to 
dewormed controls (358). Helminth induced immune hyporesponsiveness by IL-10 and 
TGFβ blocks the proliferative responses to recall responses to mycobacterial antigen 
(500).  When occupying the host, most helminths release large amounts of antigenic 
material, leading to chronic immune activation, but with the increasing burden worms 
seem to modify and down-regulate these responses to adapt and survive, potential 
exhausting the local immune potential of the host, leading to hyporesponsiveness. This 
might be another reason for such responses (501). A reduction or elimination of intestinal 
helminths using broad spectrum anthelmintic treatment resulted in enhancement of T cell 
proliferation and IFNg production by PBMC stimulated with PPD. T cell responses to 
PPD were found to be improved in filarial infected subjects after treatment with 
diethylcarbamazine (320)(502). Some studies have shown that there is no significant 
effect of anthelmintic treatment on clinical outcome of TB (356)(491). These varied 
responses may be attributed to different species of helminth, their location in the body, 
different life cycles, different secretory and excretory products, or Mtb infection. 
Different strains of mycobacteria and their route of administration may also contribute. In 
vitro studies have demonstrated that the impact of helminth infection on Mtb infection-
andon the clinical outcome is not clearly understood, which may be due to underpowered 
studies, type or intensity of infecting helminths and the different methodologies used for 
the detection of helminth infection (135). In this cohort, 7 patients were infected with 
multiple helminth species, for example- schistosoma spp, Strongyloides, filaria and 
tapeworm. The CD4+ IFNg response was lower in those patients and also mycobacterial 
growth was significantly higher at baseline by MGIA.  A case control study from 
Ethiopia showed an association between helminth and TB coinfection and the association 
was stronger in patients that were infected with multiple helminth species(503). 
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MGIA was performed in 11 patients of this cohort, who were bled at three time points- 
pre-treatment, one month after recruitment (but still pre-treatment) and post-treatment (4 
months after anthelmintic treatment). All these patients attended the clinic with diagnosed 
eosinophilia and or helminth infection and or LTBI. All of them had some symptoms 
related to helminth infection. The eosinophilia may also be secondary to a number of non-
tropical diagnosis like polyarteritis, inflammatory bowel disease, Chrug-Strauss disease, 
etc, although studies have demonstrated a helminthic aetiology for eosinophilia in 50% 
patients with travel history (404)(504). The eosinophil count normalised from the 
previously sustained eosinophilia (<0.4x 109/ml) after treatment with anthelmintic drugs. 
All the helminths were diagnosed with microscopy and serology. Serology positive 
patients had no other symptoms of filarial or any other helminth infections. The Log CFU 
in the MGIA was also observed at these three time points. There was no difference in 
MGIA response between visit 1 and the extra visit one month after visit 1. The 
CD4+IFNg response at their pre-treatment visit and one month after did not show any 
change either. In helminth infected and LTBI-helminth coinfected patients, the 
CD4+IFN-g response increased after helminth treatment and also the mycobacterial 
growth was reduced- suggesting the beneficial impact of anthelmintic treatment. 
The effect of mycobacterial and helminth antigen stimulation was explored in controls, 
helminth, LTBI, and LTBI-helminth coinfected patients using cryopreserved PBMC. 
When the cells were stimulated with PPD, ESAT-6/CFP-10, SEA of S. mansoni and 
AWA antigen of S.mansoni, there was a significant increase in mycobacterial growth in 
response to SEA and AWA antigens in comparison to PPD, or ESAT-6/CFP10. In 
response to PPD and ESAT-6/CFP10 the growth control was less in LTBI and LTBI-
helminth coinfected patients. The ESAT-6/CFP10 response was observed to be higher in 
LTBI and LTBI-helminth coinfected patients. Helminth antigens were initially aliquoted 
in PBS that was not endotoxin free. LPS can stimulate the release of IL-8, CXCL8, CXC 
ligand and other inflammatory cytokines in various cell types, leading to an acute 
inflammatory response towards pathogens. These responses are initiated by the activation 
of the TLR signalling through adaptor proteins, and include induction of gene expression 
via the activation of the NF-κB and AP-1 signal transduction pathways (505).  
Robinson et al., have shown that helminth derived molecule of F.hepatica binds directly 
to LPS preventing its interaction with the TLR4/CD14 complex on the macrophage 
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surface and prevents the release of inflammatory mediator TNFα and IL-1ß from 
macrophages (506). The experiment was repeated and cell viability was observed every 
day while the cells and antigens were in the rotator for 96 hours. There were no changes 
in viability after 96 hours. The MGIA assay was repeated using the antigens prepared 
from the stock and diluted in endotoxin free PBS. PPD responses were higher in controls 
and helminth infected patients in comparison to LTBI infected patients where ESAT-
6/CFP10 responses were higher. Strong PPD responders without evidence of LTBI might 
have distinctly different mycobacterial inhibition activity from LTBI subjects (ESAT-
6/CFP-10 responders), with similar PPD reactivity. This is because PPD reactivity may 
reflect protective immunity in the former group but not the latter. Strong PPD reactivity 
may paradoxically be associated with poor mycobactericidal activity (457). 
For all the optimization steps of MGIT assay and for most of the tests using the clinical 
samples, BCG was used. Mtb Erdman and Mtb H37Rv were then compared, to explore 
how the growth of virulent Mtb is modulated in helminth coinfection and the effect of 
anthelmintic treatment on their growth.  The association of growth inhibition of BCG and 
Mtb was also explored.  Experiments were run using PBMC from LTBI infected patients 
and healthy controls from LSHTM , comparing the assay read-out for BCG Aeras, Mtb 
H37Rv and Mtb Erdman. Other studies have used BCG as a surrogate marker for Mtb in 
the MGIT assay (387)(375). In LTBI infected patients Mtb Erdman showed increased 
mycobacterial growth compared to that in healthy controls, as well as of BCG and Mtb 
H37Rv. The Erdman strain was selected for the next experiment to see the effect of 
anthelmintic treatment and to compare the pattern of growth inhibition of the BCG and 
Mtb.The impact of anthelmintic treatment was also observed in helminth infected patients 
and LTBI-helminth coinfected patients with BCG and Mtb Erdman. There was a 
significant increase in mycobacterial growth with Mtb Erdman compared to BCG, which 
reversed after anthelmintic treatment. M bovisBCG  and Mtb share the same structure and 
metabolism, and these genomes have >99.5% identity at the nucleotide level (507). 
Manabe et al., showed in a series of infections in rabbits with three different strains 
of Mtb Erdman, Mtb H37Rv and CDC1551, that the Mtb Erdman strain appears to be the 
most virulent for rabbits, requiring the lowest number of inhaled bacilli to make one 
tubercle. This strain also has the greatest spectrum of disease at 16 to 22 weeks after 
initial aerosol infection (508). There was a weak trend of positive association in growth 
inhibition for BCG and Mtb Erdman in LTBI, helminth and LTBI-helminth coinfected 
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patients. A significant correlation was observed between the murine BMMø assay read 
out using BCG and Mtb(509). BCG can therefore be used as potential surrogate for Mtb 
in the MGIA–limiting the use of more virulent strains and Category 3 facilities. 
The treatment impact on helminth infected and LTBI-helminth coinfected patients was 
explored. There was significant reductions in mycobacterial growth after treatment, 
Evidence suggested that a skewed Th2 response caused due to  S.mansoni  infection 
protection conferred by M.bovis BCG vaccinations in humans and in mice infected with 
Mtb (498). Interestingly, this coinfection increases the mycobacterial burden in the lungs 
and this increase in burden is often transient and moderate suggesting that the effect of 
helminth coinfections on Mtb control is not significant enough to fully explain the 
increased severity of TB in helminth coinfected individuals and that Mtb control 
mechanisms are not completely suppressed in coinfected hosts (323). Other immune 
parameters like systemic cytokine levels, antibodies or the extent of gene expression may 
help dissecting the immune responses in these coinfected patients.  MGIA along with 
other immune parameters might provide an immune signature for these patients. 
The two helminth species –Strongyloides and Schistosoma spp, were compared to see 
how they might impact the mycobacterial growth inhibition. MGIA was performed to 
observe if the two helminth- Strongyloides and Schistosoma spp, show any difference in 
MGIA growth inhibition pattern- but they did not show any significant difference in the 
pattern of MGIA. The discrepency in the results in terms of reactivity to TB antigens, 
may be due to type of helminth parasites studied, the methods used for diagnosing 
helminth infection or the cutoff used for skin reactivity and the differences in 
geographical regions (135). These two helminth species have different routes and modes 
of infection, disease pathogenesis and severity, and treatment options. They share some 
common immune features like skewing of Th2 immune responses, AAMS, similar 
cytokine profile,etc. In this experiment, PBMC from patients infected with Stongyloides 
spp showed slightly reduced mycobacterial growth in comparison to those infected with 
Schistosoma, although the difference was not significant. More exploratory research can 
be useful regarding these two species,and how they affect antimycobacterial responses. 
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Chapter - 8 
8.1 Antibody and cytokine responses in LTBI, helminth infected and LTBI-
helminth infected patients 
Cell mediated immunity has been traditionally considered the sole immune mechanism 
against TB. There are several studies withevidence of multiple attempts to demonstrate 
the protective role of antibodies (510)(511). Increasing evidence suggests that antibodies 
could contribute to the defence against M.tb (32)(512). However, their role is 
insufficiently studied because of the general perception that M.tb, a largely intracellular 
pathogen, is outside the reach of extracellularly located Abs (513). Antibody responses to 
capsular AM(Arabinomannan) and the related cell wall glycolipid LAM 
(lipoarabinomannan) correlate strongly and significantly in patients with tuberculosis and 
helminth infections (514). However, a feature of the immune response to parasitic 
helminth infections, is the production of large amounts of specific and nonspecific IgE. 
The slow build-up of IgE to high levels and the early production of IgG4 antibodies, 
which may block IgE pathways were shown to be responsible for delaying the 
development of protective immunity to S.haematobium (515). To explore the quantity of 
total and parasite specific antibodies–IgE, IgG4 and IgA, plasma samples were used for 
ELISA. This chapter also describes analysis of the effect of anthelmintic treatment on 
these antibodies in helminth-infected and LTBI-helminth coinfected patients.  
Cytokines and chemokines are also important regulatory factors for protective immunity 
against tuberculosis. To explore the cytokine production in these patients, 96 hours 
culture supernatants of the MGIAwas used. The concentrations of the cytokines and the 
correlation with mycobacterial growth was explored. 
Aims: 
• To measure the quantity of total and parasite specific IgE, IgG4, ESAT-6/CFP-10 
specific IgA in plasma of controls, helminth infected, LTBI-helminth co-infected 
patients and LTBI patients.   
• To explore the association of antibodies with mycobacterial growth inhibition in 
the MGIT assay 
• To measure the cytokines in 96-hour culture supernatants from MGIA cultures 
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• To explore if there is any correlation between mycobacterial growth inhibition and 
cytokine concentrations in LTBI, helminth infected and LTBI-helminth coinfected 
patients. 
8.1.1  Methods 
At visit 1 (before treatment) and visit 2 (after anthelmintic treatment) 20 ml blood was 
collected from each patient and from that 1 ml of whole blood was placed in a 2 ml 
Eppendorf tube and 500µl of plasma collected after centrifuging the whole blood. These 
plasma samples were used to measure the quantity of total IgE, IgG and IgA. 
8.1.1.1 Measuring IgE concentrations in plasma from controls, LTBI, helminth-
infected and LTBI-helminth infected patients 
A sandwich ELISA was used for detection and quantification of the antibodies in the 
plasma obtained from the whole blood collected from the clinical samples. To measure 
the total and antigen specific IgE antibody, plasma from 11 patients from each group, 
both before and after treatment was used to perform the ELISA. S.mansoni SEA antigen 
and AWA antigen were used as the helminth antigens. There were differences in optical 
density (OD) between pre and post treatment IgE in helminth infected and LTBI-helminth 
coinfected patients (Fig. 8.1). Total IgE concentrations were not significantly changed in 
LTBI infected patients or in controls. But the total IgE was significantly different in 
helminth infected and LTBI-helminth infected patients both before and after treatment 
(p= 0.015 and p=0.005 respectively). 
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Figure 8.1: Total IgE detected by ELISA in plasma from controls, LTBI, helminth infected 
patients and LTBI-helminth coinfected patients. Plasma diluted 1 in 10 from eleven 
patients of each group were used in the ELISA.The OD value at 450nm was 
measured using an ELISA plate reader. OD values have had the background OD 
values subtracted. A repeated measures ANOVA was performed followed by a 
Bonferroni’s multiple comparison test, where * represents a p value of <0.05. 
 
To determine whether concentrations of parasite antigen specific IgE antibodies change 
with anthelmintic treatment, plasma samples were used for the ELISA. S.mansoni SEA 
and AWA antigens were used as antigen (at 10µg/ml) Antigen specific IgE responses 
were similar like those of total IgE in helminth and LTBI-helminth coinfected patients, 
although there was an increase in the IgE concentrations in the helminth infected and 
coinfected patients (Fig. 8.2). There were no significant differences in IgE antibodies to 
the two antigens in IgE responses.   
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Figure 8.2: Antigen specific IgE responses by ELISA in controls, LTBI, helminth infected 
patients and LTBI-helminth coinfected patients. Plasma diluted 1 in 10 from eleven 
patients of each group were used in the ELISA. S.mansoni SEA antigen was used as 
antigen. OD values at 450nm were measured using an ELISA plate reader. A repeated 
measures ANOVA was performed, where *** represents a p value of <0.005 and 
**** represents a p value of <0.0001. 
To determine whether levels of total and parasite antigen specific IgE antibodies have a 
significant effect on mycobacterial growth, the relationship between log CFU and ELISA 
OD were investigated. No significant correlation was observed in assays using PBMC 
from LTBI and controls. There was a weak trend observed in helminth infected patients 
in their V1 (before treatment) and similar trend was observed in LTBI-helminth 
coinfected patients both before and after treatment (Fig. 8.3). 
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(A) Helminth infected (V1)                 (B) Helminth infected (V2) 
  
      (C ) LTBI-helminth coinfected (V1)       (D) LTBI-helminth coinfected (V2) 
  
Figure 8.3: Total IgE antibody concentrations and correlation with mycobacterial growth 
inhibition. PBMC from 11 helminth infected patients both pre and post treatment 
(A,B), and LTBI-helminth coinfected patients pre and post-treatment (C,D), were 
used for MGIT. Spearman’s correlation between total IgE antibody OD by ELISA 
and log CFU in the PBMC MGIT assay was performed in the groups. OD value at 
450nm was measured using an ELISA plate reader.  
Next, whether parasite antigen-specific IgE antibodies have a significant effect on 
mycobacterial growth was explored, in terms of the relationship between log CFU and 
ELISA OD. No significant correlation was observed in LTBI and controls, in helminth 
infected patientsor in LTBI-helminth coinfected patients at their first or second visits (V1 
and V2, before and after treatment).  
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8.1.1.2  IgG4 concentrations in controls, LTBI, helminth infected and LTBI-
helminth infected patients 
To measure the total and antigen specific IgG4 antibody, plasma from 11 donors from 
each group, both before and after treatment if appropriate was used to perform the 
ELISA. S.mansoni SEA antigen was used as the helminth antigen.The total IgG4 plasma 
concentration was not significantly different in LTBI infected patients or in controls (Fig. 
8.4). However, the total IgG4 concentrations were significantly higher in helminth 
infected and LTBI-helminth infected patients both before treatment and the changes 
reversed after treatment (p= 0.015 and p=0.005 respectively). 
 
Figure 8.4: Total IgG4 concentrations measured by ELISA in controls, LTBI, helminth infected 
patients and LTBI-helminth coinfected patients. Plasma  diluted 1 in 10 from ten 
patients of each group were used in the ELISA. OD value at 450nm was measured 
using an ELISA plate reader. A repeated measures ANOVA was performed, where ** 
represents a p value of <0.005 and * represents a p value of <0.05. 
 
Next the parasite antigen specific IgG4 responses were measured in all four clinical 
groups. The antigen specific IgG4 response was mostly similar to that of total IgG4. The 
antibody response was significantly reduced after anthelmintic treatment in helminth 
infected and LTBI-helminth infected patients (Fig. 8.5). The level of IgG4 was 
significantly lower in controls than the helminth infected patients and LTBI-helminth 
coinfected patients (p<0.0001).  
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Figure 8.5: Antigen specific IgG4 concentrations measured by ELISA in controls, LTBI, 
helminth infected patients and LTBI-helminth coinfected patients. Plasma diluted 1 in 
10 from eleven patients of each group were used in the ELISA. S.mansoni SEA 
antigen was used as antigen. OD values at 450nm were measured using an ELISA 
plate reader A repeated measures ANOVA was performed, where ** represents a p 
value of <0.005. 
We explored whether there was any correlation between total IgG4 and antigen specific 
IgG4 level measured by ELISA and log CFU detected by MGIT assay. There was no 
significant correlation in any of the groups with either total IgG4 and parasite antigen 
specific IgG4 and mycobacterial growth. 
8.1.1.3  Measuring total IgA and antigen specific IgA in LTBI infected patients 
To measure the total and antigen specific IgA antibody, plasma from 10 LTBI infected 
patients were used to perform the ELISA. ESAT-6/CFP10 fusion protein was used as 
antigen. Plasma samples from 10 LTBI samples, 10 healthy controls (HC) at LSHTM and 
10 controls from the HTD clinic were used in this experiment.  There were no significant 
changes in total IgA between the three groups (Fig. 8.6). The level of antigen specific IgA 
in controls from the clinic was significantly different from that in healthy controls (HC) at 
LSHTM. 
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(A)                                                                    (B) 
  
Figure 8.6: Total IgA and ESAT-6/CFP-10 specific IgA responses. Total IgA (A) and ESAT-
6/CFP-10 specific IgA responses (B) were measured by ELISA in controls from the 
clinic, LTBI patients and healthy controls (HC) at LSHTM. Plasma diluted 1 in 10 
from 10 donors in each group were used in the ELISA. OD value at 450nm was 
measured using an ELISA plate reader. Bars represents means with SD. A repeated 
measures ANOVA was performed followed by a Bonferroni’s multiple comparison 
test, where *** represents a p value of <0.005. 
 
The correlation between LTBI infected patient’s IgA level by ELISA and log CFU by 
MGIT assay was explored and there was no significant correlation between them for both 
total IgA and antigen specific IgA.  
8.2 Cytokine responses  
To explore if there was any association between cytokine concentrations and 
mycobacterial growth and if there is a change in the expression of these cytokines after 
anthelmintic treatment, cytokines were measured in 96-hour culture supernatants from 
MGIT cultures. Culture supernatants from eight LTBI-helminth co-infected patients both 
pre and post treatment were used for this experiment. The concentration of 41 analytes in 
the culture supernatants included cytokines, chemokines and growth factors measured 
using the Multiplex MAP human cytokine/chemokine Panel-Premixed 41 Plex-
Immunology Multiplex assay. Anthelmintic treatment in LTBI-helminth coinfected 
patients was associated with increased levels of pro-inflammatory cytokines and 
decreased levels of anti-inflammatory cytokines (Fig. 8.7).  Some cytokines like IL-4, IL-
8, IL-5, IL-6, IL-9, chemokines like PDGF-AA, PDGF-BB, RANTES, VEGF etc. were 
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not detected in these samples. However, when the association between cytokine 
concentration and mycobacterial growth was assessed, there were no significant 
associations. 
 (A) 
 
(B) 	
 
Figure 8.7: Cytokine concentrations in LTBI-helminth coinfected patients (n=8) detected by 
multiplex assay (A). IP-10 concentration in LTBI-helminth coinfected patients (B) 
Cytokine concentrations were measured in the supernatants taken from MGIT 
cultures after 96 hours of culture. A repeated measures ANOVA was performed 
followed by a Bonferroni’s multiple comparison test.  
 
Cytokine production was observed in 8 LTBI-helminth coinfected  patients. MGIT 
culture supernatant from 96 hours was used for the experiment. There were some 
cytokines and chemokines that showed decreased concentrations after anthelmintic 
treatment for example, TGFα, IL-10, MCP-3, IL-12p70, PDGF-AA, G-CSF, Flt 3L, 
Fractalkine, FGF-2, IL-13, IL-1Ra. In contrast concentrations of IFNg, IFNα, and FGF-2 
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were increased after treatment. IL-1b, IL-2, IL-33, IL-6, eotaxin, and sCD40L was not 
detected in the culture supernatants of helminth infected patients. None of the cytokines 
showed any significant association with mycobacterial growth. IP10 concentration was 
significantly raised after anthelmintic treatment (p<0.0001).  
8.3  Discussion 
In man, IgE is the least abundant immunoglobulin isotype and provides protection against 
helminths but also triggers harmful allergic reactions to allergens. IgE recognizes 
exogenous antigen and triggers an immunological response that is associated with 
degranulation of mast cells and subsequent release of biogenic amines, lipid mediators 
and the production of Th2 cytokines, such as IL-4, IL-5 and IL-13 and associated 
eosinophilia. Chronic immune activation associated with intestinal helminth infection 
results in an increased and predominantly IgE response. In TB patients specific IgE 
antibodies are IL-4 dependent. In this study, total and parasite antigen (SEA) specific IgE 
concentrations were significantly higher in helminth and LTBI-helminth coinfected 
patients and dropped after anthelmintic treatment (p<0.05). When 500 TB patient’s sera 
were tested for IgE antibodies in response to PPD and H37Rv antigens by ELISA, these 
antigens were shown to be recognized by IgE antibodies.This PPD and H37Rv specific 
IgE is produced in Warao individuals by chronic exposure to TB, whereas high levels of 
total IgE may be the result of co-infection with helminth parasites (516). Chronic 
exposure to TB and coinfection with helminths may contribute to the poor outcome of 
infection by skewing the immune response to Th2 response and IgE responses, which is 
IL-4 dependent (517). In a South African community where TB and helminth infections 
were common, the adolescents exhibited high serum total IgE concentrations. Co-
infection with helminths in TB stimulates the production of anti-mycobacterial or anti 
parasite IgE antibodies but can also non-specifically induce polyclonal IgE which could 
result in highly elevated levels of total IgE. Th1 cells when stimulated with intracellular 
bacteria like Mtb, secrete IFNg which can inhibit IgE production by B cells (518). Adams 
et al., in their studies showed that serum total IgE concentrations decreased after 
successful treatment for TB in adolescent patients in South Africa. Serum IgE level can 
also be influenced by parasite burden in the patient (516). In the patients studied here, 
there was a trend for higher total IgE concentrations in the plasma associated with higher 
with CFU in helminth infected patients and in LTBI helminth infected patients there was 
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a weak trend for a positive association between total IgE and mycobacterial growth. 
Depletion of the Th2 cytokine IL-4 in mice by gene knockout or by neutralizing antibody 
was shown to reduce the degree of Mtb infection as manifested by organ CFU reduction 
(519). 
Total and antigen specific IgG4 was also higher in helminth and LTBI-helminth 
coinfected patients in this study, although there was no significant correlation with 
mycobacterial growth. Adjobimey et al., reviewed induction of IgG4 in humans and 
immunomodulation of the human responses to filarial parasites, and showed that high 
plasma concentrations of IgG4 in these patients were associated with hyporesponsiveness, 
high parasite load and high plasma levels of IL-10 and TGFβ (520). Microfilaria induce 
IL-10 and TGFβ, producing and CD4+CD25+FOXP3+regulatory T cells that might well 
be responsible for IgG4 production promoting parasite persistence (521). Schistosoma 
infected Egyptian patients, had elevated levels of IgG4 directed mainly against SEA 
antigen, suggesting that the IgG4 antibodies interfere with the effector activities of IgE 
anti-schistosome antibodies and thus inhibit complement activation and mast cell 
triggering (522)(523).  
Total plasma IgA concentrations in healthy controls of LSHTM controls, controls from 
the clinic and LTBI infected patients did not differ. However, ESAT-6/CFP10 specific 
IgA was observed to be significantly higher in healthy LSHTM controls than the controls 
in the clinic. The antigen specific IgA was higher in LTBI patients than the clinic 
controls.  During latent infection, a small number of tubercle bacilli presumably persist 
inside granulomas, where bacillary multiplication is restricted by the host immune 
response although some bacterial proteins may induce measurable levels of antibody 
including to secreted virulence factors such as ESAT-6/CFP10 or components of the 
bacterial stress response. A higher proportion of individuals with anti-mycobacterial 
antibodies has been seen in healthy, latently infected patients from TB endemic countries 
as compared to those with LTBI who live in non-endemic countries (524)(525). 
Antibodies to ESAT-6/CFP10 have also been found in individuals at risk of reactivation 
disease due to past TB, history of close contact with infectious cases and migration from 
TB endemic countries(526). A recent study examined the role of secretory IgA in host 
defence against mycobacterial infection, in the mouse model. The antibody response 
induced after intra nasal administration to Mtb  antigen demonstrated loss of antigen 
specific IgA responses  after immunization with mycobacterial antigen PstS-1 and made 
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the mice more susceptible to BCG and Mtb infection than immunized control wild-type 
mice, manifested by higher lung CFUs, and reduced production of proinflammatory 
cytokine responses like IFNg and TNFα in the lungs (527). However, experiments 
suggested that IgA could provide a protective role in Mtb  diseases particularly in the 
early stages of infection (528). Most of the LTBI patients in this experiment were health 
care workers (HCWs) who had higher levels of IgA in response to ESAT-6/CFP10 
suggesting elevated IgA might have some protective role in IFN-g positive 
immunocompetent LTBI individuals.  Frequent exposure to tubercle bacilli can possibly 
stimulate the mucosal immune system. It is also known that commensal bacteria on the 
mucosal surface induce IgA in an NO dependent manner(529), although it is still 
unknown if Mtb in TB and LTBI has a similar effect in lung mucosa. IgA antibody and 
IFNg induce TNFα and NO production inhibit Mtb growth in mouse models (530). The 
association between anti IgA and IFNg may indicate protective, mucosal immune 
activities in LTBI in HCWs (531).  
There was a lack of significant correlations between the concentrations of antibodies 
measured and mycobacterial growth.The role of antibodies in TB are still debated. 
Although there were changes in the antibody concentrations after treatment, this might be 
due to systemic effects or to other components of the immune system in the population 
studied or todifferences in host response. Although there is some evidence for a role of 
antibodies in TB, probably the role of T cells and cellular immunity are more important 
for host resistance (532). 
To explore if the production of cytokines was associated with mycobacterial growth and 
if there is a change in cytokine secretion after anthelmintic treatment, cytokines were 
measured in 96-hour culture supernatants from MGIT cultures in LTBI-helminth 
coinfected patients (both pre and post treatment). Helminth infections have been shown 
here to modulate the production of some cytokines like IFNg ,TNFα, IFNα, MCP 1, 
IL12p40, IL-17, IL-15 etc. and some of them were altered following anthelmintic 
treatment. Concurrent filarial infection has shown to inhibit the production of potentially 
protective Th1 immune responses in LTBI-helminth coinfected patients (212). Significant 
reductions of proinflammatory cytokines were also observed in previous studies in LTBI-
helminth coinfected patients(426).Helminth infections establish persistent infection, by 
mechanisms that dampen the immune responses by Tregs and CD4+T cells expressing 
 209 
IL-10.In this study, helminth coinfection was associated with a significantly enhanced 
frequency of IL-10 secretion that reduced after treatment suggesting the 
immunoregulatory role of IL-10.The concentrations of Th1 (IFNg,TNFα) and Th17 
cytokines were downregulated in coinfected patients before treatment. TNFα and IL-17 
have been reported to exhibit antimycobacterial responses either in primary or memory 
responses to infection. In patients with TB disease, peripheral blood frequencies of these 
cells are reduced, which may be due to suppression of IFNγ (533). TNFα plays a central 
part in the host response against tuberculosis, including granuloma formation and 
containment of disease. Antibodies against TNFα cause a reactivation of tuberculosis in a 
mouse model of latent infection (534).Both cytokines are important in the induction and 
maintenance of protective immune responses in TB infection. Downregulation of these 
cytokines may suggest the modulation of antimycobacterial immune responses in the 
presence of helminth infection. There was also a change in IP-10 after anthelmintic 
treatment. IFNγ-inducible protein 10 (IP-10/CXCL10) is a chemokine involved in 
delayed-type hypersensitivity and attraction of monocytes and activated T lymphocytes at 
inflammatory foci (535). MCP-1α was found to be significantly reduced after the 
treatment. This is an important cytokine that can stimulate Th2 polarisation and increased 
expression of this cytokine is associated with susceptibility to Mtb infection inman. 
Monocytes/macrophages are the major source of CCL2, which regulates the migration 
and infiltration of monocytes, memory T lymphocytes, and NK cells (536). There is an 
alternative activation of macrophages and Th2 polarization in helminth infection, so it 
would be interesting to see if there is a skewing of immune responses in helminth 
coinfected patients and whether this alters after anthelmintic treatment. This was 
investigated in the next chapter. 
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Chapter - 9   qRT-PCR 
9.1  qRT-PCR 
As blood samples from the donors studied here had been banked for later RNA 
extraction, this provided an opportunity to assess the expression of genes associated with 
classically activated or alternatively activated macrophages and whether there is a 
potential skewing from M2 to M1 macrophages. Eight genes were selected for analysis 
using a qRT-PCR assay, that are expressed by M1 (IDO-1, CXCL10, CD86) and M2 
macrophages (Arginase 1, CD163) and some other genes identified to be of interest, for 
example-HIF1α, HIF2α, IL-10 with two reference genes (CD14 and HPRT).This 
experiment was designed to see the differential expression of these genes in LTBI, 
helminth and LTBI-helminth coinfected patients, and also to observe if the expression of 
these genes changes after anthelmintic treatment which might indicate a skewing of 
immune responses from helminth induced Th2 response to Th1 type and better immune 
responses for Mtb. 
9.1.1 Results 
In the real time qRT-PCR assay, mRNA expression of the genes- IDO-1, Arginase 1, 
HIF1α, HIF2α, IL-10, CXCL10, CD163, CD86 was determined in blood samples from 
controls, helminth infected, LTBI and LTBI-helminth coinfected patients. Fifteen patients 
from each group were tested. Both the pre and post treatment samples were tested. The 
expression of these genes were normalized to the CD14 and HPRT genes.  
IDO-1 was significantly upregulated in helminth and LTBI–helminth co-infected patients 
(p=<0.0001), when the genes were normalized to CD14 (Fig. 9.1). This increase of gene 
expression was observed both before and after anthelmintic treatment. IDO-1 was also 
upregulated in LTBI patients when compared to controls. The expression pattern was 
more variable, when the genes were normalized to HPRT. IDO-1 was upregulated in 
LTBI-helminth coinfected patients and also in helminth infected patients after treatment 
but not in the pre-treatment phase or in LTBI, relative to HPRT. 
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(A) 
 
(B) 
 
Figure 9.1: Relative IDO-1 expression in controls, helminth, LTBI and LTBI-helminth coinfected 
patients when normalized to CD14 (A) and HPRT (B). Fifteen patients were tested 
per group. One way ANOVA test with a Tukey’s post-test was performed where * 
represents a p value of <0.05. 
 
Arginase 1 was observed to be highly significantly upregulated in helminth infected 
(before treatment p=<0.0001, after treatment p=0.0008) and LTBI-helminth coinfected 
patients (before treatment p=, <0.0001, after treatment p=0.0068), when the gene 
expression was normalized against HPRT (Fig. 9.2). A similar finding was also observed 
when gene expression was normalized to CD14, though the differences between the 
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groups were not statistically significant. Arginase 1 was downregulated in LTBI patients 
(p=0.0045) in comparison to controls.  
 
 
(A) 	
 
(B) 	
 
Figure 9.2: Relative arginase-1 expression in controls, helminth, LTBI and LTBI-helminth 
coinfected patients when normalized to CD14 (A) and HPRT (B). Fifteen donors 
were tested per group. One-way ANOVA test with a Tukey’s post-test was performed 
where **** represents a p value of <0.0001. 
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Figure 9.3: Heat map of average gene expression in the control, helminth, LTBI and LTBI-
helminth coinfected groups relative to the reference gene HPRT and CD14 at visit 1 
and visit 2. 
 
HIF1α gene expression was highly diverse in the different clinical groups and also 
showed disparity when normalized to CD14 and HPRT (Figure-9.3). Relative to HPRT, 
HIF1α was significantly downregulated in LTBI-helminth coinfected patients both before 
and after treatment, in helminth patients before treatment but not after treatment and also 
in LTBI patients. In contrast, when the genes were normalized to CD14, all the groups 
showed increased gene expression, except for the LTBI-helminth coinfected pre-
treatment group, though these increases in expression were not statistically significant 
(Table 1). 
HIF2α was significantly upregulated in the LTBI-helminth coinfected group, when the 
genes were normalized against CD14 (before treatment p=<0.01, after treatment 
p=0.0028). This upregulation was also evident relative to HPRT, though this was not 
statistically significant. HIF2α was significantly upregulated in helminth infected patients 
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both before and after treatment relative to HPRT (before treatment p=<0.0068, after 
treatment p=0.0218). 
IL-10 was highly significantly upregulated in LTBI-helminth coinfected patients (before 
treatment p= <0.0001, after treatment p=0.0001) compared to the controls relative to 
CD14. Expression of IL-10 gene was also upregulated in helminth infected patients and 
LTBI patients compared to the controls but this was not statistically significant.  
Interestingly, CXCL10 was highly upregulated in LTBI patients when normalized to 
HPRT but showed a contrasting result relative to CD14 and both the expressions were 
statistically significant. 
(A) 																																																																	(B)		
 
Figure 9.4: Relative expression of CXCL10 in control, LTBI, helminth infected and LTBI-  
helminth coinfected patients when normalized to CD14 (A) and HPRT (B) (15 
patients from each group). One way ANOVA test with a Tukey’s post-test was 
performed where * represents a p value of <0.05. 
CD163 did not show any substantial changes in any of the clinical groups in relation to 
either CD14 or HPRT (Table 1,2). CD86 showed significant upregulation in expression in 
LTBI-helminth coinfected patients and also in helminth infected patients after their 
treatment. Unlike CD163, it also did not show any marked changes in LTBI patients in 
relation to CD14 and HPRT (Table 2, 3). 
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Figure 9.5: Relative CD14 gene expression in controls. LTBI, helminth and LTBI-helminth 
coinfected patients when normalized to HPRT (Fifteen patients from each group). 
One way ANOVA test with a Tukey’s post-test was performed where * represents a p 
value of <0.05. 
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Gene of 
interest 
LTBI  Helminth Visit 1 Helminth Visit 2 LTBI-helminth Visit 1 LTBI-helminth Visit 2 
∆∆CT 
 
FC P value ∆∆CT 
 
FC P value ∆∆CT 
 
FC P value ∆∆CT 
 
FC P value ∆∆CT 
 
FC P value 
IDO-1 -1.0 2.0 0.75 -1.6 3.0 0.0001**** -0.9 1.9 0.0001**** -1.7 3.2 0.0001**** -1.1 2.1 0.0001**** 
Arginase 1 2.3 0.2 0.0045** -1.1 2.1 0.3522 -0.09 1.1 0.9998 -1.5 2.8 0.1158 -0.45 1.3 0.9650 
HIF1a -1.6 3.0 0.3926 -0.3 1.3 0.9999 -1.0 2.0 0.9579 0.6 0.7 0.8734 -2.3 5.2 0.1740 
HIF2a -0.9 1.9 0.7194 -0.5 1.4 0.9943 2.2 0.2 0.1464 -3.2 9.1 0.0135* -3.7 13.2 0.0028** 
IL-10 -0.3 1.2 0.9974 -0.5 1.4 0.9835 -1.0 2.0 0.6684 -3.7 11.3 0.0001*** -3.5 12.0 0.0002*** 
CXCL10 4.4 0.1 0.0001**** 1.7 0.3 0.2505 0.5 0.7 0.9827 1.2 0.4 0.5418 -0.01 1.0 0.9999 
CD163 0.3 0.8 0.9957 -2.7 0.2 0.0915 -0.7 1.7 0.9936 -0.5 1.4 0.9935 1.6 0.3 0.5222 
CD86 0.4 0.7 0.9796 1.5 0.4 0.4802 1.1 0.5 0.7701 -1.4 2.7 0.4915 -1.01 2.0 0.7966 
 
Table 9.1: Gene expression in LTBI, helminth and LTBI- helminth coinfected patients compared to controls, using CD14 as the endogenous 
control. The ∆∆CT value was determined from the subtracting the ∆CT value of control samples from ∆CT values of LTBI/ helminth/ 
LTBI-helminth samples. To compare the fold change of each of the target gene in LTBI, helminth and co-infected group compared to 
control samples a two-way ANOVA was used followed by Dunnett’s post-test. 
 
 
 
 
 
 
 
 217 
 
 
 
 
 
Gene of 
interest 
LTBI  Helminth V1 Helminth V2 LTBI-hel V1 LTBI-hel V2 
∆∆CT 
 
FC P value ∆∆CT 
 
FC P value ∆∆CT 
 
FC P value ∆∆CT 
 
FC P value ∆∆CT 
 
FC P value 
IDO-1 0.3 0.8 0.9952 1.6 0.3 0.1557 -0.3 1.2 0.9881 -0.42 1.3 0.9921 -0.10 1.1 0.9998 
Arginase 1 3.1 0.1 0.0046 -4.53 0.04 0.0001** -3.64 0.1 0.0008*** -4.63 0.04 0.0001**** -3.03 0.1 0.0068** 
CD14 1.5 0.4 0.1680 2.7 0.1 0.0013** 3.5 0.1 0.0001**** 2.4 0.2 0.0086** 2.9 0.1 0.0007*** 
HIF1a 3.69 0.1 0.0415* 3.87 0.1 0.0262* 2.3 0.2 0.3411 4.63 0.04 0.0049** 4.10 0.05 0.0161* 
HIF2a 1.5 0.4 0.9389 -4.68 0.03 0.0068** -4.08 0.06 0.0218* -1.41 0.37 0.9857 -1.08 0.47 0.9996 
IL-10 0.9 0.5 0.8301 2.64 0.2 0.0410* 3.0 0.12 0.0146* -0.71 1.64 0.8972 0.45 0.72 0.9977 
CXCL10 -2.7 6.2 0.0001**** -3.02 8.1 0.2505 -3.26 9.62 0.9827 -3.98 11.0 0.6418 -3.02 8.1 0.9999 
CD163 0.56 0.7 0.9710 1.02 0.5 0.6349 4.26 0.05 0.6465 -0.38 1.3 0.9996 5.19 -1.9 0.1965 
CD86 -2.5 5.8 0.1234 -2.4 5.6 0.1654 -3.6 9.64 0.0072** -3.26 9.6 0.0009*** -2.9 7.5 0.0031** 
 
 
Table 9.2: Gene expression in LTBI, helminth and LTBI- helminth coinfected patients compared to controls when normalized to HPRT. The ∆∆CT 
value was determined from subtracting the ∆CT value of control samples from ∆CT values of LTBI/ helminth/ LTBI-helminth samples. 
To compare the fold change of each of the target gene in LTBI, helminth and co-infected group compared to control samples a two-way 
ANOVA was used followed by Dunnett’s post-test. 
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9.1.2  Modulation of gene expression after anthelmintic treatment 
The fold changes after anthelmintic treatment were also calculated in this experiment. ΔCT 
value was obtained from subtracting the ΔCT before treatment from the ΔΔCT after 
treatment. The fold changes were determined using the formula 2-ΔΔCT. Fifteen helminth 
and LTBI-helminth coinfected patients were tested to see if there was any modulation of 
the gene expression after the anthelmintic treatment. 
mRNA expression of arginase 1, HIF2α and CD163 was significantly decreased after 
treatment in helminth infected patients when the genes were normalized to CD14. In 
LTBI- helminth coinfected patients, expression of arginase 1 and CD163 were also 
significantly deceased after treatment. There were significant increases in the gene 
expression of HIF1α and CXCL10 in these group of patient’s post-treatment. CXCL10 
was also increased in helminth infected patients after they completed their treatment. There 
was no substantial change in gene expression of CD86, IDO-1 or IL-10 after treatment 
(Table 9.3).  
 
 
 
Gene of 
interest 
Helminth infected LTBI-helminth coinfected 
∆∆C
T 
 
FC P value Gene 
expression 
after 
treatment  
∆∆
CT 
 
FC P value Gene 
expression 
after 
treatment 
IDO-1 0.7 0.6 0.3815 Decreased 0.6
01 
0.7 0.2078 Decreased 
Arginase 
1 
1.01 0.5 0.0057** Decreased 1.0
5 
0.5 0.0020** Decreased 
HIF1a -0.65 1.6 0.0916 Increased -
2.9
7 
7.5 0.0015** Increased 
HIF 2a 2.69 0.2 <0.0001***
* 
Decreased -
0.5
3 
1.4 0.3805 Increased 
IL-10 -0.54 1.4 0.1688 Increased 0.2 0.8 0.2524 Decreased 
CXCL10 -1.20 2.3 0.0209* Increased -
1.2
1 
2.3 0.0043** Increased 
CD163 2 0.3 0.0002*** Decreased 2.1 0.2 <0.0001***
* 
Decreased 
CD86 -0.39 1.3 0.3303 Increased 0.4
2 
0.7 0.3813 Decreased 
 
 
Table 9.3:  Fold changes in gene expression following anthelmintic treatment. The genes 
were normalized to CD14. 
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When normalized against HPRT, helminth infected patients showed significant changes in 
gene expression of CD163 (p=<0.0005). Arginase 1, CD14, HIF2α, IL-10, CXCL10 also 
showed a similar pattern although they were not statistically significant. HIF 1α was 
significantly increased following helminth treatment in this group. In the LTBI-helminth 
coinfected group, IDO-1 was significantly increased after treatment (p=0.0067). 
Expression of arginase 1, IL-10 and CD163 was significantly reduced after treatment in 
this group. Expression of CD14, HIF2α, CXCL10, CD86 also decreased after treatment 
but did not show any statistical significance (Table -9.4). 
 
Gene of 
interest 
Helminth infected LTBI-helminth Coinfected 
∆∆CT 
 
FC P value Gene 
expression 
after 
treatment  
∆∆CT 
 
FC P value Gene 
expression 
after 
treatment 
IDO-1 -1.9 3.7 0.5154 Increased -0.12 1.1 0.0067** Increased 
Arginase 1 0.89 0.5 0.0946 Decreased 1.59 0.3 0.0353* Decreased 
CD14 0.8 0.6 0.1044 Decreased 0.56 0.7 0.1473 Decreased 
HIF1a -1.57 2.9 0.0103* Increased -0.53 1.4 0.3088 Increased 
HIF 2a 0.63 0.6 0.1179 Decreased 0.33 0.8 0.7028 Decreased 
IL-10 0.35 0.7 0.3094 Decreased 1.17 0.4 <0.0001**** Decreased 
CXCL10 -0.24 1.2 0.5708 Increased 0.96 0.5 0.4791 Decreased 
CD163 3.2 0.1 0.0004*** Decreased 5.6 0.02 0.0054** Decreased 
CD86 -1.21 2.3 0.0833 Decreased 0.4 0.8 0.6387 Decreased 
 
Table 9.4: Fold changes in gene expression following anthelmintic treatment. The genes 
were normalized to HPRT. 
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9.2  Discussion 
In this experiment, the ΔCT method was employed to compare the relative gene 
expression of genes expressed in whole blood of controls, LTBI, helminth and LTBI-
helminth coinfected patients. The aim was to identify the differential gene expression in 
these clinical samples at different time points. This method was also used to see the fold 
changes of gene expression in helminth and LTBI-helminth coinfected patients after they 
were being treated for their helminth infection.  
In qRT-PCR, when comparing gene expression in different samples it is critical to 
consider the experimental variations such as amount of starting material, RNA extraction 
method, reverse transcription efficiencies, etc. To account for these, accuracy of qRT-PCR 
relies on the normalization to an internal control. The housekeeping gene is expected to be 
adequately expressed in the cells of interest and with minimal variability between samples 
and under the experimental conditions used. Various studies have shown that the candidate 
housekeeping genes can vary in their expression or some cases, RNA transcription levels 
may be too low to quantify accurately or reproducibly. Initially three housekeeping genes- 
HuPO, TBP and HPRT were studied to identify a housekeeping gene with minimal 
variability in all the patient groups. These three genes were selected from the previous 
publications (537)(538) as they had been examined in whole blood and PBMC samples 
and were stable in expression. Among these three genes examined, HPRT was the most 
stable housekeeping gene with an average fold change of <2 and maximal variability of 
approximately 5 fold each. TBP and HuPO showed unexpectedly high variability among 
the samples, although they had been selected as suitable gene for other studies. But the 
genes may be variable in this particular experimental model, due to the validation process 
for each gene or on individual basis. HPRT was therefore selected as the reference gene to 
be used further in the experiments.  
In these experiments the genes were also normalized to CD14. CD14 is primarily 
expressed on monocytes/macrophages but also by polymorphonuclear leucocytes as well 
as nonmyeloid cells such as B cells, in intestinal epithelial cells, etc. In humans, the two 
main subsets of monocytes are defined by their expression of CD14, a co-receptor for 
bacterial lipopolysaccharide, or CD16, the FcγRIII receptor for the Fc domain of IgG 
(539). These subpopulations are also characterized by the differential expression of 
chemokine receptors, especially CCR2 and CX3CR1. The more abundant subset in 
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humans, termed ‘classic monocytes’ are CD14+ and express high levels of CCR2 and low 
levels of CX3CR1.  
CD14 is a phosphatidylinositol glycan-linked membrane protein, is the high affinity 
receptor for lipopolysaccharide of Gram negative bacteria, however CD14 can also bind 
LAM of Mtb. Binding of Mycobacteria to macrophages occurs in cholesterol rich domains 
of the host cell membrane and involves β2 integrins, the mannose receptor, CR1 and CD14 
(540). In monocytes CD14 has been shown to be a potential gate for entry of 
mycobacteria. The dominant signalling pathway for LAM involves the membrane 
receptors CD14 and TLR2. Whether CD14, TLR-2, CR3 cooperate to facilitate the uptake 
of mycobacteria are still unanswered question. Khalid et al., demonstrated that binding of 
M. bovis BCG to CD14 induces an inside-out signalling pathway which involves TLR-2, 
PI3K  leading to enhanced CR-3 dependent bacterial internalization(541). They have also 
shown that using transfected THP-1 (a monocyte cell line) and CHO (Chinese hamster 
ovary cells), CD14 plays a major role in phagocytosis of M. bovis BCG. CD14 and other 
receptors can also sense endogenous signals resulting from tissue damage and necrosis. 
The signalling pathway induced by CD14 and TLRs  activates feedback inhibitory 
mechanisms that confine the magnitude of inflammatory signalling(542). The dynamics of 
macrophage transition from an intracellular pathogen driven strong inflammatory 
signalling into a weaker activated state may be important in the immune control of Mtb 
infection. Druszcynska et al., have demonstrated that active TB patients had more CD14 
expression on monocytes than the healthy controls and LTBI patients which might have 
resulted from the enhanced inflammatory response to mycobacterial components and 
activity of virulent Mtb contributing to TB pathogenesis (460). The interaction of 
mycobacterial constituents and CD14 (either membrane bound or soluble) can lead to the 
activation of transcription factors, production of pro-inflammatory cytokines/chemokines 
and upregulation of cell adhesion molecules that contribute to the development of the 
granuloma and adaptive immunity (543).   
Monocytes represent the main host cell for mycobacterial growth, survival and replication. 
A monocyte marker was used in this assay to see the level of expression of these target 
genes. The expression of hypoxia inducible genes, immunoregulatory genes and also 
macrophage polarization genes in LTBI patients might provide a better understanding of 
the immune mechanism underlying TB latency and also the treatment modulation of these 
genes might suggest a potential impact of helminth induced immunomodulation. 
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Monocytes also play a very important role in immunopathogenesis of helminth infection. 
Fernandes et al., exhibited that CD14++CD16- or classical monocytes participated in the 
immunopathogenesis of periportal fibrosis, a consequence of Schistosoma infection that 
was associated with expression of high levels of proinflammatory and profibrotic 
cytokines and low levels of regulatory markers (544). CD14 can influence the host 
immune responses and alternative activation of macrophages during Schistosoma infection 
(545). Gene expression changes after anthelmintic treatment in this experiment might 
provide an insight that there might be some skewing of immune responses from M2 
dominant genes towards M1 phenotype suggesting the immunoregulatory role of helminth 
that could modulate the Mtb specific responses.  
In this experiment, IDO-1 was upregulated in LTBI patients in relation to CD14. 
Blumenthal et al., demonstrated that IDO-1 is one of the most highly induced gene in 
human macrophages infected with Mtb. In mice IDO activity also increases following Mtb 
infection in an IFN-g dependent manner (537). Suzuki et al., showed that PTB patients had 
significantly Increased IDO activity in comparison to controls. In their study 22.4% of the 
patients died and those who died had significantly higher IDO activity. Li et al., 
demonstrated that an inhibitor of IDO restored decreased T cell derived cytokine 
production in the pleural fluid of TB pleurisy patients (546). IDO is also important in 
protection of the granuloma from T cell attack (547). All these data suggest a role for IDO 
-1 activity in inhibiting Mtb specific adaptive immune responses and that it may 
potentially aid the persistence of pathogen in the infected host. IDO-1 was also 
significantly upregulated in helminth (3 fold changes in V1 and 1.9 fold changes in V2) 
and LTBI-helminth co-infected patients (fold changes 3.2 Vs 2.1 in V1 and V2) in 
comparison to controls. The immunological hallmark of helminth infection is the ability to 
induce Th2 immune responses and also Tregs. Helminths are potent inducer of dendritic 
cell regulatory cells (DCRegs) which are characterized by the expression of IL-10, TGFb. 
IDO and cyclooxygenase-2. Such responses could possibly downregulate the protective 
Th1 to Mtb infection (186).  IDO- 1 potentially inhibits T cell functions and generates 
Tregs, leading to immunosuppression or tolerance. IL-4 and IL-13 have been shown to 
control IDO-1 expression by antagonizing the effects of IFNg in different cell types (548). 
IDO-1 was upregulated in LTBI-helminth coinfected patients but not in LTBI and 
helminth infected patients when the mRNA expression was normalized to HPRT. The 
result was different when normalized to CD14. Since the monocyte/macrophage is critical 
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for the bacillary growth and containment, this gene expression may be affected by 
monocyte frequency in these clinical patients. The fold changes in gene expression in 
IDO-1 in helminth infected patients in relative to CD14 showed there was downregulation 
of expression in cured patients and that the IDO-1 was upregulated when normalized 
against HPRT though this was not statistically significant. These changes can be due to 
immunomodulation due to helminth infection and after removal of helminth, the level of 
expression was decreased 0.6 fold. However, the immunomodulation underpinning the 
changes in gene expression remains to be elucidated and needs to be investigated with 
larger sample sizes per group. 
The next gene of interest investigated was arginase 1. There was a significantly significant 
upregulation of the arginase 1 genes in helminth infected and coinfected patients compared 
to controls. Arginase 1 metabolizes the amino acid L-arginine to generate urea and 
ornithine and the resultant metabolites proline and polyamines drive collagen synthesis 
and cell proliferation(549). Arginine is a crucial amino acid that modulates immune 
responses to Mtb, as it is a common substrate for both iNOS and arginase 1. Loss of 
arginase in macrophages is associated with enhanced protection against Mtb, probably due 
to availability of arginine for iNOS activity (550). Monin et al., suggested that a prominent 
effect of helminth infection during TB is the accumulation of high arginase 1 expressing 
macrophages within granulomas in the lung. Arginase 1 possesses anti-inflammatory 
effects on Th1 responses and can also mediate exacerbated inflammation and lung 
pathology during co-infection. Arginase 1 induction due to helminth co-infections, 
helminth products and host genetics might mediate the formation of more inflammatory 
TB granulomas (551). However, in coinfected STAT6-deficient mice, in which no AAMs 
are recruited to the gut, bacterial infection was not exacerbated. In terms of helminth 
infection, in mice with a macrophage-specific arginase deficiency (LysMcre Arg-1−/flox), 
schistosoma infection results in the formation of larger granulomas than those in control 
mice, and these granulomas do not shrink at chronic stages of infection, resulting in death 
due to increased fibrosis and Th2 cell-mediated inflammation (552).  It is evident from the 
results obtained here, that arginase expression was higher in post treatment patients than 
the control. Probably these cells can still undergo alternative activation, highlighting the 
role of arginase-1 in depleting arginine in the local milieu, directly suppressing T cell 
proliferation (549). After helminth treatment, the level of gene expression was 
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significantly decreased in helminth infected patients. Helminth removal may modulate the 
arginase expression, as there might be skewing of immune responses towards Th1. 
CD163 did not show any significant difference in the gene expression level in LTBI, 
helminth and co-infected patients when they were compared to controls. It was 
downregulated in LTBI patients and relatively upregulated in the helminth infected group. 
CD163 expression is also suppressed by proinflammatory mediators like LPS, IFNg, and 
TNFa, whereas IL-6 and the anti-inflammatory cytokine IL-10 strongly up-regulate 
CD163 mRNA in monocytes and macrophages- which implies a functional role of CD163 
in the anti-inflammatory response of monocytes.The haemoglobin scavenger receptor 
CD163 is expressed exclusively by monocytes and macrophages and preferentially by 
macrophages of the M2 phenotype (553)(554). Its expression is amplified  by IL-4, M-
CSF, IL-6, IL-10, and glucocorticoids, while TNFa, TGFb, IFNg, and LPS reduce its 
expression (555)(556)(554)(557). Although all CD14 monocytes express CD163, the 
CD14+CD16+ population has the highest expression (558).  
In this experiment CD163 showed a highly significant fold change after anthelmintic 
treatment and the gene expression was decreased after treatment. With helminth infection 
there is skewing of immune responses towards Th2 with decreased Th1 responses. 
sCD163 has been shown to directly inhibit T lymphocyte activation and proliferation 
(559). CD163 may therefore be a potential marker to monitor immunomodulation after the 
helminth infections has been treated.  
Many studies support a dominant role for CD86 in primary T-cell responses (560)(561). 
CD86 is constitutively expressed on resting human peripheral blood monocytes and is 
upregulated following stimulation (562).  CD86 expression is rapidly upregulated during 
B-cell and macrophage activation (563)(564). In LTBI, the gene was upregulated in 
relative to HPRT but downregulated in relative to CD14. CD86 was shown to be 
significantly upregulated in coinfected patients and its expression decreased with 
treatment, though it did not show any significant difference in helminth patients before 
treatment. In murine TB, studies have correlated lower levels of CD86 expression with 
persistence of Mtb or disease progression (562) and  within the tubercle granuloma. Flores-
Batista and colleagues indicated that HLA-DR and CD86 which are key elements for 
antigen-specific T cell immune responses against Mtb, are diminished on the lung cells of 
pulmonary TB patients. Low expression of antigen-presenting and costimulatory 
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molecules by lung cells from tuberculosis (35). Decreased expression of HLA-DR and 
CD86 might result from direct cell infection by Mtb or from a response to antigens 
released by Mtb, or may be indirectly mediated by immunosuppressive cytokines, such as 
IL-10 and/or TGFb induced by Mtb. The diminished levels of HLA-DR and CD86 
molecules may limit T cell immune responses that, in turn, favour Mtb persistence and 
progression to active disease. Deficient expression of CD86 or adhesion molecules could 
impair antigen presentation by infected cells (565). Bonato et al., showed that Mtb H37Rv 
down-modulated CD86 expression on peritoneal macrophages but did not affect CD80 
expression on these cells. In their model, the down-modulation of the CD86 expression on 
macrophages, impaired the initial steps of T-lymphocyte activation owing to a deficient 
contact between T cells and APC (566). In contrast, Subauste et al., reported an 
upregulation of CD80 and CD86 after in vitro infection of human monocytes with 
Toxoplasma gondi (567).  
Another two genes that were selected for this study were hypoxia-inducible factor HIF- 
HIF1a and HIF2a. HIFs are the major regulator of the cellular response to hypoxia and 
are responsible for optimal functional, metabolic and vascular adaptation to O2 shortage. 
HIF1 is expressed in virtually all innate and adaptive immune cell populations including 
macrophages, neutrophils, dendritic cells and lymphocytes (568). HIF2a is expressed in 
endothelial cells and certain immune cells like tumor-associated macrophages and CD8+T 
cells in response to hypoxia and this expression is influenced by cytokine exposure (569). 
When normalized against CD14, HIF1a and HIF2a both were upregulated in LTBI 
patients in comparison to controls. Similar expression levels were also observed in 
helminth and coinfected patients in our cohort. HIF2a showed significant downregulation 
in helminth infected patients after treatment. HIF1a was significantly upregulated after 
treatment in helminth and coinfected patients. HIF1a deficient macrophages have an 
impaired metabolic adaptation to hypoxia, which results in reduced motility and migration 
and also in a decreased capacity to kill bacteria (570). Peyssonnaux et al., showed that 
HIF1a was correlated with iNOS expression driving NO and TNFα production and that 
HIF activity is also important in phagocytic uptake of bacteria by macrophages under 
hypoxic conditions (571). HIF markedly increases the release of proinflammatory 
cytokines such as TNFα, IFNγ, IL-1β and expression of co-stimulatory molecules by 
murine dendritic cells (DCs), enhancing their ability to induce lymphocyte proliferation 
(572). HIF1a drives the production of chemokines and chemokine receptors that could 
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influence myeloid recruitment- for example CCL5 and C-X-C motif cytokine 12 
(CXCL12)(573). Upon activation, HIF1a is strongly induced in conditions that favour 
differentiation of CD4+ Th17 cells. HIF1a can increase the expression of RORyt, which in 
turn promotes IL-17 production and Th17 cell development.  HIF1a can bind the FOXP3 
protein and impact its function and degradation and promotes FoxP3 mRNA, induction 
and supports Treg cell function. A HIF1a driven glycolytic shift supports Th17 cell 
differentiation. HIF1a can also drive metabolic adaptations in CD8+ T cells and control 
expression of molecules associated with effector function (570). HIF deficient T cells 
show diminished expression of effector molecules such as perforin and granzymes and 
altered molecule expression involved in T cell migratory capacity. HIF1a stabilization by 
activated CD8+T cells causes increased expression of costimulatory/inhibitory molecules 
(CTLA-4, GITR, etc.), altered migration and chemokine receptor expression. 
HIF2a was significantly reduced in helminth infected patients after treatment. HIF2a  is 
also known to have a role in the glycolytic adaptation to hypoxia in macrophages (569). 
Arginase has an important role in the HIF2a contribution to IL-4 induced M2 polarization. 
Increased expression of HIF2a outcompetes HIF1, limiting the glycolytic shift associated 
to M1 polarization (574).  To observe the expression of these hypoxia induced gene in 
helminth and latent TB infected patients would provide important information about the 
differential expression of these two genes and also if there is any alteration after 
anthelmintic treatment. 
CXCL10 was downregulated in LTBI patients in relative to CD14 but was significantly 
upregulated when normalized to HPRT in comparison to controls This gene was 
downregulated in helminth and coinfected patients which was modulated after 
treatment.CXCL10 or IP-10 is a chemokine expressed in both lymphocytes and monocytes 
after paracrine stimulation of T-cells by IFNs and other proinflammatory cytokines mainly 
IFNγ and TNFα, as well as IFNα/β, IL-2, IL-17, IL-27 and IL-1β (124). IP-10 is also 
induced through cell-surface receptor interaction with T-cell (575). IP-10 is involved in the 
trafficking of monocytes and activated Th1 cells  to inflamed foci through interaction with 
the CXC chemokine receptor (CXCR) 3(576)(577). IP-10 has been identified as an 
indicator for both Mtb infection and response to treatment, but not activity or severity of 
pulmonary TB in previous studies (578). IP-10 promotes Th1 immune responses by up 
regulating the expression of IFNγ  and is involved in DTH immune responses (579)(580). 
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It has been suggested that production of this chemokine in response to Mtb antigens could 
be used as a marker of infection (535)(581). Biaro et al., have demonstrated that IP-10 can 
perform well in differentiating contacts with either latent or active TB from those who 
were uninfected and also that IP-10 had the potential to diagnose ‘recent TB infection’ in 
persons classified as having LTBI using the TST (122). 
IL-10 can be made by Th2 cells, Th1 and Th17 cells, B cells, neutrophils, macrophages, 
and some DC subsets (582).  IL-10 was upregulated in LTBI, helminth and coinfected 
patients in relative to CD14 and but downregulated expression in relative to HPRT. IL-10 
inhibits the protective immune response to pathogens by blocking the production of 
proinflammatory cytokines, such as TNFα  and the Th1 polarizing cytokine IL-12, by 
directly acting on antigen-presenting cells such as macrophages and DCs(583).  One 
mechanism of Mtb killing is mediated by IFNγ with activation of macrophages leading to 
enhanced production of reactive oxygen and nitrogen intermediates,(584) which can be 
inhibited by IL-10 (585). IL-10 produced during phagocytosis may also function to block 
antigen presentation via downregulation of major histocompatibility complex molecules. 
Inhibitory effects of IL-10 on the production of IP-10 during Mtb  infection suggest that 
IL-10 may limit recruitment of Th1 cells to the lungs of infected mice (63). In helminth 
infection and in LTBI-helminth coinfection IL-10 was upregulated when expressed in 
monocytes.  In helminth infected patients it did not change with treatment but in 
coinfected patients it was decreased in fold change. In S.mansoni infection, Th2 cytokine 
expression becomes dominant shortly after egg laying begins, with IL-4, IL-5, IL-10, and 
IL-13 being the principal cytokines secreted by lymphoid cells after stimulation with SEA. 
The secretion of Th1 cytokines, IFNγ and IL-2, is concurrently down-regulated at the time 
when Th2 responses are reaching their peak, and it has been postulated that IL-10 
production is critical for polarizing the egg-induced Th2 response (587). 
Changes in gene expression after helminth treatment was observed for some genes tested, 
for example, arginase1, HIF1a, HIF2a, CXCL10, CD163 in relation to CD14 and some 
genes were constitutively expressed in relation to HPRT. When normalized to CD14, IDO-
1, HIF 1a, HIF 2a, IL-10 was significantly upregulated in LTBI, helminth infected and 
LTBI-helminth coinfected patients in comparison to the controls. Arginase 1 and CXCL10 
was significantly downregulated in LTBI in comparison to controls. Whereas, when 
normalized to HPRT, arginase 1 was significantly upregulated in helminth and LTBI-
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helminth coinfected patients but not in terms of IDO-1, which was downregulated in 
LTBI. CXCL10 was significantly upregulated in LTBI patients and CD86 in helminth and 
LTBI-helminth coinfected patients. CD14 was significantly downregulated in helminth 
and LTBI-helminth co-infected patients when normalized against HPRT. When the gene 
expression level after treatment was normalized to CD14 and HPRT, Arginase 1, HIF 1, 
CD163 was significantly highly expressed and IDO-1 downregulated in helminth and 
LTBI-helminth coinfected patients. Although the expression level was variable post 
treatment when normalized to CD14 and HPRT. The level of gene expression and its 
modulation was different using these two normalizers as HPRT is expressed in all the 
cells, whereas CD14 is used to normalize for monocyte frequency. CD14 might be more 
appropriate for observing the gene expression which is constant for a given cell type and to 
remove non-specific variation of different cell types. 
When the gene expression was analysed in helminth-infected patients it was observed that, 
IDO-1 was significantly expressed in them in relation to CD14. The gene expression 
pattern was similar to that of LTBI-helminth coinfected patients. However, in coinfected 
patients HIF2a and IL-10 were also significantly expressed.  All these genes are expressed 
preferentially by M2 macrophages. Such responses could possibly be downregulating the 
protective Th1 response to Mtb. Interestingly with anthelmintic treatment, Arginase 1, 
HIF2a and CD163 expression was decreased and CXCL10 expression was increased 
significantly in helminth-infected patients (120). Reduction in the expression of these 
genes might be associated with enhanced protection against Mtb these possesses anti-
inflammatory effects on Th1 responses (573) (574). Expression of these genes are 
amplified by some regulatory cytokines like IL-10, and TGFb. In MGIA, the 
immunoregulatory role of IL-10 and TGFb has been explored in this study in helminth-
infected patients. This might explain the immunoregulatory role of these cytokines in 
mycobacterial growth in coinfected patients before anthelmintic treatment. HIF1a has 
been linked to the release of proinflammatory cytokines and its expression has been 
observed to be increased after treatment (564). IP10 expression was significantly 
upregulated after treatment in helminth and coinfected patients in relation to CD14. IP10 
expression is stimulated by IFNs secreted from T cells and other proinflammatory 
cytokines and is known to have a role in monocyte and Th1 trafficking (573). Increased 
expression of this gene may thus be associated with increased Th1 cell activation and 
reduction in mycobacterial growth as observed after treatment. In the Luminex study, it 
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was also observed that IP10 was increased after treatment, indicating the induction of 
protective immune activity against TB. Most of these genes are important in immunity 
against Mtb. IDO-1 can potentially inhibit T cell functions, leading to tolerance or 
immunosuppression and antagonizing the effects of IFNg (179) and alterations of the 
expression of this gene after treatment might suggest the skewing of immune responses 
towards CAM  and protective immunity against Mtb. 
The expression of these genes can be used as a potential bio signature to observe the 
helminth treatment effect on the helminth and coinfected patients. It would be interesting 
to explore the gene expression and their modulation in larger sample groups and to explore 
whether the expression of these correlate with MGIT mycobacterial growth.  
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Chapter 10 
10.1   Summary 
Tuberculosis and helminth infection are co-endemic in many parts of the world. The 
responses induced by the extracellular helminths and those induced by intracellular Mtb 
are often mutually antagonistic and helminths appear to influence the immune response to 
TB by modulating the immune responses to Mtb (135). T cells are the predominant cell 
types studied in the context of LTBI-helminth coinfection and helminth infection has been 
shown to reduce the effector T cell responses and increase regulatory T cell responses. 
Studies have shown varied responses of TB-helminth co-infection in different settings and 
assays- including effect on acquisition and progression to active disease, effects on the 
efficacy of BCG vaccination or on the diagnostics of LTBI and even no response 
depending on the type of helminth species involved, their migratory life cycle phase or 
chronicity of infection, intensity of helminth infection, patient factors, endemicity, strain 
of Mtb involved, etc (361). Functional assays such as the MGIAs directly measure the 
ability of heterogeneous populations of human lymphocytes and other cells to limit the 
intracellular growth of mycobacteria. The immune mediated inhibition of mycobacterial 
growth correlates more directly with protective TB immunity than other immunological 
responses. MGIA and other cellular parameters like cytokine profiles, antibodies, and gene 
expression might provide new information on important aspects of the underlying 
immunopathogenesis in LTBI-helminth coinfection and how it modulates 
antimycobacterial immune responses.  
In this cohort, the predominant helminth infections were Strongyloidiasis and 
Schistosomiasis: 26.9% of the patients had eosinophilia with the rest of the patients having 
normal eosinophil counts. The eosinophilia reduced significantly with treatment and the 
eosinophil count was significantly correlated with IGRA values in post treatment 
coinfected patients. Other cellular parameters - monocyte count, ML ratio, and neutrophil 
count showed significant changes in LTBI-helminth coinfected patients with anthelmintic 
treatment. The UK migrants in this cohort, had shown a reduced CD4+IFNγ responses, 
and secretion of IFNγ, TNFα and IL-12, which reversed after anthelmintic treatment. 
CD4+IFNγ responses to PPD, ESAT-6/CFP10 measured using ELISpot in the helminth 
infected and coinfected patients improved after anthelmintic treatment. It was therefore of 
 231 
interest to see how helminth co-infection would affect mycobacterial growth inhibition, 
and how anthelminthic treatment might affect this. 
Before performing the MGIA assay on clinical samples, a protocol was standardized for 
the reproducibility of the test-BCG declumping methods, impact of antibiotics, heat 
inactivation serum and various other steps in culture conditions were optimized.  Using the 
optimised protocol, helminth infected and LTBI-helminth coinfected patients exhibited 
poor mycobacterial growth inhibition before anthelmintic treatment, that reversed 
significantly with the anthelmintic treatment.  Mtb Erdman and Mtb H37Rv was also used 
to perform MGIA to see if BCG can provide an estimation of growth inhibition of the 
more virulent Mtb, although the smaller sample size made it difficult to find a significant 
correlation. Total and antigen specific IgE and IgG4 concentrations were reduced 
significantly with anthelmintic treatment, although not correlated with MGIA. The 
complex mixture of Th1, Th17 cytokines and immunosuppressive cytokine like IL-10 and 
TGF-ß appeared to play important role in the coinfection.  The expression of many genes 
like IDO-1, arginase 1, HIF1a, HIF2a, IL-10, CD163 were significantly changed with 
anthelmintic treatment indicating an alteration of antimycobacterial immune response in 
coinfected patients. Mycobacterial growth inhibition did not correlate with CD4+IFNγ+ 
response, but the MGIA assay along with cytokines, antibodies and gene expression 
provided more information about the complex host-pathogen interactions involved in the 
LTBI-helminth coinfected patients, that might indicate that the helminth infection 
modulating antimycobacterial immune responses. 
10.2   Strengths and weaknesses of the study design 
The potential impact of helminth infection on immune responses to Mtb in patients with 
LTBI with or without helminth infection (Strongyloides or Schistosoma) and whether 
anthelmintic treatment modulates the immune responses were explored in this study.  The 
study was performed in migrants in the UK, where reexposure and reinfection following 
anthelmintic treatment would not occur, as the UK is not a helminth endemic country. This 
provided a unique opportunity to study the effect of anthelmintic treatment in helminth 
infected patients. Also the issue of potential drug resistance to anthelmintic treatment as a 
result of selection through exposure of the worm population would not be an issue in the 
UK setting. Some previous studies have shown no effect of anthelmintic treatment or 
clinical improvement of TB and also the effect on the rate of progression from latent to 
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active TB.  All the studies were done in endemic countries, where there was the chance of 
reexposure and reinfection (354). This study could directly address the influence of 
anthelmintic treatment on antimycobacterial immune responses. 
In various studies, the antimycobacterial effects of ivermectin have been reported, 
although the MICs of ivermectin were several magnitudes higher than peak plasma 
concentrations, limiting the use of ivermectin as antimycobacterial agent (588). In the 
current study 21 Strongyloidiasis patients received ivermectin treatment. However, it 
would be interesting to see the bactericidal activity of this drug to kill or inhibit the growth 
of Mtb. To avoid any direct effects of the anthelminthic drugs on immune function, or on 
the BCG, the post-treatment time point was 4 months after the first visit, at which time 
such effects would not be present. 
One issue for such studies is the selection of appropriate controls. Most of the controls in 
this study that were recruited from the clinic, attended the clinic with eosinophilia and 
some symptoms of allergic, respiratory and GIT symptoms. In addition, some of the LTBI 
patients in this cohort, were health care workers, rather than migrants. Of the 90 LTBI 
patient in this cohort, 33 of them received treatment for LTBI after visit 1. Of the LTBI 
patients, 25 were healthcare workers. Twenty-two healthcare workers received treatment 
for LTBI and two were offered treatment but they declined treatment. None of the LTBI 
patients included in this study were on treatment for their LTBI at visit 1.  The average age 
of LTBI patients, who received treatment was 33.72 years of age and of the healthcare 
workers was 34.7 years. Previous UK policy was to only offer treatment for LTBI to those 
aged less than 35 years, although this was recently changed to 65 years. 
Helminth infection in this cohort were mostly diagnosed by serological tests, culture and 
microscopy. The ELISA test detected about 96% of S.mansoniand 92%S.haematobium 
infections, although this test does not distinguish between active and treated infections. In 
some patients the test may remain positive even two years after treatment and there is a 
chance of a false positive result from cross reacting responses with other helminths like 
tapeworm, trichinella, etc. In chronic infection, the intestinal worm load is very low and 
the output of larvae is minimal and irregular, hence the sensitivity of direct observation of 
larvae decreases. Multiple stool samples would have been helpful in detection of the 
larvae, which was not possible for this study(404). Also lower larvae yields made it 
difficult to detect the helminth load and intensity of infection, although with patients in 
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non-endemic settings heavy infection is rarely found. PCR was performed in 
Strongyloidiasis patients and it showed a sensitivity of 66% against culture as gold 
standard and 38% against serology as a gold standard. The detection rate in the present 
study may be low due to the presence of the resistant cuticle which is difficult to disrupt 
mechanically, irregular release of larvae and low concentrations of parasite DNA in the 
presence of PCR inhibitors.  
10.3  Features of the MGIA assay 
The haematological data collected from the clinic, provided important information on cell 
counts, IGRA results and their changes after patients had received the treatment.  In this 
cohort, 27% had eosinophilia and the rest had normal eosinophil counts. The eosinophilia 
in helminth infected and coinfected patients reduced significantly after anthelmintic 
treatment. Most of the controls also had eosinophilia and many had allergic or respiratory 
symptoms. The absolute eosinophil count was significantly higher in the LTBI-helminth 
coinfected patients before they received treatment. IFNγ modifies the effector functions of 
eosinophils-which had been showed in studies when eosinophils were stimulated with 
GM-CSF and IL-5(589). Mycobacterial growth inhibition was not related to eosinophilia, 
neither with other cell counts like neutrophils, lymphocyte count, NLR.  
Monocytes are critical for determining the outcome of the MGIA assay. There was 
reduced mycobacterial growth when monocytes were depleted from the culture. Monocyte 
frequencies were significantly reduced in LTBI and helminth coinfected patients, although 
monocyte count failed to show any correlation with mycobacterial growth.  A complex 
association of ML ratio with growth inhibition was observed in coinfected patients. 
Alteration of the ML ratio was associated with poor growth inhibition, although the 
correlation was not significant. This finding was consistent with publications on the ML 
ratio in TB (411). ML ratio changes after anthelmintic treatment might provide an 
important indicator for progression of LTBI towards active disease.  
There was a decrease in CD4+IFNγ+T cells in helminth infected patients and the 
coinfected groups when stimulated with PPD and ESAT-6/CFP10 both at the baseline in 
comparison to controls and LTBI infected patients suggesting a complex host pathogen 
interaction in coinfected patients, similarly with CD8+T cells with lesser magnitude. 
Potential factors such as negative costimulatory responses and expression of TLRs like 
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TLR2,9 etc. could be analysed and might be helpful to understand the underlying 
immunopathogenesis. Mycobacterial growth inhibition did not correlate with IFNγ-
ELISpot responses suggesting IFNγ is not a direct correlate of protection but rather MGIA 
may provide more information about the functional response and also the role of blood 
components and cytokines may provide more information about the important 
determinants of mycobacterial growth inhibition.  
Mycobacterial growth inhibition was significantly reduced in helminth and LTBI-helminth 
coinfected patients and this reversed after anthelmintic treatment. Helminth infections, in 
addition to Th2 responses, can induce inhibitory cytokines such as IL-10 and TGFβ that 
supress Th1 type responses and interfere with effector T cell activation. Helminths induce 
strong type 2 immune responses, characterized by increased production of antigen-specific 
IL-5, IgG4 and total IgE concentration, and peripheral eosinophilia. Increases in such Th2 
responses might be expected to affect the immune response, with suppressed Th1 cytokine 
responses. IL-10 and TGFβ were found to play an important immunoregulatory role in 
growth inhibition. There was a reduction of Th1 cytokines and the gene expression study 
showed expression of functionally relevant and polarization associated genes like arginase 
1 indicating development of alternatively activated macrophages that may mediate 
impaired Th1 responses to Mtb antigens.  
LTBI-helminth coinfection was associated with significantly elevated levels of pro-
inflammatory and lower levels of anti-inflammatory cytokines after anthelminthic 
treatment. Thus potentially modulating the cytokine environment in which TB is 
controlled in LTBI. 
It was hypothesized that chronic helminth infections might worsen the course of TB. This 
study suggests that helminths not only alter the Th1 and Th2 immune balance but may also 
adversely affect the ability to control mycobacterial growth. The ability to control the 
growth of the mycobacteria increases when the helminth infection is treated and 
patientsare not reexposed. Pre and post treatment IGRA values of helminth infected and 
LTBI-helminth coinfected patients showed improvement in IGRA values after the 
treatment, although the change was not significant, perhaps as the sample size was smaller. 
Helminth infection were associated with inconclusive results in the IGRAs in pregnant 
mothersin Ethiopia and children in Bangladesh (491). However, a more recent study in 
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South Africa similarly revealed no significant effect of anthelmintic treatment on 
tuberculin skin test or IGRAs in children (590).  
The influence of helminth infection on the LTBI progression to active TB is not very 
clearly understood. Among previous studies, some showed no effect of helminths on 
mycobacterial infection and three observed worsened control. In Uganda, there was a 
relationship between having Schistosomiasis and progression from LTBI to active TB 
(336). The observed differences might be due to the helminth species studied, their 
location in different tissue spaces, different life cycle and the release of different secretory 
and excretory antigens, intensity of infection and endemicity. However, with longitudinal 
follow up, these patients who did not receive prophylactic treatment for LTBI could have 
provided information regarding the clinical outcome. 
10.3   Future directions 
Various cellular components and their role in MGIA have been observed in this study, but 
further work is required to investigate the other important cellular compartments, 
especially neutrophils could be investigated in whole blood assays to see if they also 
contribute to MGIA variance. NK cells would have been present in the PMBC cultures 
used in the present study, but were not directly investigated. The MGIA can be performed 
using whole blood, but this does not allow pre- and post-treatment responses to be directly 
compared in the same assay. The frequency and cellular subtypes such as neutrophils and 
their cytokine expression profile can be observed. IL-10 has been proved to be very 
important immunoregulatory cytokine in MGIA, and the cellular source of IL-10 could be 
detected by flow cytometry. Various components of complement can also be tested for 
their role, as when the role of heat inactivation of serum was observed in the MGIA, it was 
suggested that complement did have a role in mediating the responses. More studies on 
innate cells including neutrophils, innate lymphoid cells, dendritic cells, B cells and 
cytokine expression can be conducted. 
Antibody concentrations did not correlate with MGIA in this study, although Mtb specific 
antigens like HBHA, Ag85A and other latency antigen could have been used to test the 
antibody responses, that might provide further important information to show if antibodies 
are playing any protective role.  
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Anthelmintic effects on MGIA could be compared with UK migrants and patients from 
endemic countries to observe the variation in endemic setting. The helminth load and 
number of helminth species involved can also be useful to evaluate whether individuals 
with high worm burden have an increased risk of developing TB. Malnutrition is another 
confounding factor. Data regarding nutritional assessment can also be assessed before and 
after treatment as this might affect the LTBI diagnostics, although malnutrition was not a 
factor in the UK cohort. 
One question that arose during the study was whether the depressed Th1 responses 
observed in helminth infected patients might affect the IGRA test used to identify LTBI. 
IGRA values in these patients were documented in LTBI-helminth coinfected patients only 
for the pre-treatment visit. There were a few paired samples where both pre and post 
anthelmintic treatment IGRA values were available; this showed that there was 
improvement in T cell responses with treatement, although due to the small sample size it 
was difficult to draw a conclusion. It would be interesting to see if the improvement in T 
cell responses and IFNγ responses affected the QFT-GIT reading, to see whether the 
helminth infection is modulating the IFNγ responses and might impact the LTBI diagnosis. 
At the start of this work, there was concern that the MGIA assay might not be sufficiently 
reproducible or robust to provide useful results. Following the optimisation performed 
here, the MGIA assay was found to be reproducible in the groups who were not treated, 
and to show reproducible changes in patients whose helminth infections were treated. 
Further optimization of the MGIA can be assessed like use of PANTA in 96-hour culture, 
BCG culture in plates and avoiding the use of rotating cultures etc. These changes would 
reduce the costs of the experiments and make the assay more logistically simple to use in 
endemic setting.  
It has been demonstrated earlier that helminth infection can significantly impair the 
efficiency of BCG in helminth endemic regions. Observing this effect in non-endemic 
setting also can be of great importance in the area of greatest impact of the modulation of 
the immune responses by helminth infection likely involved attenuation of vaccine-
induced immune responses.  
The influence of helminth infection on the development of active TB is still unanswered. It 
has been shown previously that patients with active TB were likely to have intestinal 
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helminth infection. In the present study, helminth infection was shown to modulate LTBI 
immune responses. Comparing the study of acute and latent TB and helminth coinfection 
might provide an important information about the immune signature in coinfected patients.  
Helminth infected patients in this study displayed poor growth inhibition in MGIA which 
was improved after anthelmintic treatment, indicating this immunomodulation was 
helminth mediated.It will be fascinating to detect the effects on progression or pathology 
in coinfected patients and during their subsequent longitudinal follow-ups as helminths 
might influence the outcome. 
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Appendix 1 
 
 
 
 
 
Observational / Interventions Research Ethics Committee 
Dr. Shaheda Anwar  
LSHTM 
 
16 December 2014 
 
Dear Shaheda, 
 
Study Title: “Investigating the effect of de-worming on the antimicrobacterial immune responses in co infected migrants” 
 
LSHTM Ethics Ref: 7758 
 
Thank you for your letter responding to the Observational Committee’s request for further information on the above research and submitting revised 
documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, 
protocol and supporting documentation as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
Approval is dependent on local ethical approval having been received, where relevant. 
 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
 
 
 
Document File Name Date Version 
Type    
Investigator CV cv 2014.docx 28/08/2014 1 
Information IDEA_consent_V5.docx 28/08/2014 1 
Sheet    
Advertisements IDEA_patientinformationleafletV5 (2).docx 28/08/2014 1 
Local Approval 11 H0713 12 Tsang (Brown)Favourable Opinion Susbstantial Amendment Revised 28/08/2014 1 
 13 1 2014.pdf   
Protocol / Protocol.docx 29/08/2014 1 
Proposal    
Covering Letter 1.docx 26/11/2014 2 
Covering Letter cover letter.docx 05/12/2014 3 
    
 
After ethical review 
Any subsequent changes to the application must be submitted to the Committee via an Amendment form on the ethics online applications website. 
The Principal Investigator is reminded that all studies are also required to notify the ethics committee of any serious adverse events which occur 
during the project via an Adverse Event form on the ethics online applications website. At the end of the study, please notify the committee via an End 
of Study form on the ethics online applications website. Ethics online applications website link: http://leo.lshtm.ac.uk 
 
Yours sincerely, 
 
 
 
Professor	John	DH	Porter	
Chair	ethics@lshtm.ac.uk	http://www.lshtm.ac.uk/ethics/	
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National Research Ethics Service 
 
NRES Committee London - Bloomsbury  
HRA NRES Centre Manchester 
Barlow House 3rd Floor 
4 Minshull Street  
Manchester 
M1 3DZ 
 
Tel: 0161 625 7815  
Fax: 0161 625 7299 
09 January 2014 Revised 14 January 2014 
 
Ms Lillian Tsang 
Research Nurse 
University College London  
Department of Infection & Immunity 
Room 1.3.1  
Cruciform Building 
Gower Street 
London  
WC1E 6BT 
 
 
Dear Ms Tsang 
 
Study title: Investigating the effect of de-worming on anti- 
mycobacterial immune responses in co-infected  
migrants. 
REC reference: 11/H0713/12 
Amendment number: Amendment 5  
Amendment date: 09 December 2013 
IRAS project ID: 66427 
 
• The amendment proposes to increase the number of participants to four hundred and 
twenty. 
 
The above amendment was reviewed by the Sub-Committee in correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion of the 
amendment on the basis described in the notice of amendment form and supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 
Document 
 
Version Date 
  
    
Protocol  7 20 December 2013  
       
  A Research Ethics Committee established by the Health Research Authority Page 1 of 3 
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Notice of Substantial Amendment (non-CTIMPs) Amendment 5 09 December 2013 
   
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
11/H0713/12: Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Signed on behalf of: 
Dr Joe Brierley 
Chair 
 
E-mail: nrescommittee.london-bloomsbury@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the  
review 
 
Copy to: Ms Anna Jones - Royal Free London NHS Foundation Trust 
 
Dr Nandi Simpson – UCLH NHS Foundation Trust 
 
Dr Michael Brown - University College London NHS Trust 
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NRES Committee London - Bloomsbury 
 
Attendance at Sub-Committee of the REC meeting on 10 January 2014 
 
 
Name 
 
Profession 
 
Capacity    
       
Dr Joe Brierley (Chair) – 
Chaired the  Consultant Intensivist  Expert 
meeting       
       
Michelle McPhail  Lecturer in Management Studies  Lay Plus 
       
Also in attendance:       
     
 Name    Position (or reason for attending) 
       
Dr Ashley Totenhofer    REC Manager   
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Appendix 2 
 
 
 
INFECTIOUS DISEASES IN EUROPE AND AFRICA - IDEA STUDY- INFORMATION FOR 
PATIENTS 
INTRODUCTION 
At this hospital we are studying how worm infections influence other infections eg: TB. 
Worm infections are common in people who have lived in the tropics. We are asking 
people who come to HTD clinics to be tested for worm infections, and people coming to 
the UCLH TB clinic to take part in this study. In this leaflet we provide information about 
the study so that you can decide if you would like to take part. 
INVITATION TO PARTICIPATE 
In these clinics, the medical staff routinely test people for TB and for worm infections. A 
research nurse will explain the study to you and answer any questions that you may have. 
If you agree to be included in the study you will be asked to sign a consent form. 
DO I HAVE TO TAKE PART? 
No. You do not have to take part. If you do agree to be included you are still free to 
withdraw at any time without giving a reason. Your decision will not affect your 
treatment in any way. 
WHAT WILL HAPPEN TO ME IF I AGREE TO BE INCLUDED IN THIS STUDY? 
Taking part in this study will not affect your treatment in any way. A copy of the signed 
consent form and this information sheet will be given to you to keep.  
 
If you agree to take part, this will be your first visit (visit one) as a participant, and you 
will be asked to attend two further appointments. We may send a letter to your GP letting 
them know that you are taking part. 
 
Visit one: At the same time as taking blood samples that are part of the routine 
assessment of patients in this clinic, the research nurse will take extra blood up to 33 ml 
(which is about 3 tablespoons), for the study. 
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Visit two: Four weeks after your first visit, you will be invited back to the clinic. If tests 
showed that you had a worm infection, you will be treated for this and a repeat blood 
sample of 23 ml will be collected. If you did not have a worm infection, a repeat blood 
sample of 23 ml will be taken.  
 
Visit three: Sixteen to twenty four weeks after your second visit, you will be asked to 
return to the clinic so that the nurse can collect a final 26 ml of blood from you. This will 
be the end of your participation in the study.  
ARE THERE ADVANTAGES OR RISKS TO TAKING PART? 
No. Being included in this study will not affect your care in any way. 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
Yes. All the information about your participation in this study will be kept confidential. 
WHO IS RESPONSIBLE FOR THIS STUDY 
Dr Mike Brown 
The Hospital for Tropical Diseases, 
Mortimer Market, Capper Street, Tottenham Court Road, 
London, WC1E 6JB 
Email: Mike.Brown@uclh.nhs.uk, Tel: 0845 155 5000 ex 5972 
 
WHAT IS THE PURPOSE OF THE STUDY? 
Scientific researchers at the London School of Hygiene & Tropical Medicine, and 
specialists in infectious diseases at this hospital are looking at the way people’s bodies 
respond to infections. They will be measuring the how peoples’ bodies respond to TB 
when they have worm infections, and how this changes when the worm infections are 
treated. These responses can be seen by using blood cells to measure immune reactions. 
This research is being done to improve our understanding about the way infections cause 
disease. The aim is to find new ways to prevent infectious diseases in the future. 
WILL ANY INFORMATION BECOME AVAILABLE THAT WILL AFFECT MY CARE? 
If results show that you have a worm infection or are infected with TB, you will be 
treated for these infections. The treatment you will get will be the same as if the infection 
had been discovered as part of routine care. We will let you know the results of these 
tests, and we will also tell your GP and the doctors here at the hospital.  
WHAT WILL HAPPEN IF I DON’T WANT TO CARRY ON WITH THE STUDY? 
If you decide you don’t want to continue being part of the study, you can stop at any time. 
If you decide to withdraw from the study, we will keep any data or samples that have 
already been collected unless you ask us to destroy these. Your routine health care will 
not be affected in any way by your decision.  
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WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
All information which is collected about you for this study will be kept strictly 
confidential, this is local NHS policy. Any information about you that is held outside of 
normal NHS facilities will have your name and address removed so that you cannot be 
recognised from it. None of your blood samples or data that go to the researchers at 
London School of Hygiene & Tropical Medicine will have your name on them. Only the 
clinic staff who have been looking after you will know your identity. All clinic staff and 
researchers will have a “duty of confidentiality” to you as a research participant, this 
means that they will not reveal your identity. 
DATA ANONYMISATION 
At the end of this study, material from the samples you provided will be stored in case 
further analysis of them is needed for this study. If the samples are used in other approved 
studies, they will be labelled so that researchers cannot see that they come from you. All 
research samples and information about you will be securely stored under the custody of 
Dr Mike Brown All data will be confidential. 
EXPENSES AND PAYMENTS 
Travel expenses on public transport will be reimbursed. 
WHAT WILL HAPPEN TO THE SAMPLES I GIVE? 
The blood sample collected for this research study will be given a code number; part of 
the sample will be analysed at UCLH, the rest will be analysed at the London School of 
Hygiene & Tropical Medicine. Only research staff working on this project will have 
access to these specimens. All research samples and information about you will be 
securely stored under the custody of Dr M. Brown. 
WHAT HAPPENS IF A PROBLEM ARISES AS A RESULT OF TAKING PART IN THIS STUDY? 
If you have a concern about any aspect of this study, you should ask to speak with Dr M. 
Brown who will answer your questions (Contact details given in part 1). If you remain 
unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital Patient Advice and Liaison Service. 
In the event that something does go wrong and you are harmed during the research study 
there are no special compensation arrangements. If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation 
against University College London Hospitals NHS Trust but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
WILL ANYONE OUTSIDE OF THE RESEARCH TEAM BE INVOLVED IN THIS STUDY 
A copy of your consent form will be placed in your medical records. No one outside of 
the named research staff will be involved in this study. This study is part of a European 
consortium research project, therefore anonymised results from this study will be shared 
with other consortium members. 
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WHAT WILL HAPPEN TO THE RESULTS OF THIS STUDY? 
The aim is to publish the results of this study in the scientific literature and present them 
at scientific meetings. You will not be identifiable by any such publication or 
presentation. 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
This research is organised by Dr M. Brown and collaborators within University College 
London Hospitals NHS Foundation Trust and the London School of Hygiene & Tropical 
Medicine. This study is funded by an EU FP7 Consortium grant. No doctor or researcher 
will receive any payment for including you in this study. 
WHO HAS REVIEWED THIS STUDY? 
This study has been reviewed and approved by the Central London Research Ethics 
Committee 2 and was given a favourable ethical opinion for conduct by the LSHTM 
Research Ethics Committee. 
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 Appendix 3   
 
 UCLH Project ID number: 
INFECTIOUS DISEASES IN EUROPE AND AFRICA 
IDEA STUDY -CONSENT FORM 
 
 
 
 
 
 
 
 
Project title:  Investigating the effect of de-worming on anti-mycobacterial immune responses in co-infected migrants. 
 
Please initial each box to indicate agreement 
   
1. I confirm that I have read and understand the information sheet 
dated 01/10/2013 (version 5) for the above study. I have had the 
opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes and data 
collected during the study, may be looked at by 
authorisedindividuals University College London Hospital or from 
regulatory authorities where it is relevant to my taking part in this 
research and that all data will be confidential. I give permission 
for these individuals to have access to my records.  
 
4. I agree to take part in this study.  
5. I agree to donate blood samples in this study as a gift.  
6. I consent to the storage and use of material from this study for 
use in future research studies, subject to approval by Research 
Ethics Committees. 
 
 
7. I understand that my GP may be informed that I am taking part in 
this study. 
 
   
Name of patient  
Signature  Date  
   
Name of investigator taking consent  
Signature  Date  
    
1 Copy to patient  1 Copy to research file  1 Copy to medical notes  
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COMMENTS OR CONCERNS DURING THE STUDY 
If you have any comments or concerns you may discuss these 
with the investigator.   If you wish to go further and complain 
about any aspect of the way you have been approached or 
treated during the course of the study, you should write or get in 
touch with the Patients Advice and Liaison Service (PALS).  
Please quote the UCLH project number at the top this consent 
form. 
 
 
Project title:  Investigating the effect of de-worming on anti-mycobacterial immune responses in co-infected migrants. 
 
Please initial each box to indicate agreement 
   
1. I confirm that I have read and understand the information sheet 
dated 01/10/2013 (version 5) for the above study. I have had the 
opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes and data 
collected during the study, may be looked at by 
authorisedindividuals University College London Hospital or from 
regulatory authorities where it is relevant to my taking part in this 
research and that all data will be confidential. I give permission 
for these individuals to have access to my records.  
 
4. I agree to take part in this study.  
5. I agree to donate blood samples in this study as a gift.  
6. I consent to the storage and use of material from this study for 
use in future research studies, subject to approval by Research 
Ethics Committees. 
 
 
7. I understand that my GP may be informed that I am taking part in 
this study. 
 
   
Name of patient  
Signature  Date  
   
Name of investigator taking consent  
Signature  Date  
    
1 Copy to patient  1 Copy to research file  1 Copy to medical notes  
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Appendix 4 
Infectious Diseases in Europe and Africa - IDEA study case record form VISIT 1 
Hospital number  Study UIN  
Gender  DOB  IDEA study 
group 
 
Contact details  
Referral route  
Doctor/Nurse  Contact  
 
 
Country of origin: _____________________________ In UK since: 
__________________ 
 
 
Inclusion Exclusion 
Age >18                       o Age <18               o 
Lived in Tropics                   o Known HIV infectiono 
Eosinophilia                          o Previous treatment for helminths      o 
(uninfected) 
Helminth infection                o  
NB: Not all inclusion criteria are necessary for participation, but any of the exclusion criteria disqualifies participation 
 
Samples collected: 
Research samples  o 
Diagnostic samples for parasitology o 
Samples for Quantiferon-Gold  o  
 
Helminth infection 
Symptoms YoNo?o 
Countries of potential exposure: _____________________________________ 
(with date last visited)                 _____________________________________ 
 
 
Eosinophilia 
Historical        date:_______________        eosinophils:    oo.ox 109/L 
   lymphocytes: oo.ox 109/L 
 
Current           date:_______________        eosinophils:    oo.ox 109/L 
       lymphocytes: oo.ox 109/L      
 
 
 
 
 
296 
Parasitology      
Parasitology (If available)      
Strongyloides   
Serology: ________________________________________Date: _________________ 
Stool microscopy: _______________________________Date: _________________ 
              charcoal: _________________________________ Date: _________________ 
Schistosoma 
Serology: ________________________________________Date: __________________ 
Urine: ___________________________________________Date: __________________ 
Additional helminth serology filaria  YoNo 
Notes: 
 
 
TB 
Previous history of TB      YoNo?o 
BCG vaccination           YoNo?o 
 
IGRA 
Date tested: ____________________ 
Result: _______________________________________________________________ 
 
Quantiferon-Gold 
Date tested: ____________________ 
Result: _______________________________________________________________ 
OR: 
Samples sent date: _____________________________________________________ 
 
 
HIV Status:    Negative/ Unknown(please delete as appropriate) 
 
Notes: 
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Appendix 5 
 
Mycobacterial Growth Inhibition Assay 
	
Reagents: 
 
• RPMI-MGIT = Sigma RPMI-1640 Medium HEPES modification with 25mM 
HEPES (Cat. R5886). Add 5ml of L-glutamine and 50ml of filtered Pooled 
Human AB Serum (PHS). 
• BCG/ Mycobacteria stock. 
• BACTEC MGIT tubes containing 7ml media 
• PANTA/OADC enrichment broth for MGIT tubes 
 
Equipment: 
 
• BACTEC MGIT 320/960 machine 
• 37°C water bath 
• Centrifuge and microcentrifuge 
• 37°C incubator 
• Cell counter/microscope  
• 2ml screw-cap tubes 
• 360°C tube rotator 
• Vortex 
	
Method: 
 
Day 1: 
	
1. Cryopreserved PBMC thawed in a water bath at 37°C, washed twice in RPMI 
media  
 
2. Count the cells, washed and resuspended in MGIT medium at a concentration of 1 
X106 per 300µl medium 
 
3. Add 300 µl of cell suspension to each of 2 duplicate 2 ml micro tubes per sample 
 
4. Prepare the BCG master mix: Calculate the total number of tubes being 
inoculated. This will be (number of samples x 2) + 2 control tubes. To make a 
master mix we would dilute the neat stock 1/10 in RPMI (900ul RPMI and 100ul 
of BCG stock).  take 10ul of your 1/10 dilution above and add it to 990ul of RPMI 
to make a 1/1000 dilution. We would then add 5ul of the 1/10 dilution to 5000ul 
of RPMI to make a working stock.  300ul of the working stock contains the 
equivalent of 0.05ul of the undiluted stock and will give you a TTP of 12 days. 
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5. Do the same for the TB master mix.  
 
6. Supplement 4 MGIT tubes with 800ul PANTA/enrichment and 200ul of 
PANTA/Enrichment supplemented Middlebrook 7H9 from a spare tube. 
 
 
7. Add 300ul of the BCG master mix to each of the 2 positive control tubes, and 
300ul of the TB master mix to the other 2. Invert to mix and place on the MGIT 
machine. 
 
8. Add 300ul of the mycobacteria master mix to each sample 2ml tube. 
 
 
9. Place tubes on a 360°C tube rotator in a 37°C incubator for 96 hours. 
 
10. Set duplicate direct-to-MGIT viability control tubes. Add 800 µl PANTA/OADC 
enrichment broth and 300 µl of BCG/M.tuberculosis and put into the machine. 
	
	
Day 2: 
 
1. After 96 hours, remove sample tubes and centrifuge at 12,000rpm for 10 minutes. 
 
2. Remove 500ul of supernatant ensuring the pellet remains intact, and store in a 2ml 
screw-cap tube. (Some supernatant can remain in the tube). 
 
 
3. Freeze supernatant at -80 degrees. 
 
4. Add 100µl sterile water to each tube and vortex for 30 seconds 
 
 
5. Leave at room temperature for 5 minutes, vortex again. And repeat the step twice 
more. 
 
6. Add 400ul of PANTA and OADC enrichment broth and vortex for 30 seconds. 
 
 
7.  Add 800ul PANTA/enrichment to the same number of MGIT tubes as you have 
2ml sample tubes and label accordingly 
 
8. Add the 500ul sample to its corresponding MGIT tube, invert to mix and place on 
BACTEC MGIT machine and incubate at 37°C until the detection of positivity. 
 
